Antibacterial piperdine derivatives

Information

  • Patent Grant
  • 8399489
  • Patent Number
    8,399,489
  • Date Filed
    Thursday, February 16, 2006
    18 years ago
  • Date Issued
    Tuesday, March 19, 2013
    11 years ago
Abstract
Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
Description
BACKGROUND OF THE INVENTION

The present invention relates to compounds which demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.


The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded as effective against both Gram-positive and certain Gram-negative pathogens.


Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus aureus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiple resistant Enterococcus faecium.


The preferred clinically effective antibiotic for treatment of last resort of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with various toxicities, including nephrotoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens. There is also now increasing resistance appearing towards agents such as β-lactams, quinolones and macrolides used for the treatment of upper respiratory tract infections, also caused by certain Gram negative strains including H. influenzae and M. catarrhalis.


Consequently, in order to overcome the threat of widespread multi-drug resistant organisms, there is an on-going need to develop new antibiotics, particularly those with either a novel mechanism of action and/or containing new pharmacophoric groups.


Deoxyribonucleic acid (DNA) gyrase is a member of the type II family of topoisomerases that control the topological state of DNA in cells (Champoux, J. J.; 2001. Ann. Rev. Biochem. 70: 369-413). Type II topoisomerases use the free energy from adenosine triphosphate (ATP) hydrolysis to alter the topology of DNA by introducing transient double-stranded breaks in the DNA, catalyzing strand passage through the break and resealing the DNA. DNA gyrase is an essential and conserved enzyme in bacteria and is unique among topoisomerases in its ability to introduce negative supercoils into DNA. The enzyme consists of two subunits, encoded by gyrA and gyrB, forming an A2B2 tetrameric complex. The A subunit of gyrase (GyrA) is involved in DNA breakage and resealing and contains a conserved tyrosine residue that forms the transient covalent link to DNA during strand passage. The B subunit (GyrB) catalyzes the hydrolysis of ATP and interacts with the A subunit to translate the free energy from hydrolysis to the conformational change in the enzyme that enables strand-passage and DNA resealing.


Another conserved and essential type II topoisomerase in bacteria, called topoisomerase IV, is primarily responsible for separating the linked closed circular bacterial chromosomes produced in replication. This enzyme is closely related to DNA gyrase and has a similar tetrameric structure formed from subunits homologous to Gyr A and to Gyr B. The overall sequence identity between gyrase and topoisomerase IV in different bacterial species is high. Therefore, compounds that target bacterial type II topoisomerases have the potential to inhibit two targets in cells, DNA gyrase and topoisomerase IV; as is the case for existing quinolone antibacterials (Maxwell, A. 1997, Trends Microbiol. 5: 102-109).


DNA gyrase is a well-validated target of antibacterials, including the quinolones and the coumarins. The quinolones (e.g. ciprofloxacin) are broad-spectrum antibacterials that inhibit the DNA breakage and reunion activity of the enzyme and trap the GyrA subunit covalently complexed with DNA (Drlica, K., and X. Zhao, 1997, Microbiol. Molec. Biol. Rev. 61: 377-392). Members of this class of antibacterials also inhibit topoisomerase IV and as a result, the primary target of these compounds varies among species. Although the quinolones are successful antibacterials, resistance generated primarily by mutations in the target (DNA gyrase and topoisomerase IV) is becoming an increasing problem in several organisms, including S. aureus and Streptococcus pneumoniae (Hooper, D. C., 2002, The Lancet Infectious Diseases 2: 530-538). In addition, quinolones, as a chemical class, suffer from toxic side effects, including arthropathy that prevents their use in children (Lipsky, B. A. and Baker, C. A., 1999, Clin. Infect. Dis. 28: 352-364). Furthermore, the potential for cardiotoxicity, as predicted by prolongation of the QTc interval, has been cited as a toxicity concern for quinolones.


There are several known natural product inhibitors of DNA gyrase that compete with ATP for binding the GyrB subunit (Maxwell, A. and Lawson, D. M. 2003, Curr. Topics in Med. Chem. 3: 283-303). The coumarins are natural products isolated from Streptomyces spp., examples of which are novobiocin, chlorobiocin and coumermycin A1. Although these compounds are potent inhibitors of DNA gyrase, their therapeutic utility is limited due to toxicity in eukaryotes and poor penetration in Gram-negative bacteria (Maxwell, A. 1997, Trends Microbiol. 5: 102-109). Another natural product class of compounds that targets the GyrB subunit is the cyclothialidines, which are isolated from Streptomyces filipensis (Watanabe, J. et al 1994, J. Antibiot. 47: 32-36). Despite potent activity against DNA gyrase, cyclothialidine is a poor antibacterial agent showing activity only against some eubacterial species (Nakada, N, 1993, Antimicrob. Agents Chemother. 37: 2656-2661).


Synthetic inhibitors that target the B subunit of DNA gyrase and topoisomerase IV are known in the art. For example, coumarin-containing compounds are described in patent application number WO 99/35155, 5,6-bicyclic heteroaromatic compounds are described in patent application WO 02/060879, and pyrazole compounds are described in patent application WO 01/52845 (U.S. Pat. No. 6,608,087).


We have discovered a new class of compounds which are useful for inhibiting DNA gyrase and topoisomerase IV.


SUMMARY OF THE INVENTION

Therefore the present invention provides a compound of formula (I):




embedded image



wherein:


R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl;


R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, —C═N—OR′ wherein R′ is H or C1-4alkyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


W is —O—, —N(R6)— or —C(R7)(R8)—;


X is a direct bond, —CH2—, —C(O)— or S(O)q— (wherein q is 1 or 2);


Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;


R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, C1-4alkoxyiminomethyl, N-hydroxyformamido, C1-4hydrazino, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkoxy)carbamoyl, N′—(C1-4alkyl)ureido, N′,N′—(C1-4alkyl)2ureido, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N′—(C1-4alkyl)hydrazinocarbonyl, N′,N′—(C1-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10— or heterocyclyl-R11—; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;


R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl;


n is 1-4; wherein the values of R4 may be the same or different;


m is 0-4; wherein the values of R5 may be the same or different;


R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14— or heterocyclyl-R15—; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R17;


R9, R13 and R17 are independently selected from C1-4alkyl, C1 -4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;


R10, R11, R14 and R15 are independently selected from a direct bond, —O—, —N(R18)—, —C(O)—, —N(R19)C(O)—, —C(O)N(R20)—, —S(O)p—, —SO2N(R21)— or —N(R22)SO2—; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;


R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;


or a pharmaceutically acceptable salt thereof.


The present invention also provides a compound of formula (IA):




embedded image



wherein:


R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl;


R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl; R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, —C═N—OR′ wherein R′ is H or C1-4alkyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl; X is a direct bond, —CH2—, —C(O)— or S(O)q— (wherein q is 1 or 2);


Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;


R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2 -4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkoxy)carbamoyl, N′—(C1-4alkyl)ureido, N′,N′—(C1-4alkyl)2ureido, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N′—(C1-4alkyl)hydrazinocarbonyl, N′,N′—(C1-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10— or heterocyclyl-R11—; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;


R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl;


n is 1-4; wherein the values of R4 may be the same or different;


m is 0-4; wherein the values of R5 may be the same or different;


R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14— or heterocyclyl-R15—; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R17;


R9, R13 and R17 are independently selected from C1-4alkyl, C1 -4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;


R10, R11, R14 and R15 are independently selected from a direct bond, —O—, —N(R18)—, —C(O)—, —N(R19)C(O)—, —C(O)N(R20)—, —S(O)p—, —SO2N(R21)— or —N(R22)SO2—; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;


R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;


or a pharmaceutically acceptable salt thereof.


The present invention also provides a compound of formula (IB):




embedded image



wherein:


R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl;


R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, —C═N—OR′ wherein R′ is H or C1-4alkyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;


R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2 -4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkoxy)carbamoyl, N′—(C1-4alkyl)ureido, N′,N′—(C1-4alkyl)2ureido, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N′—(C1-4alkyl)hydrazinocarbonyl, N′,N′—(C1-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10— or heterocyclyl-R11—; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;


R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl;


n is 1-4; wherein the values of R4 may be the same or different;


m is 0-4; wherein the values of R5 may be the same or different;


R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14— or heterocyclyl-R15—; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R17;


R9, R13 and R17 are independently selected from C1-4alkyl, C1 -4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;


R10, R11, R14 and R15 are independently selected from a direct bond, —O—, —N(R18)—, —C(O)—, —N(R19)C(O)—, —C(O)N(R20)—, —S(O)p—, —SO2N(R21)— or —N(R22)SO2—; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;


R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;


or a pharmaceutically acceptable salt thereof.


The present invention also provides a compound of formula (IC):




embedded image



wherein:


R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl;


R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, —C═N—OR′ wherein R′ is H or C1-4alkyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;


R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2 -4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkoxy)carbamoyl, N′—(C1-4alkyl)ureido, N′,N′—(C1-4alkyl)2ureido, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N′—(C1-4alkyl)hydrazinocarbonyl, N′,N′—(C1-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10— or heterocyclyl-R11—; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;


R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl;


m is 0-4; wherein the values of R5 may be the same or different;


R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14— or heterocyclyl-R15—; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R17;


R9, R13 and R17 are independently selected from C1-4alkyl, C1 -4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;


R10, R11, R14 and R15 are independently selected from a direct bond, —O—, —N(R18)—, —C(O)—, —N(R19)C(O)—, —C(O)N(R20)—, —S(O)p—, —SO2N(R21)— or —N(R22)SO2—; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;


R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;


or a pharmaceutically acceptable salt thereof.


The present invention also provides a compound of formula (IC):




embedded image



wherein:


R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl;


R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, —C═N—OR′ wherein R′ is H or C1-4alkyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


Ring A is heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;


R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkoxy)carbamoyl, N′—(C1-4alkyl)ureido, N′,N′—(C1-4alkyl)2ureido, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N′—(C1-4alkyl)hydrazinocarbonyl, N′,N′—(C1-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10— or heterocyclyl-R11—; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;


R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl;


m is 0-4; wherein the values of R5 may be the same or different;


R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14— or heterocyclyl-R15—; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R17;


R9, R13 and R17 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;


R10, R11, R14 and R15 are independently selected from a direct bond, —O—, —N(R18)—, —C(O)—, —N(R19)C(O)—, —C(O)N(R20)—, —S(O)p—, —SO2N(R21)— or —N(R22)SO2—; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;


R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;


or a pharmaceutically acceptable salt thereof.


The present invention also provides a compound of formula (IE):




embedded image



wherein: Y is NH, N(C1-4alkyl) or S;


R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl;


R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, —C═N—OR′ wherein R′ is H or C1-4alkyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


X is a direct bond, —CH2—, —C(O)— or S(O)q— (wherein q is 1 or 2);


Ring A is heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;


R4 is a substitutent on carbon selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkoxy)carbamoyl, N′—(C1-4alkyl)ureido, N′,N′—(C1-4alkyl)2ureido, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N′—(C1-4alkyl)hydrazinocarbonyl, N′,N′—(C1-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10— or heterocyclyl-R11—; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;


R5a and R5b are substituents as defined for R4 or taken together with the carbons to which they are attached form a 6-membered carbocyclyl ring substituted by one or two groups which may be the same or different and which are selected from R5;


R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl;


R12 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14— or heterocyclyl-R15—; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R17;


R9, R13 and R17 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;


R10, R11, R14 and R15 are independently selected from a direct bond, —O—, —N(R18)—, —C(O)—, —N(R19)C(O)—, —C(O)N(R20)—, —S(O)p—, —SO2N(R21)— or —N(R22)SO2—; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;


R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;


or a pharmaceutically acceptable salt thereof.


The present invention also provides a compound of formula (IF):




embedded image



wherein:


R1 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R1 may be optionally substituted on carbon by one or more halo or cyclopropyl;


R2 is selected from hydrogen, nitro, hydroxy, halo, cyano, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R2 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


R3 is selected from hydrogen, nitro, hydroxy, halo, cyano, —C═N—OR′ wherein R′ is H or C1-4alkyl, C1-4alkyl, C1-4alkoxy, C2-4alkenyl, C2-4alkynyl, C1-4alkanoyl, C1-4alkylS(O)a wherein a is 0 to 2 and C3-6cycloalkyl; wherein R3 may be optionally substituted on carbon by one or more halo or C3-6cycloalkyl;


X is a direct bond, —CH2—, —C(O)— or S(O)q— (wherein q is 1 or 2);


R4 is a substitutent on carbon selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, N-hydroxyformamido, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkoxy)carbamoyl, N′—(C1-4alkyl)ureido, N′,N′—(C1-4alkyl)2ureido, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N′—(C1-4alkyl)hydrazinocarbonyl, N′,N′—(C1-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10— or heterocyclyl-R11—; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;


R5a and R5b are substituents as defined for R4 or taken together with the carbons to which they are attached form a 6-membered carbocyclyl ring substituted by one or two groups which may be the same or different and which are selected from R5;


R6, R7 and R8 are independently selected from hydrogen or C1-4alkyl;


R12 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14— or heterocyclyl-R15—; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R17;


R9, R13 and R17 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;


R10, R11, R14 and R15 are independently selected from a direct bond, —O—, —N(R18)—, —C(O)—, —N(R19)C(O)—, —C(O)N(R20)—, —S(O)p—, —SO2N(R21)— or —N(R22)SO2—; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;


R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;


or a pharmaceutically acceptable salt thereof.


The invention also provides a compound which is

  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[(1S)-2-methoxy-1-methylethyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-O-4-[(methylamino)carbonyl]-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-methyl-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid;
  • 4-acetyl-2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[(1R)-2-methoxy-1-methylethyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[(2S)-2-methoxypropyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[(2R)-2-methoxypropyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[(1R,2S)-2-fluorocyclopropyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;
  • Cis(±)2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-benzothiazole-7-carboxylic acid;
  • Cis(±)2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(methoxymethyl)-1,3-thiazole-5-carboxylic acid;
  • Cis(±)2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinic acid;
  • 2-((3S,4R)-4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-benzothiazole-7-carboxylic acid;
  • Cis(±)-2-(3-chloro-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidin-1-yl)-4-(methoxymethyl)-1,3-thiazole-5-carboxylic acid;
  • 2-((3S,4R)-4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-4-methyl-1,3-thiazole-5-carboxylic acid;
  • Cis(±)-2-[4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(prop-2-yn-1-yloxy)piperidin-1-yl]-1,3-thiazole-5-carboxylic acid;
  • Cis(±)2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-4-carboxylic acid; or
  • 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[2-methoxy-1-(methoxymethyl)ethyl]amino}carbonyl)-1,3-thiazole-5-carboxylic acid;


or a pharmaceutically acceptable salt thereof.


The invention also provides a pharmaceutical composition that comprises a compound of formula I, IA, IB, IC, or IE or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.


The invention also provides a method of treating a bacterial infection in a warm-blooded animal, such as a human being, in need of such treatment, which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, or IE, or a pharmaceutically-acceptable salt thereof.


The invention also provides a method for inhibiting bacterial DNA gyrase in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, IA, IB, IC, or IE or a pharmaceutically acceptable salt.


The invention also provides a compound of formula I, IA, IB, IC, or IE and pharmaceutically acceptable salts thereof for use as a medicament.


The invention also provides the use of a compound of formula I, IA, IB, IC, or IE, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.


The invention also provides the use of a compound of formula I, IA, IB, IC, or IE, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.


The present invention also provides a process for preparing compounds of formula (I) or pharmaceutically-acceptable salts thereof, comprising:


Process a) for compounds of formula (I) wherein W is —C(R7)(R8)—; converting a compound of formula (II):




embedded image



wherein Ra is cyano and Rb is dimethyamino or diethylamino; or Ra and Rb are independently selected from C1-4alkylthio; or Ra and Rb together form 1,3-dithianyl or 1,3-dithiolanyl; into a compound of formula (I);


Process b) for compounds of formula (I) wherein W is —O—; reacting a compound of formula (III):




embedded image



with a compound of formula (IV):




embedded image



Process c) for compounds of formula (I) wherein W is —N(R6)—; reacting a compound of formula (V):




embedded image



with a compound of formula (IV) or an activated acid derivative thereof;


Process d) for compounds of formula (I) wherein W is —C(R7)(R8)—; reacting a compound of formula (VI):




embedded image



wherein L is a displaceable group; with a compound of formula (VII):




embedded image



Process e) for compounds of formula (I) wherein W is —C(R7)(R8)—; reacting a compound of formula (VIII):




embedded image



wherein M is an organometallic group; with a compound of formula (IX):




embedded image



wherein L is a displaceable group;


Process f) reacting a compound of formula (X):




embedded image



with a compound of formula (XI):




embedded image



wherein D is a displaceable group;


Process g) for compounds of formula (I) wherein X is —C(O)—; reacting a compound of formula (X) with a compound of formula (XII):




embedded image



and thereafter if necessary:

  • i) converting a compound of the formula (I) into another compound of the formula (I);
  • ii) removing any protecting groups;
  • iii) forming a pharmaceutically acceptable salt.







DETAILED DESCRIPTION OF THE INVENTION

Definitions


In this specification the term alkyl includes both straight and branched chain alkyl groups. For example, “C1-4alkyl” includes methyl, ethyl, propyl, isopropyl and t-butyl. However references to individual alkyl groups such as propyl are specific for the straight chain version only. An analogous convention applies to other generic terms.


Where optional substituents are chosen from one or more groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.


A “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a —CH2-group can optionally be replaced by a —C(O)— and a ring nitrogen and/or a ring sulphur atom may be optionally oxidised to form the N- or S-oxide(s). In one aspect of the invention a “heterocyclyl” is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a —CH2— group can optionally be replaced by a —C(O)— and a ring sulphur atom may be optionally oxidised to form the S-oxides. In a further aspect of the invention a “heterocyclyl” is an unsaturated, carbon-linked, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen. Examples and suitable values of the term “heterocyclyl” are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, N-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-N-oxide and quinoline-N-oxide. Further examples and suitable values of the term “heterocyclyl” are thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl and pyridinyl.


A “carbocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a —CH2— group can optionally be replaced by a —C(O)—. Particularly “carbocyclyl” is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for “carbocyclyl” include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. A particular example of “carbocyclyl” is phenyl.


An example of “C1-4alkanoyloxy” is acetoxy. Examples of “C1-4alkoxycarbonyl” include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl. Examples of “C1-4alkoxycarbonylamino” include methoxycarbonylamino, ethoxycarbonylamino, n- and t-butoxycarbonylamino Examples of “C1-4alkoxy” include methoxy, ethoxy and propoxy. Examples of “C1-4alkanoylamino” include formamido, acetamido and propionylamino Examples of “C1-4alkylS(O)a wherein a is 0 to 2” include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of “C1-4alkanoyl” include propionyl and acetyl. Examples of “N—(C1-4alkyl)amino” include methylamino and ethylamino Examples of “N,N—(C1-4alkyl)2amino” include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino Examples of “C2-4alkenyl” are vinyl, allyl and 1-propenyl. Examples of “C2-4alkynyl” are ethynyl, 1-propynyl and 2-propynyl. Examples of “N—(C1-4alkyl)sulphamoyl” are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of “N,N—(C1-4alkyl)2sulphamoyl” are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl. Examples of “N—(C1-4alkyl)carbamoyl” are methylaminocarbonyl and ethylaminocarbonyl. Examples of “N,N—(C1-4alkyl)2carbamoyl” are dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of “N—(C1-4alkoxy)carbamoyl” are methoxyaminocarbonyl and isopropoxyaminocarbonyl. Examples of “N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl” are N-methyl-N-methoxyaminocarbonyl and N-methyl-N-ethoxyaminocarbonyl. Examples of “C3-6cycloalkyl” are cyclopropyl, cyclobutyl, cyclopropyl and cyclohexyl. Examples of “N′—(C1-4alkyl)ureido” are N′-methylureido and N′-isopropylureido. Examples of “N′,N′—(C1-4alkyl)2ureido” are N′N′-dimethylureido and N′-methyl-N′-isopropylureido. Examples of “N′—(C1-4alkyl)hydrazinocarbonyl” are N′-methylhydrazinocarbonyl and N′-isopropylhydrazinocarbonyl. Examples of “N′,N′—(C1-4alkyl)2hydrazinocarbonyl” are N′N′-dimethylhydrazinocarbonyl and N′-methyl-N′-isopropylhydrazinocarbonyl. Examples of “C1-4alkylsulphonylamino” include methylsulphonylamino, isopropylsulphonylamino and t-butylsulphonylamino Examples of “C1-4alkylsulphonylaminocarbonyl” include methylsulphonylaminocarbonyl, isopropylsulphonylaminocarbonyl and t-butylsulphonylaminocarbonyl. Examples of “C1-4alkylsulphonyl” include methylsulphonyl, isopropylsulphonyl and t-butylsulphonyl.


A compound of formula (I) may form stable acid or basic salts, and in such cases administration of a compound as a salt may be appropriate, and pharmaceutically acceptable salts may be made by conventional methods such as those described following.


Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, tosylate, α-glycerophosphate, fumarate, hydrochloride, citrate, maleate, tartrate and (less preferably) hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine, tris-(2-hydroxyethyl)amine, tromethamine, N-methyl d-glucamine and amino acids such as glycine or lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-acceptable salt is the sodium salt.


However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.


Within the present invention it is to be understood that a compound of the formula (I) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which inhibits DNA gyrase and/or topoisomeraseIV and is not to be limited merely to any one tautomeric form utilised within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein. The same applies to compound names. It will be appreciated by those skilled in the art that certain compounds of formula (I) contain an asymmetrically substituted carbon and/or sulphur atom, and accordingly may exist in, and be isolated in, optically-active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic or stereoisomeric form, or mixtures thereof, which form possesses properties useful in the inhibition of DNA gyrase and/or topoisomeraseIV, it being well known in the art how to prepare optically-active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, by enzymatic resolution, by biotransformation, or by chromatographic separation using a chiral stationary phase) and how to determine efficacy for the inhibition of DNA gyrase and/or topoisomeraseIV by the standard tests described hereinafter.


It is also to be understood that certain compounds of the formula (I) and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which inhibit DNA gyrase and/or topoisomeraseIV.


Particular and suitable values for certain substituents and groups referred to in this specification are listed below. These values may be used where appropriate with any of the definitions and embodiments disclosed herein. Each stated species represents a particular and independent aspect of the invention.


Referring to a compound of formula I, R1 is C1-4alkyl. R1 is methyl. R1 is halo. R1 is hydrogen.


R2 is methyl. R2 is halo. R2 is fluoro or chloro. R2 is hydrogen. R2 is chloro.


R3 is C1-4alkyl. R3 is methyl. R3 is halo. R3 is fluoro or chloro. R3 is hydrogen. R3 is CN. R3 is C═N—OH. R3 is chloro.


W is —O—. W is —N(R6)—. W is —NH—. W is —C(R7)(R8)—.


X is a direct bond. X is —CH2—. X is —C(O)—. X is S(O)q— (wherein q is 1 or 2).


Ring A is carbocyclyl. Ring A is heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9. Ring A is heterocyclyl. Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl. Ring A is thiazol-2-yl, quinolin-4-yl, benzothiazol-2-yl, pyrimidin-4-yl, pyridin-2-yl or pyridin-4-yl.


R4 is a substituent on carbon and is selected from halo, hydroxy, carboxy, C1-4alkyl, C1-4alkoxy, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkoxycarbonyl or heterocyclyl-R11—; wherein R4 may be optionally substituted on carbon by one or more R12. R12 is selected from hydroxy, C2-4alkenyl, C1-4alkoxy, N—(C1-4alkyl)amino or N,N—(C1-4alkyl)2amino; and R11 is —C(O)—.


Alternatively, R4 is a substituent on carbon and is selected from fluoro, hydroxy, carboxy, methyl, methoxy, propoxy, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N-methyl-N-methoxycarbamoyl, methoxycarbonyl or morpholino-R11—; wherein R4 may be optionally substituted on carbon by one or more R12. R12 is selected from hydroxy, ethenyl, methoxy, N-methylamino or N,N-dimethylamino; and R11 is —C(O)—.


Alternatively, R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N,N-dimethylcarbamoyl, morpholinocarbonyl, N-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, N-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl and carboxy.


Alternatively, R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N,N-dimethylcarbamoyl, morpholinocarbonyl, N-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, N-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy, N-methyl-N-methoxycarbamoyl, N-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfinyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, ethoxy, oxyacetic acid, ethylaminocarbonyloxy, allylaminocarbonyloxy, pyridinylmethoxy, hydroxypropoxy, methoxy(methyl)amino, and azido.


Alternatively R4 is halo, particularly fluoro.


R5 is a substituent on carbon and is selected from halo, carboxy, carbamoyl, C1-4alkyl, C1-4alkoxy, N—(C1-4alkyl)carbamoyl, N—(C1-4alkoxy)carbamoyl or C1-4alkoxycarbonyl; wherein R5 may be optionally substituted on carbon by one or more R12. R12 is selected from C1-4alkoxy or carbocyclyl-R14—; and R14 is a direct bond.


Alternatively, R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxy, N-(isopropyl)carbamoyl, N-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl; wherein R5 may be optionally substituted on carbon by one or more R12. R12 is selected from methoxy or phenyl-R14—; and R14 is a direct bond.


Alternatively, R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(1-methyl-1-phenylethyl)carbamoyl, N-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl.


Alternatively, R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(1-methyl-1-phenylethyl)carbamoyl, N-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl, N-methoxycarbamoyl, formyl, (methoxyimino)methyl, isopropoxycarbonyl, ethoxy, morpholinocarbonyl, hydroxy-1-methylethyl, amino, methoxycarbonylamino, methylsulfonylamino, N-(1-methyl-1-phenylethyl)carbamoyl, N-2-morpholin-4-ylethylcarbamoyl, piperidinocarbonyl, N-methylcarbamoyl, N-2-hydroxyethylcarbamoyl, N-2-methoxyethylcarbamoyl, N-2-hydroxypropylcarbamoyl, N-2-hydroxy-1-methylethylcarbamoyl, N-isoxazolylcarbamoyl, N-2,2-difluoroethylcarbamoyl, N-tetrahydrofuran-3-ylcarbamoyl, N-cyclopropylcarbamoyl, N-1-cyanocyclopropylcarbamoyl, N-2-fluorocyclopropylcarbamoyl, N-2-hydroxy-1,1-dimethylethylcarbamoyl, N-1-cyano-1-methylethylcarbamoyl, N-1-(hydroxymethyl-2-methoxy-2-oxoethylcarbamoyl, N-1,3-dioxolan-2-ylmethylcarbamoyl, N-3-(2-oxopyrrolidin-1-ylpropylcarbamoyl, N-pyridin-2-ylmethylcarbamoyl, N-2-(methylthio)ethylcarbamoyl, N-1,3-oxazol-2-ylmethylcarbamoyl, N-2-fluoroethylcarbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, morpholin-4-ylmethyl, tert-butylaminomethyl, piperidine-1-ylmethyl, (3-hydroxypyrrolidin-1-yl)methyl, (hydroxyimino)methyl, 1,1-difluoromethyl, azidomethyl, cyano(morpholin-4-yl)methyl, N-2-(methylsulfonyl)ethylcarbamoyl, cyano, 1-hydroxy-1-methylethyl, cyclopropylmethyl, N-methylcarbamoyl, N-1-carboxycycloproylcarbamoyl, N-isoxazol-3-ylcarbamoyl, N-prop-2-yn-1 ylcarbamoyl, N-1-carboxy-2-hydroxymethylcarbamoyl, N-[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, N-methoxy-N-methylcarbamoyl, N-2-(methylsulfonyl)ethylcarbamoyl, N-methoxypropylcarbamoyl, and methoxymethyl)ethyl]amino}carbamoyl.


Alternatively R5 is carboxy.


R6 is hydrogen.


n is 1.


m is 1 or 2; wherein the values of R5 may be the same or different. m is 1. m is 2.


In a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:


R1 is selected from C1-4alkyl;


R2 is selected from halo.


R3 is selected from hydrogen or halo;


W is —N(R6)—;


X is a direct bond;


Ring A is heterocyclyl;


R4 is a substituent on carbon and is selected from halo, hydroxy, carboxy, C1-4alkyl, C1-4alkoxy, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkoxycarbonyl or heterocyclyl-R11—; wherein R4 may be optionally substituted on carbon by one or more R12;


R5 is a substituent on carbon and is selected from halo, carboxy, carbamoyl, C1-4alkyl, C1-4alkoxy, N—(C1-4alkyl)carbamoyl, N—(C1-4alkoxy)carbamoyl or C1-4alkoxycarbonyl; wherein R5 may be optionally substituted on carbon by one or more R12;


R6 is hydrogen;


R11 is —C(O)—;


R12 is selected from hydroxy, C2-4alkenyl, C1-4alkoxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino or carbocyclyl-R14—;


R14 is a direct bond;


n is 1; and


m is 1 or 2; wherein the values of R5 may be the same or different;


or a pharmaceutically acceptable salt thereof.


In a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:


R1 is selected from methyl;


R2 is fluoro or chloro;


R3 is selected from hydrogen, fluoro or chloro;


W is —NH—;


X is a direct bond;


Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl;


R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N,N-dimethylcarbamoyl, morpholinocarbonyl, N-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, N-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl and carboxy;


R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(1-methyl-1-phenylethyl)carbamoyl, N-(methoxy)carbamoyl, methoxymethyl)ethyl]amino}carbamoyl, methoxycarbonyl or ethoxycarbonyl;


n is 1; and


m is 1 or 2; wherein the values of R5 may be the same or different; or a pharmaceutically acceptable salt thereof.


In a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:


R1 is selected from hydrogen or methyl;


R2 is hydrogen, bromo, fluoro, chloro, CN, or —C═NOMe;


R3 is selected from hydrogen, fluoro or chloro;


W is —NH—;


X is a direct bond;


Ring A is thiazolyl, quinolinyl, benzothiazolyl, pyrimidinyl or pyridinyl;


R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N,N-dimethylcarbamoyl, morpholinocarbonyl, N-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, N-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy, N-methyl-N-methoxyxcarbamoyl, N-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfinyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, ethoxy, oxyacetic acid, ethylaminocarbonyloxy, allylaminocarbonyloxy, pyridinylmethoxy, hydroxypropoxy, methoxy(methyl)amino, and azido;


R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(1-methyl-1-phenylethyl)carbamoyl, N-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl, N-methoxycarbamoyl, formyl, (methoxyimino)methyl, isopropoxycarbonyl, ethoxy, morpholinocarbonyl, hydroxy-1-methylethyl, amino, methoxycarbonylamino, methylsulfonylamino, N-(1-methyl-1-phenylethyl)carbamoyl, N-2-morpholin-4-ylethylcarbamoyl, piperidinocarbonyl, N-methylcarbamoyl, N-2-hydroxyethylcarbamoyl, N-2-methoxyethylcarbamoyl, N-2-hydroxypropylcarbamoyl, N-2-hydroxy-1-methylethylcarbamoyl, N-isoxazolylcarbamoyl, N2,2-difluoroethylcarbamoyl, N-tetrahydrofuran-3-ylcarbamoyl, N-cyclopropylcarbamoyl, N-1-cyanocyclopropylcarbamoyl, N-2-fluorocyclopropylcarbamoyl, N-2-hydroxy-1,1-dimethylethylcarbamoyl, N-1-cyano-1-methylethylcarbamoyl, N-1-(hydroxymethyl-2-methoxy-2-oxoethylcarbamoyl, N-1,3-dioxolan-2-ylmethylcarbamoyl, N-3-(2-oxopyrrolidin-1-ylpropylcarbamoyl, N-pyridin-2-ylmethylcarbamoyl, N-2-(methylthio)ethylcarbamoyl, N-1,3-oxazol-2-ylmethylcarbamoyl, N-2-fluoroethylcarbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, morpholin-4-ylmethyl, tert-butylaminomethyl, piperidine-1-ylmethyl, (3-hydroxypyrrolidin-1-yl)methyl, (hydroxyimino)methyl, 1,1-difluoromethyl, azidomethyl, cyano(morpholin-4-yl)methyl, N-2-(methylsulfonyl)ethylcarbamoyl, cyano, 1-hydroxy-1-methylethyl, cyclopropylmethyl, N-methylcarbamoyl, N-1-carboxycycloproylcarbamoyl, N-isoxazol-3-ylcarbamoyl, N-prop-2-yn-1 ylcarbamoyl, N-1-carboxy-2-hydroxymethylcarbamoyl, N-[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, N-methoxy-N-methylcarbamoyl, N-2-(methylsulfonyl)ethylcarbamoyl, N-methoxypropylcarbamoyl, and methoxymethyl)ethyl]amino}carbamoyl;


n is 1; and


m is 1 or 2; wherein the values of R5 may be the same or different; or a pharmaceutically acceptable salt thereof.


In a further aspect of the invention, there is provided a compound of the invention which is a compound of formula (IA)




embedded image



wherein:


R1 is selected from hydrogen, halo, cyano, or C1-4alkyl;


R2 is selected from hydrogen, halo, cyano, or C1-4alkyl;


R3 is selected from hydrogen, halo, cyano, C1-4alkyl, or —C═N—OH;


X is a direct bond, —CH2—, —C(O)— or S(O)q— (wherein q is 1 or 2);


Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R9;


R4 and R5 are substituents on carbon and are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, sulfo, formyl, ureido, hydroxyiminomethyl, C1-4alkoxyiminomethyl, N-hydroxyformamido, C1-4hydrazino, hydrazinocarbonyl, N-hydroxyethanimidoyl, amino(hydroxyimino)methyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, N—(C1-4alkoxy)carbamoyl, N′—C1-4alkyl)ureido, N′,N′—(C1-4alkyl)2ureido, N—(C1-4alkyl)-N—(C1-4alkoxy)carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkylsulphonylaminocarbonyl, N′—(C1-4alkyl)hydrazinocarbonyl, N′,N′—(C1-4alkyl)2hydrazinocarbonyl, carbocyclyl-R10— or heterocyclyl-R11—; wherein R4 and R5 independently of each other may be optionally substituted on carbon by one or more R12; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R13;


R6 is hydrogen or C1-4alkyl;


n is 1-4; wherein the values of R4 may be the same or different;


m is 0-4; wherein the values of R5 may be the same or different;


R12 is selected from azido, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, C1-4alkoxy, C1-4alkanoyl, C1-4alkanoyloxy, N—(C1-4alkyl)amino, N,N—(C1-4alkyl)2amino, C1-4alkanoylamino, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)2carbamoyl, C1-4alkylS(O)a wherein a is 0 to 2, C1-4alkoxycarbonyl, N—(C1-4alkyl)sulphamoyl, N,N—(C1-4alkyl)2sulphamoyl, C1-4alkylsulphonylamino, C1-4alkoxycarbonylamino, carbocyclyl-R14— or heterocyclyl-R15—; wherein R12 independently of each other may be optionally substituted on carbon by one or more R16; and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from R17;


R9, R13 and R17 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;


R10, R11, R14 and R15 are independently selected from a direct bond, —O—, —N(R18)—, —C(O)—, —N(R19)C(O)—, —C(O)N(R20)—, —S(O)p—, —SO2N(R21)— or —N(R22)SO2—; wherein R18, R19, R20, R21 and R22 are independently selected from hydrogen or C1-4alkyl and p is 0-2;


R16 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, ethenyl, ethynyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl;


or a pharmaceutically acceptable salt thereof.


In a further aspect of the invention, there is provided a compound of formula (IA) which is a compound of formula (IB):




embedded image



wherein:


R4 is a substituent on carbon and is selected from methoxy, hydroxy, methoxycarbonyl, fluoro, allyloxy, propoxy, N,N-dimethylcarbamoyl, morpholinocarbonyl, N-ethylcarbamoyl, N-(2-hydroxyethyl)carbamoyl, dimethylaminomethyl, N-methyl-N-methoxycarbamoyl, methoxymethyl, methylaminomethyl, carboxy, N-methyl-N-methoxyxcarbamoyl, N-hydroxyethylcarbamoyl, hydroxymethyl, (methylthio)methyl, (methylsulfinyl)methyl, (methylsulfonyl)methyl, benzyloxy, propynyloxy, methoxyethoxy, methoxypropoxy, chloro, methyl, cyclopropylmethoxy, thiazolylmethoxy, ethoxy, oxyacetic acid, ethylaminocarbonyloxy, allylaminocarbonyloxy, pyridinylmethoxy, hydroxypropoxy, methoxy(methyl)amino, and azido;


R5 is a substituent on carbon and is selected from chloro, carboxy, carbamoyl, methyl, methoxymethyl, methoxy, N-(1-methyl-1-phenylethyl)carbamoyl, N-(methoxy)carbamoyl, methoxycarbonyl or ethoxycarbonyl, N-methoxycarbamoyl, formyl, (methoxyimino)methyl, isopropoxycarbonyl, ethoxy, morpholinocarbonyl, hydroxy-1-methylethyl, amino, methoxycarbonylamino, methylsulfonylamino, N-(1-methyl-1-phenylethyl)carbamoyl, N-2-morpholin-4-ylethylcarbamoyl, piperidinocarbonyl, N-methylcarbamoyl, N-2-hydroxyethylcarbamoyl, N-2-methoxyethylcarbamoyl, N-2-hydroxypropylcarbamoyl, N-2-hydroxy-1-methylethylcarbamoyl, N-isoxazolylcarbamoyl, N2,2-difluoroethylcarbamoyl, N-tetrahydrofuran-3-ylcarbamoyl, N-cyclopropylcarbamoyl, N-1-cyanocyclopropylcarbamoyl, N-2-fluorocyclopropylcarbamoyl, N-2-hydroxy-1,1-dimethylethylcarbamoyl, N-1-cyano-1-methylethylcarbamoyl, N-1-(hydroxymethyl-2-methoxy-2-oxoethylcarbamoyl, N-1,3-dioxolan-2-ylmethylcarbamoyl, N-3-(2-oxopyrrolidin-1-ylpropylcarbamoyl, N-pyridin-2-ylmethylcarbamoyl, N-2-(methylthio)ethylcarbamoyl, N-1,3-oxazol-2-ylmethylcarbamoyl, N-2-fluoroethylcarbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, morpholin-4-ylmethyl, tert-butylaminomethyl, piperidine-1-ylmethyl, (3-hydroxypyrrolidin-1-yl)methyl, (hydroxyimino)methyl, 1,1-difluoromethyl, azidomethyl, cyano(morpholin-4-yl)methyl, N-2-(methylsulfonyl)ethylcarbamoyl, cyano, 1-hydroxy-1-methylethyl, cyclopropylmethyl, N-methylcarbamoyl, N-1-carboxycycloproylcarbamoyl, N-isoxazol-3-ylcarbamoyl, N-prop-2-yn-1 ylcarbamoyl, N-1-carboxy-2-hydroxymethylcarbamoyl, N-[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl, N-(2-hydroxy-2-methylpropyl)carbamoyl, N-methoxy-N-methylcarbamoyl, N-2-(methylsulfonyl)ethylcarbamoyl, N-methoxypropylcarbamoyl, and methoxymethyl)ethyl]amino}carbamoyl;


n is 1; wherein the values of R4 may be the same or different; and


m is 1 or 2; wherein the values of R5 may be the same or different.


In a further aspect of the invention, there is provided a compound of formula (IB) which is a compound of formula (IC).




embedded image


In a further aspect of the invention, there is provided a compound of formula (IC):




embedded image



wherein:


Ring A is heterocyclyl; wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl.


In a further aspect of the invention, there is provided a compound of formula (IC) which is a compound of formula (IE):




embedded image



wherein:


Y is N—H, N—C1-4alkyl, S, or O;


R5a is H or as defined for R5;


R5b is H or as defined for R5; or


R5a and R5b taken together with the carbons to which they are attached form a 6-membered carbocyclyl ring substituted by one or two groups selected from R5 which may be the same or different.


In a further aspect of the invention, there is provided a compound of formula (IE) which is a compound of formula (IF):




embedded image


Particular compounds of the invention are the compounds of the Examples, each of which provides a further independent aspect of the invention. In further aspects, the present invention also comprises any two or more compounds of the Examples.


In one embodiment of the invention are provided compounds of formula (I), in an alternative embodiment are provided pharmaceutically-acceptable salts of compounds of formula (I).


In a further aspect the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically-acceptable salt thereof.


Thus, the present invention also provides that the compounds of the formula (I) and pharmaceutically-acceptable salts thereof, can be prepared by a process as follows (wherein the variables are as defined above unless otherwise stated)


Process a) for compounds of formula (I) wherein W is —C(R7)(R8)—; converting a compound of formula (II):




embedded image



wherein Ra is cyano and Rb is dimethyamino or diethylamino; or Ra and Rb are independently selected from C1-4alkylthio; or Ra and Rb together form 1,3-dithianyl or 1,3-dithiolanyl; into a compound of formula (I);


Process b) for compounds of formula (I) wherein W is —O—; reacting a compound of formula (III):




embedded image



with a compound of formula (IV):




embedded image



Process c) for compounds of formula (I) wherein W is —N(R6)—; reacting a compound of formula (V):




embedded image



with a compound of formula (IV) or an activated acid derivative thereof;


Process d) for compounds of formula (I) wherein W is —C(R7)(R8)—; reacting a compound of formula (VI):




embedded image



wherein L is a displaceable group; with a compound of formula (VII):




embedded image



Process e) for compounds of formula (I) wherein W is —C(R7)(R8)—; reacting a compound of formula (VIII):




embedded image



wherein M is an organometallic group; with a compound of formula (IX):




embedded image



wherein L is a displaceable group;


Process f) reacting a compound of formula (X):




embedded image



with a compound of formula (XI):




embedded image



wherein D is a displaceable group;


Process g) for compounds of formula (I) wherein X is —C(O)—; reacting a compound of formula (X) with a compound of formula (XII):




embedded image



and thereafter if necessary:

  • i) converting a compound of the formula (I) into another compound of the formula (I);
  • ii) removing any protecting groups;
  • iii) forming a pharmaceutically acceptable salt.


L is a displaceable group. Suitable values for L include halo, for example chloro and bromo, pentafluorophenoxy and 2,5-oxopyrrolidin-1-yloxy.


D is a displaceable group. Suitable values for D include halo, for example chloro, bromo and iodo, tosylate and mesylate.


M is an organometallic group, suitable values for M include organocuprates, for example CuLi, organozincs, Zn, or a Grignard reagent for example MgG where G is halo for example chloro.


Specific reaction conditions for the above reaction are as follows.


Process a) Compounds of formula (II) may be converted into compounds of formula (I):




  • (i) where Ra is cyano and Rb is dimethyamino or diethylamino; in the presence of a base for example sodium hydroxide, in a suitable solvent for example aqueous methanol at room temperature.

  • (ii) wherein or Ra and Rb are independently selected from C1-4alkylthio; or Ra and Rb together form 1,3-dithianyl or 1,3-dithiolanyl; in the presence of a reagent such as a mercury, copper or silver salt for example Hg(ClO4)2, CuCl2 or AgNO3/Ag2O in the presence of a suitable solvent for example methanol, acetone or ethanol from a temperature ranging from room temperature to reflux.



Compounds of formula (II) may be prepared according to Scheme 1:




embedded image



wherein Pg is a hydroxy protecting group as defined hereinbelow; and D is a displaceable group as defined hereinabove.


Deprotection of hydroxy protecting groups are well known in the art. Examples of such deprotections are given hereinbelow.


FGI stands for Functional Group Interconversion. In the above scheme such conversions between a hydroxy group and a D group are well known in the art and are well within the capabilities of a person skilled in the art.


Compounds of formula (IIa) and (IId) are known in the literature, or they are prepared by standard processes known in the art.


Process b) Compounds of formula (III) and (IV) may be reacted together may be reacted together in the presence of a coupling reagent, for example dicyclohexylcarbodiimide or EDC, in a suitable solvent, for example dichloromethane, THF or diethylether.


Compounds of formula (III) may be prepared according to Scheme 2:




embedded image



wherein Pg is a hydroxy protecting group as defined hereinbelow.


Deprotection of hydroxy protecting groups are well known in the art. Examples of such deprotections are given hereinbelow.


Compounds of formula (IIIa) and (IV) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.


Process c) Compounds of formula (V) and (IV) may be coupled together in the presence of a suitable coupling reagent. Standard peptide coupling reagents known in the art can be employed as suitable coupling reagents, or for example carbonyldiimidazole and dicyclohexyl-carbodiimide, optionally in the presence of a catalyst such as dimethylaminopyridine or 4-pyrrolidinopyridine, optionally in the presence of a base for example triethylamine, pyridine, or 2,6-di-alkyl-pyridines such as 2,6-lutidine or 2,6-di-tert-butylpyridine. Suitable solvents include dimethylacetamide, dichloromethane, benzene, tetrahydrofuran and dimethylformamide. The coupling reaction may conveniently be performed at a temperature in the range of −40 to 40° C.


Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of −40 to 40° C.


Compounds of formula (V) may be prepared according to Scheme 3:




embedded image



wherein Pg is a amino protecting group as defined hereinbelow. The skilled reader will appreciate that where R6 is hydrogen, this hydrogen also needs protecting by way of a suitable protecting group.


Deprotection of amino protecting groups are well known in the art. Examples of such deprotections are given hereinbelow.


Compounds of formula (Va) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.


Process d) Compounds of formula (VI) and (VII) may be reacted in a suitable solvent such a DCM or 1,2-dichloroethane, optionally in the presence of a Lewis acid, for example AlCl3, from 0° C. to room temperature.


Compounds of formula (VI) may be prepared according to Scheme 4:




embedded image



wherein RaOC(O) is an ester group.


Suitable values for Ra include C1-6alkyl. Deprotection of the Ra carboxy protecting group may be achieved under standard conditions, for example acid or base hydrolysis, such as those conditions give hereinbelow.


FGI stands for Functional Group Interconversion. In the above scheme such conversions between an acid group and a —C(O)L group are well known in the art and are well within the capabilities of a person skilled in the art.


Compounds of formula (VIa) and (VII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.


Process e) Compounds of formula (VIII) and (IX) may be reacted in a suitable aprotic solvent such as THF or ether, at temperatures in the range of −78° C. to 0° C.


Compounds of formula (VIII) may be prepared from compounds of formula (IIc) under standard conditions known in the art. For example where M is an organocuprous reagent such compounds could be prepared according to Scheme 5:




embedded image


Compounds of formula (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.


Process f) Compounds of formula (X) and (XI) may be reacted in a suitable solvent such as DMF, N-methylpyrrolidinone or dimethylacetamide in the presence of a base such as triethylamine or diisopropylethylamine under thermal conditions or a microwave reactor.


Compounds of formula (X) may be prepared according to Scheme 6:




embedded image



wherein M is an organometallic group as defined hereinabove.


Compounds of formula (Xa), (Xb) and (XI) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.


Process g) Compounds of formula (X) and (XII) may be coupled together under the conditions outlined in Process c).


Compounds of formula (XII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.


The formation of a pharmaceutically-acceptable salt is within the skill of an ordinary organic chemist using standard techniques.


It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. The reagents used to introduce such ring substituents are either commercially available or are made by processes known in the art.


Introduction of substituents into a ring may convert one compound of the formula (I) into another compound of the formula (I). Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents, oxidation of substituents, esterification of substituents, amidation of substituents, formation of heteroaryl rings. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of alkoxides, diazotization reactions followed by introduction of thiol group, alcohol group, halogen group. Examples of modifications include; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.


The skilled organic chemist will be able to use and adapt the information contained and referenced within the above references, and accompanying Examples therein and also the Examples herein, to obtain necessary starting materials, and products. If not commercially available, the necessary starting materials for the procedures such as those described above may be made by procedures which are selected from standard organic chemical techniques, techniques which are analogous to the synthesis of known, structurally similar compounds, or techniques which are analogous to the above described procedure or the procedures described in the examples. It is noted that many of the starting materials for synthetic methods as described above are commercially available and/or widely reported in the scientific literature, or could be made from commercially available compounds using adaptations of processes reported in the scientific literature. The reader is further referred to Advanced Organic Chemistry, 4th Edition, by Jerry March, published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents.


It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in compounds. The instances where protection is necessary or desirable are known to those skilled in the art, as are suitable methods for such protection. Conventional protecting groups may be used in accordance with standard practice (for illustration see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991).


Examples of a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, a silyl group such as trimethylsilyl or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively a silyl group such as trimethylsilyl may be removed, for example, by fluoride or by aqueous acid; or an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation in the presence of a catalyst such as palladium-on-carbon.


A suitable protecting group for an amino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine or 2-hydroxyethylamine, or with hydrazine.


A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.


The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art, or they may be removed during a later reaction step or work-up.


When an optically active form of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using an optically active starting material (formed, for example, by asymmetric induction of a suitable reaction step), or by resolution of a racemic form of the compound or intermediate using a standard procedure, or by chromatographic separation of diastereoisomers (when produced). Enzymatic techniques may also be useful for the preparation of optically active compounds and/or intermediates.


Similarly, when a pure regioisomer of a compound of the invention is required, it may be obtained by carrying out one of the above procedures using a pure regioisomer as a starting material, or by resolution of a mixture of the regioisomers or intermediates using a standard procedure.


Enzyme Potency Testing Methods


Compounds were tested for inhibition of GyrB ATPase activity using an ammonium molybdate/malachite green-based phosphate detection assay (Lanzetta, P. A., L. J. Alvarez, P. S. Reinach, and O. A. Candia, 1979, 100: 95-97). Assays were performed in multiwell plates in 100 μl reactions containing: 50 mM TRIS buffer pH 7.5, 75 mM ammonium acetate, 5.5 mM magnesium chloride, 0.5 mM ethylenediaminetetraacetic acid, 5% glycerol, 1 mM 1,4-Dithio-DL-threitol, 200 nM bovine serum albumin, 16 μg/ml sheared salmon sperm DNA, 4 nM E. coli GyrA, 4 nM E. coli GyrB, 250 μM ATP, and compound in dimethylsulfoxide. Reactions were quenched with 150 μl of ammonium molybdate/malachite green detection reagent containing 1.2 mM malachite green hydrochloride, 8.5 mM ammonium molybdate tetrahydrate, and 1 M hydrochloric acid. Plates were read in an absorbance plate reader at 625 nm and percent inhibition values were calculated using dimethylsulfoxide (2%)-containing reactions as 0% inhibition and novobiocin-containing (2 μM) reactions as 100% inhibition controls. Compounds were tested for inhibition of topoisomeraseIV ATPase activity as described above for GyrB except the 100 μl reactions contained the following: 20 mM TRIS buffer pH 8, 50 mM ammonium acetate, 8 mM magnesium chloride, 5% glycerol, 5 mM 1,4-Dithio-DL-threitol, 0.005% Brij-35, 5 μg/ml sheared salmon sperm DNA, 10 nM E. coli GyrA, 10 nM E. coli GyrB, 160 μM ATP, and compound in dimethylsulfoxide. Compound potency was based on IC50 measurements determined from reactions performed in the presence of 10 different compound concentrations.


Compounds of the Examples generally have IC50 values of <20 μg/ml.


Bacterial Susceptibility Testing Methods


Compounds were tested for antimicrobial activity by susceptibility testing in liquid media. Compounds were dissolved in dimethylsulfoxide and tested in 10 doubling dilutions in the susceptibility assays. The organisms used in the assay were grown overnight on suitable agar media and then suspended in a liquid medium appropriate for the growth of the organism. The suspension was a 0.5 McFarland and a further 1 in 10 dilution was made into the same liquid medium to prepare the final organism suspension in 100 μL. Plates were incubated under appropriate conditions at 37 degrees C. for 24 hrs prior to reading. The Minimum Inhibitory Concentration was determined as the lowest drug concentration able to reduce growth by 80% or more.


Example 48 had an MIC of 0.13 μg/ml against Streptococcus pneumoniae. Other examples are provided in the following table.

















Example
MIC
MIC
MIC
MIC



No.
HIN446
MCA445
SPN548
SAU516
MIC EFM073




















333
4
0.13
0.063
2
0.5


60
4
0.25
2
2
8


315
2
0.13
0.5
4
4


345
0.25
0.031
0.03
0.5
0.13


294
0.031
0.001
0.0039
0.031
0.016









According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically-acceptable salt thereof for use in a method of treatment of the human or animal body by therapy.


We have found that compounds of the present invention inhibit bacterial DNA gyrase and topoisomeraseIV and are therefore of interest for their antibacterial effects.


According to a further feature of the present invention there is provided a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt thereof.


According to a further feature of the invention there is provided a method for inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.


According to a further feature of the invention there is provided a method of treating a bacterial infection in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined hereinbefore.


A further feature of the present invention is a compound of formula (I) and pharmaceutically acceptable salts thereof for use as a medicament. Suitably the medicament is an antibacterial agent.


According to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.


According to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal such as a human being.


Thus according to a further aspect of the invention there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.


According to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the production of an anti-bacterial effect in a warm-blooded animal such as a human being.


According to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in a warm-blooded animal such as a human being.


Thus according to a further aspect of the invention there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection in a warm-blooded animal such as a human being.


In order to use a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, (hereinafter in this section relating to pharmaceutical composition “a compound of this invention”) for the therapeutic (including prophylactic) treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.


Therefore in another aspect the present invention provides a pharmaceutical composition that comprises a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.


According to a further aspect of the invention there is provided a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in producing an anti-bacterial effect in an warm-blooded animal, such as a human being.


According to a further aspect of the invention there is provided a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in inhibition of bacterial DNA gyrase and/or topoisomeraseIV in an warm-blooded animal, such as a human being.


According to a further aspect of the invention there is provided a pharmaceutical composition that comprises a compound of formula (I) as defined hereinbefore or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier for use in the treatment of a bacterial infection in an warm-blooded animal, such as a human being.


The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).


The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.


Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal tract, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.


Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.


Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation products of an alkylene oxide with fatty acids (for example polyoxethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).


Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.


Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.


The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.


Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.


The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.


Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.


For further information on formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.


The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.


In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain or be co-administered (simultaneously, sequentially or separately) with one or more known drugs selected from other clinically useful antibacterial agents (for example, macrolides, quinolones, β-lactams or aminoglycosides) and/or other anti-infective agents (for example, an antifungal triazole or amphotericin). These may include carbapenems, for example meropenem or imipenem, to broaden the therapeutic effectiveness. Compounds of this invention may also contain or be co-administered with bactericidal/permeability-increasing protein (BPI) products or efflux pump inhibitors to improve activity against gram negative bacteria and bacteria resistant to antimicrobial agents.


As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily dose in the range of 1-50 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.


In addition to its use in therapeutic medicine, compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in-vitro and in-vivo test systems for the evaluation of the effects of inhibitors of DNA gyrase in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.


In the above other, pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and particular embodiments of the compounds of the invention described herein also apply.


EXAMPLES

The invention is now illustrated but not limited by the following Examples in which unless otherwise stated:—

  • (i) evaporations were carried out by rotary evaporation in-vacuo and work-up procedures were carried out after removal of residual solids by filtration;
  • (ii) operations were carried out at ambient temperature, that is typically in the range 18-26° C. and without exclusion of air unless otherwise stated, or unless the skilled person would otherwise work under an inert atmosphere;
  • (iii) column chromatography (by the flash procedure) was used to purify compounds and was performed on Merck Kieselgel silica (Art. 9385) unless otherwise stated;
  • (iv) yields are given for illustration only and are not necessarily the maximum attainable;
  • (v) the structure of the end-products of the invention were generally confirmed by NMR and mass spectral techniques [proton magnetic resonance spectra is quoted and was generally determined in DMSO-d6 unless otherwise stated using a Bruker DRX-300 spectrometer operating at a field strength of 300 MHz. Chemical shifts are reported in parts per million downfield from tetramethysilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet; d, doublet; AB or dd, doublet of doublets; dt, doublet of triplets; dm, doublet of multiplets; t, triplet, m, multiplet; br, broad; fast-atom bombardment (FAB) mass spectral data were generally obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected] or using Agilent 1100 series LC/MSD equipped with Sedex 75ELSD, run in APCI mode and, where appropriate, either positive ion data or negative ion data were collected; optical rotations were determined at 589 nm at 20° C. using a Perkin Elmer Polarimeter 341; reverse phase HPLC was carried out using YMC Pack ODS-AQ (100×20 mmID, S-5μ particle size, 12 nm pore size);
  • (vi) each intermediate was purified to the standard required for the subsequent stage and was characterised in sufficient detail to confirm that the assigned structure was correct; purity was assessed by HPLC, TLC, or NMR and identity was determined by infra-red spectroscopy (IR), mass spectroscopy or NMR spectroscopy as appropriate;
  • (vii) in which the following abbreviations may be used:—


DMF is N,N-dimethylformamide; DMA is N,N-dimethylacetamide; TLC is thin layer chromatography; HPLC is high pressure liquid chromatography; DMSO is dimethylsulfoxide; CDCl3 is deuterated chloroform; MS is mass spectroscopy; APCI is atmospheric pressure chemical ionisation; EtOAc is ethyl acetate; MeOH is methanol; DIEA is diisopropylethylamine; TFA is trifluoroacetic acid; HATU is N—[(dimethylamino)-1H,2,3-triazolo[4,5-b-]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide; HOAT is 1-hydroxy-7-azabenzotriazole; NMP is N-methylpyrrolidinone; THF is tetrahydrofuran; EtOH is ethanol; LCMS is liquid chromatography/mass spectrometry; DCM is dichloromethane;

  • (viii) temperatures are quoted as ° C.;
  • (ix) Smith Microwave Synthesizer refers to an equipment that uses microwave energy to heat organic reactions in a short period of time; it was used according to the manufacturers instruction and was obtained from Personal Chemistry Uppsala AB;
  • (x) Kugelrohr distillation refers to a piece of equipment that distils liquids and heats sensitive compounds using air-bath oven temperature; it was used according to the manufacturers instruction and was obtained from Buchi, Switzerland or Aldrich, Milwaukee, USA;
  • (xi) Where cis(±) or trans(±) is used it is to be understood that this refers to a racemic mixture of the cis or the trans isomers, (−) or (+) refers to the single enantiomer as does R,R or S,S where quoted. Rotations were measured for the first chiral compound in the synthetic scheme (see for example Intermediates 57 and 58) by measuring the rotation of the effluent from the chiral column, using a Perkin Elmer Polarimeter 341, at the point at which the enantiomer eluted, the nomenclature cis(−) or cis (+) was then continued for all the compounds in the synthesis (for example, Example 42 is the final compound in the synthesis which started from Intermediate 57); and
  • (xii) GCMS is Gas phase chromatography (model 6890N) with Mass Spectrometer (model 5973) manufactured by Agilent and was used according to manufacturers instructions.


Example 1
Cis(±)methyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate



embedded image



Method 1


Cis(±)3,4-dichloro-N-(3-methoxypiperidin-4-yl)-5-methyl-1H-pyrrole-2-carboxamide (Intermediate 50; 380 mg), methyl 2-bromo-1,3-thiazole-5-carboxylate (276 mg), were dissolved in anhydrous DMA (5 ml). DIEA (216 μl) was added and the mixture was heated at 120° C. for 7 hours (h). The mixture was diluted with EtOAc, washed well with citrate buffer, water, brine, and dried over Na2SO4. The organic phase was concentrated in vacuo to give the title compound as a brown solid (337 mg).


Method 2


Alternatively the title compounds were prepared using a Smith Microwave Synthesizer by subjecting the reaction mixture to single-mode microwave at 150° C. for 30 minutes (min.) or until the reaction is complete as judged by LCMS, using polar aprotic solvent such as DMA, NMP or 1-butyl-3-methyl imidazolium-tetrafluoroborate as reaction solvents. MS (ES) MH+: 447 for C17H20Cl2N4O4S; NMR: 1.65 (m, 2H), 2.09 (s, 3H), 3.07 (m, 3H), 3.48 (m, 1H), 3.63 (s, 3H), 3.86 (m, 1H), 4.15 (m, 2H), 6.91 (d, 1H), 7.45 (s, 1H), 11.19 (s, 1H).


Examples 2-33

The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated.















Ex
Compound
Data
SM


















2
methyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 447 for
Intermediate 51 and



dichloro-5-methyl-1H-
C17H20Cl2N4O4S; NMR: 1.87
methyl 2-bromo-1,3-



pyrrol-2-
(m, 2H), 2.05 (m, 2H), 2.27 (s,
thiazole-5-



yl)carbonyl]amino}-3-
3H), 3.01 (m, 2H), 3.25 (s,
carboxylate



methoxypiperidin-1-yl)-1,3-
3H), 3.65 (m, 1H), 3.83 (s,



thiazole-5-carboxylate
3H), 4.12 (m, 1H), 4.46 (m,




2H), 7.40 (d, 1H), 8.00 (s, 1H),




12.38 (s, 1H)


3
methyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH+: 447 for
Intermediate 52 and



dichloro-5-methyl-1H-
C17H20Cl2N4O4S; NMR: 1.89
methyl 2-bromo-1,3-



pyrrol-2-
(m, 2H), 2.11 (m, 2H), 2.23 (s,
thiazole-5-



yl)carbonyl]amino}-3-
3H), 3.33 (m, 2H), 3.46 (s,
carboxylate



methoxypiperidin-1-yl)-1,3-
3H), 3.59 (m, 1H), 3.85 (s,



thiazole-5-carboxylate
3H), 4.09 (m, 1H), 4.46 (m,




2H), 7.31 (d, 1H), 7.92 (s, 1H),




12.30 (s, 1H)


4
Cis(±)methyl 2-(4-{[(3,4-
MS (ES) MH+: 414 for
Intermediate 56 and



difluoro-5-methyl-1H-
C17H20F2N4O4S; NMR: 1.72
methyl 2-bromo-1,3-



pyrrol-2-
(m, 2H), 1.79 (s, 3H), 2.3 (m,
thiazole-5-



yl)carbonyl]amino}-3-
2H), 3.45 (s, 3H), 3.61 (s, 1H),
carboxylate



methoxypiperidin-1-yl)-1,3-
3.8 (s, 3H), 4.08 (m, 1H), 4.41



thiazole-5-carboxylate
(m, 2H), 6.88 (d, 1H), 8.00 (s,




1H), 11.5 (brs, 1H)





5
Cis(±)methyl 2-(4-{[(3,4- dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}-3- propoxypiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 475 for C19H24Cl2N4O4S; NMR: 0.89 (m, 3H), 1.54 (m, 2H), 1.87 (m, 2H), 2.26 (s, 3H), 3.37 (m, 2H), 3.71 (m, 2H), 3.81 (s, 3H), 4.15 (m, 1H), 4.42 (m, 2H), 7.18 (d, 1H), 7.98 (s, 1H), 12.29 (s, 1H)
Intermediate 53 and methyl 2-bromo-1,3- thiazole-5- carboxylate





6
Cis(±)methyl 2-(3-
MS (ES) MH+: 473 for
Intermediate 54 and



(allyloxy)-4-{[(3,4-
C19H22Cl2N4O4S; NMR: 1.94
methyl 2-bromo-1,3-



dichloro-5-methyl-1H-
(m, 2H), 2.23 (s, 3H), 3.56 (m,
thiazole-5-



pyrrol-2-
2H), 3.58 (m, 2H), 3.84 (s,
carboxylate



yl)carbonyl]amino}piperidin-
3H), 4.07 (m, 2H), 4.21 (m,



1-yl)-1,3-thiazole-5-
1H), 4.46 (m, 2H), 5.37 (m,



carboxylate
2H), 5.95 (m, 1H), 7.29 (d,




1H), 7.96 (s, 1H), 12.32 (s, 1H)


7
Cis(±)ethyl 4-(3-(allyloxy)-
MS (ES) MH+: 531 for
Intermediate 54 and



4-{[(3,4-dichloro-5-methyl-
C26H28Cl2N4O4
Intermediate 10



1H-pyrrol-2-



yl)carbonyl]amino}piperidin-



1-yl)quinoline-2-



carboxylate


8
Cis(±)ethyl 4-(4-{[(3,4-
MS (ES) MH+: 533 for
Intermediate 53 and



dichloro-5-methyl-1H-
C26H30Cl2N4O4
Intermediate 10



pyrrol-2-



yl)carbonyl]amino}-3-



propoxypiperidin-1-



yl)quinoline-2-carboxylate


9
Cis(±)methyl-2-(4-{[(3,4-
MS (ES) MH+: 435, 437 for
Intermediate 32 and



dichloro-5-methyl-1H-
C16H17Cl2FN4O3S; NMR:
methyl 2-bromo-1,3-



pyrrol-2-
1.77-1.79 (m, 2H), 2.12 (s,
thiazole-5-



yl)carbonyl]amino}-3-
3H), 3.25-3.27 (m, 2H), 3.49-
carboxylate



fluoropiperidin-1-yl)-1,3-
3.62 (dd, 1H), 3.68 (s, 3H),



thiazole-5-carboxylate
3.95 (m, 1H), 4.00-4.24 (m,




1H), 4.82-4.99 (m, 1H), 7.21




(d, 1H), 7.79 (s, 1H), 12.05




(brs, 1H)





10
Trans(±)methyl-2-(4-{[(3,4-
MS (ES) MH+: 435, 437 for
Intermediate 34 and



dichloro-5-methyl-1H-
C16H17Cl2FN4O3S
methyl 2-bromo-1,3-



pyrrol-2-

thiazole-5-



yl)carbonyl]amino}-3-

carboxylate



fluoropiperidin-1-yl)-1,3-



thiazole-5-carboxylate





embedded image







11
methyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH+: 435, 437 for
Intermediate 33 and



dichloro-5-methyl-1H-
C16H17Cl2FN4O3S; NMR:
methyl 2-bromo-1,3-



pyrrol-2-
1.77-1.79 (m, 2H), 2.12 (s,
thiazole-5-



yl)carbonyl]amino}-3-
3H), 3.25-3.27 (m, 2H), 3.49-
carboxylate



fluoropiperidin-1-yl)-1,3-
3.62 (dd, 1H), 3.68 (s, 3H),



thiazole-5-carboxylate
3.95 (m, 1H), 4.00-4.24 (m,




1H), 4.82-4.99 (m, 1H), 7.21




(d, 1H), 7.79 (s, 1H), 12.05




(brs, 1H)


12
Cis(±)ethyl 2-(4-{[(3,4-
MS (ES) MH+: 499, 501 for
Intermediate 32 and



dichloro-5-methyl-1H-
C16H17Cl2FN4O3S
ethyl 2-bromo-1,3-



pyrrol-2-

benzothiazole-7-



yl)carbonyl]amino}-3-

carboxylate (U.S. Pat.



fluoropiperidin-1-yl)-1,3-

No. 5,770,758)



benzothiazole-7-



carboxylate


13
Cis(±)Ethyl 2-(4-{[(3,4-
MS (ES) MH+: 511, 513 for
Intermediate 50 and



dichloro-5-methyl-1H-
C22H24Cl2N4O4S; NMR: 1.45
ethyl 2-bromo-1,3-



pyrrol-2-
(t, 3H), 1.87 (m, 2H), 3.44 (s,
benzothiazole-7-



yl)carbonyl]amino}-3-
3H), 3.46 (m, 2H), 3.67 (m,
carboxylate (U.S. Pat.



methoxypiperidin-1-yl)-1,3-
1H), 4.23 (m, 1H), 4.28 (m,
No. 5,770,758)



benzothiazole-7-
1H), 4.36 (m, 1H), 4.47 (q,



carboxylate
2H), 7.27 (d, 1H), 7.50 (t, 1H),




7.77 (t, 1H0, 12.26 (s, 1H)


14
Cis(±)Methyl 2-chloro-6-
MS (ES) MH+: 477, 479 for
Intermediate 50 and



(4-{[(3,4-dichloro-5-
C18H20Cl3N5O4; NMR: 1.62
methyl 2,6-



methyl-1H-pyrrol-2-
(m, 1H), 1.77 (m, 1H), 2.18 (s,
dichloropyrimidine-



yl)carbonyl]amino}-3-
3H), 3.15 (m, 1H), 3.28 (s,
4-carboxylate



methoxypiperidin-1-
3H), 3.56 (m, 1H), 3.87 (s,



yl)pyrimidine-4-carboxylate
3H), 4.11 (m, 1H), 4.30 (m,




1H), 5.00 (m, 1H), 7.15 (m,




1H0, 7.36-7.48 (m, 1H), 12.16




(m, 1H)





15
Cis(±)Ethyl 2-(4-{[(4- chloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-4-carboxylate embedded image
MS (ES) MH+: 427, 429 for C18H23ClN4O3; NMR: 1.27 (t, 3H), 1.60 (m, 1H), 1.93 (m, 1H), 2.14 (s, 3H), 3.23 (m, 1H), 3.28 (s, 3H), 3.43 (m, 1H), 3.53 (m, 1H), 3.85 (m, 1H), 4.12 (m, 1H), 4.24 (m, 2H), 6.89 (s, 1H)
Intermediate 55 and ethyl 2-bromo-1,3- thiazole-4- carboxylate





16
Cis(±)ethyl 2-(4-{[(3,4-
MS (ES) (M + H): 461, 463 for
Intermediate 50 and



dichloro-5-methyl-1H-
C18H22Cl2N4O4S
ethyl 2-bromo-1,3-



pyrrol-2-

thiazole-4-



yl)carbonyl]amino}-3-

carboxylate



methoxypiperidin-1-yl)-1,3-



thiazole-4-carboxylate


17
Cis(±)ethyl 4-(4-{[(3,4-
MS (ES) MH+: 455 for
Intermediate 50 and



dichloro-5-methyl-1H-
C20H24Cl2N4O4
ethyl 4-



pyrrol-2-

chloropyridine-2-



yl)carbonyl]amino}-3-

carboxylate (WO



methoxypiperidin-1-

2004007657)



yl)pyridine-2-carboxylate


18
Cis(±)methyl 2-[4-{[(3,4-
MS (ES) MH+: 461 for
Intermediate 74 and



dichloro-5-methyl-1H-
C18H22Cl2N4O4S
methyl-2-



pyrrol-2-

bromothiazole-5-



yl)carbonyl]amino}-3-

carboxylate



(methoxymethyl)piperidin-



1-yl]-1,3-thiazole-5-



carboxylate


19
Cis(±)methyl-2-{4-{[(3,4-
MS (ES) MH+: 460 for
Intermediate 75 and



dichloro-5-methyl-1H-
C18H23Cl2N5O3S
methyl-2-



pyrrol-2-

bromothiazole-5-



yl)carbonyl]amino}-3-

carboxylate



[(methylamino)methyl]



piperidin-1-yl}-1,3-thiazole-5-



carboxylate





20
Cis(±)methyl 2-{4-{[(3,4-
MS (ES) MH+: 474 for
Intermediate 76 and



dichloro-5-methyl-1H-
C19H25Cl2N5O3S
methyl-2-



pyrrol-2-

bromothiazole-5-



yl)carbonyl]amino}-3-

carboxylate



[(dimethylamino)methyl]



piperidin-1-yl}-1,3-thiazole-



5-carboxylate





embedded image







21
Cis(±)methyl-2-(4-{[(4-
MS (ES) MH+: 574 for
Intermediate 16 and



chloro-5-methyl-1H-pyrrol-
C27H32ClN5O5S
Intermediate 55



2-yl)carbonyl]amino}-3-



methoxypiperidin-1-yl)-4-



{[(1-methyl-1-



phenylethyl)amino]carbonyl}-



1,3-thiazole-5-



carboxylate


22
Cis(±)methyl-2-(4-{[(4-
MS (ES) MH+: 413 for
Intermediate 55 and



chloro-5-methyl-1H-pyrrol-
C17H21ClN4O4S; NMR: 1.63
methyl 2-bromo-1,3-



2-yl)carbonyl]amino}-3-
(s, 1H), 1.90 (s, 1H), 2.14 (s,
thiazole-5-



methoxypiperidin-1-yl)-1,3-
3H), 3.28 (s, 3H), 3.39 (s, 1H),
carboxylate



thiazole-5-carboxylate
3.47 (s, 2H), 3.74 (s, 3H), 3.93




(s, 1H), 4.21 (s, 2H), 6.89 (d,




J = 2.64 Hz, 1H), 7.71 (d,




J = 7.91 Hz, 1H), 7.84 (s, 1H),




11.64 (s, 1H)





23
Cis(±)methyl-2-chloro-6-
MS (ES) MH+: 442 for
Intermediate 55 and



(4-{[(4-chloro-5-methyl-
C18H21Cl2N5O4; NMR: 1.63 (s,
methyl 2,6-



1H-pyrrol-2-
1H), 1.79 (s, 1H), 2.09-2.20
dichloropyrimidine-



yl)carbonyl]amino}-3-
(m, 3H), 3.08 (s, 1H), 3.17 (d,
4-carboxylate



methoxypiperidin-1-
J = 5.27 Hz, 1H), 3.25 (s, 3H),



yl)pyrimidine-4-carboxylate
3.30 − 3.81 − 3.89 (m, 3H), 4.22




(s, 2H), 4.91 (s, 1H), 6.87 (d,




J = 2.64 Hz, 1H), 7.37 (s, 1H),




7.67 (d, J = 7.72 Hz, 1H), 11.62




(s, 1H)


24
Cis(±)methyl-2-(4-{[(4-
MS (ES) MH+: 457 for
Intermediate 55 and



chloro-5-methyl-1H-pyrrol-
C19H25ClN4O5S; NMR: 1.63
Intermediate 17



2-yl)carbonyl]amino}-3-
(s, 1H), 1.84-1.99 (m, 1H),



methoxypiperidin-1-yl)-4-
2.12-2.19 (m, 3H), 3.33 (s,



(methoxymethyl)-1,3-
3H), 3.35-3.38 (m, 1H), 3.52-



thiazole-5-carboxylate
3.57 (m, 1H), 3.72 (s, 3H),




3.97 (s, 1H), 4.15-4.29 (m,




3H), 4.52-4.61 (m, 2H), 6.89




(d, J = 2.64 Hz, 1H), 7.70 (d,




J = 7.91 Hz, 1H), 11.63 (s, 1H)





25
Cis(±)methyl-2-(4-{[(3,4- dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- (methoxymethyl)-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 491 for C19H24Cl2N4O5S; NMR: 1.66- 1.81 (m, 2H), 2.14-2.22 (m, 3H), 3.29 (s, 3H), 3.33 (s, 2H), 3.36 (s, 3H), 3.55 (s, 1H), 3.73 (s, 3H), 3.97 (s, 1H), 4.20- 4.35 (m, 2H), 4.57 (d, J = 1.32 Hz, 2H), 7.15 (d, J = 8.29 Hz, 1H), 12.15 (s, 1H)
Intermediate 50 and Intermediate 17





26
Cis(±)ethyl 4-(4-{[(4-
MS (ES) MH+: 471 for
Intermediate 55 and



chloro-5-methyl-1H-pyrrol-
C24H27ClN4O4; NMR: 1.38 (t,
Intermediate 10



2-yl)carbonyl]amino}-3-
J = 7.06 Hz, 3H), 1.80 (s, 1H),



methoxypiperidin-1-
2.15 (s, 3H), 3.27 (s, 3H), 3.36-



yl)quinoline-2-carboxylate
3.42 (m, 3H), 3.64 (s, 3H),




3.84 (s, 1H), 4.41 (q, J = 7.10




Hz, 2H), 6.95 (d, J = 2.64 Hz,




1H), 7.57 (s, 1H), 7.69 (d,




J = 7.16 Hz, 1H), 7.73-7.82




(m, 2H), 8.11 (dd, J = 17.14,




8.29 Hz, 2H), 11.65 (s, 1H


27
Cis(±)ethyl-2-(4-{[(3,4-
MS (ES) MH+: 455 for
Intermediate 50 and



dichloro-5-methyl-1H-
C20H24Cl2N4O4; NMR: 1.32 (t,
ethyl 2-



pyrrol-2-
J = 7.06 Hz, 3H), 1.72 (d,
fluoroisonicotinate



yl)carbonyl]amino}-3-
J = 0.75 Hz, 2H), 2.18 (s, 3H),
(Konno, Akinori J.



methoxypiperidin-1-
3.13 (d, J = 13.38 Hz, 2H), 3.29-
Fluorine Chemistry



yl)isonicotinate
3.31 (m, 3H), 3.50 (s, 1H),
(1998), 87(2), 137-




4.23 (s, 2H), 4.32 (q, J = 7.03
140)




Hz, 2H), 4.67 (s, 1H), 6.97 (dd,




J = 5.09, 0.94 Hz, 1H), 7.14 (d,




J = 8.10 Hz, 1H), 7.23 (s, 1H),




8.24 (d, J = 5.09 Hz, 1H), 12.15




(s, 1H)


28
Cis(±)ethyl-4-(4-{[(4-
MS (ES) MH+: 421 for
Intermediate 55 and



chloro-5-methyl-1H-pyrrol-
C20H25ClN4O4; NMR: 1.31 (t,
ethyl 4-



2-yl)carbonyl]amino}-3-
J = 7.06 Hz, 3H), 1.61 (s, 1H),
chloropyridine-2-



methoxypiperidin-1-
1.85 (s, 1H), 2.12-2.18 (m,
carboxylate (WO



yl)pyridine-2-carboxylate
3H), 3.23 (s, 3H), 3.50 (s, 1H),
2004007657)




3.89 (s, 2H), 4.19 (s, 3H), 4.30




(q, J = 7.16 Hz, 2H), 6.89 (d,




J = 2.83 Hz, 1H), 7.05 (dd,




J = 6.03, 2.64 Hz, 1H), 7.44 (d,




J = 2.64 Hz, 1H), 7.67 (d,




J = 8.10 Hz, 1H), 8.20 (d,




J = 5.84 Hz, 1H), 11.63 (s, 1H)


29
Cis(±)3,4-dicholoro-N-[3-
MS (ES) MH+: 447 for
Intermediate 50 and



methoxy-1-(2-
C22H24Cl2N4O2
4-chloro-2-



methylquinolin-4-

methylquinoline



yl)piperidin-4-yl]-5-methyl-



1H-pyrrole-2-carboxamide





30
Cis(±)Methyl 4-{[(3,4- dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}-1-[5- (methoxycarbonyl)-1,3- thiazol-2-yl]piperidine-3- carboxylate embedded image
MS (ES) MH+: 474 C18H22ClN5O5S; NMR: 1.98 (m, 2H), 2.23 (s, 3H), 3.08 (m, 1H), 3.24 (m, 1H), 3.55 (m, 1H), 3.66 (s, 3H), 3.79 (s, 3H), 3.97 (m, 1H), 4.23 (m, 1H), 4.63 (m, 1H), 7.64 (d, 1H), 7.95 (s, 1H), 12.01 (s, 1H)
Intermediate 35 and methyl 2-bromo-1,3- thiazole-5- carboxylate





31
Cis(±)ethyl 2-(4-{[(4-
MS(ES) MH+: 477, 479 for
Intermediate 55 and



chloro-5-methyl-1H-pyrrol-
C22H25ClN4O4S; NMR: 1.33 (t,
ethyl 2-bromo-1,3-



2-yl)carbonyl]amino}-3-
3H), 1.76 (m, 1H), 1.83 (m,
benzothiazole-7-



methoxypiperidin-1-yl)-1,3-
1H), 2.10 (s, 3H), 3.37 (m,
carboxylate (U.S. Pat.



benzothiazole-7-
2H), 3.45 (s, 3H), 3.54 (m,
No. 5,770,758)



carboxylate
1H), 4.21-4.29 (m, 3H), 4.36




(q, 2H), 6.86 (m, 1H), 7.38 (t,




1H), 7.62-7.69 (m, 3H), 11.60




(s, 1H)


32
Cis(±)ethyl 4-(4-{[(3,4-
MS (ES) MH: 472 for for
Intermediate 56 and



difluoro-5-methyl-1H-
C24H26F2N4O4
Intermediate 10



pyrrol-2-



yl)carbonyl]amino}-3-



methoxypiperidin-1-



yl)quinoline-2-carboxylate


33
methyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 435, 437 for
Intermediate 36 and



dichloro-5-methyl-1H-
C16H17Cl2FN4O3S; NMR: 1.77-
methyl 2-bromo-1,3-



pyrrol-2-
1.79 (m, 2H), 2.12 (s, 3H),
thiazole-5-



yl)carbonyl]amino}-3-
3.25-3.27 (m, 2H), 3.49-3.62
carboxylate



fluoropiperidin-1-yl)-1,3-
(dd, 1H), 3.68 (s, 3H), 3.95 (m,



thiazole-5-carboxylate
1H), 4.00-4.24 (m, 1H), 4.82-




4.99 (m, 1H), 7.21 (d, 1H),




7.79 (s, 1H), 12.05 (br s, 1H)









Example 34
Cis(±)methyl 4-(aminocarbonyl)-2-(4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate

Cis(±)methyl-2-(4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-1,3-thiazole-5-carboxylate (Example 21; 0.058 g, 0.1 mmol) was dissolved in equal volumes of TFA and DCM. The reaction was heated in a sealed tube to an external temperature of 85° C. overnight. The reaction mixture was concentrated to remove the DCM and excess TFA. The residue was partitioned with EtOAc and NaHCO3 and the organic extracts were dried with MgSO4 and concentrated to a yellow solid (0.050 g, 100%). MS (ES) MH+: 456 for C18H22ClN5O5S.


Example 35
Cis(±)2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid



embedded image


Cis(±)methyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate (Example 1; 200 mg) was dissolved in THF (50 ml). 2N LiOH (100 ml) was added and the mixture was heated at 50° C. for 18 h. The reaction mixture was cooled to ambient and acidified with 20% aqueous citric acid. The aqueous phase was extracted with EtOAc and the organic phase was washed with water, brine, dried over Na2SO4. The organic phase was concentrated in vacuo and triturated with diethyl ether to give the title compound as an off white solid. (164 mg). MS (ES) MH+: 433, 431 for C16H18Cl2N4O4S; NMR: 1.87 (m, 2H), 2.28 (s, 3H), 3.32 (m, 6H), 3.63 (s, 1H), 3.87 (m, 1H), 4.45 (m, 2H), 7.04 (d, 1H), 7.90 (s, 1H), 11.97 (s, 1H), 12.30 (s, 1H).


Examples 36-71

The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.
















Ex
Compound
NMR
m/z
SM







36
Cis(±)2-(4-{[(3,4-dichloro-5-
0.87 (m, 3H), 1.57 (m, 2H),
461
Example 5 



methyl-1H-pyrrol-2-
1.93 (m, 2H), 2.24 (s, 3H),



yl)carbonyl]amino}-3-
2.6 (m, 2H), 3.45 (m, 2H),



propoxypiperidin-1-yl)-1,3-
3.69 (m, 2H), 4.36 (m, 2H),



thiazole-5-carboxylic acid
7.23 (d, 1H), 7.87 (s, 1H),




12.34 (s, 1H)


37
Cis(±)2-(3-(allyloxy)-4-{[(3,4-
1.79 (m, 2H), 2.20 (s, 3H),
459
Example 6 



dichloro-5-methyl-1H-pyrrol-2-
3.38 (m, 2H), 3.71 (s, 1H),



yl)carbonyl]amino}piperidin-1-
3.95 (m, 2H), 4.15 (m, 2H),



yl)-1,3-thiazole-5-carboxylic
5.26 (m, 2H), 5.91 (m, 1H),



acid
7.18 (d, 1H), 7.76 (s, 1H),




12.19 (s, 1H)


38
Cis(±)4-(3-(allyloxy)-4-{[(3,4-
2.06 (m, 2H), 2.20 (s, 3H),
503
Example 7 



dichloro-5-methyl-1H-pyrrol-2-
3.1-4.0 (m, 4H), 4.51 (m,



yl)carbonyl]amino}piperidin-1-
3H), 5.18 (m, 2H), 5.82 (m,



yl)quinoline-2-carboxylic acid
1H), 7.29 (d, 1H), 7.57 (s,




1H), 7.71 (m, 1H), 7.95 (m,




1H), 8.36 (m, 2H), 12.23 (s, 1H)


39
Cis(±)4-(4-{[(3,4-dichloro-5-
0.62 (t, 3H), 1.35 (m, 2H),
505
Example 8 



methyl-1H-pyrrol-2-
2.13 (s, 3H), 5.36 (m, 2H),



yl)carbonyl]amino}-3-
3.5-4.0 (m, 4H), 4.05 (m,



propoxypiperidin-1-
2H), 4.43 (m, 2H), 7.20 (d,



yl)quinoline-2-carboxylic acid
1H), 7.55 (s, 1H), 7.71 (m,




1H), 8.00 (m, 1H), 8.22 (m,




2H), 12.24 (s, 1H)





40
Cis(±)2-(4-{[(3,4-dichloro-5-
1.75-1.79 (m, 2H), 2.13 (s,
 421,
Example 9 



methyl-1H-pyrrol-2-
3H), 3.39-3.57 (m, 2H), 3.93-
423



yl)carbonyl]amino}-3-
3.96 (d, 1H), 4.25 (m, 2H),



fluoropiperidin-1-yl)-1,3-
4.81-4.97 (m, 1H), 7.28 (d,



thiazole-5-carboxylic acid
1H), 7.63 (s, 1H), 12.12 (s, 1H)





embedded image







41
Trans(±)2-(4-{[(3,4-dichloro-5-
1.74-1.79 (m, 2H), 2.11 (s,
 421,
Example 10



methyl-1H-pyrrol-2-
3H), 3.49-3.58 (m, 2H), 3.86-
423



yl)carbonyl]amino}-3-
3.92 (d, 1H), 4.22 (m, 2H),



fluoropiperidin-1-yl)-1,3-
4.84-4.97 (m, 1H), 7.26 (d,



thiazole-5-carboxylic acid
1H), 7.61 (s, 1H), 12.11 (s, 1H)





42
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.62-1.90 (m, 2H), 2.12 (s,
 421,
Example 33



methyl-1H-pyrrol-2-
3H), 3.23 (m, 1H), 3.50 (dd,
423



yl)carbonyl]amino}-3-
1H), 3.83-4.03 (m, 1H), 4.12-



fluoropiperidin-1-yl)-1,3-
4.43 (m, 2H), 4.90 (d, 1H),



thiazole-5-carboxylic acid
7.21 (d, 1H), 7.69 (s, 1H),




12.04 (s, 1H), 12.61 (brs, 1H)


43
2-((3R,4S)-4-{[(3,4-dichloro-5-
1.63-1.92 (m, 2H), 2.13 (s,
 421,
Example 11



methyl-1H-pyrrol-2-
3H), 3.21 (m, 1H), 3.50 (dd,
423



yl)carbonyl]amino}-3-
1H), 3.87-4.02 (m, 1H), 4.14-



fluoropiperidin-1-yl)-1,3-
4.42 (m, 2H), 4.90 (d, 1H),



thiazole-5-carboxylic acid
7.21 (d, 1H), 7.69 (s, 1H),




12.04 (s, 1H), 12.61 (brs, 1H)


44
Cis(±)2-(4-{[(3,4-dichloro-5-
1.82 (m, 2H), 2.13 (s, 3H),
 471,
Example 12



methyl-1H-pyrrol-2-
3.48-3.67 (m, 2H), 4.12-4.41
473



yl)carbonyl]amino}-3-
(m, 3H), 4.92 (d, 1H), 7.22 (d,



fluoropiperidin-1-yl)-1,3-
1H), 7.34 (t, 1H), 7.62 (m, 1H),



benzothiazole-7-carboxylic acid
12.06 (s, 1H), 13.45 (brs, 1H)





45
Cis(±)2-(4-{[(3,4-dichloro-5-
1.86 (m, 2H), 2.25 (s, 3H), 3.46
 483,
Example 13



methyl-1H-pyrrol-2-
(s, 3H), 3.48 (m, 2H), 3.65 (m,
485



yl)carbonyl]amino}-3-
1H), 4.35 (m, 2H), 4.46 (m,



methoxypiperidin-1-yl)-1,3-
1H), 7.25 (d, 1H), 7.48 (t, 1H),



benzothiazole-7-carboxylic acid
7.73 (t, 1H), 12.26 (s, 1H)





embedded image







46
Cis(±)2-(4-{[(4-chloro-5-
1.60 (m, 1H), 1.83 (m, 1H),
 449,
Example 31



methyl-1H-pyrrol-2-
2.07 (s, 3H), 3.25 (s, 3H),
451



yl)carbonyl]amino}-3-
3.35 (m, 2H), 3.52 (m, 1H),



methoxypiperidin-1-yl)-1,3-
4.09-4.17 (m, 3H), 6.84 (d,



benzothiazole-7-carboxylic acid
1H), 7.37 (t, 1H), 7.58-7.67




(m, 3H), 11.58 (s, 1H)


47
Cis(±)2-(4-{[(3,4-dichloro-5-
1.74 (m, 2H), 2.17 (s, 3H),
 433,
Example 16



methyl-1H-pyrrol-2-
3.26 (m, 2H), 3.35 (s, 3H),
435



yl)carbonyl]amino}-3-
3.52 (m, 1H), 3.84 (m, 1H),



methoxypiperidin-1-yl)-1,3-
4.21 (m, 2H), 7.13 (d, 1H),



thiazole-4-carboxylic acid
7.57 (s, 1H), 12.15 (s, 1H),




12.61 (brs, 1H)


48
Cis(±)2-Chloro-6-(4-{[(3,4-
1.59 (m, 1H), 1.77 (m, 1H),
 463,
Example 14



dichloro-5-methyl-1H-pyrrol-2-
2.18 (s, 3H), 3.16 (m, 1H),
465



yl)carbonyl]amino}-3-
3.17 (m, 1H), 3.56 (m, 1H),



methoxypiperidin-1-
4.11 (m, 1H), 4.30 (m, 1H),



yl)pyrimidine-4-carboxylic acid
4.55 (m, 1H), 4.98 (m, 1H),




7.15 (m, 1H), 7.38 (m, 1H),




12.10 (m, 1H)


49
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.85 (m, 2H), 2.24 (s, 3H),
433
Example 2 



methyl-1H-pyrrol-2-
3.32 (s, 3H), 3.42 (m, 2H),



yl)carbonyl]amino}-3-
3.69 (s, 1H), 4.07 (m, 1H),



methoxypiperidin-1-yl)-1,3-
4.49 (m, 2H), 7.31 (d, 1H),



thiazole-5-carboxylic acid
7.87 (s, 1H), 12.27 (s, 1H),




12.69 (s, 1H)





50
Cis(±)2-(4-{[(4-chloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-4-carboxylic acid embedded image
1.61 (m, 1H), 1.92 (m, 1H), 2.14 (s, 3H), 3.24 (m, 1H), 3.28 (s, 3H), 3.43 (m, 1H), 3.53 (m, 1H), 3.84 (m, 1H), 4.10 (m, 1H), 4.21 (m, 1H), 6.91 (s, 1H), 7.51 (s, 1H), 7.69 (m, 1H), 11.64 (s, 1H)
 399, 401
Example 15





51
2-((3S,4S)-4-{[(3,4-Dichloro-5-
1.64 (m, 1H), 1.88 (m, 1H),
 433,
Example 86



methyl-1H-pyrrol-2-
2.11 (s, 3H), 3.13-3.20 (m,
435



yl)carbonyl]amino}-3-
3H), 3.29 (s, 3H), 3.68 (m,



methoxypiperidin-1-yl)-1,3-
1H), 4.03 (m, 1H), 7.29 (d,



thiazole-5-carboxylic acid
1H0, 7.71 (s, 1H), 11.95 (s,




1H), 12.63 (brs, 1H)


52
2-((3R,4R)-4-{[(3,4-Dichloro-5-
1.63 (m, 1H), 1.88 (m, 1H),
 433,
Example 85



methyl-1H-pyrrol-2-
2.11 (s, 3H), 3.16-3.27 (m,
435



yl)carbonyl]amino}-3-
3H), 3.29 (s, 3H), 3.69 (m,



methoxypiperidin-1-yl)-1,3-
1H), 4.03-4.07 (m, 2H), 7.37



thiazole-5-carboxylic acid
(d, 1H), 7.69 (s, 1H), 12.03 (s,




1H)


53
Cis(±)2-[4-{[(3,4-dichloro-5-
1.62 (m, 1H), 2.03 (m, 1H),
447
Example 18



methyl-1H-pyrrol-2-
2.16 (s, 3H), 2.98 (m, 1H),



yl)carbonyl]amino}-3-
3.21 (s, 3H), 3.25 (m, 3H),



(methoxymethyl)piperidin-1-
3.41 (dd, 1H), 3.89 (m, 2H),



yl]-1,3-thiazole-5-carboxylic
4.06 (dd, 1H), 7.51 (d, 1H),



acid
7.63 (s, 1H)


54
Cis(±)2-{4-{[(3,4-dichloro-5-
1.63 (m, 1H), 1.83 (m, 1H),
446
Example 19



methyl-1H-pyrrol-2-
1.97 (m, 1H), 2.18 (s, 3H),



yl)carbonyl]amino}-3-
2.44 (s, 3H), 2.64 (m, 1H),



[(methylamino)methyl]piperidin-
2.79 (m, 1H), 2.98 (m, 2H),



1-yl}-1,3-thiazole-5-carboxylic
3.87 (m, 1H), 4.07 (m, 2H),



acid
7.33 (s, 1H), 8.14 (d, 1H)





55
Cis(±)2-{4-{[(3,4-dichloro-5-
1.66 (m, 1H), 1.88 (m, 1H0,
460
Example 20



methyl-1H-pyrrol-2-
2.05 (m, 1H), 2.16 (s, 3H), 2.26



yl)carbonyl]amino}-3-
(s, 6H), 2.40 (m, 2H), 2.94 (t,



[(dimethylamino)methyl]piperidin-
1H), 3.18 (t, 1H), 3.86 (m, 1H),



1-yl}-1,3-thiazole-5-
3.98 (dd, 2H), 7.63 (s, 1H),



carboxylic acid
7.67 (d, 1H), 12.3 (brs, 1H)





embedded image







56
Cis(±)2-(4-{[(4-chloro-5-
1.63 (d, J = 3.39 Hz, 1H), 1.84-
399
Example 22



methyl-1H-pyrrol-2-
1.99 (m, 1H), 2.14 (s, 3H),



yl)carbonyl]amino}-3-
3.28 (s, 3H), 3.54 (s, 1H),



methoxypiperidin-1-yl)-1,3-
3.91 (s, 1H), 4.15-4.29 (m,



thiazole-5-carboxylic acid
1H), 6.90 (d, J = 2.83 Hz, 1H),




7.71 (d, J = 8.10 Hz, 1H), 7.74




(s, 1H), 11.64 (d, J = 1.70 Hz,




1H), 12.62 (s, 1H)


57
Cis(±)2-chloro-6-{4-{[(4-
1.64 (s, 1H), 1.78 (s, 1H), 2.13
428
Example 23



chloro-5-methyl-1H-pyrrol-2-
(s, 3H), 3.13 (s, 1H), 3.25 (s,



yl)carbonyl]amino}-3-
3H), 3.54 (s, 1H), 4.22 (s, 2H),



methoxypiperidin-1-
4.60 (s, 1H), 4.93 (s, 1H), 6.87



yl)pyrimidine-4-carboxylic acid
(d, J = 2.45 Hz, 1H),




7.34 (s, 1H), 7.65 (s, 1H),




11.62 (s, 1H), 13.69 (s, 1H)


58
Cis(±)2-(4-{[(4-chloro-5-
1.62 (s, 1H), 1.93 (s, 1H),
443
Example 24



methyl-1H-pyrrol-2-
2.14 (s, 3H), 3.28 (d, J = 2.26



yl)carbonyl]amino}-3-
Hz, 3H), 3.36 (s, 3H), 3.54 (s,



methoxypiperidin-1-yl)-4-
2H), 3.91 (s, 1H), 4.19 (s,



(methoxymethyl)-1,3-thiazole-
2H), 4.56 (s, 2H), 6.89 (s, 1H),



5-carboxylic acid
7.69 (s, 1H), 11.63 (s, 1H)


59
Cis(±)2-(4-{[(3,4-dichloro-5-
1.75 (s, 2H), 2.18 (s, 3H),
477
Example 25



methyl-1H-pyrrol-2-
3.28 (s, 3H), 3.37 (s, 3H),



yl)carbonyl]amino}-3-
3.54 (s, 3H), 3.91 (s, 1H),



methoxypiperidin-1-yl)-4-
4.26 (s, 2H), 4.56 (s, 2H),



(methoxymethyl)-1,3-thiazole-
7.14 (s, 1H), 12.15 (s, 1H)



5-carboxylic acid





60
Cis(±)4-(4-{[(4-chloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1- yl)quinoline-2-carboxylic acid embedded image
1.80 (s, 1H), 2.15 (s, 3H), 3.15 (s, 3H), 3.64 (s, 3H), 3.80 (s, 2H), 4.09 (s, 1H), 4.30 (s, 1H), 6.93 (d, J = 2.45 Hz, 1H), 7.57 (s, 1H), 7.68 (s, 1H), 7.85 (s, 2H), 8.19 (s, 2H), 11.65 (s, 1H)
443
Example 26





61
Cis(±)4-(4-{[(3,4-dichloro-5-
1.67 (s, 1H), 1.81 (s, 1H),
393
Example 17



methyl-1H-pyrrol-2-
2.18 (s, 3H), 3.28 (s, 3H),



yl)carbonyl]amino}-3-
3.59 (s, 2H), 4.20 (s, 2H),



methoxypiperidin-1-
4.32 (s, 1H), 4.55 (d, J = 12.43



yl)pyridine-2-carboxylic acid
Hz, 1H), 7.14 (d, J = 8.29 Hz,




1H), 7.18 (dd, J = 7.06, 2.92




Hz, 1H), 7.44 (d, J = 2.64 Hz,




1H), 7.97 (d, J = 6.97 Hz, 1H),




12.18 (s, 1H)


62
Cis(±)2-(4-{[(3,4-dichloro-5-
1.72 (s, 2H), 2.18 (s, 3H),
427
Example 27



methyl-1H-pyrrol-2-
3.04-3.18 (m, 2H), 3.30 (s,



yl)carbonyl]amino}-3-
3H), 3.49 (s, 1H), 4.25 (s,



methoxypiperidin-1-
2H), 4.66 (s, 1H), 6.97 (d,



yl)isonicotinic acid
J = 4.71 Hz, 1H), 7.16 (s, 1H),




7.24 (s, 1H), 8.22 (d, J = 4.90




Hz, 1H), 12.16 (s, 1H), 13.39




(s, 1H)


63
Cis(±)2-[4-{[(3,4-Dichloro-5-
MS (ES+): 516, 518 for

Example 78



methyl-1H-pyrrol-2-
C20H23Cl2N4O5S; NMR: 1.82



yl)carbonyl]amino}-3-
(m, 2H), 2.15 (s, 3H), 3.32



(morpholin-4-
(m, 6H), 3.61 (m, 5H), 3.99



ylcarbonyl)piperidin-1-yl]-1,3-
(t, 2H), 4.40 (m, 1H), 7.18 (d,



thiazole-5-carboxylic acid
1H), 7.78 (s, 1H), 12.03 (s,




1H), 12.8 (brs, 1H)


64
Cis(±)2-{4-{[(3,4-Dichloro-5-
1.75 (m, 1H), 1.89 (m, 1H),
 474,
Example 79



methyl-1H-pyrrol-2-
2.14 (s, 3H), 2.87 (s, 3H),
476



yl)carbonyl]amino}-3-
3.09 (s, 3H), 3.36 (m [under



[(dimethylamino)carbonyl]
water peak], 3H), 4.00 (m,



piperidin-1-yl}-1,3-thiazole-5-
2H), 4.36 (m, 1H), 7.19 (d,



carboxylic acid
1H), 7.78 (s, 1H), 11.98 (s,




1H), 12.71 (brs, 1H)





65
Cis(±)2-{4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- [(ethylamino)carbonyl]piperidin- 1-yl}-1,3-thiazole-5-carboxylic acid embedded image
0.92 (t, 3H), 1.58 (m 1H), 1.99 (d, 1H), 2.15 (s, 3H), 2.62 (dd, 1H), 3.02 (m, 2H), 3.30 (q, 2H), 3.92 (d, 1H), 4.07 (d, 1H), 4.27 (m, 1H), 7.03 (d, 1H), 7.77 (s, 1H), 7.92 (t, 1H), 12.01 (s, 1H), 12.71 (brs, 1H)
 474, 476
Example 80





66
Cis(±)2-(4-{[(3,4-dichloro-5-
1.50 (m, 1H), 1.96 (d, 1H),
 490,
Example 81



methyl-1H-pyrrol-2-
2.41 (s, 3H), 2.61 (m, 1H),
492



yl)carbonyl]amino}-3-{[(2-
3.07 (m, 2H), 3.26 (q, 2H),



hydroxyethyl)amino]carbonyl}
3.32 (under water peak, 2H),



piperidin-1-yl)-1,3-thiazole-5-
3.89 (d, 1H), 4.04 (d, 1H),



carboxylic acid
4.22 (m, 1H), 4.72 (brs, 1H),




7.39 (brs, 1H), 7.62 (s, 1H),




8.07 (t, 1H), 12.32 (brs, 1H)


67
Cis(±)2-(4-{[(3,4-dichloro-5-
1.66 (m, 1H), 1.85 (m, 1H),
 490,
Example 82



methyl-1H-pyrrol-2-
2.14 (s, 3H), 3.08 (m, 1H),
492



yl)carbonyl]amino}-3-
3.09 (s, 3H), 3.15 (m, 1H),



{[methoxy(methyl)amino]
3.33 (under water peak, 1H),



carbonyl}piperidin-1-yl)-1,3-
3.74 (brs, 3H), 3.83 (m, 1H),



thiazole-5-carboxylic acid
4.00 (m, 1H), 4.33 (m, 1H),




7.19 (s, 1H), 7.81 (brs, 1H),




12.98 (brs, 1H)


68
Cis(±)4-(aminocarbonyl)-2-(4-
1.63 (s, 1H), 1.90 (s, 1H),
442
Example 34



{[(4-chloro-5-methyl-1H-
2.14 (s, 3H), 3.17 (s, 1H),



pyrrol-2-yl)carbonyl]amino}-3-
3.37 (s, 3H), 3.54 (s, 2H),



methoxypiperidin-1-yl)-1,3-
4.14-4.28 (m, 2H), 6.90 (s,



thiazole-5-carboxylic acid
1H), 7.72 (s, 1H), 8.93 (s,




2H), 11.63 (s, 1H)


69
2-((3R,4S)-4-{[(3,4-dichloro-5-
1.89 (m, 2H), 2.11 (s, 3H),
433
Example 3 



methyl-1H-pyrrol-2-
2.23 (s, 3H), 3.33 (m, 2H),



yl)carbonyl]amino}-3-
3.46 (s, 3H), 3.59 (s, 1H),



methoxypiperidin-1-yl)-1,3-
4.09 (m, 1H), 4.46 (m, 2H),



thiazole-5-carboxylic acid1,3-
7.31 (d, 1H), 7.92 (s, 1H),



thiazole-5-carboxylic acid
12.28 (s, 1H), 12.67 (brs, 1H)





70
Cis(±)2-(4-{[(3,4-difluoro-5-
1.75 (m, 2H), 2.13 (s, 3H),
441
Example 4 



methyl-1H-pyrrol-2-
3.33 (s, 3H), 3.36 (m, 2H),



yl)carbonyl]amino}-3-
3.54 (s, 1H), 3.89 (m, 1H),



methoxypiperidin-1-yl)-1,3-
3.94 (m, 2H), 6.73 (d, 1H),



thiazole-5-carboxylic acid
7.90 (s, 1H), 11.40 (s, 1H)




embedded image







71
Cis(±)4-(4-{[(3,4-difluoro-5-
1.69 (m, 2H), 2.01 (s, 3H),
444
Example 32



methyl-1H-pyrrol-2-
3.16 (m, 1H), 3.16 (s, 3H),



yl)carbonyl]amino}-3-
3.8-4.02 (m, 2H), 4.18-4.38



methoxypiperidin-1-
(m, 2H), 6.57-6.84 (d, 1H),



yl)quinoline-2-carboxylic acid
7.44-7.56 (s, 1H), 7.56-7.72




(m, 1H), 7.78-7.94 (m, 1H),




8.04-8.27 (m, 2H), 11.23 (br,




1H)









Example 72
Cis(±)2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2 -yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-N-methoxy-1,3-thiazole-5-carboxamide

Cis(±)2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2 -yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (Example 35; 100 mg) was dissolved in anhydrous DMA (2 ml). HATU (97 mg), HOAT (31 mg), DIEA (41 μl) were added and the mixture was stirred for 30 min. N-Methoxyamine hydrochloride (19.3 mg) was added followed by DIEA (41 μl), and the mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with EtOAc, washed with H2O, 20% citric acid solution, H2O, sat. NaHCO3, H2O, brine and dried over Na2SO4. The organic phase was concentrated in vacuo to give the title compound as an off-white solid (82 mg). MS (ES)(MH+): 462, 460 for C17H21Cl2N5O4S; NMR: 1.64 (m, 2H), 1.85 (m, 1H), 2.05 (s, 3H), 2.83 (m, 1H), 3.33 (m, 5H), 3.73 (s, 3H), 4.07 (m, 1H), 4.38 (m, 2H), 7.24 (d, 1H), 7.74 (s, 1H), 11.39 (s, 1H), 12.05 (s, 1H).


Example 73

The following Example was prepared by the procedure described in Example 72 from the starting material (SM) indicated.















Ex
Compound
Data
SM







73
2-((3R,4R)-4-{[(3,4-Dichloro-
MS (ES) (M + H): 462,
Example 52



5-methyl-1H-pyrrol-2-
464 (M + H), for C17H21Cl2N5O4S;



yl)carbonyl]amino}-3-
NMR: 1.61 (m, 1H), 1.87 (m,



methoxypiperidin-1-yl)-N-
1H), 2.11 (s, 3H), 3.14 (m,



methoxy-1,3-thiazole-5-
1H), 3.29 (s, 3H), 3.33 (m,



carboxamide
1H), 3.59 (s, 3H), 3.64 (m,




1H,) 3.95-4.06 (m, 3H),




7.29 (d, 1H), 7.66 (s, 1H),




11.31 (brs, 1H), 11.95 (s, 1H)









Example 74
Cis(±)2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2 -yl)carbonyl]amino}-3-hydroxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid

Cis(±)2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2 -yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (Example 35; 100 mg) was suspended in anhydrous DCM. BBr3/DCM (15 ml) was added and the mixture was heated at 40° C. for 18 h. The reaction mixture was cooled to −50° C. and water was added. The mixture was extracted with EtOAc and the organic phase was washed with water, dried over Na2SO4. The organic phase was concentrated in vacuo to yield a pale brown solid which was dissolved in acetonitrile/water mixture and was lyophilized (46 mg). MS (ES) MH+: 419 for C15H16Cl2N4O4S; NMR: 1.87 (m, 2H), 2.20 (s, 3H), 3-4 (brm, 6H), 6.9 (d, 1H), 7.51 (s, 1H), 12.19 (s, 1H).


Example 75

The following Example was prepared by the procedure described in Example 74 from the starting material (SM) indicated.















Ex
Compound
Data
SM







75
Cis(±)4-(4-{[(3,4-dichloro-5-
MS (ES) MH+: 463 for
Example 76



methyl-1H-pyrrol-2-
C21H20Cl2N4O4; NMR: 1.24 (m,



yl)carbonyl]amino}-3-
2H), 2.13 (m, 2H), 2.38 (s, 3H), 3.54



hydroxypiperidin-1-
(m, 2H), 4.14 (m, 2H), 4.57 (m, 1H),



yl)quinoline-2-carboxylic acid
7.07 (s, 1H), 7.87 (m, 1H), 8.23





embedded image


(m, 2H), 8.52 (m, 2H), 12.06 (s, 1H)









Example 76
Cis(±)-4-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2 -yl)carbonyl]amino}-3-methoxypiperidin-1-yl)quinoline-2-carboxylic acid

Cis(±)3,4-dicholoro-N-[3-methoxy-1-(2-methylquinolin-4 -yl)piperidin-4-yl]-5-methyl-1H-pyrrole-2-carboxamide (Example 29; 170 mg) was dissolved in pyridine (5 ml). Selenium dioxide (211 mg) was added and the mixture was heated at 130° C. for 3 h. The brown solution was cooled to room temperature, diluted with water and filtered through a bed of celite. The filtrate was extracted with EtOAc, washed with water and dried over Na2SO4, concentrated in vacuo. The brown solid that separated was triturated with Et2O, filtered, washed well with n-hexanes and dried in vacuo to give the title compound as a brown solid (176 mg). MS (ES) MH+: 477 for C22H22Cl2N4O4; NMR: 1.34 (m, 1H), 2.01 (m, 1H), 2.28 (s, 3H), 3.10 (s, 3H), 3.42 (m, 3H), 3.72 (m, 2H), 4.23 (m, 1H), 7.36 (d, 1H), 7.63 (s, 1H), 7.78 (m, 1H), 7.92 (m, 1H), 8.30 (m, 2H), 12.30 (brs, 1H).


Example 77
Cis(±)4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-[5-(methoxycarbonyl)-1,3-thiazol-2-yl]piperidine-3-carboxylic acid

Cis(±)4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-3-carboxylic acid hydrochloride (Intermediate 79; 1.84 g) was dissolved in anhydrous DMF (20 ml) under an argon atmosphere in a 100-ml round bottom flask. Methyl 2-bromothiazole-5-carboxylate (1.43 g) was added followed by N,N-diisopropylethylamine (3.6 ml) at room temperature. The reaction was heated to 55° C. for 14 h cooled to room temperature. The reaction mixture was diluted with EtOAc (250 ml) and washed with a saturated aqueous ammonium chloride solution (125 ml), followed by a saturated aqueous sodium chloride solution (100 ml). The EtOAc solution was dried over anhydrous MgSO4 and concentrated in vacuo. The crude product was purified by silica gel chromatography using 0-10% CH3OH in DCM. The recovered product was recrystallised from EtOAc to further enhance the diastereomeric excess, increasing it from a 90:10 cis:trans mixture to a 96:4 cis:trans mixture (by HPLC analysis). The recrystallised product was carried on to the next reaction (2 g). MS (ES−(M+H)+): 461, 463 for C17H18Cl2N4O5S; NMR: 1.71 (m, 1H), 1.91 (m, 1H), 2.16 (s, 3H), 2.81 (dt, 1H), 3.42 (m, 2H), 3.74 (s, 3H), 3.86 (m, 1H), 4.34 (m, 2H), 7.43 (d, 1H), 7.88 (s, 1H), 8.50 (brs, 1H), 12.06 (s, 1H).


Example 78
Cis(±)methyl 2-[4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(morpholin-4-ylcarbonyl)piperidin-1-yl]-1,3-thiazole-5-carboxylate

The title compound was prepared in a manner analogous to (Intermediate 37) starting from cis(±)4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1-[5-(methoxycarbonyl)-1,3-thiazol-2-yl]piperidine-3-carboxylic acid (Example 77) and morpholine. MS (ES+): 530, 532 for C21H25Cl2N5O5S.


Examples 79-82

The following compounds were synthesized by an analogous method to Example 78 from Example 77 and the starting materials given in the table below.















Ex
Compound
m/z
SM







79
Cis(±)methyl 2-{4-{[(3,4-
M/z 488, 490
Dimethylamine



dichloro-5-methyl-1H-pyrrol-2-

(2 M in THF)



yl)carbonyl]amino}-3-



[(dimethylamino)carbonyl]



piperidin-1-yl}-1,3-thiazole-5-



carboxylate





80
Cis(±)methyl 2-{4-{[(3,4-
M/z 488, 490
Ethylamine (2



dichloro-5-methyl-1H-pyrrol-2-

M in THF)



yl)carbonyl]amino}-3-



[(ethylamino)carbonyl]



piperidin-1-yl}-1,3-thiazole-5-



carboxylate





embedded image







81
Cis(±)methyl 2-(4-{[(3,4-
M/z 504, 506
Ethanolamine



dichloro-5-methyl-1H-pyrrol-2-



yl)carbonyl]amino}-3-{[(2-



hydroxyethyl)amino]carbonyl}



piperidin-1-yl)-1,3-thiazole-5-



carboxylate


82
Cis(±)methyl 2-(4-{[(3,4-
M/z 504, 506; NMR: 1.78 (m,
N,O-Dimethyl-



dichloro-5-methyl-1H-pyrrol-2-
1H), 1.93 (m, 1H), 2.14 (s, 3H),
hydroxylamine



yl)carbonyl]amino}-3-
3.06 (brs, 3H), 3.24 (m, 1H), 3.32
hydrochloride



{[methoxy(methyl)amino]
(s, 1H), 3.38 (m, 1H), 3.72 (brs,



carbonyl}piperidin-1-yl)-1,3-
1H), 3.74 (s, 3H), 3.98 (m, 1H),



thiazole-5-carboxylate
4.12 (m, 1H), 4.38 (m, 1H), 7.19




(d, 1H), 7.88 (s, 1H), 11.99 (s, 1H)









Example 83
Cis(±)6-(4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-2-methoxypyrimidine-4-carboxylic acid

Cis(±)methyl 2-chloro-6-(4-{[(4-chloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)pyrimidine-4-carboxylate (Example 23; 0.12 g, 0.27 mmol) was dissolved in 0.5 M sodium methoxide in MeOH (5.4 ml, 2.7 mmol) and heated in the microwave for 1.5 h at 85° C. The reaction mixture was acidified with 1N HCl and the product was extracted with EtOAc, dried with MgSO4 and concentrated to a solid which was purified by reverse phase chromatography (gradient elution from 20-50% CH3CN in water with 0.5% TFA). Freeze drying yielded product as a white solid. MS (ES) MH+: 424 for C18H22ClN5O5; NMR: 1.62 (s, 1H), 1.75 (s, 1H), 2.14 (s, 3H), 3.26 (s, 3H), 3.53 (m, 3H), 3.87 (s, 3H), 4.22 (s, 2H), 6.88 (d, J=2.64 Hz, 1H), 7.07 (s, 1H), 7.66 (d, J=7.91 Hz, 1H), 11.63 (s, 1H).


Example 84

The following compound was prepared by the procedure of Example 83 from the starting material (SM) indicated.
















Ex
Compound
NMR
M/z
SM







84
Cis(±)6-(4-{[(3,4-dichloro-5-
1.61 (m, 1H), 1.74 (m, 1H),
458,
Example



methyl-1H-pyrrol-2-
2.18 (s, 3H), 3.21 (m, 1H), 3.33 (s, 3H),
460
14



yl)carbonyl]amino}-3-
3.51 (m, 1H), 3.53 (m, 1H),



methoxypiperidin-1-yl)-2-
3.85 (s, 3H), 4.28 (m, 2H), 5.10 (m,



methoxypyrimidine-4-
1H), 7.03 (m, 1H), 7.12 (m, 1H),



carboxylic acid
12.15 (m, 1H)









Examples 85-86

The following compounds were prepared by the procedure of Intermediate 37 using the starting materials (SM) indicated.















Ex
Compound
Data
SM







85
Methyl 2-((3R,4R)-4-{[(3,4-
MS (ES) MH+: 447 for
Intermediate 30 and



dichloro-5-methyl-1H-
C17H20ClN4O4S; NMR: 1.71 (m, 1H),
Intermediate 1



pyrrol-2-yl)carbonyl]amino}-3-
1.93 (m, 1H), 2.18 (s, 3H), 3.24-3.28 (m,



methoxypiperidin-1-yl)-1,3-
2H), 3.31 (s, 3H), 3.75 (s, 3H), 3.79 (m,



thiazole-5-carboxylate
1H), 4.02-4.11 (m, 2H), 7.35 (d, 1H),





embedded image


7.88 (s, 1H0, 12.00 (s, 1H)





86
Methyl 2-((35,4S)-4-{[(3,4-
MS (ES) MH+: 447 for
Intermediate 31 and



dichloro-5-methyl-1H-
C17H20ClN4O4S; NMR: 1.71 (m,
Intermediate 1



pyrrol-2-
1H), 1.93 (m, 1H), 2.18 (s, 3H),



yl)carbonyl]amino}-3-
3.24-3.28 (m, 2H), 3.31 (s, 3H),



methoxypiperidin-1-yl)-1,3-
3.75 (s, 3H), 3.79 (m, 1H), 4.02-



thiazole-5-carboxylate
4.11 (m, 2H), 7.35 (d, 1H), 7.88 (s,




1H0, 12.00 (s, 1H)









Preparation of Starting Materials for Examples 1-86
Intermediate 1
3,4-Dichloro-5-methyl-1H-pyrrole-2-carboxylic acid



embedded image


Ethyl 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 2; 7.765 g, 0.03496 mol) was dissolved in MeOH (80 ml) and DCM (10 ml) and slowly added to a 70° C. solution of 2 N LiOH (105 ml, 0.21 mol). After 2 h, the reaction mixture was cooled to room temperature and then in an ice bath, followed by acidification with 2 N HCl. The mixture was stirred at 0° C. for 1 h, and a purple solid was filtered, washed with water and lyophilized overnight to give 4.314 g (0.0222 mol, 64% yield) of the desired product. MS (ES): 192.13, 194.13 for C6H5Cl2NO2; NMR: 2.17 (s, 3H).


Intermediate 2
Ethyl 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylate

Method 1


A solution of ethyl 5-methyl-1H-pyrrole-2-carboxylate (Intermediate 3; 7.00 g, 0.0457 mol) in tetrachloromethane (30 ml) was cooled to 0° C. under nitrogen. The rubber septum used in the apparatus was pierced with a needle, and SO2Cl2 (7.8 ml, 0.096 mol) was then added dropwise over 25 min. Within 1 h, the reaction mixture had formed a slurry. The solid was collected by suction filtration, washed with cold tetrachloromethane, and dried under vacuum overnight to give the title product as a peach coloured solid (7.84 g, 0.0353 mol, 77% yield). MS (ES): 222.00, 224.00 for C8H9Cl2NO2; NMR: 1.34-1.40 (t, 3H), 2.28 (s, 3H), 4.32-4.38 (m, 2H).


Method 2


A 4-neck 22 L round bottom flask equipped with an overhead stirrer, reflux condenser, nitrogen inlet and an internal temperature probe was charged with (Intermediate 253, 1000 g, 3.9 mol), 1-methyl-2-pyrrolidinone (10 L) and sodium cyanoborohydride (382 g, 6.1 mol, 1.56 eq). The resulting solution was heated at 75-80° C. for 6 h and allowed to cool to ambient overnight. Reaction solution was poured into water (20 L) resulting in a light brown suspension and product was extracted with methyl tert-butyl ether (2×10 L). Organic layer was dried with sodium sulfate and concentrated under reduced pressure to a thick slurry, which was filtered and solid dried in convection oven yielding 4 (518 g, 60%) as a light brown solid.


Intermediate 3
Ethyl 5-methyl-1H-pyrrole-2-carboxylate

Sodium (2.79 g, 0.121 mmol) was dissolved in anhydrous EtOH (100 ml), then 2,2,2-trichloro-1-(5-methyl-1H-pyrrol-2-yl)ethanone (Intermediate 4; 22.5 g, 0.099 mmol) was added in small portions. The dark brown solution was stirred at room temperature for 30 min then concentrated under vacuum to a small volume. The mixture was cooled in an ice bath and 3 N HCl was added slowly then extracted with diethyl ether (3×100 ml). The ether extracts were washed with 10% NaHCO3, water and brine, dried over Na2SO4 and concentrated in vacuo to give the title compound as a brown solid. (15.04 g). NMR: 1.32 (t, 3H), 2.1 (s, 3H), 4.371 (q, 2H), 5.96 (dd, 1H), 6.78 (dd, 1H), 11.67 (s, 1H).


Intermediate 4
2,2,2-Trichloro-1-(5-methyl-1H-pyrrol-2-yl)ethanone

2-Methyl-1H-pyrrole (Intermediate 5; 10 g, 0.123 mmol) in anhydrous diethyl ether (30 ml) was added dropwise over 1 h to a stirred solution of triacetyl chloride (29 g, 0.16 mmol) in anhydrous Et2O (100 ml). The mixture was stirred for a further 1 h then K2CO3 (10 g/30 ml) was added slowly through a dropping funnel. The organic phase was dried over Na2SO4 and treated with decolourizing charcoal (3 g) for 30 min at room temperature. The resulting purple solution was concentrated and triturated with n-hexanes to give the title compound as a purple solid. (16.72 g). NMR (CDCl3): 2.36 (s, 3H), 6.04 (dd, 1H), 7.45 (dd, 1H), 10.344 (s, 1H).


Intermediate 5
2-Methyl-1H-pyrrole

Potassium hydroxide (50 g, 0.89 mmol) was added to a solution of ethylene glycol (750 ml) and 1H-pyrrole-2-carbaldehyde (50 g, 0.53 mmol). Hydrazine hydrate (37 ml, 0.745 mmol) was added slowly over 15 min. The reaction mixture was refluxed at 90° C. for 90 min. The mixture was cooled to room temperature and cold water (250 ml) was added. The aqueous mixture was extracted with DCM (250 ml). The organic phase was washed with water (250 ml), dried over Na2SO4 and concentrated in vacuo. Kugelrohr distillation gave the title compound as a clear colourless liquid (29.75 g). NMR: 2.1 (s, 3H), 5.77 (s, 1H), 5.9 (dd, 1H), 6.25 (dd, 1H), 10.54 (s, 1H).


Intermediate 6
4-Chloro-5-methyl-1H-pyrrole-2-carboxylic acid



embedded image


Lithium hydroxide (2 M, 4 ml) was warmed to 50° C. and a solution of ethyl 4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 7; 0.30 g, 1.60 mmol) in MeOH was added to it. The reaction was heated to 80° C. and stirred for two hours. The MeOH was removed and the aqueous solution was cooled to 0° C. and acidified with 30% HCl. The precipitated product (0.23 g, 92%) was filtered and dried. MS (ES): 160 (M+1) for C6H6ClNO2; NMR (CDCl3): 2.25 (s, 3H), 6.85 (s, 1H), 8.98 (brs, 1H).


Intermediate 7
Ethyl 4-chloro-5-methyl-1H-pyrrole-2-carboxylate

N-Chlorosuccinimide (0.67 g, 5.08 mmol) was added to a solution of ethyl 5 -methyl-1H-pyrrole-2-carboxylate (Intermediate 3; 0.65 g, 4.23 mmol) in chloroform (20 ml). The reaction was warmed to 40° C. and stirred for 4 h, then poured to a beaker containing 2 N NaOH (20 ml) at 0° C. The layers were separated and the aqueous layer was extracted with chloroform (×3). The combined organic extracts were dried over magnesium sulfate and concentrated. The resultant off-white solid was purified by flash chromatography (hexanes/EtOAc, 16:1) to give the title product as a white solid (0.3 g, 38%). MS (ES): 188 (M+1) for C8H10ClNO2; NMR (CDCl3): 1.34 (t, 3H), 2.27 (s, 3H), 4.30 (q, 2H), 6.76 (s, 1H), 9.07 (brs, 1H).


Intermediate 8
3,4-Difluoro-2-methyl-1H-pyrrole

BH3THF (400 ml, 1M in THF) was added dropwise to a solution of 3, 4-difluoro-1H-pyrrole-2-carbaldehyde (Intermediate 19; 3.82 g) in THF (50 ml) cooled in an ice-water bath under N2. The reaction mixture was stirred at room temperature for 3 days. MeOH was added slowly to quench excess of BH3 and then the solvent was removed in vacuo at 0° C. The resulting yellow oil was triturated with hexanes/DCM and the yellow precipitate was removed by filtration. The filtrate was washed with NaHCO3, H2O and brine, dried over Na2SO4, filtered and concentrated at 0° C. in vacuo to give a pale yellow oil (3.8 g). MS (ES) MH+: 116 for C5H5F2N; NMR (CDCl3): 2.15 (s, 3H), 6.22 (m, 1H).


Intermediate 9
1-tert-Butyl-3-methyl-4-hydroxy-5,6-dihydropyridine-1,3-(2H)-dicarboxylate

Methyl-4-hydroxy-1,2,5,6-tetrahydropyridine-3-carboxylate-hydrochloride (25 g) was suspended in DCM (250 ml). DIEA (41.6 g) was added in a single portion and the resultant homogeneous solution was cooled to 0° C. A DCM solution of di-tert-butyl dicarbonate (29.5 g, 1.05 moles) was added dropwise over a 1 h period. After the addition, the reaction was warmed to room temperature and stirred overnight. The reaction mixture was concentrated to one-half the volume and washed with water, brine, dried over Na2SO4, filtered and concentrated in vacuo to an oil. The crude product was purified by flash column chromatography eluting with (20% EtOAc/80% hexanes) to give the title product (33 g). NMR (CDCl3): 1.48 (s, 9H), 2.37 (m, 2H), 3.57 (t, 2H), 3.78 (s, 3H), 4.06 (brs, 2H), 11.9 (s, 1H).


Intermediate 10
Ethyl 4-chloroquinoline-2-carboxylate



embedded image


Phosphorous oxychloride (5 ml) was added to ethyl 4-hydroxyquinoline-2-carboxylate (1.01 g). The reaction mixture was subjected to single-mode microwave at 100° C. for 30 min using a Smith Microwave Synthesizer. The solvent was removed in vacuo and recrystallized with acetone to gave the title compound as a white solid (1.90 g). MS (ES) MH+: 235, 237 for C12H10ClNO2; NMR (CDCl3): 1.44 (t, 3H, J=7.16), 4.51 (q, 2H, J=7.16), 7.19 (s, 1H), 7.71 (m, 1H), 7.81 (m, 1H), 8.22 (m, 1H), 8.36 (d, 1H, J=8.29).


Intermediate 11
2-(Methylthio)-1,3-thiazole-4-carboxylic acid

Ethyl 2-(methylthio)-1,3-thiazole-4-carboxylate (5.0 g) (Sinha, Subhash C et al. Tet. Lett. 2000, 41 (43), 8243-8246) was dissolved in MeOH (50 ml) and 2N LiOH (74 ml) was added. After stirring at room temperature for five minutes the reaction mixture was concentrated to remove MeOH and the residue was suspended in water and acidified with conc. HCl to pH 3. The white precipitate was filtered and dried to yield the title compound (3.42 g). NMR: 2.72 (s, 3H), 8.35 (s, 1H).


Intermediate 12
2-(Methylthio)-4-thiazolecarbonyl chloride

2-(Methylthio)-1,3-thiazole-4-carboxylic acid (Intermediate 11; 1.0 g) in thionyl chloride (10 ml) was heated to reflux for 30 min. The solution was cooled to room temperature and concentrated in vacuo. The residue was washed with anhydrous THF and concentrated to yield a black solid which was dried and stored cold under nitrogen (1.2 g). NMR (CDCl3): 2.76 (s, 3H), 8.32 (s, 1H).


Intermediate 13
N-(1-Methyl-1-phenylethyl)-2-(methylthio)-1,3-thiazole-4-carboxamide

Triethylamine (2.24 ml) was added to a solution of cumylamine (3.2 ml) in anhydrous THF (30 ml). After stirring for 15 min, a solution of 2-(methylthio)-4 -thiazolecarbonyl chloride (Intermediate 12; 3.1 g) in anhydrous THF was added and the reaction mixture was concentrated in vacuo after 15 min. The residue was partitioned with EtOAc and water, dried with MgSO4, and concentrated to an orange oil. Flash purification on silica gel with isocratic elution of DCM yielded the product as a yellow oil (3.7 g). MS (ES) MH+: 293 for C14H16N2OS2; NMR: 1.68 (s, 6H), 2.76 (s, 3H), 7.20 (d, J=7.16 Hz, 1H), 7.29 (t, J=7.54 Hz, 2H), 7.36-7.41 (m, 2H), 8.04 (s, 1H), 8.08 (s, 1H).


Intermediate 14
4-{[(1-Methyl-1-phenylethyl)amino]carbonyl}-2-(methylthio)-1,3-thiazole-5-carboxylic acid

Diisopropylamine (4.2 ml) was dissolve in anhydrous THF (100 ml) was cooled to −78° C. and to this was added n-butyl lithium (12 ml) slowly. The solution was slowly warmed to 0° C. and then cooled back to −78° C. A solution of N-(1 -methyl-1-phenylethyl)-2-(methylthio)-1,3-thiazole-4-carboxamide (Intermediate 13; 2.8 g) in anhydrous THF was added slowly maintaining the temperature below −70° C. After stirring for 30 min, a solution of methyl cyano formate (1.6 ml) in anhydrous THF was added in one portion and the reaction was stirred at −78° C. for 30 min followed by slow warming to room temperature. The reaction mixture was diluted with water and extracted with ether. The aqueous portion was acidified with conc. HCl, extracted with EtOAc, dried with MgSO4 and concentrated to an orange solid (0.9 g). MS (ES) MH+: 337 for C15H16N2O3S2; NMR: 1.66-1.74 (m, 6H), 2.80 (s, 3H), 7.23 (d, J=7.16 Hz, 1H), 7.33 (t, J=7.54 Hz, 2H), 7.45 (s, 2H), 9.07 (s, 1H).


Intermediate 15
Methyl 4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-2 -(methylthio)-1,3-thiazole-5-carboxylate



embedded image


Potassium carbonate (0.37 g) and iodomethane (0.17 ml) were added to a solution of 4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-2-(methylthio)-1,3-thiazole-5-carboxylic acid (Intermediate 14; 0.9 g) in DMF (20 ml) and heated in a sealed tube at an external temperature of 85° C. for 30 min. The reaction mixture was concentrated to remove DMF and partitioned with EtOAc and water. The combined organic extracts were washed with water, dried with MgSO4, and concentrated to an orange solid (0.63 g). NMR: 1.60-1.65 (m, 6H), 2.76 (s, 3H), 3.78-3.83 (m, 3H), 7.22 (d, J=7.16 Hz, 1H), 7.33 (t, J=7.63 Hz, 2H), 7.46 (d, J=7.35 Hz, 2H), 8.75 (s, 1H).


Intermediate 16
Methyl 4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-2-(methylsulfonyl)-1,3-thiazole-5-carboxylate

3-Chloroperbenzoic acid (0.89 g) was added to a solution of methyl 4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-2-(methylthio)-1,3-thiazole-5-carboxylate (Intermediate 15; 0.63 g) in DCM (25 ml). After stirring overnight the reaction was complete. Aqueous sodium bisulfite was added to quench any unreacted peroxides and the solution was washed with sat. NaHCO3. The organic portion was dried with MgSO4 and concentrated to a yellow solid (0.6 g). NMR: 1.63-1.68 (m, 6H), 3.58 (s, 3H), 3.89 (s, 3H), 7.23 (d, J=7.16 Hz, 1H), 7.34 (t, J=7.63 Hz, 2H), 7.47 (d, J=7.54 Hz, 2H), 8.91 (s, 1H).


Intermediate 17
Methyl-2-chloro-4-(methoxymethyl)-1,3-thiazole-5-carboxylate

tert-Butyl nitrite (2.2 ml, 18.6 mmol) and cuprous chloride (1.5 g) were suspended in anhydrous CH3CN (100 ml). Methyl 2-amino-4-(methoxymethyl)-1,3-thiazole-5-carboxylate (2.5 g) prepared as described in (Kennedy, Alan R. et al. Acta Crystallographica, Section C: Crystal Structure Communications (1999, C55 (7) 2) was added in one portion. The mixture was stirred at room temperature for 2 h and the temperature was raised to 70° C. for 1 h. The mixture was cooled to room temperature and filtered. The filtrate was poured into 6 N HCl, extracted with EtOAc, dried with MgSO4 and concentrated to a black oil. Flash purification on silica gel with gradient elution (hexane to EtOAc) yielded product as a yellow liquid (0.82 g). NMR: 3.31 (s, 3H), 3.85 (s, 3H), 4.71 (s, 2H).


Intermediate 18
3,4-Difluoro-1H-pyrrole

3,4-Difluoro-1H-pyrrole was prepared as described in Eric K. Woller et al., J. Org. Chem., 1998 63(16), 5706-5707) and references therein. Thus, to a solution of 3,3,4,4-tetrafluoro-pyrrolidine hydrochloride (30.2 g) in dry DMSO (250 ml) cooled in an ice-water bath, t-BuOK was added (100 g) under N2. After the addition was complete (˜0.5 h), the reaction mixture was stirred at room temperature for another 0.5 h. It was cooled to 0° C. and quenched with ice water (300 ml). After the solid dissolved, the mixture was diluted to ˜1.51 with water, neutralized to pH 7 with HCl, and extracted with DCM. The combined DCM extracts were washed with water, brine, dried over MgSO4 and filtered. DCM was removed in vacuo at 0° C., and the resulting orange oil was dissolved in pentane at room temperature, cooled to −20° C. overnight and filtered under N2 to give the title compound as golden crystals (4.6 g). NMR (CDCl3): 6.38 (d, 1H), 6.41 (d, 1H).


Intermediate 19
3,4-Difluoro-1H-pyrrole-2-carbaldehyde

DMF (4.3 ml) was cooled in ice-water bath under N2 and POCl3 (5.2 ml) was added dropwise. The mixture was stirred at room temperature for 10 min. The ice-water bath was replaced, and the mixture was diluted with DCM (45 ml). A solution of 3,4-difluoro-1H-pyrrole (Intermediate 18; 4.57 g) in DCM (45 ml) was added dropwise. The mixture was refluxed for 30 min, cooled to room temperature and a solution of NaOAc (23 g) in water (60 ml) was added slowly. The resulting mixture was refluxed for 30 min, organic phase was separated and aqueous phase was extracted with DCM. The combined organic phase was washed with NaHCO3, dried over Na2SO4, and concentrated in vacuo. The crude solid was triturated with DCM (20 ml)/pentane (100 ml), and then cooled to −20° C. to give the title compound as pale brown needles (4.73 g). NMR (CDCl3): 6.87 (m, 1H), 9.6 (m, 1H).


Intermediate 20
3,4-Difluoro-5-methyl-1H-pyrrole-2-carboxylic acid



embedded image


2,2,2-Trichloro-1-(3,4-difluoro-5-methyl-1H-pyrrol-2-yl)ethanone (Intermediate 80; 1.03 g) was added to an aqueous solution of NaOH (18 ml) at 0° C. under N2. The mixture was stirred at room temperature for a further 2 h, cooled to 0° C. and acidified with HCl to ˜pH 2. A brown precipitate of product was collected by filtration. The crude product was purified by column chromatography on silica gel elution with EtOAc/hexanes (1:1). Trituration with DCM (1 ml)/pentane (6 ml) gave the title compound as a pale brown solid (306 mg). M.p. 140° C. (dec.). MS (ES) MH+: 160, 161 for C6H5F2NO2; NMR (CDCl3): 2.15 (s, 3H), 11.5 (s, 1H), 12.8 (brs, 1H).


Intermediate 21
Cis(±)ethyl 4-amino-3-methoxypiperidine-1-carboxylate hydrochloride salt

The title compound can be prepared as described in Lee, C. et al. Synth. Comm. 2001, 31(7), 10881-10890 and/or WO 94/12494 or from Intermediate 157 by the following procedure;


To a stirred solution of the benzylamine (36.45 g, 125 mmol) and 10% palladium on activated carbon (50% wet; approximately 4 g) in methanol (250 mL), at room temperature and under an atmosphere of N2, was added ammonium formate (31.50 g, 500 mmol) as a solid. Temperature was increased to 70° C.; the reaction was stirred overnight at this temperature, under an atmosphere of N2. Complete conversion was suggested by TLC (6% methanol in ethyl acetate; Rf˜0.06 in a solution of 15% methanol and 30% acetone in methylene chloride) in the morning. The reaction mixture was filtered through Celite and concentrated under vacuum. To the residue was added approximately 50 mL water; from this mixture was extracted the crude product with a solution of ˜3% methanol in chloroform (4×300 mL). Organic layers were combined, dried over magnesium sulfate, and concentrated. Obtained 24.18 g (96%) of an off-white solid.


MS (ES) MH+: 202 for C9H18N2O3.


Intermediate 22
Cis(±)ethyl 4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylate

Benzyl chloroformate (3.3 ml) was added dropwise to a cold solution of Cis(±)ethyl 4-amino-3-methoxypiperidine-1-carboxylate hydrochloride salt (Intermediate 21; 5 g) in saturated NaHCO3. The mixture was stirred at room temperature for 14 h. The white precipitate was filtered, washed well with water, dried in vacuo to give the title compound as a white solid (6.66 g). MS (ES) MH+: 336 for C17H24N2O5; NMR: 1.21 (t, 3H), 1.52-1.67 (m, 2H), 3.08 (m, 2H), 3.28 (s, 3H), 3.41 (s, 2H), 3.74-3.92 (m, 2H), 3.96 (m, 2H), 4.14 (m, 1H), 5.10 (s, 2H), 7.24 (d, 1H), 7.44 (m, 5H).


Intermediate 23 and Intermediate 24
ethyl (3R,4S)-4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylate and ethyl (3S,4R)-4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylate

Cis(±)ethyl 4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylate (Intermediate 22; 6.2 g) were separated into its enantiomers by chiral chromatography over a Chiralcel OJ column (eluant: hexanes/MeOH/EtOH; 70/15/15; 0.1% diethylamine). The fractions corresponding to the first chromatographic peak (Cis(−)isomer) were collected and evaporated yielding the title compound as a white solid (2.62 g). The fractions corresponding to the second chromatographic peak (Cis(+)isomer) were collected and evaporated yielding the title compound as a white solid (2.71 g). MS (ES)(M+Na)+: 360 for C17H24N2O5; NMR: 1.21 (t, 3H), 1.52-1.67 (m, 2H), 3.08 (m, 2H), 3.28 (s, 3H), 3.41 (s, 2H), 3.74-3.92 (m, 2H), 3.96 (m, 2H), 4.14 (m, 1H), 5.10 (s, 2H), 7.24 (d, 1H), 7.44 (m, 5H).


Intermediate 25
ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate



embedded image


ethyl (3S,4R)-4-{[(benzyloxy)carbonyl]amino}-3-methoxypiperidine-1-carboxylate (Intermediate 24; 3.98 g) was dissolved in MeOH (100 ml) and 1N HCl (50 ml). 10% Pd-charcoal (600 mg) was added, degassed and hydrogenolysed under an atmosphere of H2 gas at room temperature for 3 h. The catalyst was filtered through a bed of celite, concentrated in vacuo and lyophilized giving the title compound (2.8 g). MS (ES) MH+: 202 for C9H18N2O3.


Intermediate 26

The following compound was prepared in a manner analogous to Intermediate 25 from the starting material indicated.















Int
Compound
MS
SM







26
ethyl (3R,4S)-4-amino-3-
MS (ES) MH+: 202
Intermediate



methoxypiperidine-1-carboxylate
for C9H18N2O3
23









Intermediate 27
Cis(±)ethyl-3-(allyloxy)-4-[(tert-butoxycarbonyl)amino]piperidine-1-carboxylate

A 50% aqueous solution of sodium hydroxide (3 ml) was added to a suspension of allyl bromide (693 mg, 5.70 mmol), cis(±)ethyl 4-[(tert-butoxycarbonyl)amino]-3-hydroxypiperidine-1-carboxylate (reference: C. H. Lee et al. Syn. Commun., 2001, 31, 1081), (750 mg, 2.6 mmol), benzyltriethylammonium chloride (4 mg, cat.) and toluene (8 ml). The resultant mixture was stirred overnight at room temperature. The reaction mixture was diluted with EtOAc (150 ml) and water (35 ml). The organic phase was separated and the aqueous phase was back extracted with EtOAc (2×30 ml). The combined organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated. The crude residue was purified by flash column chromatography (hexane/EtOAc, 3:2) to yield 734 mg of the title compound. MS (ES)(M+H): 329. for C16H28N2O5; NMR: 1.28 (t, 3H), 1.47 (s, 9H), 1.68 (m, 2H), 2.88 (brt, 2H), 3.50 (m, 1H), 3.68 (m, 1H), 3.90 (m, 1H), 4.00-4.45 (m, 3H), 4.10 (q, 2H), 4.92 (brs, 1H), 5.20 (m, 2H), 5.86 (m, 1H).


Intermediate 28
Cis(±)ethyl-3-(allyloxy)-4-amino]piperidine-1-carboxylate hydrochloride salt

4N HCl/dioxane (20 ml) was added to cis(±)ethyl-3-(allyloxy)-4-[(tert-butoxycarbonyl)amino]piperidine-1-carboxylate (Intermediate 27; 572 mg). The mixture was stirred at room temperature for 90 min. The solvent was removed in vacuo, dried in vacuo to give the title compound as an oily foam which was used without further purification (449 mg). MS (ES)(M+H): 228. for C11H20N2O3.


Intermediates 29-36

The following compounds were prepared in a manner analogous to Intermediate 28 from the starting material (SM) indicated.















Int
Compound
Data
SM







29
Cis(±)ethyl-4-amino-3-
MS (ES)(M + H): 220 for
Intermediate 81



propyoxypiperidine-1-carboxylate
C11H22N2O3



hydrochloride salt





30
Methyl 2-[(3R,4R)-4-amino-3- methoxypiperidin-1-yl]-1,3-thiazole- 5-carboxylate hydrochloride salt embedded image
NMR: 1.63 (m, 1H), 2.08 (d, 1H), 2.97-3.01 (m, 1H), 3.21-3.24 (m, 2H), 3.25 (m, 2H), 3.40 (s, 3H), 3.73 (s, 3H), 3.88 (d, 1H), 4.34 (m, 1H), 7.87 (s, 1H), 8.28 (brs, 3H)
Intermediate 68





31
Methyl 2-[(3S,4S)-4-amino-3-
NMR: 1.63 (m, 1H), 2.08 (d,
Intermediate 69



methoxypiperidin-1-yl]-1,3-thiazole-
1H), 2.97-3.01 (m, 1H),



5-carboxylate hydrochloride salt
3.21-3.24 (m, 2H), 3.25 (m,




2H), 3.40 (s, 3H), 3.73 (s,




3H), 3.88 (d, 1H), 4.34 (m,




1H), 7.87 (s, 1H), 8.28 (brs, 3H)


32
Cis(±)3,4-dichloro-N-[3-
NMR: 1.92-1.96 (m, 2H),
Intermediate 49



fluoropiperidin-4-yl]-5-methyl-1H-
2.20 (s, 3H), 3.10 (m, 1H),



pyrrole-2-carboxamide
3.43-3.51 (m, 2H), 3.64 (m,



hydrochloride salt
1H), 4.27-4.38 (m, 1H), 5.05




(d, 1H), 7.58 (d, 1H), 8.75




(brs, 1H), 9.43 (brs, 1H),




12.32 (s, 1H)


33
3,4-dichloro-N-[(3R,4S)-3-
MS (ES) (M + H): 294, 296
Intermediate 45



fluoropiperidin-4-yl]-5-methyl-1H-
for C11H14Cl2FN3O



pyrrole-2-carboxamide



hydrochloride


34
Trans(±)3,4-dichloro-N-[3-
MS (ES) (M + H): 294, 296
Intermediate 44



fluoropiperidin-4-yl]-5-methyl-1H-
for C11H14Cl2FN3O



pyrrole-2-carboxamide



hydrochloride





35
Cis(±)methyl 4-{[(3,4-dichloro-5-
MS (ES) (M + H): 332 for
Intermediate 46



methyl-1H-pyrrol-2-
C13H17Cl2N3O3



yl)carbonyl]amino}piperidine-3-



carboxylate hydrochloride salt





embedded image







36
3,4-dichloro-N-[(3S,4R)-3-
MS (ES) M + H): 294, 296 for
Intermediate 48



fluoropiperidin-4-yl]-5-methyl-1H-
C11H14Cl2FN3O



pyrrole-2-carboxamide



hydrochloride









Intermediate 37
Cis(±)ethyl 4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidine-1-carboxylate

3,4-Dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (Intermediate 1; 304 mg) was dissolved in anhydrous DMF. HATU (596 mg), HOAT (213 mg) and DIEA (274 μl) were added and stirred at ambient for 15 min. Cis(±)ethyl 4-amino-3-methoxypiperidine-1-carboxylate (Intermediate 21; 317 mg) was added and the mixture was stirred at ambient for 18 h. The mixture was diluted with EtOAc and washed with water, 1N HCl, bicarbonate buffer, water, brine and dried over Na2SO4. The solution was concentrated in vacuo to give the title compound as a brown solid (503 mg). MS (ES) MH+: 378, 380 for C15H21Cl2N3O4; NMR: 1.29 (t, 3H), 1.79 (m, 2H), 2.27 (s, 3H), 3.12 (m, 2H), 3.30 (s, 3H), 3.37 (m, 1H), 3.83-4.16 (m, 5H), 7.25 (d, 1H), 12.23 (s, 1H).


Intermediates 38-49

The following compounds were prepared in a manner analogous to Intermediate 37 from the starting material (SM) indicated.















Int
Compound
Data
SM







38
Cis(±)ethyl-4-{[(3,4-difluoro-5-
MS (ES) MH+: 344 for
Intermediate 20



methyl-1H-pyrrol-2-
C15H21F2N3O4; NMR: 1.3 (t,
and Intermediate 21



yl)carbonyl]amino}-3-
3H), 1.69 (m, 2H), 2.21 (s,



methoxypiperidine-1-
3H), 3.11 (m, 2H), 3.22 (s,



carboxylate
3H), 3.39 (m, 2H), 3.85 (q,




2H), 4.41 (m, 1H), 6.83 (d,




1H), 11.54 (s, 1H)


39
ethyl (3S,4R)-4-{[(3,4-dichloro-
MS (ES) MH+: 377 for
Intermediate 25



5-methyl-1H-pyrrol-2-
C15H21Cl2N3O4; NMR: 1.32
and Intermediate 1



yl)carbonyl]amino}-3-
(t, 3H), 1.74 (m, 2H), 2.31 (s,



methoxypiperidine-1-
3H), 3.14 (m, 2H), 3.18-3.52



carboxylate
(s, 3H), 3.75-4.44 (m, 5H),




7.30 (d, 1H), 12.39 (s, 1H)





40
ethyl (3R,4S)-4-{[(3,4-dichloro-
MS (ES) MH+: 377 for
Intermediate 26



5-methyl-1H-pyrrol-2-
C15H21Cl2N3O4; NMR: 1.32
and Intermediate 1



yl)carbonyl]amino}-3-
(t, 3H), 1.74 (m, 2H), 2.31 (s,



methoxypiperidine-1-
3H), 3.14 (m, 2H), 3.18-3.52



carboxylate
(s, 3H), 3.75-4.44 (m, 5H),





embedded image


7.30 (d, 1H), 12.39 (s, 1H)





41
Ethyl 4-{[(4-chloro-5-methyl-
MS (ES) MH+: for
Intermediate 21



1H-pyrrol-2-
C15H22ClN3O4; NMR: 1.18 (t,
and Intermediate 6



yl)carbonyl]amino}-3-
J = 7.06 Hz, 3H), 1.48 (d,



methoxypiperidine-1-
J = 3.58 Hz, 1H), 1.75 (td,



carboxylate
J = 12.29, 7.82 Hz, 1H), 2.10-




2.18 (m, 3H), 2.95 (d,




J = 13.38 Hz, 2H), 3.20-3.27




(m, 3H), 3.27-3.35 (m, 2H),




3.38 (s, 1H), 3.97-4.09 (m,




J = 10.53, 7.08, 7.08, 3.39 Hz,




2H), 4.19 (s, 1H), 6.88 (d,




J = 2.64 Hz, 1H), 7.62 (d,




J = 7.91 Hz, 1H), 11.60 (s, 1H)


42
Cis(±)ethyl 3-(allyloxy)-4-
MS (ES) MH+: 402, 404 for
Intermediate 1 and



{[(3,4-dichloro-5-methyl-1H-
C17H23Cl2N3O4
Intermediate 28



pyrrol-2-



yl)carbonyl]amino}piperidine-



1-carboxylate


43
Cis(±)ethyl 4-{[(3,4-dichloro-5-
MS (ES) MH+: 404, 406 for
Intermediate 1 and



methyl-1H-pyrrol-2-
C17H25Cl2N3O4
Intermediate 29



yl)carbonyl]amino}-3-



propoxypiperidine-1-



carboxylate


44
Trans(±)tert-butyl-4-{[(3,4-
MS (ES) (M + Na): 416, 418
Intermediate 60



dichloro-5-methyl-1H-pyrrol-2-
for C16H22Cl2FN3O3
and Intermediate 1



yl)carbonyl]amino}-3-



fluoropiperidine-1-carboxylate





45
tert-butyl (3R,4S)-4-{[(3,4-
MS (ES) (M + Na): 416, 418
Intermediate 61



dichloro-5-methyl-1H-pyrrol-2-
for C16H22Cl2FN3O3
and Intermediate 1



yl)carbonyl]amino}-3-



fluoropiperidine-1-carboxylate





embedded image







 46,
1-tert-Butyl 3-methyl 4-{[(3,4-
46: MS (ES − (M + H)+): 434,
Intermediate 70


47
dichloro-5-methyl-1H-pyrrol-2-
436 for C18H25Cl2N3O5; NMR
and Intermediate 1



yl)carbonyl]amino}piperidine-
1.45 (s, 9H), 2.16 (m, 1H),



1,3-dicarboxylate
2.27 (s, 3H), 2.55 (dt, 1H),



Note for Examples 46 and 47:
2.93 (m, 1H), 3.09 (m, 2H),



The resultant crude mixture
3.66 (s, 3H), 4.08 (m, 1H),



dissolved in DCM, added to a
4.29 (m, 2H), 6.68 (d, 1H),



silica gel column, and was
9.66 (s, 1H)



purified using a gradient of 10-
47: MS (ES) MH)+: 434, 436



50% EtOAc in hexanes. The
for C18H25Cl2N3O5; NMR:



recovered mixture of
1.44 (s, 9H), 1.75 (m, 1H),



diastereomers were taken up in
2.09 (m, 1H), 2.26 (s, 3H),



EtOAc (200 ml), heated to
2.86 (m, 1H), 2.98 (m, 1H),



50° C., and filtered. The solid
3.17 (dd, 1H), 3.71 (s, 3H),



was washed with EtOAc and
4.04 (m, 1H), 4.44 (m, 2H),



dried, to show a 90:10 cis:trans
7.57 (d, 1H), 9.53 (s, 1H)



mixture of diastereomers (2.3 g,



30.6% yield) (Intermediate 46).



The filtrate was then subjected



to a recrystallisation using



EtOAc and n-heptane, and a



90:10 trans:cis mixture (2.65 g,



35.3% yield) (Intermediate 47)



was recovered.


48
tert-butyl (3S,4R)-4-{[(3,4-
MS (ES) (M + Na): 416, 418
Intermediate 64



dichloro-5-methyl-1H-pyrrol-2-
for C16H22Cl2FN3O3
and Intermediate 1



yl)carbonyl]amino}-3-



fluoropiperidine-1-carboxylate


49
Cis(±)tert-butyl-4-{[(3,4-
NMR (CDCl3): 1.47 (s, 9H),
Intermediate 59



dichloro-5-methyl-1H-pyrrol-2-
1.84-1.88 (m, 2H), 2.28 (s,
and Intermediate 1



yl)carbonyl]amino}-3-
3H), 2.76-3.02 (m, 2H), 4.11-



fluoropiperidine-1-carboxylate
4.26 (m, 2H), 4.43-4.51 (m,




1H), 4.77 (d, 1H)









Intermediate 50
Cis(±)3,4-dichloro-N-(3-methoxypiperidin-4-yl)-5-methyl-1H-pyrrole-2-carboxamide



embedded image


The title compound was prepared by the methods described below:


Method A


Cis(±)ethyl 4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidine-1-carboxylate (Intermediate 37; 503 mg) was dissolved in MeOH (30 ml). 1 M NaOH was added and the mixture was heated at 100° C. for 12 h. The reaction mixture was cooled to ambient and extracted with EtOAc, washed with water, dried over Na2SO4 and concentrated in vacuo to give the title compound as a brown oily gum which was used without further purification (336 mg).


Method B


Cis(±)ethyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidine-1-carboxylate (Intermediate 37; 3.85 g) was suspended in anhydrous CH3CN. Iodotrimethylsilane (2.2 ml) was added slowly. The reaction was heated to reflux for several hours until complete by LCMS. The crude reaction mixture was diluted with water and acidified with 1N HCl to pH 3. The solution was extracted with EtOAc. The aqueous layer was basified with 50% NaOH to pH 10. The aqueous layer as saturated with sodium chloride and extracted with THF, dried with MgSO4 and concentrated to a tan solid (2.1 g). MH+: 306 for C12H17Cl2N3O2; NMR: 1.61 (d, J=3.77 Hz, 2H), 1.76 (dt, J=6.50, 3.16 Hz, 1H), 2.16-2.20 (m, 3H), 2.56-2.69 (m, 2H), 2.90 (d, J=13.19 Hz, 1H), 3.18 (dd, J=13.75, 3.01 Hz, 1H), 3.30-3.35 (m, 3H), 3.56-3.64 (m, 1H), 4.04-4.15 (m, J=8.10, 7.72, 7.72, 3.01 Hz, 1H), 7.14 (d, J=8.29 Hz, 1H).


Intermediates 51-56

The following Intermediates were prepared as described by the general methods described in Intermediate 50 from the starting materials (SM) indicated.















Int
Compound
Data
SM







51
3,4-dichloro-N-[(3S,4R)-3-
M/z 306; 1.73 (m, 2H), 2.31 (s, 3H), 2.64 (m,
Intermediate



methoxypiperidin-4-yl]-5-
1H), 2.98 (m, 1H), 3.22 (m, 1H), 3.34 (m,
39



methyl-1H-pyrrole-2-
1H), 3.34 (s, 3H), 3.42 (m, 2H), 4.25 (m,



carboxamide
1H), 7.31 (d, 1H).


52
3,4-dichloro-N-(3R,4S)[3-
M/z 306; 1.73 (m, 2H), 2.31 (s, 3H), 2.64 (m,
Intermediate



methoxypiperidin-4-yl]-5-
1H), 2.98 (m, 1H), 3.22 (m, 1H), 3.34 (m,
40



methyl-1H-pyrrole-2-
1H), 3.34 (s, 3H), 3.42 (m, 2H), 4.25 (m,



carboxamide
1H), 7.31 (d, 1H).


53
Cis(±)3,4-dichloro-5-
M/z 334
Intermediate



methyl-N-(3-

43



propoxypiperidin-4-yl)-



1H-pyrrole-2-carboxamide


54
Cis(±)3,4-dichloro-5-
M/z 332
Intermediate



methyl-N-(3-

42



allyoxypiperidin-4-yl)-1H-



pyrrole-2-carboxamide


55
Cis(±)4-chloro-N-(3-
M/z 272; 1.41 (s, 1H), 1.67 (s, 1H), 2.13 (s,
Intermediate



methoxypiperidin-4-yl)-5-
3H), 2.47 (s, 1H), 2.55 (s, 1H), 2.86 (s, 1H),
41



methyl-1H-pyrrole-2-
3.08 (d, J = 13.19 Hz, 1H), 3.25 (s, 3H),



carboxamide
3.31 (s, 1H), 6.89 (d, J = 2.45 Hz, 1H), 7.52 (s,




1H), 11.59 (s, 1H)


56
Cis(±)3,4-difluoro-N-(3-
M/z 273; 1.74 (m, 2H), 2.24 (s, 3H), 3.00 (m,
Intermediate



methoxypiperidin-4-yl)-5-
1H), 3.21 (m, 1H), 3.36 (s, 3H), 3.42 (m,
38



methyl-1H-pyrrole-2-
4H), 4.20 (brm, 1H), 6.74 (brm, 1H),



carboxamide
11.60 (brs, 1H).









Intermediate 57 and Intermediate 58
tert-Butyl-(3S,4R)-4-(benzylamino)-3-fluoropiperidine-1-carboxylate and tert-Butyl-(3R,4S)-4-(benzylamino)-3-fluoropiperidine-1-carboxylate



embedded image


Cis(±)tert-butyl-4-(benzylamino)-3-fluoropiperidine-1-carboxylate (Intermediate 82; 2.2 g) was separated into the title compounds using chiral HPLC, in a manner analogous to Intermediate 23 and Intermediate 24 over a Chiralpak AD column (eluent: hexanes/MeOH/EtOH; 90/2.5/2.5; 0.1% diethylamine). The fractions corresponding to the first chromatographic peak (Cis(+) isomer; Intermediate 57) were collected and evaporated yielding the title compound as a white solid (942 mg). The fractions corresponding to the second chromatographic peak (Cis(−) isomer; Intermediate 58) were collected and evaporated yielding the title compound as a white solid (980 mg). NMR (CDCl3): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, 1H), 4.66 (d, 1H).


Intermediate 59
Cis(±)tert-butyl-4-amino-3-fluoropiperidine-1-carboxylate

Cis(±)tert-butyl-4-(benzylamino)-3-fluoropiperidine-1-carboxylate (Intermediate 82; 711 mg), ammonium formate (582 mg), and 10% Pd/C (200 mg) in MeOH (10 ml) was heated to 50° C. for 1 h. The reaction mixture was cooled to room temperature, filtered through diatomaceous earth and concentrated under reduced pressure to give the title compound (503 mg, quantitative). NMR (CDCl3): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, 1H), 4.66 (d, 1H).


Intermediates 60-64

The following Intermediates were prepared by the procedure described in Intermediate 59 from the starting materials (SM) indicated.















Int
Compound
Data
SM







60
Trans(±)tert-butyl-4-amino-3-
NMR (CDCl3): 1.38 (s, 9H), 1.88
Intermediate 65



fluoropiperidine-1-carboxylate
(m, 2H), 2.87 (m, 2H), 3.59 (m,





embedded image


2H), 3.77 (m, 1H), 4.66 (d, 1H)





61
tert-butyl (3R,4S)-4-amino-3-
NMR (CDCl3): 1.40 (s, 9H),
Intermediate 58



fluoropiperidine-1-carboxylate
1.88 (m, 2H), 3.01 (m, 2H), 3.55




(m, 2H), 3.77 (m, 1H), 4.66 (d,




1H)


62
tert-Butyl [(3R,4R)-3-
NMR (CDCl3): 1.45 (s, 9H),
Intermediate 66



methoxypiperidin-4-
2.43 (m, 1H), 2.50-2.57 (m,



yl]carbamate
1H), 2.59-2.66 (m, 1H), 2.89




(m, 1H), 3.01 (m, 1H), 3.24 (m,




1H), 3.41 (s, 3H), 3.67 (m, 1H),




4.71 (m, 1H)


63
tert-Butyl [(3S,4S)-3-
NMR (CDCl3): 1.45 (s, 9H),
Intermediate 67



methoxypiperidin-4-
2.43 (m, 1H), 2.50-2.57 (m,



yl]carbamate
1H), 2.59-2.66 (m, 1H), 2.89




(m, 1H), 3.01 (m, 1H), 3.24 (m,




1H), 3.41 (s, 3H), 3.67 (m, 1H),




4.71 (m, 1H)


64
tert-butyl (3S,4R)-4-amino-3-
NMR (CDCl3): 1.40 (s, 9H), 1.88
Intermediate 57



fluoropiperidine-1-carboxylate
(m, 2H), 3.01 (m, 2H), 3.55 (m,




2H), 3.77 (m, 1H), 4.66 (d, 1H)









Intermediate 65
Trans(±)tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate



embedded image


The title compound was prepared as described in Monique B. van Neil et al. J. Med. Chem., 1999, 42, 2087-2104 and the references therein. NMR (CDCl3): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, 1H), 4.66 (d, 1H).


Intermediate 66
tert-Butyl [(3R,4R)-1-benzyl-3-methoxypiperidin-4-yl]carbamate

The title compound (150 mg) was prepared from tert-butyl [(3R,4R)-1-benzyl-3-hydroxypiperidin-4-yl]carbamate by the procedure described (for similar compounds) in Synth. Commun., 2001, 31, 1081-1089. NMR (CDCl3): 1.44 (s, 9H), 1.97-2.11 (m, 3H), 2.68 (d, 1H), 3.07-3.12 (m, 2H), 3.36 (s, 3H), 3.41 (m, 1H), 3.52 (m, 2H), 4.51 (m, 1H), 7.23-7.32 (m, 5H).


Intermediate 67
tert-Butyl [(3 S,4 S)-1-benzyl-3-methoxypiperidin-4-yl]carbamate

The title compound (426 mg) was prepared from tert-butyl [(3S,4S)-1-benzyl-3-hydroxypiperidin-4-yl]carbamate by the procedure described (for similar compounds) in Synth. Commun., 2001, 31, 1081-1089. NMR (CDCl3): 1.44 (s, 9H), 1.97-2.11 (m, 3H), 2.68 (d, 1H), 3.07-3.12 (m, 2H), 3.36 (s, 3H), 3.41 (m, 1H), 3.52 (m, 2H), 4.51 (m, 1H), 7.23-7.32 (m, 5H).


Intermediates 68-69

The following Intermediates were prepared by the procedure described in Example 1 from the starting materials (SM) indicated.















Int
Compound
Data
SM







68
2-{(3R,4R)-4-[(tert-
MS (ES) (M + Na): 394 for
Intermediate 62 and



Butoxycarbonyl)amino]-3-
C16H25N3O5S; NMR (CDCl3):
methyl 2-bromo-



methoxypiperidin-1-yl}-1,3-
1.46 (s, 9H), 1.66 (m, 1H),
1,3-thiazole-5-



thiazole-5-carboxylate
1.89 (m, 1H), 2.29 (m, 1H),
carboxylate




3.13-3.20 (m, 3H), 3.47 (s, 3H), 3.75 (m,




1H), 3.83 (s, 3H), 4.20 (m, 1H),




4.60 (brs, 1H), 7.85 (s, 1H)


69
2-{(3S,4S)-4-[(tert-
MS (ES) (M + Na): 394 for
Intermediate 63 and



Butoxycarbonyl)amino]-3-
C16H25N3O5S; NMR (CDCl3):
methyl 2-bromo-



methoxypiperidin-1-yl}-1,3-
1.46 (s, 9H), 1.66 (m, 1H),
1,3-thiazole-5-



thiazole-5-carboxylate
1.89 (m, 1H), 2.29 (m, 1H),
carboxylate




3.13-3.20 (m, 3H), 3.47 (s, 3H), 3.75 (m,




1H), 3.83 (s, 3H), 4.20 (m, 1H),




4.60 (brs, 1H), 7.85 (s, 1H)









Intermediate 70
1-tert-Butyl-3-methyl-4-aminopiperidine-1,3-dicarboxylate



embedded image


The title compound was prepared according to (Cordero, F. M et al. Gazz. Chim. Ital. 1997, 127, 25-29). Thus, 1-tert-butyl-3-methyl-4-hydroxy-5,6-dihydropyridine-1,3-(2H)-dicarboxylate (Intermediate 9; 33 g) and NH4OAc (100 g) were dissolved in dry MeOH (250 ml). NaCNBH3 (8.1 g) was added in three equal portions at 1 h intervals. The reaction mixture was stirred at room temperature overnight. The reaction was monitored by GC/MS and additional NH4OAc (2.5 equiv.) and NaCNBH3 (0.25 equiv.) were added until reaction was completed. The reaction was cooled to −10° C. and acidified to pH=2 with concentrated HCl and solvent was removed in vacuo. The solid residue was dissolved in water, and extracted with Et2O. The pH of the aqueous phase was adjusted to 8-9 with solid KOH, solution saturated with NaCl and extracted with EtOAc. The organic layer was dried over K2CO3, filtered and concentrate to an oil (25 g). GC/MS: 258 for C12H22N2O4.


Intermediate 71
Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(hydroxymethyl)piperidine-1-carboxylate

Cis(±)1-tert-butyl-3-methyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-piperidine-1,3-dicarboxylate (Intermediate 46; 4.26 g) and LiBH4 (321 mg) were combined in dry THF (20 ml). MeOH (600 μl) was added in a single portion. The reaction was heated to reflux for 1 h. The mixture was cooled to room temperature, diluted with EtOAc and washed with 0.5% HCl. The organic layer was dried over Na2SO4, filtered and concentrated to a solid which was purified by flash column chromatography eluting with (60% EtOAc/40% hexanes), to yield title compound (3.11 g). MS (ES)(MH+): 406 for C17H25Cl2N3O4; NMR (CDCl3): 1.47 (s, 9H), 1.56 (m, 1H), 1.96 (m, 1H), 2.27 (s, 3H), 2.84 (m, 1H), 2.9 (m, 1H), 3.49 (m, 1H), 3.71 (m, 1H), 4.16 (m, 5H), 6.58 (d, 1H), 10.1 (brs, 1H).


Intermediate 72
Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-({[(4-methylphenyl)sulfonyl]oxy}methyl)piperidine-1-carboxylate

Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(hydroxymethyl)piperidine-1-carboxylate (Intermediate 71; 1.46 g) was dissolved in dry pyridine (20 ml) and cooled to 0° C. Tosylchloride (822 mg) was added in a single portion. The reaction was allowed to slowly warm to room temperature and stirred overnight. The mixture was diluted with EtOAc and washed with water, dried over Na2SO4, filtered and concentrated in vacuo. The foam was purified by flash column chromatography eluting with (40% EtOAc/60% hexanes) to give title compound (1.58 g). MS (ES)(MH+): 560 for C24H31Cl2N3O6S; NMR (CDCl3): 1.46 (brs, 11H), 1.89 (m, 1H), 1.98 (m, 1H), 2.31 (s, 3H), 2.35 (s, 3H), 2.8 (m, 2H), 3.96-4.23 (m, 4H), 6.4 (d, 1H), 7.19 (d, 2H), 7.68 (d, 2H), 10.3 (brs, 1H).


Intermediate 73
Cis(±)4-[(3,4-Dichloro-5-methyl-1H-pyrrole-2-carbonyl) -amino]-3-methoxymethyl-piperidine-1-carboxylic acid tert-butyl ester

Cis-tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-({[(4-methylphenyl)sulfonyl]oxy}methyl)piperidine-1-carboxylate (Intermediate 72; 325 mg) was dissolved in 5 ml of a 30 wt % MeOH solution containing NaOMe and an additional 5 ml of dry MeOH. The homogeneous reaction was stirred at room temperature for 2 days. Upon reacting, solids began to precipitate from solution. The reaction was concentrated to a solid residue, re-dissolved in EtOAc and washed with saturated NH4Cl (2×10 ml). The organic layer was dried over Na2SO4, filtered and concentrated. The residual material was purified by flash column chromatography eluting with (1:1 EtOAc/hexanes) to give the title compound (192 mg). MS (ES)(MH+): 420 for C19H27Cl2N3O4.


Intermediate 74
Cis(±)3,4-dichloro-N-[3-(methoxymethyl)piperidin-4-yl]-5-methyl-1H-pyrrole-2-carboxamide hydrochloride

Cis(±)tert-butyl 4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-(methoxymethyl)piperidine-1-carboxylate (Intermediate 73; 192 mg, 0.45 mmol) was dissolved in 4N HCl in dioxane (10 ml) and 10 ml of MeOH. The mixture was stirred at room temperature for 3 h, concentrated to dryness and azeotroped with MeOH to remove excess HCl (5×20 ml) to yield the title compound which was used without purification. (crude mixture 195 mg). MS (ES)(MH+): 320 for C13H19Cl2N3O2.


Intermediates 75-76

The following Intermediates were prepared by the procedure described in Intermediate 74 from the starting materials (SM) indicated.















Int
Compound
Data
SM







75
Cis(±)3,4-Dichloro-5-methyl-1H-pyrrole-2-
MS (ES) MH+: 319 for
Intermediate



carboxylic acid (3-methylaminomethyl-
C13H20Cl2N4O
77



piperidin-4-yl)-amide hydrochloride





embedded image







76
Cis-3,4-dichloro-5-methyl-1H-pyrrole-2-
MS (ES) MH+: 333 for
Intermediate



carboxylic acid (3-dimethylaminomethyl-
C14H22Cl2N4O
78



piperidin-4-yl)-amide hydrochloride









Intermediate 77
Cis(±)4-[(3,4-Dichloro-5-methyl-1H-pyrrole-2-carbonyl) -amino]-3-methylaminomethyl-piperidine-1-carboxylic acid tert-butyl ester

Cis(±)tert-butyl-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-({[(4-methylphenyl)sulfonyl]oxy}methyl)-piperidine-1-carboxylate (Intermediate 72; 500 mg, 0.89 mmol) was dissolved in 5 ml of a 2.0 M THF solution containing MeNH2. The reaction vessel was sealed and heated to 100° C. for 2 h. The mixture was cooled to room temperature and diluted with EtOAc, then washed with water. The organic layer was dried over Na2SO4, filtered and concentrated to a crude solid foam which was used without further purification. MS (ES)MH+: 419 for C18H28Cl2N4O3.


Intermediate 78

The title compound was prepared in a manner analogous to Intermediate 77 from the starting material indicated.















Int
Compound
MS
SM







78
Cis(±)4-[(3,4-Dichloro-5-
MS (ES) MH+:
Intermediate 72



methyl-1H-pyrrole-2-carbonyl)-
433 for
and



amino]-3-
C19H30Cl2N4O3
dimethylamine



dimethylaminomethyl-



piperidine-1-carboxylic acid



tert-butyl ester









Intermediate 79
Cis(±)4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-3-carboxylic acid hydrochloride

THF (10 ml) and MeOH (8 ml) were added to cis(±)1-tert-butyl 3-methyl 4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-1,3-dicarboxylate (Intermediate 46; 2.24 g). The resultant mixture was cooled to 0° C., and a solution of lithium hydroxide (0.37 g) in water (5 ml) at 0° C. was added dropwise via pipette, producing a clear, lightly yellow solution. The reaction was stirred at 0° C. for 2 h, stored overnight in a freezer without stirring, then stirred again at 0° C. for six hours. The reaction was acidified to pH 3 with 2N HCl 9-7 ml), and was concentrated in vacuo. The resultant mixture was dissolved in EtOAc (125 ml) and a saturated aqueous sodium chloride solution (40 ml), followed by the addition of 2N HCl (˜1 ml) to acidify the aqueous layer to pH 1. The phases were separated and the aqueous layer was washed with EtOAc (2×60 ml). The combined EtOAc layers were dried over anhydrous MgSO4 and concentrated in vacuo. The resultant white solid was suspended in anhydrous THF (35 ml) under an argon atmosphere, cooled to 0° C., followed by the addition of 4 M HCl in 1,4-dioxane (10 ml, 40 mmol). The reaction was warmed to room temperature, producing a clear orange-red solution. The reaction was stirred overnight at room temperature, followed by the addition of 5 ml of 4 M HCl in 1,4-dioxane. The reaction was stirred for two days at room temperature, then heated to 50° C. for two hours, and allowed to slowly cool to room temperature overnight. The reaction was concentrated in vacuo, and carried on to the next reaction without further purification (5.16 mmol). MS (ES)(M+H)): 320, 322 for C12H15Cl2N3O3.


Intermediate 80
2,2,2-Trichloro-1-(3,4-difluoro-5-methyl-1H-pyrrol-2-yl)ethanone



embedded image


3,4-Difluoro-2-methyl-1H-pyrrole (Intermediate 8; 3.8 g) was dissolved in anhydrous diethyl ether (100 ml). Anhydrous K2CO3 (12.5 g) was added followed by trichloroacetyl chloride (10 ml). The mixture was stirred at room temperature under N2 for 2 h, poured into a cold saturated solution of NaHCO3, stirred for 10 min, and extracted with ether. The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a red brown oil. Trituration with pentane (50 ml)/DCM (2 ml), at −20° C. overnight to gave the title compound as a brown powder (1.3 g). MS (ES) MH+: 262 for C7H4Cl3F2NO; NMR (CDCl3): 2.35 (d, 3H), 9.0 (brs, 1H).


Intermediate 81
Cis(±)ethyl-4-[(tert-butoxycarbonyl)amino]-3-(propoxypiperidine-1-carboxylate

Cis(±)ethyl-3-(allyloxy)-4-[(tert-butoxycarbonyl)amino]piperidine-1-carboxylate (Intermediate 27; 528 mg) was dissolved in MeOH (20 ml). 10% Pd—C (100 mg) was added and the mixture was evacuated and replaced with H2 gas twice. The mixture was stirred under an atmosphere of H2 gas for 12 h. The catalyst was removed over a bed of celite and solvent was removed in vacuo to give the title compound as an oil (445 mg). NMR: 0.94 (m, 3H), 1.25 (m, 3H), 1.43 (s, 9H), 1.53 (m, 2H), 1.71 (m, 1H), 3.04 (m, 2H), 3.37 (m, 2H), 3.50 (m, 2H), 3.69 (m, 1H), 3.89 (m, 1H), 4.15 (m, 2H), 6.5 (d, 1H).


Intermediate 82
Cis(±)tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate

The title compound was prepared as described in Monique B. van Neil et al. J. Med. Chem., 1999, 42, 2087-2104 and the references therein. NMR (CDCl3): 1.40 (s, 9H), 1.88 (m, 2H), 3.01 (m, 2H), 3.55 (m, 2H), 3.77 (m, 1H), 4.66 (d, 1H).


Examples 87-193

The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated.















Ex
Compound
Data
SM


















87
Cis(±)-methyl 2-[4-{[(3,4-
MS (ES) MH+: 447, 449 for
Intermediate 115 and



dichloro-5-methyl-1H-pyrrol-2-
C17H20Cl2N4O4S.
methyl 2-bromo-



yl)carbonyl]amino}-3-

1,3-thiazole-5-



(hydroxymethyl)piperidin-1-yl]-

carboxylate



1,3-thiazole-5-carboxylate.


88
Cis(±)-methyl 2-{4-{[(3,4-
MS (ES) MH+: 477, 479 for
Intermediate 116 and



dichloro-5-methyl-1H-pyrrol-2-
C18H22Cl2N4O3S2.
methyl 2-bromo-



yl)carbonyl]amino}-3-

1,3-thiazole-5-



[(methylthio)methyl]piperidin-

carboxylate



1-yl}-1,3-thiazole-5-



carboxylate.


89
Cis(±)-methyl 2-{4-{[(3,4-
MS (ES) MH+: 493, 495 for
Example 88 and



dichloro-5-methyl-1H-pyrrol-2-
C18H22Cl2N4O4S2.
methyl 2-bromo-



yl)carbonyl]amino}-3-

1,3-thiazole-5-



[(methylsulfinyl)methyl]piperidin-

carboxylate



1-yl}-1,3-thiazole-5-



carboxylate





90
Cis(±)-methyl 2-{4-{[(3,4-
MS (ES) MH+: 509, 511 for
Example 88 and



dichloro-5-methyl-1H-pyrrol-2-
C18H22Cl2N4O5S2.
methyl 2-bromo-



yl)carbonyl]amino}-3-

1,3-thiazole-5-



[(methylsulfonyl)methyl]piperidin-

carboxylate



1-yl}-1,3-thiazole-5-carboxylate





embedded image







91
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 463, 465 for
Intermediate 36 and



dichloro-5-methyl-1H-pyrrol-2-
C18H21Cl2FN4O3S.
Intermediate 179



yl)carbonyl]amino}-3-



fluoropiperidin-1-yl)-5-methyl-



1,3-thiazole-4-carboxylate.


92
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 475, 477 for
Intermediate 51 and



dichloro-5-methyl-1H-pyrrol-2-
C19H24Cl2N4O4S.
Intermediate 179



yl)carbonyl]amino}-3-



methoxypiperidin-1-yl)-5-



methyl-1,3-thiazole-4-carboxylate


93
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 477, 479 for
Intermediate 36 and



dichloro-5-methyl-1H-pyrrol-2-
C18H19Cl2FN4O4S.
Intermediate 181



yl)carbonyl]amino}-3-



fluoropiperidin-1-yl)-5-formyl-



1,3-thiazole-4-carboxylate


94
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 506, 508 for
Intermediate 93 and



dichloro-5-methyl-1H-pyrrol-2-
C19H22Cl2FN5O4S; 1H NMR
methoxyamine



yl)carbonyl]amino}-3-
(CDCl3): 1.41 (m, 6H), 2.0
hydrochloride



fluoropiperidin-1-yl)-5-
(m, 4H), 2.3 (s, 6H), 3.2 (m,



[(methoxyimino)methyl]-1,3-
4H), 3.9 (s, 3H), 4.0 (s, 3H),



thiazole-4-carboxylate
4.4 (m, 10H), 4.8 (s, 1H),




4.9 (s, 1H), 7.0 (s, 2H), 8.5




(s, 1H), 8.8 (s, 1H), 9.6 (s, 2H)





95
Cis(±)-methyl 2-[(-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- (methylthio)piperidin-1-yl]-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 463.1 for C17H20Cl2N4O3S2; NMR: 1.90 (m, 2H); 2.14 (s, 3H); 2.28 (s, 3H); 3.28-3.45 (m, 2H); 3.74 (s, 3H); 3.77 (m, 1H); 3.95 (m, 2H); 4.44 (m, 1H); 7.25 (d, 1H); 7.85 (s, 1H); 12.14 (s, 1H)
Intermediate 117 and Intermediate 1





96
Cis(±)-methyl 2-[4-{[(3,4-
MS (ES) MH+: 495 for
Intermediate 95



dichloro-5-methyl-1H-pyrrol-2-
C17H20Cl2N4O5S2; NMR:



yl)carbonyl]amino}-3-
1.88 (m, 2H); 2.18 (s, 3H);



(methylsulfonyl)piperidin-1-yl]-
3.07 (s, 3H); 3.45 (t, 1H);



1,3-thiazole-5-carboxylate
3.61 (t, 1H); 3.60-3.85 (m,




2H); 3.77 (s, 3H); 4.48 (m,




1H); 4.68 (m, 1H); 7.52 (d,




1H); 7.93 (s, 1H); 12.07 (s, 1H)


97
Cis(±)methyl 2-(3-(benzyloxy)-
MS (ES) MH+: 523 for
Intermediate 118



4-{[(3,4-dichloro-5-methyl-1H-
C23H24Cl2N4O4S; NMR:
and methyl 2-



pyrrol-2-
1.73 (m, 2H); 2.12 (s, 3H);
bromo-1,3-thiazole-



yl)carbonyl]amino}piperidin-1-
3.36 (m, 2H); 3.68 (s, 3H);
5-carboxylate



yl)-1,3-thiazole-5-carboxylate
3.71 (m, 2H); 3.90 (m, 1H);




4.25 (m, 1H), 4.40 (d, 1H),




4.65 (d, 1H); 7.02 (d, 1H);




7.19 (s, 5H); 7.79 (s, 1H);




12.06 (s, 1H)


98
Cis(±)-methyl 2-[4-{[(3,4-
MS (ES) MH+: 471 for
Intermediate 119



dichloro-5-methyl-1H-pyrrol-2-
C19H20Cl2N4O4S; NMR:
and methyl-2-



yl)carbonyl]amino}-3-(prop-2-
1.76 (m, 2H); 2.18 (s, 3H);
bromo-1,3-thiazole-



yn-1-yloxy)piperidin-1-yl]-1,3-
3.36 (m, 2H); 3.44 (t, 1H);
5-carboxylate



thiazole-5-carboxylate
3.74 (s, 3H); 3.87 (s, 1H);




3.98 (m, 1H); 4.22-4.36 (m,




4H); 7.15 (d, 1H); 7.83 (s,




1H); 12.15 (s, 1H)


99
Trans-(±)methyl 2-(4-{[(3,4-
MS (ES) MH+: 433 for
Intermediate 120



dichloro-5-methyl-1H-pyrrol-2-
C16H18Cl2N4O4S; NMR:
and methyl 2-



yl)carbonyl]amino}-3-
1.62 (m, 1H), 2.02 (m, 1H),
bromo-1,3-thiazole-



hydroxypiperidin-1-yl)-1,3-
2.18 (s, 3H), 3.12 (m, 1H),
5-carboxylate



thiazole-5-carboxylate
3.63 (m, 1H), 3.75 (s, 3H),




3.87 (m, 2H), 4.02 (m, 1H),




5.37 (d, 1H), 5.76 (s, 1H),




7.19 (d, 1H), 7.87 (s, 1H),




11.99 (s, 1H)





100
methyl 2-((3S,4R)-4-{[(3- chloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image
1.87 (m, 2H); 2.17 (s, 3H); 3.34 (m 1H); 3.60 (m 1H); 3.75 (s, 3H); 4.01 (m, 1H); 4.33 (m, 2H); 4.96 (d, br, 1H); 5.95 (s, 1H); 7.10 (d, 1H); 7.85 (s, 1H); 11.63 (s, 1H)
Intermediate 121 and methyl 2- bromo-1,3-thiazole- 5-carboxylate





101
ethyl 2-((3S,4R)-4-{[(3-chloro-
1.37 (t, 3H); 2.00 (m, 2H);
Intermediate 121



5-methyl-1H-pyrrol-2-
2.26 (s, 3H); 3.31 (m 2H);
and ethyl 2-bromo-



yl)carbonyl]amino}-3-
4.21 (m, 1H); 4.34 (q, 2H);
1,3-thiazole-4-



fluoropiperidin-1-yl)-1,3-
4.45 (m, 2H); 4.90 (d, br,
carboxylate



thiazole-4-carboxylate
1H); 5.93 (s, 1H); 6.97 (d,




1H); 7.46 (s, 1H); 8.98 (s,




br, 1H)


102
ethyl 2-((3S,4R)-4-{[(3-chloro-
MS (ES) MH+: 465 for
Intermediate 121



5-methyl-1H-pyrrol-2-
C21H22ClFN4O3S
and ethyl 2-bromo-



yl)carbonyl]amino}-3-
NMR δ: 1.44 (t, 3H); 2.03
1,3-benzothiazole-



fluoropiperidin-1-yl)-1,3-
(m, 2H); 2.27 (s, 3H); 3.40
7-carboxylate



benzothiazole-7-carboxylate
(m 2H); 4.36 (m, 2H); 4.44




(q, 2H); 4.67 (m, 1H); 4.90




(d, br, 1H); 5.93 (s, 1H);




7.05 (d, 1H); 7.37 (t, 1H);




7.71 (d, 1H); 7.79 (d, 1H);




9.89 (s, br, 1H)


103
methyl 2-((3S,4R)-4-{[(4-
MS (ES) MH+: 446 for
Intermediate 122



bromo-5-methyl-1H-pyrrol-2-
C16H18BrFN4O3S; NMR:
and methyl 2-



yl)carbonyl]amino}-3-
1.97 (m, 2H); 2.23 (s, 3H);
bromo-1,3-thiazole-



fluoropiperidin-1-yl)-1,3-
3.34 (m 2H); 3.80 (s, 3H);
5-carboxylate



thiazole-5-carboxylate
4.26 (m, 2H); 4.55 (m, 1H);




4.86 (d, br, 1H); 6.0 (d, 1H);




6.53 (s, 1H); 7.82 (s, 1H);




9.83 (s, br, 1H)


104
methyl 2-((3S,4R)-4-{[(4-
MS (ES) MH+: 480 for
Intermediate 123



bromo-3-chloro-5-methyl-1H-
C16H17BrClFN4O3S; NMR
and methyl 2-



pyrrol-2-yl)carbonyl]amino}-3-
δ: 1.86 (m, 2H); 2.19 (s,
bromo-1,3-thiazole-



fluoropiperidin-1-yl)-1,3-
3H); 3.44 (m 1H); 3.60 (m
5-carboxylate



thiazole-5-carboxylate
1H); 3.75 (s, 3H); 4.01 (m,




1H); 4.33 (m, 2H); 4.96 (d,




br, 1H); 7.28 (d, 1H); 7.85




(s, 1H); 12.18 (s, 1H)





105
ethyl 2-((3S,4R)-4-{[(4-bromo- 3-chloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-4-carboxylate embedded image
MS (ES) MH+: 494 for C17H19BrClFN4O3S; NMR δ: 1.22 (t, 3H); 1.81 (m, 2H); 2.15 (s, 3H); 3.41 (m 2H); 3.90 (m, 1H); 4.20 (q, 2H); 4.30 (m, 1H); 4.92 (d, br, 1H); 5.72 (s, 1H); 7.24 (d, 1H); 7.65 (s, 1H); 12.13 (s, 1H)
Intermediate 123 and ethyl 2-bromo- 1,3-thiazole-4- carboxylate





106
isopropyl 2-((3S,4R)-4-{[(4-
1.32 (d, 6H); 1.80 (m, 2H);
Intermediate 123



bromo-3-chloro-5-methyl-1H-
2.19 (s, 3H); 3.07 (m 1H);
and isopropyl 2-



pyrrol-2-yl)carbonyl]amino}-3-
3.27 (m, 1H); 4.37 (m, 2H);
bromo-isonicotinate



fluoropiperidin-1-
4.71 (m, 1H); 4.97 (d, br,



yl)isonicotinate
1H); 5.15 (m, 1H); 6.70 (d,




1H), 7.22 (d, 1H), 7.25 (s,




1H); 8.17 (d, 1H); 12.11 (s,




br, 1H)


107
methyl 2-((3S,4R)-4-{[(4-
MS (ES) MH+: 524 for
Intermediate 123



bromo-3-chloro-5-methyl-1H-
C18H21BrClFN4O4S; NMR
and Intermediate 17



pyrrol-2-yl)carbonyl]amino}-3-
δ: 1.86 (m, 2H); 2.19 (s,



fluoropiperidin-1-yl)-4-
3H); 3.29 (s, 2H); 3.60 (m



(methoxymethyl)-1,3-thiazole-
2H); 3.73 (s, 3H); 4.04 (m,



5-carboxylate
1H); 4.30 (m, 2H); 4.57 (s,




3H); 4.90 (d, br, 1H); 7.27




(d, 1H); 12.17 (s, 1H)


108
ethyl 2-((3S,4R)-4-{[(3-chloro-
MS (ES) MH+: 409 for
Intermediate 121



5-methyl-1H-pyrrol-2-
C19H22ClFN4O3
and ethyl 2-bromo-



yl)carbonyl]amino}-3-
NMR: 1.40 (t, 3H); 1.98 (m,
isonicotinate



fluoropiperidin-1-
2H); 2.27 (s, 3H); 3.09 (m



yl)isonicotinate
2H); 4.38 (q, 2H); 4.47 (m,




2H); 4.84 (m, 1H); 4.90 (d,




br, 1H); 5.92 (s, 1H); 7.03




(d, 1H); 7.15 (d, 1H); 7.30




(s, 1H); 8.27 (d, 1H); 9.88




(s, br, 1H)


109
ethyl 2-((3S,4R)-4-{[(4-bromo-
MS (ES) MH+: 409 for
Intermediate 122



5-methyl-1H-pyrrol-2-
C19H22BrFN4O3
and ethyl 2-bromo-



yl)carbonyl]amino}-3-
NMR: 1.40 (t, 3H); 1.98 (m,
isonicotinate



fluoropiperidin-1-
2H); 2.27 (s, 3H); 3.09 (m



yl)isonicotinate
2H); 4.38 (q, 2H); 4.43 (m,




2H); 4.84 (m, 1H); 4.90 (d,




br, 1H); 6.16 (d, 1H); 6.59




(s, 1H); 7.15 (d, 1H); 7.29




(s, 1H); 8.27 (d, 1H); 9.76




(s, br, 1H)





110
Cis(±)-Methyl 2-[4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3-(2- methoxyethoxy)piperidin-1-yl]- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 491 for C19H24Cl2N4O5S; NMR: 1.72-1.80 (m, 2H), 2.17 (s, 3H), 3.13 (s, 3H), 3.25-3.42 (m, 4H), 3.52-3.60 (m, 1H), 3.65-3.75 (m, 2H), 3.73 (s, 3H); 3.85-4.05 (m, 1H); 4.20-4.35 (m, 2H), 7.14 (d, 1H), 7.82 (s, 1H), 12.14 (brs, 1H)
Intermediate 124 and methyl 2-bromo- 1,3-thiazole-5- carboxylate





111
Cis(±)-Ethyl 2-[4-{[(3,4-
MS (ES) MH+: 505 for
Intermediate



dichloro-5-methyl-1H-pyrrol-2-
C20H26Cl2N4O5S
124 and



yl)carbonyl]amino}-3-(2-

ethyl 2-bromo-1,3-



methoxyethoxy)piperidin-1-yl]-

thiazole-4-



1,3-thiazole-4-carboxylate

carboxylate


112
Cis(±)-Ethyl 2-[4-{[(3,4-
MS (ES) MH+: 519 for
Intermediate



dichloro-5-methyl-1H-pyrrol-2-
C21H28Cl2N4O5S; NMR:
124 and



yl)carbonyl]amino}-3-(2-
1.22 (t, 3H), 1.70-1.75 (m,
ethyl 2-chloro-1,3-



methoxyethoxy)piperidin-1-yl]-
2H), 2.17 (s, 3H), 2.41 (s,
thiazole-5-



4-methyl-1,3-thiazole-5-
3H), 3.14 (s, 3H), 3.32-3.40
carboxylate



carboxylate
(m, buried under water




peak), 3.45-3.62 (m, 1H),




3.67-3.73 (m, 2H), 3.86-3.98




(m, 1H), 4.16 (q, 2H), 4.19-




4.30 (m, 2H), 7.13 (d, 1H),




12.14 (s, 1H)


113
Cis(±)-Ethyl 2-[4-{[(3,4-
MS (ES) MH+: 499 for
Intermediate 124



dichloro-5-methyl-1H-pyrrol-2-
C22H28Cl2N4O5
and ethyl 2-



yl)carbonyl]amino}-3-(2-

fluoroisonicotinate



methoxyethoxy)piperidin-1-

(Konno, Akinori J.



yl]isonicotinate

Fluorine Chemistry





(1998), 87(2), 137-





140)


114
Cis(±)-Ethyl 2-[4-{[(3,4-
MS (ES) MH+: 555 for
Intermediate 124



dichloro-5-methyl-1H-pyrrol-2-
C24H28Cl2N4O5S
and ethyl 2-bromo-



yl)carbonyl]amino}-3-(2-

1,3-benzothiazole-



methoxyethoxy)piperidin-1-yl]-

7-carboxylate



1,3-benzothiazole-7-carboxylate





115
Methyl 2-((3S,4R)-4-{[(4- chloro-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 387 for C15H16ClFN4O3S; NMR: 1.55-1.76 (m, 1H), 1.85-2.00 (m, 1H), 3.36-3.45 (m, 1H), 3.50 (dd, 1H), 3.74 (s, 3H), 4.02-4.10 (m, 1H), 4.15-4.36 (m, 2H), 4.90 (d, 1H), 6.94- 6.97 (m, 2H), 7.85 (s, 1H), 8.10 (d, 1H), 11.82 (s, 1H)
Intermediate 95 and methyl 2-bromo- 1,3-thiazole-5- carboxylate





116
Ethyl 2-((3S,4R)-4-{[(4-chloro-
MS (ES) MH+: 429 for
Intermediate 260



5-methyl-1H-pyrrol-2-
C18H22ClFN4O3S; NMR:
and ethyl 2-chloro-



yl)carbonyl]amino}-3-
1.23 (t, 3H), 1.62-1.77 (m,
4-methyl-1,3-



fluoropiperidin-1-yl)-4-methyl-
1H), 1.83-2.00 (m, 1H), 2.13
thiazole-5-



1,3-thiazole-5-carboxylate
(s, 3H), 2.43 (s, 3H), 3.33-
carboxylate




3.41 (m, 1H), 3.50 (dd, 1H),




3.98-4.02 (m, 1H), 4.16 (q,




2H), 4.23-4.35 (m, 2H), 4.86




(d, 1H), 6.89 (d, 1H), 7.97




(d, 1H), 11.65 (s, 1H)


117
Ethyl 2-((3S,4R)-4-{[(4-chloro-
MS (ES) MH+: 415 for
Intermediate 95



1H-pyrrol-2-
C17H20ClFN4O3S; NMR:
ethyl 2-chloro-4-



yl)carbonyl]amino}-3-
1.23 (t, 3H), 1.69-1.74 (m,
methyl-1,3-thiazole-



fluoropiperidin-1-yl)-4-methyl-
1H), 1.86-2.03 (m, 1H), 2.43
5-carboxylate



1,3-thiazole-5-carboxylate
(s, 3H), 3.27-3.35 (m, 1H),




3.51 (dd, 1H), 3.98-4.05 (m,




1H), 4.16 (q, 2H), 4.23-4.33




(m, 2H), 4.88 (d, 1H), 6.94-




6.98 (m, 2H), 8.85 (d, 1H),




11.81 (s, 1H)


118
Ethyl 2-((3S,4R)-4-{[(4,5-
MS (ES) MH+: 449 for
Intermediate



dichloro-1H-pyrrol-2-
C17H19Cl2FN4O3S; NMR:
128 and ethyl 2-



yl)carbonyl]amino}-3-
1.23 (t, 3H), 1.65-1.74 (m,
chloro-4-methyl-



fluoropiperidin-1-yl)-4-methyl-
1H), 1.85-2.00 (m, 1H),
1,3-thiazole-5-



1,3-thiazole-5-carboxylate
2.43 (s, 3H), 3.30-3.40 (m,
carboxylate




1H), 3.51 (dd, 1H), 3.98-




4.05 (m, 1H), 4.16 (q, 2H),




4.21-4.35 (m, 2H), 4.88 (d,




1H), 7.06 (d, 1H), 8.15 (d,




1H), 12.78 (s, 1H)


119
Methyl 2-((3S,4R)-4-{[(4,5-
MS (ES) MH+: 421 for
Intermediate



dichloro-1H-pyrrol-2-
C15H15Cl2FN4O3S
128 and methyl 2-



yl)carbonyl]amino}-3-

bromo-1,3-thiazole-



fluoropiperidin-1-yl)-1,3-

5-carboxylate



thiazole-5-carboxylate





120
Cis(±)-Methyl 2-[4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3-(2- hydroxypropoxy)piperidin-1- yl]-1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 491 for C19H24Cl2N4O5S; NMR: 0.95 (d, 3H), 1.75-1.90 (m, 2H), 2.17 (s, 3H), 3.15-3.47 (peaks overlapping with H2O signal), 3.55-3.68 (m, 2H), 3.73 (s, 3H), 3.94-3.97 (m, 1H), 4.23-4.35 (m, 2H), 7.17 (d, 1H), 7.82 (s, 1H), 12.11 (s, 1H)
Intermediate 126 and methyl 2-bromo- 1,3-thiazole-5- carboxylate





121
Cis(±)-Methyl 2-[4-{[(3,4-
MS (ES) MH+: 505 for
Intermediate 125



dichloro-5-methyl-1H-pyrrol-2-
C20H26Cl2N4O5S
and methyl 2-



yl)carbonyl]amino}-3-(2-

bromo-1,3-thiazole-



methoxypropoxy)piperidin-1-

5-carboxylate



yl]-1,3-thiazole-5-carboxylate


122
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 511 for
Intermediate 51 and



dichloro-5-methyl-1H-pyrrol-2-
C22H24Cl2N4O4S; NMR:
2-bromo-1,3-



yl)carbonyl]amino}-3-
1.36 (t, 3H), 1.79 (m, 2H),
benzothiazole-7-



methoxypiperidin-1-yl)-1,3-
2.18 (s, 3H), 3.32-3.59 (m,
carboxylate (U.S. Pat.



benzothiazole-7-carboxylate
4H), 4.21 (m, 1H), 4.37 (m,
No. 5770758)




1H), 4.37 (q, 2H), 7.19 (d,




1H), 7.41 (t, 1H), 7.66 (m,




2H), 12.17 (s, 1H)


123
ethyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH+: 511 for
Intermediate 52 and



dichloro-5-methyl-1H-pyrrol-2-
C22H24Cl2N4O4S; NMR:
2-bromo-1,3-



yl)carbonyl]amino}-3-
1.36 (t, 3H), 1.79 (m, 2H),
benzothiazole-7-



methoxypiperidin-1-yl)-1,3-
2.18 (s, 3H), 3.32-3.59 (m,
carboxylate (U.S. Pat.



benzothiazole-7-carboxylate
4H), 4.21 (m, 1H), 4.37 (m,
No. 5770758)




1H), 4.37 (q, 2H), 7.19 (d,




1H), 7.41 (t, 1H), 7.66 (m,




2H), 12.17 (s, 1H)


124
Cis (±)ethyl 2-(4-{[(3,4-
MS (ES) MH+: 448 for
Intermediate 32 and



dichloro-5-methyl-1H-pyrrol-2-
C17H19Cl2FN4O3S
ethyl 2-bromo-1,3-



yl)carbonyl]amino}-3-

thiazole-4-



fluoropiperidin-1-yl)-1,3-

carboxylate



thiazole-4-carboxylate





125
ethyl 2-((3S,4R)-4-{[(4-chloro-
MS (ES) MH+: 475 for
Intermediate 129



5-methyl-1H-pyrrol-2-
C22H24ClN4O4S
and 2-bromo-1,3-



yl)carbonyl]amino}-3-

benzothiazole-7-



methoxypiperidin-1-yl)-1,3-

carboxylate (U.S. Pat.



benzothiazole-7-carboxylate

No. 5770758)





embedded image







126
Cis(±)methyl 2-(4-{[(4-chloro-
MS (ES) MH+: 427 for
Intermediate 130



3,5-dimethyl-1H-pyrrol-2-
C18H23ClN4O4S
and methyl 2-



yl)carbonyl]amino}-3-

bromo-1,3-thiazole-



methoxypiperidin-1-yl)-1,3-

5-carboxylate



thiazole-5-carboxylate


127
Cis(±)ethyl 2-(4-{[(3,4-
MS (ES) MH+: 513 for
Intermediate 51 and



dichloro-5-methyl-1H-pyrrol-2-
C21H23Cl2N5O4S
Intermediate 204



yl)carbonyl]amino}-3-



methoxypiperidin-1-



yl)[1,3]thiazolo[4,5-b]pyridine-



7-carboxylate


128
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 448 for
Intermediate 31 and



dichloro-5-methyl-1H-pyrrol-2-
C17H19Cl2FN4O3S
ethyl 2-bromo-1,3-



yl)carbonyl]amino}-3-

thiazole-4-



fluoropiperidin-1-yl)-1,3-

carboxylate



thiazole-4-carboxylate


129
ethyl 2-((3S,4R)-4-{[(4-chloro-
MS (ES) MH+: 448 for
Intermediate 130



3,5-dimethyl-1H-pyrrol-2-
C18H22ClFN4O3S
and ethyl 2-bromo-



yl)carbonyl]amino}-3-

1,3-thiazole-4-



fluoropiperidin-1-yl)-1,3-

carboxylate



thiazole-4-carboxylate





130
ethyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH+: 448 for
Intermediate 33 and



dichloro-5-methyl-1H-pyrrol-2-
C17H19Cl2FN4O3S
ethyl 2-bromo-1,3-



yl)carbonyl]amino}-3-

thiazole-4-



fluoropiperidin-1-yl)-1,3-

carboxylate



thiazole-4-carboxylate





embedded image







131
Cis(±)methyl 2-(3-chloro-4-
MS (ES) MH+: 451 for
Intermediate 131



{[(3,4-dichloro-5-methyl-1H-
C16H17Cl3N4O3S; NMR:
and 2-bromo-1,3-



pyrrol-2-
1.17 (t, 3H), 1.84 (m, 1H),
thiazole-5-



yl)carbonyl]amino}piperidin-1-
1.93 (m, 1H), 2.20 (s, 3H),
carboxylate



yl)-1,3-thiazole-5-carboxylate
3.45 (m, 1H), 3.75 (s, 3H),




3.82 (d, 1H), 4.02 (m, 1H),




4.26 (m, 1H), 4.50 (m, 1H),




4.76 (s, 1H), 7.15 (d, 1H),




7.85 (s, 1H), 12.12 (s, 1H)


132
methyl 2-{(3S,4R)-4-[({4-
MS (ES) MH+: 456 for
Intermediate 132



chloro-3-[(E)-
C18H21ClFN5O4S;
and methyl-2-



(methoxyimino)methyl]-5-

bromo-1,3-thiazole-



methyl-1H-pyrrol-2-

5-carboxylate



yl}carbonyl)amino]-3-



fluoropiperidin-1-yl}-1,3-



thiazole-5-carboxylate


133
Cis(±)-ethyl 2-(3-chloro-4-
MS (ES) MH+: 515 for
Intermediate 131



{[(3,4-dichloro-5-methyl-1H-
C21H21Cl3N4O3S
and 2-bromo-1,3-



pyrrol-2-

benzothiazole-7-



yl)carbonyl]amino}piperidin-1-

carboxylate (U.S. Pat.



yl)-1,3-benzothiazole-7-

No. 5770758)



carboxylate


134
Cis(±)-ethyl 2-(3-chloro-4-
MS (ES) MH+: 495 for
Intermediate 131



{[(3,4-dichloro-5-methyl-1H-
C18H21Cl3N4O4S and Intermediate



pyrrol-2-

215



yl)carbonyl]amino}piperidin-1-



yl)-4-(hydroxymethyl)-1,3-



thiazole-5-carboxylate





135
Cis(±)-methyl 2-(3-chloro-4-
MS (ES) MH+: 417 for
Intermediate 133



{[(4-chloro-5-methyl-1H-
C16H18Cl2N4O3S
and methyl 2-



pyrrol-2-yl)carbonyl]amino}piperidin-1-

bromo-1,3-thiazole-



yl)-1,3-thiazole-5-carboxylate

5-carboxylate





embedded image







136
Cis(±)-methyl 2-(3-chloro-4-
MS (ES) MH+: 495 for
Intermediate 131



{[(3,4-dichloro-5-methyl-1H-
C18H21Cl3N4O4S
and Intermediate 17



pyrrol-2-



yl)carbonyl]amino}piperidin-1-



yl)-4-(methoxymethyl)-1,3-



thiazole-5-carboxylate


137
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 500 for
Intermediate 226



dichloro-5-methyl-1H-pyrrol-2-
C20H23Cl2N5O6; NMR: 1.3
and Intermediate 50



yl)carbonyl]amino}-3-
(t, 3H), 1.65 (m, 1H), 1.8



methoxypiperidin-1-yl)-5-
(m, 1H), 2.2 (s, 3H), 3.2-3.3



nitroisonicotinate
(m 6H), 3.6 (m 1H), 4.3 (m,




3H), 7.1 (m, 2H), 8.9 (s,




1H), 12.1 (s, 1H)


138
Cis(±)-methyl 2-(4-{[(3,4-
MS (ES) MH+: 431 for
methyl 2-bromo-



dichloro-5-methyl-1H-pyrrol-2-
C17H20Cl2N4O3S; NMR: 0.9
1,3-thiazole-5-



yl)carbonyl]amino}-3-
(d, 3H), 1.8 (m, 2H), 2.2 (m,
carboxylate and



methylpiperidin-1-yl)-1,3-
4H), 3.2 (m 3H), 3.4-3.7 (m,
Intermediate 134



thiazole-5-carboxylate
3H), 3.7 (s, 3H), 4.1 (m,




1H), 4.25 (m, 1H), 7.1 (d,




1H), 7.9 (s, 1H), 12.0 (s, 1H)


139
Cis(±)-methyl 2-(4-{[(3,4-
MS (ES) MH+: 431 for
methyl 2-bromo-



dichloro-5-methyl-1H-pyrrol-2-
C17H20Cl2N4O3S; NMR: 1.3
1,3-thiazole-5-



yl)carbonyl]amino}-2-
(d, 1H), 1.8-2.1 (m, 4H), 2.2
carboxylate and



methylpiperidin-1-yl)-1,3-
(s, 3H), 3.5 (m, 1H), 3.7 (m,
Intermediate 135



thiazole-5-carboxylate
4H), 4.1 (m, 2H), 7.3 (s,




1H), 7.9 (s, 1H), 12.0 (s, 1H)





140
Cis(±)-isopropyl 2-(4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-6- methylisonicotinate embedded image
MS (ES) MH+: 483 for C22H28Cl2N4O4; NMR: 0.9 (m, 1H), 1.3 (d, 6H), 1.7, (m, 1H), 2.2 (s, 3H), 2.4 (s, 3H), 3.1 (m, 2H), 3.5 (m, 1H), 4.2 (m, 2H), 4.7 (d, 1H), 5.1 (m, 1H), 6.8 (s, 1H), 7.0 (s, 1H), 7.15 (s, 1H), 12.1 (s, 1H)
Intermediate 227 and Intermediate 50





141
Cis(±)-isopropyl 5-chloro-4-(4-
MS (ES) MH+: 503 for
Intermediate 226



{[(3,4-dichloro-5-methyl-1H-
C21H25Cl3N4O4
and Intermediate 50



pyrrol-2-yl)carbonyl]amino}-3-



methoxypiperidin-1-yl)pyridine-



2-carboxylate


142
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 479 for
Intermediate 215



dichloro-5-methyl-1H-pyrrol-2-
C18H21Cl2FN4O4S; NMR:
and Intermediate 36



yl)carbonyl]amino}-3-
1.2 (t, 3H), 1.9 (m, 2H), 2.2



fluoropiperidin-1-yl)-4-
(s, 3H), 3.6 (dd, 1H), 4.0-4.2



(hydroxymethyl)-1,3-thiazole-5-
(m, 1H), 4.2 (q, 2H), 4.25-



carboxylate
4.45 (m, 1H), 4.6 (s, 2H),




4.9 (m, 1H), 5.05 (m, 1H),




7.2 (d, 1H), 12.1 (s, 1H)


143
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 491 for
Intermediate 215



dichloro-5-methyl-1H-pyrrol-2-
C19H24Cl2N4O5S; NMR: 1.2
and Intermediate 50



yl)carbonyl]amino}-3-
(t, 3H), 1.7 (m, 2H), 2.2 (s,



methoxypiperidin-1-yl)-4-
3H), 3.4 (s, 3H), 3.55 (m,



(hydroxymethyl)-1,3-thiazole-5-
1H), 4.0 (m, 1H), 4.1-4.4 (m,



carboxylate
4H), 4.6 (s, 2H), 7.1 (d, 1H),




12.1 (s, 1H)


144
Cis(±)-ethyl 2-(4-{[(4-chloro-3-
MS (ES) MH+: 438 for
Intermediate 136



cyano-5-methyl-1H-pyrrol-2-
C18H20ClN5O4S; NMR: 1.6-
and methyl 2-



yl)carbonyl]amino}-3-
1.9 (m, 2H), 2.2 (s, 3H), 3.3
bromo-1,3-thiazole-



methoxypiperidin-1-yl)-1,3-
(s, 3H), 3.6 (m, 1H), 3.7 (s,
5-carboxylate



thiazole-5-carboxylate
3H), 3.9 (m, 1H), 4.3 (m,




3H), 7.75 (d, 1H), 12.7 (s,




1H)





145
Cis(±)-ethyl 2-(4-{[(4-chloro-3- cyano-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- benzothiazole-7-carboxylate embedded image
MS (ES) MH+: 502 for C23H24ClN5O4S; NMR: 1.35 (t, 3H), 1.6-2.0 (m, 2H), 2.2 (s, 3H), 3.3 (s, 3H), 3.4 (m, 1H), 3.6 (s, 3H), 4.1 (m, 1H), 4.3 (m, 1H), 4.4 (q, 2H), 7.7 (m, 2H), 7.8 (m, 1H), 7.9 (t, 1H), 12.7 (s, 1H)
Intermediate 136 and ethyl 2-bromo- 1,3-benzothiazole- 7-carboxylate (U.S. Pat. No. 5770758)





146
Cis(±)-ethyl 2-(4-{[(4-chloro-3-
MS (ES) MH+: 460 for
Intermediate 136



cyano-5-methyl-1H-pyrrol-2-
C22H26ClN5O4 NMR: 1.3 (d,
and Intermediate



yl)carbonyl]amino}-3-
6H), 1.7 (m, 2H), 2.2 (s,
230



methoxypiperidin-1-yl)-1,3-
3H), 3.1 (s, 2H), 3.3 (s, 3H),



thiazole-5-carboxylate
3.5 (s, 3H), 4.2 (m, 1H), 4.6




(d, 1H), 5.1 (m, 1H), 7.0 (s,




1H), 7.2 (s, 1H), 7.7 (d, 1H),




8.2 (d, 1H), 12.7 (s, 1H)


147
methyl 2-((3S,4R)-4-{[(4-
MS (ES) MH+: 426 for
Intermediate 137



chloro-3-cyano-5-methyl-1H-
C17H17ClFN5O3S; NMR: 1.9
and methyl 2-



pyrrol-2-yl)carbonyl]amino}-3-
(m, 2H), 2.2 (s, 3H), 3.3 (s,
bromo-1,3-thiazole-



fluoropiperidin-1-yl)-1,3-
3H), 3.5 (dd, 1H), 3.75 (s,
5-carboxylate



thiazole-5-carboxylate
3H), 4.0 (m, 1H), 4.2-4.5 (m,




2H), 5.0 (d, 1H), 7.9 (s, 1H),




8.15 (m, 1H), 12.6 (s, 1H)


148
ethyl 2-((3S,4R)-4-{[(4-chloro-
MS (ES) MH+: 490 for
Intermediate 137



3-cyano-5-methyl-1H-pyrrol-2-
C22H21ClFN5O3S; NMR:
and ethyl 2-bromo-



yl)carbonyl]amino}-3-
1.35 (t, 3H), 1.6-2.0 (m, 2H),
1,3-benzothiazole-



fluoropiperidin-1-yl)-1,3-
2.2 (s, 3H), 3.3 (m), 3.4 (m,
7-carboxylate (U.S.



benzothiazole-7-carboxylate
1H), 3.6 (s, 3H), 4.1 (m,
Pat. No. 5770758)




1H), 4.3 (m, 1H), 4.4 (q,




2H), 7.7 (m, 2H), 7.8 (m,




1H), 7.9 (t, 1H), 12.7 (s, 1H)


149
isopropyl 2-((3S,4R)-4-{[(4-
MS (ES) MH+: 460 for
Intermediated 137



chloro-3-cyano-5-methyl-1H-
C21H23ClFN5O3 NMR: 1.3
and Intermediate



pyrrol-2-yl)carbonyl]amino}-3-
(d, 6H), 1.8 (m, 2H), 2.2 (s,
230



fluoropiperidin-1-
3H), 3.0 (m, 2H), 3.3 (m),



yl)isonicotinate
4.1-4.2 (m, 1H), 4.45 (d,




1H), 4.9 (d, 1H), 5.0 (m,




1H), 5.1 (m, 1H), 7.0 (d,




1H), 7.3 (s, 1H), 8.1 (d, 1H),




8.3 (d, 1H), 12.6 (s, 1H)





150
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 579 for
Intermediate 231



dichloro-5-methyl-1H-pyrrol-2-
C23H29Cl2N5O6S; NMR: 1.2
and Intermediate 50



yl)carbonyl]amino}-3-
(m, 3H), 1.75 (m, 2H), 2.2



methoxypiperidin-1-yl)-5-
(s, 3H), 3.3 (s, 3H), 3.4 (m,



(morpholin-4-ylcarbonyl)-1,3-
1H), 3.5-3.6 (m, 4H), 3.8 (m,



thiazole-4-carboxylate
1H), 4.2 (m, 4H), 7.15 (d,





embedded image


1H), 12.1 (s, 1H)





151
Cis(±)-isopropyl 6-cyano-4-(4-
MS (ES) MH+: 494 for
Intermediate 231



{[(3,4-dichloro-5-methyl-1H-
C22H25Cl2N5O4; NMR: 1.3
and Intermediate 50.



pyrrol-2-yl)carbonyl]amino}-3-
(s, 6H), 1.8 (m, 2H), 2.25 (s,



methoxypiperidin-1-yl)pyridine-
3H), 3.4 (s, 3H), 3.6 (m,



2-carboxylate
1H), 4.1 (d, 1H), 4.3 (m,




1H), 4.5 (d, 1H), 5.2 (m,




1H), 7.2 (d, 1H), 7.65 (s,




1H), 7.8 (s, 1H), 12.2 (s, 1H)


152
Cis(±)-2-(4-{[(3,4-dichloro-5-
MS (ES) MH+: 475 for
2-chloro-1,3-



methyl-1H-pyrrol-2-
C17H20Cl2N6O4S; NMR: 1.7
thiazole-4,5-



yl)carbonyl]amino}-3-
(m, 2H), 2.2 (s, 3H), 3.3 (s,
dicarboxamide



methoxypiperidin-1-yl)-1,3-
3H), 3.5 (m, 1H), 4.0 (m,
(Robba, M.; Le



thiazole-4,5-dicarboxamide
1H), 4.2 (m, 1H), 4.4 (m,
Guen, Y. Bulletin




1H), 7.1 (d, 1H), 7.6 (s, 1H),
de la Societe




8.1 (s, 1H), 8.2 (s, 1H), 10.4
Chimique de France




(s, 1H), 12.1 (s, 1H)
(1969), (6), 2152-7)





and Intermediate 50.


153
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 463 for
2-chloro-1,3-



methyl-1H-pyrrol-2-
C16H17Cl2N6O3S; NMR: 1.8-
thiazole-4,5-



yl)carbonyl]amino}-3-
1.9 (m, 2H), 2.2 (s, 3H), 3.3
dicarboxamide



methoxypiperidin-1-yl)-1,3-
(s, 3H), 3.4 (dd, 1H), 4.1 (m,
(Robba, M.; Le



thiazole-4,5-dicarboxamide
1H), 4.4 (m, 2H), 4.95 (d,
Guen, Y. Bulletin




1H), 7.3 (d, 1H), 7.6 (s, 1H),
de la Societe




8.1 (s, 1H), 8.2 (s, 1H), 10.4
Chimique de France




(s, 1H), 12.1 (s, 1H)
(1969), (6), 2152-7)





and Intermediate 36.


154
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 483 for
Intermediate 202



dichloro-5-methyl-1H-pyrrol-2-
C21H24Cl2N4O5
and Intermediate 50



yl)carbonyl]amino}-3-



methoxypiperidin-1-yl)-5-



formylisonicotinate


155
ethyl 2-((3S,4R)-4-{[(3,5-
MS (ES) MH+: 449 for
Intermediate 138



dichloro-4-methyl-1H-pyrrol-2-
C17H19Cl2FN4O3S: NMR:
and ethyl 2-bromo-



yl)carbonyl]amino}-3-
1.25 (m, 5H), 1.9 (s, 3H),
1,3-thiazole-5-



fluoropiperidin-1-yl)-1,3-
3.6 (dd, 1H), 3.9 (m, 1H),
carboxylate



thiazole-5-carboxylate
4.3 (m, 2H), 5.0 (d, 1H),




7.3(d, 1H), 7.8 (s, 1H), 12.6




(s, 1H)


156
2-((3S,4R)-4-{[(3,5-dichloro-4-
MS (ES) MH+: 465 for
Intermediate 138



methyl-1H-pyrrol-2-
C18H19Cl2FN4O5S; NMR:
and Intermediate



yl)carbonyl]amino}-3-
1.25 (t, 3H), 1.8 (m, 2H), 1.9
252



fluoropiperidin-1-yl)-5-
(s, 3H), 3.5-3.8 (m, 2H), 3.9



(ethoxycarbonyl)-1,3-thiazole-
(m, 1H), 4.2 (q, 2H), 4.3 (m,



4-carboxylic acid
2H), 5.0 (d, 1H), 7.4 (d, 1H),




12.6 (s, 1H), 13.6 (s, 1H)


157
methyl 4-acetyl-2-((3S,4R)-4-
MS (ES) MH+: 489 for
Intermediate 212



{[(3,4-dichloro-5-methyl-1H-
C19H24Cl2N4O5S; NMR:
and Intermediate 51



pyrrol-2-yl)carbonyl]amino}-3-
1.75 (m, 2H), 2.2 (s, 3H),



methoxypiperidin-1-yl)-1,3-
2.45 (s, 3H), 3.2-3.4 (m), 3.9



thiazole-5-carboxylate
(m, 1H), 4.3 (m, 2H), 7.15




(d, 1H), 12.15 (s, 1H)


158
methyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 505 for
Intermediate 214



dichloro-5-methyl-1H-pyrrol-2-
C20H26Cl2N4O5S;
and Intermediate 51



yl)carbonyl]amino}-3-
NMR: 1.5 (s, 6H), 1.75 (m,



methoxypiperidin-1-yl)-4-(1-
2H), 2.2 (s, 3H), 3.3 (s, 3H),



hydroxy-1-methylethyl)-1,3-
3.55 (m, 1H), 3.8 (s, 3H),



thiazole-5-carboxylate
3.8-4.0 (m, 2H), 4.2 (m, 1H),




4.5 (m, 1H), 7.15 (d, 1H),




12.2 (s, 1H)


159
methyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 503 for
Intermediate 213



dichloro-5-methyl-1H-pyrrol-2-
C19H20Cl2N4O4S2; NMR: 1.8
and Intermediate 51.



yl)carbonyl]amino}-3-
(m, 2H), 2.2 (s, 3H), 3.3 (m),



methoxypiperidin-1-
3.6 (m, 1H), 3.95 (m, 1H),



yl)thieno[2,3-d][1,3]thiazole-6-
4.3 (m, 2H), 7.2 (d, 1H), 8.0



carboxylate
(s, 1H), 12.2 (s, 1H)





160
Cis(±)-methyl 2-(3- (cyclopropylmethoxy)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}piperidin- 1-yl)-1,3-thiazole-5-carboxylate embedded image
MS (ESI) M: 487 for C20H24Cl2N4O4S; NMR 0.11 (m, 2H), 0.38 (m, 2H), 0.91 (m, 1H), 1.76 (m, 2H), 2.17 (s, 3H), 3.24-3.45 (m, 4H), 3.68 (bs, 1H), 3.73 (s, 3H), 3.94 (m, 1H), 4.25 (m, 2H), 7.14 (d, 1H), 7.82 (s, 1H), 12.16 (s, 1H)
Intermediate 139 and methyl 2-bromo- 1,3-thiazole-5- carboxylate





161
Cis(±)-methyl 2-[4-{[(3,4-
MS (ESI) M: 530 for
Intermediate 140 and



dichloro-5-methyl-1H-pyrrol-2-
C20H21Cl2N5O4S2; NMR
methyl 2-bromo-



yl)carbonyl]amino}-3-(1,3-
1.66 (s, 2H), 1.91 (m, 1H),
1,3-thiazole-5-



thiazol-2-ylmethoxy)piperidin-
2.10 (qd, 1H), 2.27 (s, 3H),
carboxylate



1-yl]-1,3-thiazole-5-carboxylate
3.20-3.37 (m, 2H), 3.82 (s,




3H), 3.96 (m, 2H), 4.40 (m,




1H), 4.64 (d, 1H), 4.96 (dd,




2H), 7.19 (d, 1H), 7.28 (d,




1H), 9.67 (bs, 1H)


162
Cis(±)-Methyl 2-(4-{[(3,4-
MS (ES) MH+: 461, 463 for
Intermediate



dichloro-5-methyl-1H-pyrrol-2-
C18H22Cl2N4O4S; 1H-NMR:
141 and methyl-2-



yl)carbonyl]amino}-3-
1.04 (t, 3H); 1.75 (m, 2H);
bromo-1,3-thiazole-



ethoxypiperidin-1-yl)-1,3-
2.17 (s, 3H); 3.35-3.45 (m,
5 carboxylate



thiazole-5-carboxylate
3H); 3.63 (m, 2H); 3.73 (s,




3H); 3.96 (m, 1H); 4.25 (m,




2H); 7.11 (d, 1H); 7.82 (s,




1H); 12.12 (s, 1H)


163
Cis(±)-Methyl 2-(4-{[(3,4-
MS (ES) MH+: 505, 507 for
Intermediate 141



dichloro-5-methyl-1H-pyrrol-2-
C20H26Cl2N4O5S; 1H-NMR:
and Intermediate 17



yl)carbonyl]amino}-3-
1.05 (t, 3H); 1.74 (m, 2H);



ethoxypiperidin-1-yl)-4-
2.17 (s, 3H); 3.27 (s, 3H);



(methoxymethyl)-1,3-thiazole-
3.39-3.47 (m, 3H); 3.63 (m,



5-carboxylate
2H); 3.71 (s, 3H); 3.96 (m,




1H); 4.23 (m, 2H); 4.55 (s,




2H); 7.12 (d, 1H); 12.16 (br




s, 1H)


164
Cis(±)-Ethyl 2-(4-{[(3,4-
MS (ES) MH+: 475, 477 for
Intermediate 50 and



dichloro-5-methyl-1H-pyrrol-2-
C19H24Cl2N4O4S; 1H-NMR:
Intermediate 236



yl)carbonyl]amino}-3-
1.22 (t, 3H); 1.72 (m, 2H);



methoxypiperidin-1-yl)-4-
2.17 (s, 3H); 2.42 (s, 3H);



methyl-1,3-thiazole-5-
3.31 (m, 5H); 3.52 (m, 1H);



carboxylate
3.90 (m, 1H), 4.16 (q, 2H),




4.26 (m, 2H); 7.14 (d, 1H);




12.14 (brs, 1H)





165
Ethyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-4-methyl- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 463 465 for C18H21Cl2FN4O3S; NMR: 1.23 (t, 3H); 1.85 (m, 2H); 2.18 (s, 3H); 2.43 (s, 3H); 3.35 (m, 1H overlapping water) 3.53 (dd, 1H); 4.00 (m, 1H); 4.16 (q, 2H); 4.30 (m, 2H); 4.94 (d, 1H); 7.24 (d, 1H); 12.09 (s, 1H)
Intermediate 36 and Intermediate 236





166
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 475, 477 for
Intermediate 51 and



dichloro-5-methyl-1H-pyrrol-2-
C19H24Cl2N4O4S; NMR:
Intermediate



yl)carbonyl]amino}-3-
1.22 (t, 3H); 1.72 (m, 2H);
236



methoxypiperidin-1-yl)-4-
2.17 (s, 3H); 2.42 (s, 3H);



methyl-1,3-thiazole-5-
3.31 (m, 5H); 3.52 (m, 1H);



carboxylate
3.90 (m, 1H); 4.16 (q, 2H);




4.26 (m, 2H); 7.14 (d, 1H);




12.14 (br s, 1H)


167
Trans(±)methyl 2-[4-{[(3,4-
MS (ES) MH+: 530, 532 for
Intermediate 142



dichloro-5-methyl-1H-pyrrol-2-
C21H25Cl2N5O5S; NMR:



yl)carbonyl]amino}-3-
1.89 (m, 1H), 2.14 (m, 1H),



(morpholin-4-
2.17 (s, 3H), 3.73 (s, 3H),



ylcarbonyl)piperidin-1-yl]-1,3-
3.23-3.79 (m, 12H), 3.93



thiazole-5-carboxylate
(dd, 1H), 4.51 (m, 1H), 7.33




(d, 1H), 7.84 (s, 1H), 12.08




(s, 1H)


168
Cis(±)methyl 2-[4-{[(3,4-
MS (ES) MH+: 530, 532 for
Intermediate 143



dichloro-5-methyl-1H-pyrrol-2-
C21H25Cl2N5O5S; NMR:



yl)carbonyl]amino}-3-
1.79 (dq, 1H), 1.90 (m, 1H),



(morpholin-4-
2.15 (s, 3H), 3.22-3.42 (m,



ylcarbonyl)piperidin-1-yl]-1,3-
6H), 3.51-3.71 (m, 5H), 3.74



thiazole-5-carboxylate
(s, 3H), 3.96 (m, 1H), 4.02




(m, 1H), 4.40 (m, 1H), 7.17




(d, 1H), 7.88 (s, 1H), 12.02




(s, 1H)


169
Cis(±)({4-{[(3,4-dichloro-5-
MS (ES) MH+: 491, 493 for
Intermediate 144



methyl-1H-pyrrol-2-
C18H20Cl2N4O6S; NMR:



yl)carbonyl]amino}-1-[5-
1.61 (dq, 1H), 2.03 (m, 1H),



(methoxycarbonyl)-1,3-thiazol-
2.17 (s, 3H), 3.25 (dd, 1H),



2-yl]piperidin-3-yl}oxy)acetic
3.35 (m, 1H), 3.63 (m, 1H),



acid
3.74 (s, 3H), 3.88 (m, 1H),




4.06 (m, 1H), 4.17 (s, 2H),




4.23 (dd, 1H), 7.58 (d, 1H),




7.86 (s, 1H), 11.99 (s, 1H),




12.76 (s, 1H)





170
Cis(±)methyl 2-[4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3-(2- morpholin-4-yl-2- oxoethoxy)piperidin-1-yl]-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 560, 562 for C22H27Cl2N5O6S; NMR: 1.59 (dq, 1H), 2.07 (m, 1H), 2.17 (s, 3H), 3.24 (dd, 1H), 3.27-3.56 (m, 8H), 3.61 (m, 1H), 3.74 (s, 3H), 3.85 (m, 1H), 4.05 (m, 1H), 4.24 (dd, 2H), 4.35 (q, 2H), 7.78 (d, 1H), 7.86 (s, 1H), 11.95 (s, 1H)
Example 169





171
Methyl 2-(4-{[(3,4-dichloro-5-
MS (ES) MH+: 433, 435 for
Intermediate 244



methyl-1H-pyrrol-2-
C16H18Cl2N4O4S



yl)carbonyl]amino}-3-



hydroxypiperidin-1-yl)-1,3-



thiazole-5-carboxylate


172
Methyl 2-(4-{[(3,4-dichloro-5-
MS (ES) MH+: 504, 506 for
Example 171



methyl-1H-pyrrol-2-
C19H23Cl2N5O5S



yl)carbonyl]amino}-3-



{[(ethylamino)carbonyl]oxy}



piperidin-1-yl)-1,3-thiazole-5-



carboxylate


173
Methyl 2-(3-
MS (ES) MH+: 516, 518 for
Example 171



{[(allylamino)carbonyl]oxy}-4-
C20H23Cl2N5O5S



{[(3,4-dichloro-5-methyl-1H-



pyrrol-2-



yl)carbonyl]amino}piperidin-1-



yl)-1,3-thiazole-5-carboxylate


174
ethyl 4-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 443 for
Intermediate 32 and



dichloro-5-methyl-1H-pyrrol-2-
C19H21Cl2FN4O3; NMR:
ethyl 4-



yl)carbonyl]amino}-3-
1.31 (t, 3H) 1.81 (s, 2H)
chloropyridine-2-



fluoropiperidin-1-yl)pyridine-2-
2.19 (s, 3H) 2.69 (s, 1H)
carboxylate (WO



carboxylate
3.33 (s, 3H) 4.05 (s, 1H)
2004007657)




4.30 (q, 2H) 4.40 (s, 1H)




4.86 (d, 1H) 7.07 (dd, 2.73




Hz, 1H) 7.21 (d, 1H) 7.46




(d, 1H) 8.23 (d, 1H) 12.09




(s, 1H)





175
Cis(±)-diethyl 2-(4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-4,5-dicarboxylate embedded image
MS (ES) MH+: 533 for C21H26Cl2N4O6S; NMR: 1.22 (t, 3H) 1.28 (t, 3H) 1.76 (d, 2H) 2.15-2.21 (m, 3H) 3.29-3.34 (m, 3H) 3.36 (s, 3H) 3.42 (s, 1H) 3.56 (s, 1H) 3.95 (s, 1H) 4.19 (q, 2H) 4.23-4.32 (m, 3H) 7.19 (d, 1H) 12.20 (s, 1H)
Intermediate 50 and Intermediate 244





176
diethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 521 for
Intermediate 32 and



dichloro-5-methyl-1H-pyrrol-2-
C20H23Cl2FN4O5S; NMR:
Intermediate 247



yl)carbonyl]amino}-3-
1.22 (t, 3H) 1.28 (t, 3H)



fluoropiperidin-1-yl)-1,3-
1.86 (d, 2H) 2.19 (s, 3H)



thiazole-4,5-dicarboxylate
3.31 (s, 1H) 3.41 (s, 2H)




3.68-3.71 (dd, 1H) 3.99 (s,




1H) 4.20 (q, 2H) 4.29 (q,




2H) 4.89-5.05 (d, 1H) 7.27




(d, 1H) 12.09 (s, 1H)


177
Cis(±)-ethyl 4-(4-{[(4-chloro-5-
MS (ES) MH+: 521 for
Intermediate 55 and



methyl-1H-pyrrol-2-
C20H25ClN4O4
ethyl 4-



yl)carbonyl]amino}-3-
NMR: 1.31 (t, 3H) 1.62 (s,
chloropyridine-2-



methoxypiperidin-1-yl)pyridine-
1H) 1.79-1.95 (m, 1H)
carboxylate (WO



2-carboxylate
2.10-2.19 (m, 3H) 3.07-
2004007657)




3.19 (m, 2H) 3.23 (s, 3H)




3.45-3.54 (m, 1H) 3.89 (s,




1H) 4.18 (s, 1H) 4.22 (d,




1H) 4.30 (q, 2H) 6.89 (d,




1H) 7.04 (dd, 1H) 7.44 (d,




1H) 7.67 (d, 1H) 8.20 (d,




1H) 11.63 (s, 1H)


178
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 622 for
Intermediate 50 and



dichloro-5-methyl-1H-pyrrol-2-
C28H33Cl2N5O5S
Intermediate 55



yl)carbonyl]amino}-3-



methoxypiperidin-1-yl)-4-{[(1-



methyl-1-



phenylethyl)amino]carbonyl}-



1,3-thiazole-5-carboxylate


179
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 443 for
Intermediate 32 and



dichloro-5-methyl-1H-pyrrol-2-
C19H21Cl2FN4O3
ethyl 2-



yl)carbonyl]amino}-3-

fluoroisonicotinate



fluoropiperidin-1-

(Konno, Akinori J.



yl)isonicotinate

Fluorine Chemistry





(1998), 87(2), 137-





140)





180
methyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-4- (methoxymethyl)-1,3-thiazole- 5-carboxylate embedded image
MS (ES) MH+: 479 for C18H21Cl2FN4O4S NMR: 1.86 (s, 2H) 2.19 (s, 3H) 3.25-3.31 (s, 3H) 3.53-3.67 (dd, 1H) 3.73 (s, 3H) 4.00 (s, 2H) 4.33 (s, 2H) 4.57 (s, 2H) 4.89-5.05 (d, 1H) 7.27 (d, 1H) 12.10 (s, 1H)
Intermediate 32 and Intermediate 17





181
ethyl 4-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 493 for
Intermediate 32 and



dichloro-5-methyl-1H-pyrrol-2-
C23H23Cl2FN4O3
Intermediate 10



yl)carbonyl]amino}-3-



fluoropiperidin-1-yl)quinoline-



2-carboxylate


182
ethyl 2-((3S,4R)-4-{[(4-chloro-
MS (ES) MH+: 421 for
Intermediate 55 and



5-methyl-1H-pyrrol-2-
C20H25ClN4O4
ethyl 2-



yl)carbonyl]amino}-3-
NMR: 1.32 (t, 3H) 1.60 (d,
fluoroisonicotinate



methoxypiperidin-1-
1H) 1.84 (s, 1H) 2.14 (s,
(Konno, Akinori J.



yl)isonicotinate
1H) 3.13 (d, 2H) 3.20-3.24
Fluorine Chemistry




(m, 3H) 3.49 (s, 1H) 4.20
(1998), 87(2), 137-




(d, 2H) 4.33 (q, 2H) 4.56
140)




(s, 1H) 6.89 (d, 1H) 6.97




(d, 1H) 7.23 (s, 1H) 7.64




(d, 1H) 8.24 (d, 1H) 11.62




(s, 1H)


183
methyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 491 for
Intermediate 51 and



dichloro-5-methyl-1H-pyrrol-2-
C19H24Cl2N4O5S
Intermediate 17



yl)carbonyl]amino}-3-
NMR: 1.86-1.95 (m, 1H)



methoxypiperidin-1-yl)-4-
1.97-2.04 (m, 1H) 2.26-



(methoxymethyl)-1,3-thiazole-
2.31 (m, 3H) 3.16-3.31 (m,



5-carboxylate
2H) 3.47 (s, 3H) 3.48 (s,




2H) 3.50-3.55 (m, 1H) 3.82




(s, 3H) 4.05 (d, 1H) 4.25-




4.37 (m, 1H) 4.54 (s, 1H)




4.69-4.81 (m, 2H) 7.19-




7.27 (m, 1H) 9.54 (s, 1H)


184
methyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH+:491 for
Intermediate 52 and



dichloro-5-methyl-1H-pyrrol-2-
C19H24Cl2N4O5S
Intermediate 17



yl)carbonyl]amino}-3-



methoxypiperidin-1-yl)-4-



(methoxymethyl)-1,3-thiazole-



5-carboxylate





185
Cis(±)-isopropyl 4-(4-{[(3,4-
MS (ES) MH+: 582 for
Intermediate 50 and



dichloro-5-methyl-1H-pyrrol-2-
C26H33Cl2N5O6
Intermediate 249



yl)carbonyl]amino}-3-



methoxypiperidin-1-yl)-6-(morpholin-4-



ylcarbonyl)pyridine-2-carboxylate





embedded image







186
isopropyl 4-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 570 for
Intermediate 32 and



dichloro-5-methyl-1H-pyrrol-2-
C25H30Cl2FN5O5
Intermediate 249



yl)carbonyl]amino}-3-
NMR: 1.32 (d, 6H) 1.78-



fluoropiperidin-1-yl)-6-
1.93 (m, 2H) 2.19 (s, 3H)



(morpholin-4-
3.27-3.33 (m, 4H) 3.39 (d,



ylcarbonyl)pyridine-2-
2H) 3.53-3.60 (m, 2H)



carboxylate
3.65 (d, 4H) 4.12 (s, 1H)




4.39 (s, 1H) 5.07-5.19 (m,




1H) 7.16-7.26 (m, 2H)




7.47 (d, 1H) 12.08 (s, 1H)


187
isopropyl 4-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 528 for
Intermediate 32 and



dichloro-5-methyl-1H-pyrrol-2-
C23H28Cl2FN5O4
Intermediate 250



yl)carbonyl]amino}-3-



fluoropiperidin-1-yl)-6-



[(dimethylamino)carbonyl]



pyridine-2-carboxylate


188
Cis(±)-2-(4-{[(3,4-dichloro-5-
MS (ES) MH+: 505 for
Intermediate 50 and



methyl-1H-pyrrol-2-
C19H22Cl2N4O6S
Intermediate 252



yl)carbonyl]amino}-3-
NMR: 1.24 (t, 3H) 1.74 (s,



methoxypiperidin-1-yl)-5-
2H) 2.18 (s, 3H) 3.36 (s,



(ethoxycarbonyl)-1,3-thiazole-
4H) 3.56 (s, 1H) 3.93 (s, 1H)



4-carboxylic acid
4.19 (s, 3H) 4.29 (s, 2H)




7.13 (s, 1H) 12.11 (s, 1H)




13.51 (s, 1H)


189
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 493 for
Intermediate 32 and



methyl-1H-pyrrol-2-
C18H19Cl2FN4O5S
Intermediate 252



yl)carbonyl]amino}-3-
NMR: 1.19-1.27 (m, 3H)



fluoropiperidin-1-yl)-5-
1.85 (d, 2H) 2.18 (s, 3H)



(ethoxycarbonyl)-1,3-thiazole-
3.26-3.35 (m, 1H) 3.53 (d,



4-carboxylic acid
1H) 3.98 (s, 2H) 4.18 (q,




1H) 4.31 (s, 2H) 4.88-5.04




(s, 1H) 7.26 (d, 1H) 12.08




(s, 1H) 13.55 (s, 1H)





190
2-((3R,4S)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-5- (ethoxycarbonyl)-1,3-thiazole- 4-carboxylic acid embedded image
MS (ES) MH+: 505 for C19H22Cl2N4O6S NMR: 1.16 (t, 3H) 1.69 (s, 2H) 2.12 (s, 2H) 3.30 (s, 3H) 3.50 (s, 2H) 3.89 (s, 2H) 4.13 (q, 2H) 4.17-4.29 (m, 2H) 7.10 (d, 1H) 12.10 (s, 1H) 13.50 (s, 1H)
Intermediate 52 and Intermediate 252





191
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 505 for
Intermediate 51 and



dichloro-5-methyl-1H-pyrrol-2-
C19H22Cl2N4O6S
Intermediate 252



yl)carbonyl]amino}-3-
NMR: 1.22 (t, 3H) 1.75 (s,



methoxypiperidin-1-yl)-4-
2H) 2.18 (s, 3H) 3.31 (d,



carboxy-1,3-thiazole-5-
1H) 3.36 (s, 3H) 3.42 (s, 1H)



carboxylate
3.56 (s, 1H) 3.95 (s, 1H)




4.14-4.22 (m, 2H) 4.29 (s,




1H) 7.16 (d, 1H) 12.16 (s,




2H) 13.56 (s, 1H)


192
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 461 for
Intermediate 51 and



dichloro-5-methyl-1H-pyrrol-2-
C18H22Cl2N4O4S
ethyl 2-bromo-1,3-



yl)carbonyl]amino}-3-

thiazole-4-



methoxypiperidin-1-yl)-1,3-

carboxylate



thiazole-4-carboxylate


193
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 455 for
Intermediate 51 and



dichloro-5-methyl-1H-pyrrol-2-
C20H24Cl2N4O4
ethyl 2-



yl)carbonyl]amino}-3-
NMR: 1.32 (s, 3H) 1.84 (s,
fluoroisonicotinate



methoxypiperidin-1-
2H) 2.22 (s, 3H) 3.36 (s,
(Konno, Akinori J.



yl)isonicotinate
3H) 3.45 (s, 1H) 4.16 (s, 1H)
Fluorine Chemistry




4.25 (s, 1H) 4.31 (s, 2H)
(1998), 87(2), 137-




4.81 (s, 1H) 7.04 (s, 1H)
140)




7.26 (s, 1H) 8.21 (s, 1H)




10.53 (s, 1H)









Example 194
Cis(±)-ethyl 5-amino-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate

A solution of SnCl2 dihydrate (870 mg, 3.8 mmol) in 5 ml concentrated HCl was added to a solution of 436 mg (0.87 mmol) of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-nitroisonicotinate (Example 308) in 30 ml acetic acid. The mixture was stirred at room temperature overnight. Solvent was removed and the residue was partitioned between water and EtOAc. The EtOAc was separated and washed with brine. Drying (MgSO4), removal of solvent and chromatography on silica gel (100% CH2Cl2 followed by gradient elution to 100% EtOAc and then to 10% MeOH in EtOAc) gave 230 mg of product. MS (ES)(MH+): 470 for C20H25Cl2N5O4; NMR (CDCl3): 1.5 (t, 3H), 2.1 (m, 2H) 2.4 (s, 3H), 3.2 (m, 2H), 3.6 (s, 3H), 3.65 (m, 1H), 4.0 (m, 1H), 4.4 (m, 1H), 4.5 (q, 2H), 7.3 (s, 1H), 8.0 (s, 1H), 9.5 (s, 1H).


Example 195
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-[(methoxycarbonyl)amino]isonicotinate



embedded image


Methylchlorofomate (15 μl, 0.19 mmol) was added to a solution of 60 mg (0.13 mmol) of Cis(±)-ethyl 5-amino-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate (Example 194) in 3 ml pyridine. After stirring at room temperature overnight, 7 μl more methylchloroformate was added. Solvent was removed and the residue was partitioned between EtOAc and NaHCO3 (aqueous). The EtOAc was separated and washed with water and brine. Drying (MgSO4) and removal of solvent gave 43 mg of product. NMR (d6-DMSO): 1.3 (t, 3H), 1.7 (m, 2H) 2.2 (s, 3H), 3.1 (m, 2H), 3.3 (s, 3H), 3.5 (m, 1H), 3.6 (s, 3H), 4.0-4.3 (m, 4H), 4.6 (m, 1H), 7.05 (m, 1H), 7.15 (m, 1H), 8.2 (s, 1H), 9.1 (s, 1H), 12.2 (s, 1H).


Example 196
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-[(methylsulfonyl)amino]isonicotinate

Methanesulfonyl chloride (16 μl, 21 mmol) was added to 66 mg (0.14 mmol) of Cis(±)-ethyl 5-amino-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate (Example 194) in 3 ml pyridine. After stirring for 1 h, 5 μl more methanesulfonyl chloride was added. Stirred at room temperature overnight. Solvent was removed, and the residue was partitioned between EtOAc and Na2CO3 (aqueous). The EtOAc was separated and washed with water and brine. Drying (MgSO4) and removal of solvent gave 63 mg of product. MS (ES)(MH+): 534 for C21H27Cl2N5O6S, NMR (d6-DMSO): 1.4 (t, 3H), 1.8 (m, 2H) 2.2 (s, 3H), 2.9 (s, 3H), 3.1-3.2 (m, 2H), 3.3-3.5 (m), 3.6 (m, 1H), 4.2-4.3 (m, 2H), 4.4 (q, 2H), 4.7 (m, 1H), 7.1 (s, 1H), 7.2 (d, 1H), 8.2 (s, 1H), 12.2 (s, 1H).


Example 197
Cis(±)-6-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(ethoxycarbonyl)nicotinic acid

A solution of 133 mg (0.84 mmol) KMnO4 in 5 ml water was added to a solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-formylisonicotinate (Example 154) in 20 ml acetone, and the mixture was stirred at room temperature for 4 h. After quenching with aqueous NaHSO3, the mixture was acidified to about pH=4 with 1N HCl and extracted twice with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO4) and concentrated to give a solid that was triturated with MeOH to give 175 mg of product. MS (ES) MH+: 499 for C21H24Cl2N4O6; NMR: 1.25 (t, 3H), 1.5-1.8, (m, 3H), 2.1 (s, 3H), 3.1 (m, 3H), 3.3 (s, 3H), 3.5 (m, 1H), 4.2 (m, 2H), 4.4 (m, 1H), 4.9 (m, 1H), 6.9 (s, 1H), 7.1 (d, 1H), 8.6 (s, 1H), 12.1 (s, 1H), 13.3 (s, 1H).


Example 198
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-{[(1-methyl-1-phenylethyl)amino]carbonyl}isonicotinate

HATU (87 mg, 24 mmol) was added to a solution of 118 mg (0.24 mmol) Cis(±)-6-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(ethoxycarbonyl)nicotinic acid (Example 197), 0.040 ml (28 mmol) Et3N and 33 mg (0.24 mmol) cumylamine in 3 ml DMF. After stirring at room temperature overnight, the mixture was diluted with water and extracted with EtOAc. The EtOAc was washed 2 times with water and once with brine before being dried (MgSO4) and concentrated to give 103 mg of a solid. MS (ES) MH+: 616 for C30H35Cl2N5O5.


Examples 199-200

The following Examples were prepared by the procedure described in Example 198 from the starting materials (SM) indicated.















Ex
Compound
Data
SM







199
ethyl 2-((3S,4R)-4-{[(3,5-
MS (ES) MH+: 610 for
Example 156 and



dichloro-4-methyl-1H-pyrrol-
C27H30Cl2FN5O4S;
cumylamine



2-yl)carbonyl]amino}-3-
NMR: 1.2 (t, 3H), 1.5 (s,




fluoropiperidin-1-yl)-4-{[(1-
6H), 1.65 (m, 2H), 1.9




methyl-1-
(s, 3H), 3.6 (m, 1H), 4.0




phenylethyl)amino]carbonyl}-
(m, 1H), 4.1-4.3 (m,




1,3-thiazole-5-carboxylate
4H), 4.3 (dd, 1H), 4.95





(d, 1H), 7.0-7.5 (m, 5H),





8.6 (s, 1H), 12.6 (s, 1H)



200
ethyl 2-((3S,4R)-4-{[(3,5- dichloro-4-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-4-{[(2- morpholin-4- ylethyl)amino]carbonyl}-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 605 for C24H31Cl2FN6O6S; NMR: 1.2 (t, 3H), 1.8 (m, 2H), 1.9 (s, 3H), 2.3 (m, 4H), 3.6 (m, 5H), 4.0 (m, 1H), 4.2 (q, 2H), 4.3 (m, 2H), 4.95 (d, 1H), 7.35 (d, 1H), 8.4 (t, 1H), 12.6 (s, 1H)
Example 156 and (2- morpholin-4- ylethyl)amine









Example 201
Cis(±)-ethyl 5-(aminocarbonyl)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate

A solution of 103 mg (0.17 mmol) of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-{[(1-methyl-1-phenylethyl)amino]carbonyl} isonicotinate (Example 198) in 10 ml TFA was heated at 40° C. overnight and at 50° C. for 6 h. Solvent was removed and the residue was triturated with MeOH to give 62 mg of a white solid. MS (ES) MH+: 498 for C21H25Cl2N5O5.


Example 202

The following Example was prepared by the procedure described in Example 201 from the starting materials (SM) indicated.















Ex
Compound
Data
SM







202
5-thiazolecarboxylic acid, 4-
MS (ES) MH+:
Example



(aminocarbonyl)-2-[(3S,4R)-4-
492 for
199



[[(3,5-dichloro-4-
C18H20Cl2FN5O4SE



methyl-1H-pyrrol-2-



yl)carbonyl]amino]-3-fluoro-1-



piperidinyl]-, ethyl ester









Example 203
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-[(dimethylamino)carbonyl]-1,3-thiazole-5-carboxylate

A solution of Cis(±)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-5-(ethoxycarbonyl)-1,3-thiazole-4-carboxylic acid (0.062 g, 0.12 mmol, Example 188), dimethylamine (0.06 mL, 2M solution in THF, Aldrich), HATU (0.05 g, 0.13 mmol) and triethylamine (0.018 mL, 0.13 mmol) was stirred at room temperature until complete by LCMS (about 30 min). The crude reaction mixture was slowly poured into water and the resulting white precipitate was filtered, washed with water and dried under vacuum to yield pure product (0.028 g). MS (ES) MH+: 532 for C21H27Cl2N5O5S; NMR: 1.20 (t, 3 H) 1.76 (s, 2 H) 2.18 (s, 3 H) 2.78 (s, 3 H) 2.93 (s, 3 H) 3.29 (d, 1 H) 3.36 (s, 3 H) 3.39-3.43 (m, 1 H) 3.55 (s, 1 H) 3.91 (s, 1 H) 4.15 (q, 2 H) 4.29 (s, 2 H) 7.15 (d, 1 H) 12.14 (s, 1 H).


Examples 204-241

The following Examples were prepared by the procedure described in Example 203 from the starting materials (SM) indicated















Ex
Compound
Data
SM







204
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 574 for
Example 188 and



dichloro-5-methyl-1H-pyrrol-
C23H29Cl2N5O6S;
morpholine



2-yl)carbonyl]amino}-3-
NMR: 1.21 (t, 3H) 1.74 (s, 2




methoxypiperidin-1-yl)-4-
H) 2.17 (s, 3H), 3.11-3.17




(morpholin-4-ylcarbonyl)-
(m, 2H) 3.34 (s, 3H) 3.38 (s,




1,3-thiazole-5-carboxylate
1H) 3.47-3.59 (m, 5H) 3.62





(s, 2H) 3.87 (s, 1H) 4.17 (q,





2H) 4.29 (s, 2H) 7.13 (d, 1





H) 12.13 (s, 1H)



205
ethyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-4- (morpholin-4-ylcarbonyl)- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 562 for C22H26Cl2FN5O5S; NMR: 1.16 (t, 3H) 1.80 (s, 2H) 2.12 (s, 3H) 3.09 (d, 2H) 3.45 (s, 2H) 3.50 (s, 2H) 3.57 (s, 2H) 3.92 (s, 1H) 4.12 (q, 2H) 4.26 (s, 3H) 4.82 (s, 1H) 4.99 (s, 1H) 7.19 (s, 1H) 12.02 (s, 1H)
Example 189 and morpholine





206
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 534 for
Example 188 and



dichloro-5-methyl-1H-pyrrol-
C20H25Cl2N5O6S; NMR: 1.18-
methoxylamine



2-yl)carbonyl]amino}-3-
1.25 (m, 3H) 1.75 (s, 2H)
hydrochloride



methoxypiperidin-1-yl)-4-
2.17 (s, 3H) 3.35 (s, 3H)




[(methoxyamino)carbonyl]-
3.54 (s, 2H) 3.67 (s, 3H)




1,3-thiazole-5-carboxylate
3.95 (s, 2H) 4.14-4.22 (m, 2





H), 4.28 (s, 2H) 7.13 (d, 1H)





11.48 (s, 1H) 12.13 (s, 1H)



207
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 522 for
Example 189 and



dichloro-5-methyl-1H-pyrrol-
C19H22cL2FN5O5S; NMR:
methoxylamine



2-yl)carbonyl]amino}-3-
1.16 (t, 3H) 1.79 (s, 2H)
hydrochloride



fluoropiperidin-1-yl)-4-
2.12 (s, 3H) 3.29 (s, 2H)




[(methoxyamino)carbonyl]-
3.62 (s, 3H) 3.94 (s, 1H)




1,3-thiazole-5-carboxylate
4.12 (q, 2H) 4.25 (s, 2H)





4.82-4.98 (s, 1H) 7.18 (d, 1





H) 11.44 (s, 1H) 12.03 (s, 1





H)



208
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 572 for
Example 188 and



dichloro-5-methyl-1H-pyrrol-
C24H31Cl2N5O5S; NMR: 1.22
piperidine



2-yl)carbonyl]amino}-3-
(s, 3H) 1.43 (s, 2H) 1.56 (s,




methoxypiperidin-1-yl)-4-
4H) 1.74 (s, 2H) 2.17 (s, 3




(piperidin-1-ylcarbonyl)-1,3-
H) 3.12 (s, 2H) 3.36 (s, 3H)




thiazole-5-carboxylate
3.52 (s, 3H) 4.16 (s, 2H)





4.27 (s, 2H) 7.15 (s, 1H)





12.18 (s, 1H)



209
ethyl 2-((3R,4S)-4-{[(3,4-
MS (ES) MH+: 622 for
Example 190 and



dichloro-5-methyl-1H-pyrrol
C28H33Cl2N5O5S; NMR: 1.18
cumylamine



2-yl)carbonyl]amino}-3-
(t, 3H) 1.53 (s, 3H) 1.56 (s, 3




methoxypiperidin-1-yl)-4-
H) 1.71 (s, 2H) 2.13 (s, 3H)




{[(1-methyl-1-
3.34 (s, 3H) 3.51 (s, 2H)




phenylethyl)amino]carbonyl}-
3.92 (s, 2H) 4.15 (q, 2H)




1,3-thiazole-5-carboxylate
4.26 (s, 2H) 7.12 (dd, 2H)





7.23 (t, 2H) 7.40 (d, 2H) 8.56





(s, 1H) 12.11 (s, 1H)



210
ethyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-4-{[(1- methyl-1- phenylethyl)amino]carbonyl}- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 610 for C27H30Cl2FN5O4S; NMR: 1.23 (t, 3H) 1.61 (s, 6H) 1.86 (s, 2H) 2.19 (s, 3H) 3.31 (s, 3H) 3.55 (s, 1H) 4.04 (s, 1H) 4.22 (q, 1H) 4.32 (s, 2H) 4.90-5.06 (d, 1H) 7.20 (d, 1H) 7.31 (t, 3H) 7.47 (d, 2H) 8.63 (s, 1H) 12.12 (s, 1H)
Example 189 and cumylamine





211
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 506 for
Example 189 and



dichloro-5-methyl-1H-pyrrol-
C19H22Cl2FN5O4S; NMR:
methylamine



2-yl)carbonyl]amino}-3-
1.14 (t, 3H) 1.77 (s, 2H)




fluoropiperidin-1-yl)-4-
2.12 (s, 3H) 2.62 (d, 3H) 3.33




[(methylamino)carbonyl]-1,3-
(s, 1H) 3.43-3.63 (s, 1H)




thiazole-5-carboxylate
3.94 (s, 1H) 4.09 (q, 2H)





4.23 (s, 2H) 4.82-4.98 (s, 1





H) 7.20 (d, 1H) 8.27 (d, 1H)





12.03-12.12 (m, 1H)



212
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 548 for
Example 188 and 2-



dichloro-5-methyl-1H-pyrrol-
C21H27Cl2N5O6S
aminoethanol



2-yl)carbonyl]amino}-3-





methoxypiperidin-1-yl)-4-





{[(2-





hydroxyethyl)amino]carbonyl}-





1,3-thiazole-5-carboxylate




213
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 622 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C28H33Cl2N5O5S;
cumylamine



2-yl)carbonyl]amino}-3-
NMR: 1.23 (t, 3H) 1.59 (s, 3




methoxypiperidin-1-yl)-4-
H) 1.62 (s, 3H) 1.77 (s, 2H)




{[(1-methyl-1-
2.19 (s, 3H) 3.31 (s, 1H)




phenylethyl)amino]carbonyl}-
3.36 (s, 1H) 3.40 (s, 3H)




1,3-thiazole-5-carboxylate
3.57 (s, 1H) 3.96 (s, 1H)





4.21 (q, 2H) 4.32 (s, 2H)





7.12-7.22 (m, 2H) 7.29 (t, 2





H) 7.46 (d, 2H) 8.62 (s, 1H)



214
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 518 for
Example 188 and



dichloro-5-methyl-1H-pyrrol-
C20H25Cl2N5O5S;
methylamine



2-yl)carbonyl]amino}-3-
NMR: 1.20 (s, 3H) 1.74 (s, 2




methoxypiperidin-1-yl)-4-
H) 2.17 (s, 3H) 2.68 (s, 3H)




[(methylamino)carbonyl]-1,3-
3.30 (s, 2H) 3.36 (s, 3H)




thiazole-5-carboxylate
3.55 (s, 1H) 3.99 (s, 1H)





4.15 (s, 2H) 4.26 (s, 2H)





7.14 (s, 1H) 8.32 (s, 1H)





12.18 (s, 1H)



215
Cis(±)-ethyl 2-(4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- {[(2- methoxyethyl)amino]carbonyl}- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 562 for C22H29Cl2N5O6S; NMR: 1.15-1.25 (m, 3H) 1.74 (s, 2H) 2.18 (s, 3H) 3.26 (s, 3H) 3.30 (s, 1H) 3.36 (s, 3H) 3.41 (d, 3H) 3.55 (s, 1H) 4.00 (s, 1H) 4.10-4.19 (m, 2H) 4.26 (s, 2+nlH) 7.15 (d, 1H) 8.44-8.56 (m, 1H) 12.16 (s, 1H)
Example 188 and (2-methoxyethyl)amine





216
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 562 for
Example 188 and 2-



dichloro-5-methyl-1H-pyrrol-
C22H29Cl2N5O6S;
aminopropan-1-ol



2-yl)carbonyl]amino}-3-
NMR: 1.08 (d, 2H) 1.22 (t, 3




methoxypiperidin-1-yl)-4-
H) 1.75 (s, 2H) 2.18 (s, 3H)




{[(2-hydroxy-1-
3.37 (s, 3H) 3.47 (d, 1H)




methylethyl)amino]carbonyl}-
3.55 (s, 1H) 3.81-3.92 (m, 1




1,3-thiazole-5-carboxylate
H) 3.99 (s, 1H) 4.17 (q, 2H)





4.27 (s, 2H) 4.62 (s, 2H)





7.15 (d, 1H) 8.20 (d, 1H)





12.17 (s, 1H)



217
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 562 for
Example 188 and 1-



dichloro-5-methyl-1H-pyrrol-
C22H29Cl2N5O6S;
aminopropan-2-ol



2-yl)carbonyl]amino}-3-
NMR: 1.07 (d, 3H) 1.21 (t, 3




methoxypiperidin-1-yl)-4-
H) 1.75 (s, 2H) 2.18 (s, 3H)




{[(2-
3.03-3.18 (m, 2H) 3.36 (s, 3




hydroxypropyl)amino]carbon
H) 3.41 (s, 1H) 3.55 (s, 1H)




yl}-1,3-thiazole-5-carboxylate
3.74 (s, 1H) 3.98 (s, 1H)





4.11-4.19 (m, 2H) 4.19 (s, 1





H) 4.30 (s, 1H) 4.61 (s, 1H)





7.15 (d, 1H) 8.33-8.43 (m, 1





H) 12.16 (s, 1H)



218
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 518 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C20H25Cl2N5O5S;
methylamine



2-yl)carbonyl]amino}-3-
NMR: 1.21 (s, 3H) 1.74 (s, 2
hydrochloride



methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3H) 2.69 (s, 3H)




[(methylamino)carbonyl]-1,3-
3.17 (s, 2H) 3.36 (s, 3H)




thiazole-5-carboxylate
3.55 (s, 1H) 3.98 (s, 1H)





4.14 (s, 2H) 4.27 (s, 2H)





7.13 (s, 1H) 8.33 (s, 1H)





12.17 (s, 1H)



219
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 562 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C22H29Cl2N5O6S
(2-methoxyethyl)amine



2-yl)carbonyl]amino}-3-





methoxypiperidin-1-yl)-4-





{[(2-





methoxyethyl)amino]carbonyl}-





1,3-thiazole-5-carboxylate




220
ethyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- ({[(1S)-2-hydroxy-1- methylethyl]amino}carbonyl)- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 562 for C22H29Cl2N5O6S
Example 191 and (2S)-2- aminopropan-1-ol





221
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 562 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C22H29Cl2N5O6S
[(1R)-2-methoxy-1-



2-yl)carbonyl]amino}-3-

methylethyl]amine



methoxypiperidin-1-yl)-4-





({[(1R)-2-hydroxy-1-





methylethyl]amino}carbonyl)-





1,3-thiazole-5-carboxylate




222
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 568 for
Example 188 and



dichloro-5-methyl-1H-pyrrol-
C21H25Cl2F2N5O5S;
difluoroethylamine



2-yl)carbonyl]amino}-3-
NMR: 1.21 (t, 3H) 1.75 (s, 2




methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3H) 3.36 (s, 3H)




{[(2,2-
3.44 (s, 1H) 3.55 (s, 3H)




difluoroethyl)amino]carbonyl}-
3.98 (s, 1H) 4.16 (q, 2H)




1,3-thiazole-5-carboxylate
4.26 (s, 2H) 5.88-6.26 (t, 1H)





7.15 (d, 1H) 8.88 (s, 1H)





12.16 (s, 1H)



223
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 571 for
Example 188 and



dichloro-5-methyl-1H-pyrrol-
C22H24Cl2N6O6S;
isoxazol-3-amine



2-yl)carbonyl]amino}-3-
NMR: 1.12 (t, 3H) 1.77 (d, 2




methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3H) 3.38 (s, 3H)




[(isoxazol-3-
3.56 (s, 2H) 3.98 (s, 2H)




ylamino)carbonyl]-1,3-
4.14 (q, 2H) 4.19-4.34 (m, 2




thiazole-5-carboxylate
H) 6.99 (d, 1H) 7.16 (d, 1H)





8.86 (d, 1H) 11.59 (s, 1H)





12.17 (s, 1H)



224
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 574 for
Example 188 and



dichloro-5-methyl-1H-pyrrol-
C23H29Cl2N5O6S;
(3R)-



2-yl)carbonyl]amino}-3-
NMR: 1.21 (t, 3H) 1.75 (d, 2
tetrahydrofuran-3-



methoxypiperidin-1-yl)-4-
H) 1.87 (s, 1H) 2.09 (s, 1H)
amine 4-



{[(3R)-tetrahydrofuran-3-
2.18 (s, 3H) 3.36 (s, 3H)
methylbenzensulfonate



ylamino]carbonyl}-1,3-
3.42 (s, 1H) 3.55 (s, 2H)




thiazole-5-carboxylate
3.69 (s, 1H) 3.78 (s, 2H)





4.01 (s, 1H) 4.17 (d, 2H)





4.28 (s, 3H) 7.15 (d, 1H)





8.67 (d, 1H) 12.17 (s, 1H)



225
Cis(±)-ethyl 2-(4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- ({[(1R,2S)-2- fluorocyclopropyl]amino} carbonyl)-1,3-thiazole-5- carboxylate embedded image
MS (ES) MH+: 562 for C22H26Cl2FN5O5S; NMR: 1.07 (s, 2H) 1.21 (t, 3+nlH) 1.75 (s, 2H) 2.18 (s, 3H) 2.73 (s, 1H) 3.36 (s, 3H) 3.41 (s, 1H) 3.55 (s, 1H) 3.99 (s, 1H) 4.17 (s, 2H) 4.26 (s, 3H) 4.62-4.84 (d, 1H) 7.16 (s, 1H) 8.64 (s, 1H) 12.17 (s, 1H)
Example 188 and (1R,2S)-2- fluorocyclo- propanamine 4- methylbenzenesulfonate





226
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 576 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C23H31Cl2N5O6S;
[(1S)-2-methoxy-1-



2-yl)carbonyl]amino}-3-
NMR: 1.09 (d, 3H) 1.22 (t, 3
methylethyl]amine



methoxypiperidin-1-yl)-4-
H) 1.75 (s, 2H) 2.18 (s, 3H)




({[(1S)-2-methoxy-1-
3.17 (s, 2H) 3.26 (s, 3H)




methylethyl]amino}carbonyl)-
3.37 (s, 3H) 3.55 (s, 1H)




1,3-thiazole-5-carboxylate
4.01 (d, 1H) 4.17 (d, 2H)





4.27 (s, 2H) 7.16 (s, 1H)





8.32 (d, 1H) 12.16 (s, 1H)



227
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 542 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C22H25Cl2N5O5S;
propargylamine



2-yl)carbonyl]amino}-3-
NMR: 1.22 (s, 3H) 1.74 (s, 2




methoxypiperidin-1-yl)-4-
H) 2.18 9s, 3H) 3.16 (s, 1H)




[(prop-2-yn-1-
3.40 (m, 5H) 3.55 (d, 1H)




ylamino)carbonyl]-1,3-
3.96 (s, 3H) 4.17 (s, 2H)




thiazole-5-carboxylate
4.28 (s, 2H) 7.14 (s, 1H)





8.87 (s, 1H) 12.16 (s, 1H)



228
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 576 for
Example 191 and 2-



dichloro-5-methyl-1H-pyrrol-
C23H31Cl2N5O6S
amino-2-



2-yl)carbonyl]amino}-3-
NMR: 1.26 (s, 6H) 1.75 (s, 2
methylpropan-1-ol



methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3H) 3.37 (s, 3H)




{[(2-hydroxy-1,1-
3.44 (s, 3H) 3.56 (s, 1H)




dimethylethyl)amino]carbonyl}-
4.03 (s, 1H) 4.19 (s, 2H)




1,3-thiazole-5-carboxylate
4.28 (s, 2H) 4.67 (s, 1H)





7.16 (s, 1H) 7.87 (s, 1H)





12.17 (s, 1H)



229
2-((3S,4R)-4-{[(3,4-dichloro-
MS (ES) MH+: 562 for
Example 191 and



5-methyl-1H-pyrrol-2-
C22H26Cl2FN5O5S;
(1R,2S)-2-



yl)carbonyl]amino}-3-
NMR: 1.08 (s, 3H) 1.21 (t, 3
fluorocyclo-



methoxypiperidin-1-yl)-4-
H) 1.76 (s, 2H) 2.18 (s, 3H)
propanamine 4-



{[(2-hydroxy-1,1
3.36 (s, 3H) 3.41 (s, 1H)
methylbenzenesulfonate



dimethylethyl)amino]carbonyl}-
3.55 (s, 1H) 3.97 (s, 1H)




1,3-thiazole-5-carboxylic
4.09-4.19 (m, 2H) 4.27 (s, 2




acid
H) 4.61-4.83 (s, 1H) 7.15 (d,





1H) 8.64 (s, 1H) 12.16 (s, 1H)



230
ethyl 4-{[(1- cyanocyclopropyl)amino] carbonyl}-2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 569 for C23H26Cl2N6O5S; NMR: 1.21 (q, 5H) 1.50- 1.61 (m, 2H) 1.75 (s, 2H) 2.18 (s, 3H) 3.36 (s, 3H) 3.40 (s, 1H) 3.55 (s, 1H) 4.01 (s, 1H) 4.13-4.22 (m, 2 H) 4.28 (s, 2H) 7.14 (d, 1H) 9.36 (s, 1H) 12.17 (s, 1H)
Example 191 and 1- aminocyclopropane carbonitrile





231
ethyl 4-
MS (ES) MH+: 544 for
Example 191 and



[(cyclopropylamino)carbonyl]-
C22H27Cl2N5O5S;
cyclopropylamine



2-((3S,4R)-4-{[(3,4-
NMR: 0.49 (s, 2H) 0.66 (d, 2




dichloro-5-methyl-1H-pyrrol-
H) 1.22 (s, 3H) 1.75 (s, 2H)




2-yl)carbonyl]amino}-3-
2.18 (s, 3H) 2.72 (s, 1H)




methoxypiperidin-1-yl)-1,3-
3.38 (m, 4H) 3.55 (s, 1H)




thiazole-5-carboxylate
3.99 (s, 1H) 4.17 (s, 2H)





4.27 (s, 2H) 7.16 (s, 1H)





8.44 (s, 1H) 12.17 (s, 1H)



232
ethyl 4-{[(1-cyano-1-
MS (ES) MH+: 571 for
Example 191 and 2-



methylethyl)amino]carbonyl}-
C23H28Cl2N6O5S;
amino-2-



2-((3S,4R)-4-{[(3,4-
NMR: 1.23 (t, 3H) 1.62 (s, 6
methylpropanenitrile



dichloro-5-methyl-1H-pyrrol-
H) 1.76 (s, 2H) 2.18 (s, 3H)




2-yl)carbonyl]amino}-3-
3.37 (s, 3H) 3.56 (s, 1H)




methoxypiperidin-1-yl)-1,3-
4.04 (s, 1H) 4.15-4.22 (m, 2




thiazole-5-carboxylate
H) 4.23 (s, 2H) 7.15 (d, 1H)





9.07 (s, 1H) 12.17 (s, 1H)



233
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 606 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C23H29Cl2N5O8S
methyl serinate



2-yl)carbonyl]amino}-3-
NMR: 1.21 (t, 3H) 1.75 (s, 2




methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3H) 3.37 (s, 3H)




({[1-(hydroxymethyl)-2-
3.56 (s, 1H) 3.66 (s, 2H)




methoxy-2-
3.69-3.75 (m, 1H) 4.00 (s, 1




oxoethyl]amino}carbonyl)-
H) 4.16 (q, 2H) 4.27 (s, 2H)




1,3-thiazole-5-carboxylate
4.42-4.54 (m, 1H) 4.98 (s, 1





H) 7.16 (d, 1H) 8.75 (dd, 1





H) 12.17 (s, 1H)



234
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 617 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C25H34Cl2N6O6S;
(2-morpholin-4-



2-yl)carbonyl]amino}-3-
NMR: 1.22 (d, 3H) 1.75 (s, 2
ylethyl)amine



methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3H) 3.34 (m, 5H)




{[(2-morpholin-4-
3.36 (s, 3H) 3.55 (s, 1H)




ylethyl)amino]carbonyl}-1,3-
3.80 (s, 2H) 3.91 (s, 2H)




thiazole-5-carboxylate
4.02 (s, 1H) 4.16 (s, 2H)





4.27 (s, 2H) 4.94 (s, 1H)





7.14 (s, 1H) 8.59 (s, 1H)





12.16 (s, 1H)



235
ethyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- {[(1,3-dioxolan-2- ylmethyl)amino]carbonyl}- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 590 for C23H29Cl2N5O7S NMR: 1.22 (d, 3H) 1.75 (s, 2+nlH) 2.18 (s, 3H) 3.36 (s, 4H) 3.55 (s, 1H) 3.80 (s, 2H) 3.91 (s, 2H) 4.00 (s, 1H) 4.16 (s, 3H) 4.28 (s, 2H) 4.94 (s, 1H) 7.14 (s, 1H) 8.59 (s, 1H) 12.16 (s, 1H)
Example 191 and (1,3-dioxolan-2- ylmethyl)amine





236
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 629 for
Example 191 and 1-(3-



dichloro-5-methyl-1H-pyrrol-
C26H34Cl2N6O6S
aminopropyl)pyrrolidin-



2-yl)carbonyl]amino}-3-

2-one



methoxypiperidin-1-yl)-4-





({[3-(2-oxopyrrolidin-1-





yl)propyl]amino}carbonyl)-





1,3-thiazole-5-carboxylate




237
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 595 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C25H28Cl2N6O5S;
(pyridin-2-



2-yl)carbonyl]amino}-3-
NMR: 1.18 (t, 3H) 1.76 (s, 2
ylmethyl)amine



methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3H) 3.46 (s, 2H)




{[(pyridin-2-
3.57 (s, 1H) 3.99 (s, 1H)




ylmethyl)amino]carbonyl}-
4.16 (q, 2H) 4.28 (s, 2H)




1,3-thiazole-5-carboxylate
4.50 (d, 2H) 7.16 (d, 1H)





7.34 (s, 1H) 7.53 (d, 1H)





7.81-7.93 (m, 1H) 8.53 (s, 1





H) 9.07 (t, 1H) 12.17 (s, 1H)



238
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 578 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C22H29Cl2N5O5S2
[2-(methylthio



2-yl)carbonyl]amino}-3-





methoxypiperidin-1-yl)-4-





({[2-





(methylthio)ethyl]amino}





carbonyl)-1,3-thiazole-5-





carboxylate




239
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 585 for
Example 191 and 1-



dichloro-5-methyl-1H-pyrrol-
C23H26Cl2N6O6S;
(1,3-oxazol-2-



2-yl)carbonyl]amino}-3-
NMR: 1.17 (t, 3H) 1.74 (s, 2
yl)methanamine



methoxypiperidin-1-yl)-4-
H) 2.18 (s, 3H) 3.37 (s, 3H)
hydrochloride



{[(1,3-oxazol-2-
3.55 (s, 1H) 4.00 (s, 1H)




ylmethyl)amino]carbonyl}-
4.13 (d, 2H) 4.26 (s, 2H)




1,3-thiazole-5-carboxylate
4.49 (d, 2H) 7.11-7.25 (m, 2





H) 8.08 (s, 1H) 9.07 (s, 1H)





12.16 (s, 1H)



240
ethyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- {[(2- fluoroethyl)amino]carbonyl}- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 550 for C21H26Cl2FN5O5S; NMR: 1.21 (t, 3H) 1.74 (d, 2+nlH) 2.18 (s, 3H) 3.40 (s, 3H) 3.55 (s, 3H) 3.99 (s, 1H) 4.17 (d, 2H) 4.27 (s, 2H) 4.42 (s, 1H) 4.58 (s, 1H) 7.14 (s, 1H) 8.70 (s, 1H) 12.17 (s, 1H)
Example 191 and 2- fluoroethanamine hydrochloride





241
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 576 for
Example 191 and 1-



dichloro-5-methyl-1H-pyrrol-
C23H31Cl2N5O6S;
amino-2-



2-yl)carbonyl]amino}-3-
NMR: 1.11 (s, 6H) 1.22 (d, 3
methylpropan-2-ol



methoxypiperidin-1-yl)-4-
H) 1.75 (s, 2H) 2.18 (s, 3H)




{[(2-hydroxy-2-
3.14 (s, 3H) 3.38 (s, 3H)




methylpropyl)amino]carbonyl}-
3.55 (s, 1H) 3.95 (s, 1H)




1,3-thiazole-5-carboxylate
4.17 (s, 2H) 4.27 (s, 2H)





4.39 (s, 1H) 7.14 (s, 1H)





8.28 (s, 1H) 12.17 (s, 1H)









Examples 242-245

The following Examples were prepared by the procedure described in Example 34 from the starting materials (SM) indicated.















Ex
Compound
Data
SM







242
Cis(±)-ethyl 4-(aminocarbonyl)-
MS (ES) MH+: 504 for
Example 178



2-(4-{[(3,4-dichloro-5-methyl-
C19H23Cl2N5O5S




1H-pyrrol-2-yl)carbonyl]amino}-





3-methoxypiperidin-1-yl)-1,3-





thiazole-5-carboxylate




243
ethyl 4-(aminocarbonyl)-2-
MS (ES) MH+: 504 for
Example 209



((3R,4S)-4-{[(3,4-dichloro-5-
C19H23Cl2N5O5S




methyl-1H-pyrrol-2-





yl)carbonyl]amino}-3-





methoxypiperidin-1-yl)-1,3-





thiazole-5-carboxylate




244
ethyl 4-(aminocarbonyl)-2-
MS (ES) MH+: 492 for
Example 210



((3S,4R)-4-{[(3,4-dichloro-5-
C18H20Cl2FN5O4S




methyl-1H-pyrrol-2-





yl)carbonyl]amino}-3-





fluoropiperidin-1-yl)-1,3-





thiazole-5-carboxylate




245
ethyl 4-(aminocarbonyl)-2- ((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 504 for C19H23Cl2N5O5S NMR: 1.22 (t, 3H) 1.74 (d, 2H) 2.18 (s, 3H) 3.31 (s, 1H) 3.37 (s, 3H) 3.38-3.43 (m, 1H) 3.55 (s, 1H) 3.95 (s, 1H) 4.17 (q, 2H) 4.27 (s, 2H) 7.15 (d, 1H) 7.53 (s, 1H) 7.82 (s, 1H) 12.17 (s, 1H)
Example 213









Example 246
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(morpholin-4-ylmethyl)-1,3-thiazole-5-carboxylate

To a solution of ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole-5-carboxylate (0.15 g, 0.31 mmol, Example 252) in methylene chloride (20 mL) was added sodium triacetoxyborohydride (0.1 g, 0.47 mmol) and morpholine (0.03 mL, 0.34 mmol). Reaction was stirred at room temperature and monitored by LCMS. Upon completion, the reaction mixture was diluted with 1N HCl and then partitioned with EtOAc/sat. sodium bicarbonate. Washing with brine, drying with MgSO4 and concentrating yielded a solid. Purification by silica gel flash column (gradient elution 70-100% EtOAc/CH2Cl2) afforded pure product (0.091 g) MS (ES) M+H+: 560 for C23H31Cl2N5O5S; NMR: 1.24 (t, 3 H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.32 (s, 2 H) 3.36 (s, 3 H) 3.52 (s, 2 H) 3.54 (d, 4 H) 3.65-3.75 (m, 2 H) 3.76-3.86 (m, 2 H) 3.93 (s, 1 H) 4.18 (q, 2 H) 4.27 (s, 1 H) 7.16 (d, 1 H) 12.16 (s, 1 H).


Examples 247-249

The following Examples were prepared by the procedure described in Example 246 from the starting materials (SM) indicated.















Ex
Compound
Data
SM







247
Cis(±)-ethyl 4-[(tert-
MS (ES) MH+: 546 for
Example 252



butylamino)methyl]-2-(4-{[3,4-
C23H33Cl2N5O4S;
and tert-



dichloro-5-methyl-1H-pyrrol-2-
NMR: 1.04 (s, 9 H) 1.22 (t, 3 H)
butylamine



yl)carbonyl]amino}-3-
1.72 (d, 2 H) 2.17 (s, 3 H)



methoxypiperidin-1-yl)-1,3-
3.32 (s, 1 H) 3.35 (s, 3 H) 3.53 (s, 1



thiazole-5-carboxylate
H) 3.78-3.92 (m, 2 H) 4.17 (q,




2 H) 4.23 (d, 2 H) 7.14 (d, 1 H)


248
Cis(±)-ethyl 2-(4-{[(3,4-
MS (ES) MH+: 558 for
Example 252



dichloro-5-methyl-1H-pyrrol-2-
C24H33Cl2N5O4S
and piperidine



yl)carbonyl]amino}-3-



methoxypiperidin-1-yl)-4-



(piperidin-1-ylmethyl)-1,3-



thiazole-5-carboxylate


249
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 560 for
Example 252



dichloro-5-methyl-1H-pyrrol-2-
C23H31Cl2N5O5S
and pyrrolidin-



yl)carbonyl]amino}-3-

3-ol



methoxypiperidin-1-yl)-4-[(3-



hydroxypyrrolidin-1-yl)methyl]-



1,3-thiazole-5-carboxylate









Example 250
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-[(E)-(hydroxyimino)methyl]-1,3-thiazole-5-carboxylate



embedded image


A solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole -5-carboxylate (0.10 g, 0.2 mmol, Example 252), sodium acetate (0.041 g, 0.5 mmol) and hydroxylamine hydrochloride (0.028 g, 0.4 mmol) were heated to reflux in absolute ethanol for 3 hours. After cooling to room temperature the ethanol was removed under reduced pressure followed by EtOAc/H2O partitioning, drying with MgSO4 and concentrating to a yellow solid (0.081 g) MS (ES): 504 NMR: 1.25 (t, 3H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.31 (s, 3 H) 3.36 (s, 3 H) 3.55 (s, 1 H) 3.95 (s, 1 H) 4.18-4.26 (m, 2 H) 4.26 (d, 2 H) 7.16 (d, 1 H) 8.61 (s, 1 H) 11.72 (s, 1 H) 12.16 (s, 1 H).


Example 251

The following Example was prepared by the procedure described in Example 250 from the starting materials (SM) indicated.















Ex
Compound
Data
SM







251
ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 518 for
Example 252



dichloro-5-methyl-1H-pyrrol-2-
C20H25Cl2N5O5S;
and



yl)carbonyl]amino}-3-
NMR: 1.25 (t, 3 H) 1.76 (s, 2 H)
methoxylamine



methoxypiperidin-1-yl)-4-[(E)-
2.19 (s, 3 H) 3.30-3.32 (m, 2 H)
hydrochloride



(methoxyimino)methyl]-1,3-
3.35-3.39 (m, 3 H) 3.57 (s, 1 H)



thiazole-5-carboxylate
3.92 (s, 3 H) 4.04 (s, 1 H)




4.19-4.25 (m, 2 H) 4.25-4.33 (m, 2




H) 7.16 (d, 1 H) 8.66 (s, 1 H)




12.16 (s, 1 H)









Example 252
Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole-5-carboxylate

To a solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate (0.63 g, 1.3 mmol, Example 143) in methylene chloride was added Dess-Martin periodinane (0.61 g, 1.4 mmol). After 1 hr stirring at room temperature the reaction was complete. The crude reaction mixture was washed with water (×2) and brine, followed by drying with MgSO4 and concentrating to a minimal volume of methylene chloride after which it was directly deposited on a silica gel flash column (gradient elution to 1:1 EtOAc in CH2 Cl2). Pure fractions concentrated to clean, yellow solid (0.56 g). NMR: 1.29 (t, 3 H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.38 (s, 4 H) 3.44 (s, 1 H) 3.57 (s, 1 H) 4.03 (d, 1H) 4.22-4.35 (m, 4 H) 7.15 (d, 1 H) 10.31 (s, 1 H) 12.16 (s, 1 H).


Example 253
ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(difluoromethyl)-1,3-thiazole-5-carboxylate

Diethylaminosulfurtrifluoride (0.03 mL, 0.22 mmol) was added to a solution of ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole-5-carboxylate (0.10 g, 0.2 mmol, Example 252) in methylene chloride. The reaction was complete after heating at reflux overnight. Upon cooling to room temperature, the reaction was washed with water (×3) and brine (×1), dried with MgSO4 and concentrated to a yellow solid which, upon trituration, yielded a clean white solid (0.021 g). MS (ES) M+H: 511 for C19H22Cl2F2N4O4S; NMR: 1.26 (t, 3 H) 1.75 (s, 2 H) 2.18 (s, 3 H) 3.37 (s, 3 H) 3.43 (s, 1 H) 3.56 (s, 1 H) 3.96 (s, 1 H) 4.25 (s, 1 H) 4.36 (s, 2 H) 7.16 (s, 1 H) 7.31 (s, 1 H) 12.17 (s, 1 H).


Example 254
ethyl 4-(azidomethyl)-2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate

To a suspension of ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate (0.10 g, 0.2 mmol, Example 143) in anhydrous toluene was added diphenylphosphorylazide (0.053 mL, 0.24 mmol). The reaction was cooled to 0 deg and DBU was added slowly. After stirring at 0 deg for 30 min the reaction was warmed to room temperature and stirred overnight. The biphasic reaction mixture was washed with water (×3), 1NHCl (×1), brine (×1), dried with MgSO4 and concentrated (0.048 g). MS (ES) M+H: 516 for C19H23Cl2N7O4S.


Example 255
Cis(±)-ethyl 4-[cyano(morpholin-4-yl)methyl]-2-(4-{[3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate



embedded image


A solution of sodium cyanide (0.011 g, 0.22 mmol) and morpholine (0.018 mL, 0.21 mmol) in water (5 mL) was cooled to 0 deg. 1N HCl (0.22 mL, 0.22 mmol) was added slowly. After warming to room temperature, a solution of Cis(±)-ethyl 2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-methoxypiperidin-1-yl)-4-formyl-1,3-thiazole-5-carboxylate (0.10 g, 0.2 mmol, Example 252) in methanol (10 mL) was added. After stirring at room temperature for six weeks the reaction was complete. The reaction mixture was concentrated to remove methanol and the residue was diluted with water and extracted with EtOAc (×3), washed with brine (×1), dried with MgSO4 and concentrated to a pink solid (0.055 g). MS (ES) M+H: 585 for C24H30Cl2N6O5S.


Example 256
ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[2-(methylsulfonyl)ethyl]amino}carbonyl) -1,3-thiazole-5-carboxylate

m-CPBA (0.091 g, 0.37 mmol) was added to a cold solution of ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-({[2-(methylthio)ethyl]amino}carbonyl)-1,3-thiazole-5-carboxylate (0.107 g, 0.18 mmol, Example 238) in methylene chloride. After stirring at room temperature for 2 hours, the reaction mixture was washed with sat. sodium bicarbonate (×3), dried with MgSO4, and concentrated to a white solid (0.092 g). MS (ES) M+H: 610 for C22H29Cl2N5O7S2; NMR: 1.21 (q, 3H) 1.66-1.80 (m, 2 H) 2.18 (s, 3 H) 3.04 (s, 3 H) 3.29 (s, 4 H) 3.36 (s, 3 H) 3.51-3.62 (m, 3 H) 3.99 (s, 1 H) 4.17 (q, 2 H) 4.28 (s, 2 H) 7.15 (d, 1 H) 8.72 (t, 1 H) 12.17 (s, 1 H).


Examples 257-381

The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.
















Ex
Compound
NMR
m/z
SM







257
Cis(±)-2-{4-{[(3,4-dichloro-5-
1.85 (m, 2H), 2.16 (s, 3H), 2.2
479
Example 89



methyl-1H-pyrrol-2-
(m, 1H), 2.5 (s, 3H), 2.6-2.9 (m,





yl)carbonyl]amino}-3-
2H), 3.0 (m, 1H), 3.2 (m, 1H), 3.9





[(methylsulfinyl)methyl]piperidin-
(m, 2H), 4.17 (m, 1H), 7.4 (s,





1-yl}-1,3-thiazole-5-
1H), 7.7 (dd. 1H), 7.9 (broad s, 1H).





carboxylic acid





258
Cis(±)-2-{4-{[(3,4-dichloro-5-
1.71 (m, 2H), 2.12 (s, 3H), 2.96
496
Example 90



methyl-1H-pyrrol-2-
(s, 3H), 2.99 (m, 2H), 3.12 (m,





yl)carbonyl]amino}-3-
3H), 3.95 (m, 2H), 4.3 (m, 1H),





[(methylsulfonyl)methyl]piperidin-
7.37 (d, 1H), 7.7 (s, 1H), 12





1-yl}-1,3-thiazole-5-
(broad s, 1H), 12.6 (broad s, 1H).





carboxylic acid





259
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.75 (m, 2H), 2.12 (s, 3H), 2.45
435
Example 91



methyl-1H-pyrrol-2-
(s, 3H), 3.14 (m, 1H), 3.27 (dd,





yl)carbonyl]amino}-3-
1H), 3.8 (d, 1H), 4.0 (m, 2H),





fluoropiperidin-1-yl)-5-methyl-
4.78 (d, 1H), 5.9 (broad s, 1H),





1,3-thiazole-4-carboxylic acid
7.16 (d, 1H), 12 (s, 1H).




260
2-((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-5- methyl-1,3-thiazole-4- carboxylic acid embedded image
1.67 (m, 2H), 2.1 (s, 3H), 2.45 (s, 3H), 3.1 (m, 2H), 3.3 (s, 3H), 3.7 (d, 2H), 4.0 (dd, 2H), 4.4 (broad s, 1H), 7.0 (d, 1H), 12.1 (s, 1H).
447
Example 92





261
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.86 (m, 4H), 2.2 (s, 6H), 3.4 (m,
478
Example 94



methyl-1H-pyrrol-2-
4H), 3.8 (s, 3H), 3.9 (s, 3H), 4.0





yl)carbonyl]amino}-3-
(m, 2H), 4.3 (m, 4H), 4.9 (s, 1H),





fluoropiperidin-1-yl)-5-
5.0 (s, 1H), 7.2 (d, 2H), 8.4 (s,





[(methoxyimino)methyl]-1,3-
1H), 8.7 (s, 1H), 12.1 (s, 2H),





thiazole-4-carboxylic acid
13.2 (s, 2H).




262
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.93 (m, 2H), 2.16 (s, 3H), 3.3-
566
Example 93



methyl-1H-pyrrol-2-
3.8 (m, 11H), 4.0 (m, 2H), 4.4 (m,





yl)carbonyl]amino}-3-
1H), 7.2 (d, 1H), 7.4 (t, 1H), 7.6





(morpholin-4-
(d, 1H), 7.7 (d, 1H), 9.8 (broad s,





ylcarbonyl)piperidin-1-yl]-
1H), 12.0 (s, 1H).





1,3-benzothiazole-7-






carboxylic acid





263
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.65-1.90 (m, 2H); 2.14 (s, 3H);
449
Example 95



methyl-1H-pyrrol-2-
2.19 (s, 3H); 3.20-3.45 (m, 2H);





yl)carbonyl]amino}-3-
3.73 (d, 1H); 3.94 (d, 1H); 4.02





(methylthio)piperidin-1-yl]-
(dd, 1H); 4.43 (m, 1H); 7.24 (d,





1,3-thiazole-5-carboxylic acid
1H); 7.75 (s, 1H); 12.13 (s, 1H);






12.66 (s, 1H).




264
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.70 (m, 1H); 1.90 (m, 1H); 2.11
481
Example 96



methyl-1H-pyrrol-2-
(s, 3H); 3.00 (s, 3H); 3.30-3.45





yl)carbonyl]amino}-3-
(m, 2H); 3.45 (m, 1H); 3.62 (m,





(methylsulfonyl)piperidin-1-
2H); 4.30 (bd, 1H); 7.39 (s, 1H);





yl]-1,3-thiazole-5-carboxylic
8.20 (m, 1H); 12.10 (s, 1H);





acid
12.60 (s, 1H).




265
Cis(±)2-(3-(benzyloxy)-4- {[(3,4-dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}piperidin-1- yl)-1,3-thiazole-5-carboxylic acid embedded image
1.79 (m, 2H); 2.18 (s, 3H); 3.35 (m, 2H); 3.81 (s, 1H); 3.95 (d, 1H); 4.29 (m, 1H); 4.46 (m, 2H); 4.71 (d, 1H); 7.09 (d, 1H); 7.25 (s, 5H); 7.75 (s, 1H); 12.12 (s, 1H); 12.63 (s, 1H).
509
Example 97





266
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.76 (m, 2H); 2.18 (s, 3H); 3.30
457
Example 98



methyl-1H-pyrrol-2-
(m, 2H); 3.44 (t, 1H); 3.87 (s,





yl)carbonyl]amino}-3-(prop-2-
1H); 3.96 (m, 1H); 4.22-4.36 (m,





yn-1-yloxy)piperidin-1-yl]-1,3-
4H); 7.15 (d, 1H); 7.73 (s, 1H);





thiazole-5-carboxylic acid
12.15 (s, 1H); 12.62 (s, 1H).




267
Trans(±)2-(3-(benzyloxy)-4-
1.72 (m, 1H), 1.98 (m, 1H), 2.17
509
Example 99



{[(3,4-dichloro-5-methyl-1H-
(s, 3H), 3.26 (m, 1H), 3.67 (m,

and benzyl



pyrrol-2-
1H), 3.82 (m, 1H), 4.14 (m, 2H),

bromide



yl)carbonyl]amino}piperidin-1-
4.63 (dd, 2H), 7.28 (m, 5H), 7.34





yl)-1,3-thiazole-5-carboxylic
(d, 2H), 7.76 (s, 1H), 12.00 (s,





acid
1H), 12.66 (br s, 1H)




268
Trans(±)2-(3-(allyloxy)-4-
1.67 (m, 1H), 1.98 (m, 1H), 2.17
459
Example 99



{[(3,4-dichloro-5-methyl-1H-
(s, 3H), 3.22 (m, 1H), 3.37 (m,

and allyl



pyrrol-2-
1H), 3.57 (m, 1H), 3.79 (m, 1H),

bromide



yl)carbonyl]amino}piperidin-1-
4.09 (m, 4H), 5.10 (d, 1H), 5.23





yl)-1,3-thiazole-5-carboxylic
(dd, 1H), 5.85 (m, 1H), 7.31 (d,





acid
2H), 7.76 (s, 1H), 11.99 (s, 1H)




269
Trans(±)2-(4-{[(3,4-dichloro-5-
1.60 (m, 1H), 2.01 (m, 1H), 2.17
419
Example 99



methyl-1H-pyrrol-2-
(s, 3H), 3.07 (m, 1H), 3.30 (m,





yl)carbonyl]amino}-3-
1H), 3.61 (m, 1H), 3.82 (m, 1H),





hydroxypiperidin-1-yl)-1,3-
3.90 (m, 1H) 3.99 (m, 1H), 4.58





thiazole-5-carboxylic acid
(m, 1H), 7.18 (d, 1H), 7.31 (m,






1H), 7.75 (s, 1H), 11.97 (s, 1H)




270
Trans(±)2-[4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3-(pyridin- 2-ylmethoxy)piperidin-1-yl]- 1,3-thiazole-5-carboxylic acid embedded image
1.74 (m, 1H), 2.00 (m, 1H), 2.16 (s, 3H), 3.36 (m, 2H), 3.79 (m, 2H), 4.18 (m, 2H), 4.80 (dd, 2H), 7.41 (brd, 1H), 7.46 (brt, 2H), 7.54 (brd, 1H), 7.76 (s, 1H), 7.94 (brt, 1H), 8.58 (brd, 1H), 11.99 (s, 1H)
510
Example 99 and 2- chloromethyl- pyridine





271
2-((3S,4R)-4-{[(3-chloro-5-
1.85 (m, 2H); 2.17 (s, 3H); 3.48
387
Example 100



methyl-1H-pyrrol-2-
(m 2H); 4.0 (m, 1H); 4.33 (m,





yl)carbonyl]amino}-3-
2H); 4.96 (d, br, 1H); 5.95 (s,





fluoropiperidin-1-yl)-1,3-
1H); 7.10 (d, 1H); 7.76 (s, 1H);





thiazole-5-carboxylic acid
11.63 (s, 1H); 12.68 (s, br, 1H)




272
2-((3S,4R)-4-{[(3-chloro-5-
1.88 (m, 2H); 2.17 (s, 3H); 3.31
387
Example 101



methyl-1H-pyrrol-2-
(m 2H); 3.94 (m, 1H); 4.23 (m,





yl)carbonyl]amino}-3-
2H); 4.90 (d, br, 1H); 5.93 (s,





fluoropiperidin-1-yl)-1,3-
1H); 7.10 (d, 1H); 7.62 (s, 1H);





thiazole-4-carboxylic acid
11.62 (s, 1H)




273
2-((3S,4R)-4-{[(3-chloro-5-
1.88 (m, 2H); 2.17 (s, 3H); 3.31
437
Example 102



methyl-1H-pyrrol-2-
(m 2H); 4.19 (m, 1H); 4.46 (m,





yl)carbonyl]amino}-3-
2H); 4.97 (d, br, 1H); 5.93 (s,





fluoropiperidin-1-yl)-1,3-
1H); 7.10 (d, 1H); 7.41 (t, 1H);





benzothiazole-7-carboxylic
7.68 (d, 1H); 7.69 (d, 1H); 11.62





acid
(s, 1H)




274
2-((3S,4R)-4-{[(3-chloro-5-
1.80 (m, 2H); 2.16 (s, 3H); 3.06
381
Example 108



methyl-1H-pyrrol-2-
(m 2H); 4.40 (m, 2H); 4.71 (m,





yl)carbonyl]amino}-3-
1H); 4.90 (d, br, 1H); 5.94 (s,





fluoropiperidin-1-
1H); 7.03 (m, 2H); 7.26 (s, 1H);





yl)isonicotinic acid
8.22 (d, 1H); 11.61 (s, br, 1H)




275
2-((3S,4R)-4-{[(4-bromo-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylic acid embedded image
1.94 (m, 1H); 1.98 (m, 1H); 2.14 (s, 3H); 3.31 (m 2H); 4.01 (m, 1H); 4.28 (m, 2H); 4.86 (d, br, 1H); 6.94 (s, 1H); 7.75 (s, 1H); 8.02 (d, 1H); 11.73 (s, 1H).
432
Example 103





276
2-((3S,4R)-4-{[(4-bromo-5-
1.72 (m, 1H); 1.92 (m, 1H); 2.15
426
Example 109



methyl-1H-pyrrol-2-
(s, 3H); 3.10 (m, 1H); 3.30 (m,





yl)carbonyl]amino}-3-
1H); 4.24 (m, 1H); 4.44 (m, 1H);





fluoropiperidin-1-
4.69 (m, 1H); 4.86 (d, br, 1H);





yl)isonicotinic acid
6.96 (s, 1H); 7.05 (d, 1H); 7.33 (s,






1H); 7.95 (d, 1H); 8.24 (d, 1H);






11.74 (s, br, 1H).




277
2-((3S,4R)-4-{[(4-bromo-3-
1.86 (m, 2H); 2.19 (s, 3H); 3.48
466
Example 104



chloro-5-methyl-1H-pyrrol-2-
(m 1H); 3.53 (m, 1H); 4.01 (m,





yl)carbonyl]amino}-3-
1H); 4.33 (m, 2H); 4.96 (d, br,





fluoropiperidin-1-yl)-1,3-
1H); 7.32 (d, 1H); 7.76 (s, 1H);





thiazole-5-carboxylic acid
12.24 (s, 1H); 12.69 (br, 1H).




278
2-((3S,4R)-4-{[(4-bromo-3-
1.85 (m, 2H); 2.19 (s, 3H); 3.31
466
Example 105



chloro-5-methyl-1H-pyrrol-2-
(m 2H); 3.95 (m, 1H); 4.23 (m,





yl)carbonyl]amino}-3-
2H); 4.90 (d, br, 1H); 7.45 (d,





fluoropiperidin-1-yl)-1,3-
1H); 7.63 (s, 1H); 12.39 (s, br,





thiazole-4-carboxylic acid
1H).




279
2-((3S,4R)-4-{[(4-bromo-3-
1.86 (m, 2H); 2.19 (s, 3H); 3.29
510
Example 107



chloro-5-methyl-1H-pyrrol-2-
(s, 2H); 3.60 (m 2H); 4.04 (m,





yl)carbonyl]amino}-3-
1H); 4.30 (m, 2H); 4.57 (s, 3H);





fluoropiperidin-1-yl)-4-
4.90 (d, br, 1H); 7.32 (d, 1H);





(methoxymethyl)-1,3-thiazole-
12.25 (s, 1H); 12.78 (br, 1H)





5-carboxylic acid





280
2-((3S,4R)-4-{[(4-bromo-3- chloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1- yl)isonicotinic acid embedded image
1.86 (m, 2H); 2.19 (s, 3H); 3.07 (m, 1H); 4.04 (m, 1H); 4.28 (m, 2H); 4.69 (m, 1H); 4.90 (d, br, 1H); 7.01 (d, 1H); 7.27 (s, 1H); 7.82 (m, 1H); 8.02 (m, 1H); 13.38 (s, br, 1H)
460
Example 106





281
Cis(±)-2-[4-{[(3,4-Dichloro-5-
1.74-1.76 (m, 2H), 2.17 (s, 3H),
477
Example 110



methyl-1H-pyrrol-2-
3.14 (s, 3H), 3.25-3.42 (m, 4H),





yl)carbonyl]amino}-3-(2-
3.50-3.60 (m, 1H), 3.67-3.73 (m,





methoxyethoxy)piperidin-1-
2H), 3.75-4.00 (m, 2H), 4.20-





yl]-1,3-thiazole-5-carboxylic
4.35 (m, 2H), 7.14 (d, 1H), 7.72





acid
(s, 1H), 12.14 (brs, 1H)




282
Cis(±)-2-[4-{[(3,4-Dichloro-5-
1.74-1.80 (m, 2H), 2.17 (s, 3H),
477
Example 111



methyl-1H-pyrrol-2-
3.14 (s, 3H), 3.25-3.42 (peaks





yl)carbonyl]amino}-3-(2-
overlapping with H2O signal),





methoxyethoxy)piperidin-1-
3.50-3.60 (m, 1H), 3.67-3.73 (m,





yl]-1,3-thiazole-4-carboxylic
2H), 3.86-3.90 (m, 1H), 4.12-





acid
4.35 (m, 2H), 7.15 (d, 1H), 7.57






(s, 1H), 12.13 (brs, 1H), 12.55






(brs, 1H)




283
Cis(±)-2-[4-{[(3,4-Dichloro-5-
1.70-1.75 (m, 2H), 2.17 (s, 3H),
471
Example 113



methyl-1H-pyrrol-2-
3.05-3.20 (m, 2H), 3.09 (s, 3H),





yl)carbonyl]amino}-3-(2-
3.25-3.35 (m, 2H), 3.45--3.73





methoxyethoxy)piperidin-1-
(peaks overlapping with H2O





yl]isonicotinic acid
signal), 4.20-4.25 (m, 2H), 4.60-






4.70 (m, 1H), 6.97 (d, 1H), 7.13






(d, 1H), 7.26 (s, 1H), 8.19 (d,






1H), 12.13 (s, 1H)




284
Cis(±)-2-[4-{[(3,4-Dichloro-5-
1.79-1.75 (m, 2H), 2.19 (s, 3H),
527
Example 114



methyl-1H-pyrrol-2-
3.12 (s, 3H), 3.27-3.45 (peaks





yl)carbonyl]amino}-3-(2-
overlapping with H2O signal),





methoxyethoxy)piperidin-1-
3.51-3.62 (m, 1H), 3.72-3.80 (m,





yl]-1,3-benzothiazole-7-
2H), 4.05-4.13 (m, 1H), 4.24-4.42





carboxylic acid
(m, 2H), 7.18 (d, 1H), 7.39 (t,






1H), 7.65 (t, 2H), 12.16 (s, 1H),






13.48 (brs, 1H)




285
Cis(±)-2-[4-{[(3,4-Dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3-(2- methoxyethoxy)piperidin-1- yl]-4-methyl-1,3-thiazole-5- carboxylic acid embedded image
1.70-1.75 (m, 2H), 2.17 (s, 3H), 2.39 (s, 3H), 3.15 (s, 3H), 3.32- 3.40 (m, buried under water peak), 3.50-3.60 (m, 1H), 3.68- 3.75 (m, 2H), 3.86-3.98 (m, 1H), 4.20-4.30 (m, 2H), 7.14 (d, 1H), 12.14 (s, 1H), 12.38 (brs, 1H)
490
Example 112





286
2-((3S,4R)-4-{[(4-chloro-1H-
1.62-1.76 (m, 1H), 1.85-2.03 (m,
373
Example 115



pyrrol-2-yl)carbonyl]amino}-3-
1H), 3.22 (s, 3H), 3.36-3.45 (m,





fluoropiperidin-1-yl)-1,3-
1H), 3.50 (dd, 1H), 3.75 (s, 1H),





thiazole-5-carboxylic acid
4.02-4.10 (m, 1H), 4.15-4.36 (m,






2H), 4.90 (d, 1H), 6.94-6.97 (m,






2H), 7.85 (s, 1H), 8.10 (d, 1H),






11.82 (s, 1H)




287
2-((3S,4R)-4-{[(4-chloro-5-
1.62-1.74 (m, 1H), 1.84-2.05 (m,
401
Example 116



methyl-1H-pyrrol-2-
1H), 2.13 (s, 3H), 2.41 (s, 3H),





yl)carbonyl]amino}-3-
3.19-3.30 (m, 1H), 3.50 (dd, 1H),





fluoropiperidin-1-yl)-4-methyl-
3.96-4.02 (m, 1H), 4.20-4.31 (m,





1,3-thiazole-5-carboxylic acid
2H), 4.87 (d, 1H), 6.89 (d, 1H),






7.97 (d, 1H), 11.65 (s, 1H)




288
2-((3S,4R)-4-{[(4-chloro-1H-
1.68-1.74 (m, 1H), 1.85-2.00 (m,
387
Example 117



pyrrol-2-yl)carbonyl]amino}-3-
1H), 2.39 (s, 3H), 3.30-3.54





fluoropiperidin-1-yl)-4-methyl-
(peaks buried under water peak),





1,3-thiazole-5-carboxylic acid
3.94-4.00 (m, 1H), 4.10-4.32 (m,






2H), 4.82 (d, 1H), 6.94-6.97 (m,






2H), 8.11 (d, 1H), 11.84 (s, 1H)




289
2-((3S,4R)-4-{[(4,5-dichloro-
1.69-1.74 (m, 1H), 1.86-2.00 (m,
419
Example 118



1H-pyrrol-2-
1H), 2.40 (s, 3H), 3.25-3.35 (m,





yl)carbonyl]amino}-3-
1H, buried under water peak),





fluoropiperidin-1-yl)-4-methyl-
3.51 (dd, 1H), 3.96-4.00 (m, 1H),





1,3-thiazole-5-carboxylic acid
4.16-4.31 (m, 2H), 4.87 (d, 1H),






7.06 (d, 1H), 8.15 (d, 1H), 12.48






(brs, 1H), 12.78 (s, 1H)




290
2-((3S,4R)-4-{[(4,5-Dichloro- 1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylic acid embedded image
1.64-1.74 (m, 1H), 1.85-2.00 (m, 1H), 3.30-3.40 (m, 1H, buried under water peak), 3.53 (dd, 1H), 4.00-4.08 (m, 1H), 4.12-4.40 (m, 2H), 4.89 (d, 1H), 7.06 (d, 1H), 7.75 (s, 1H), 8.16 (d, 1H), 12.78 (s, 1H)
405
Example 119





291
Cis(±)-2-[4-{[(3,4-dichloro-5-
0.95 (d, 3H), 1.73-1.85 (m, 2H),
477
Example 120



methyl-1H-pyrrol-2-
2.16 (s, 3H), 3.19-3.36 (m, 6 H,





yl)carbonyl]amino}-3-(2-
broad peaks), 3.61-3.67 (m, 3H),





hydroxypropoxy)piperidin-1-
3.94-4.30 (m, difficult to integrate





yl]-1,3-thiazole-5-carboxylic
as the peaks are buried under





acid
water peak), 7.16 (d, 1H), 7.71 (s,






1H), 12.11 (s, 1H)




292
Cis(±)-2-[4-{[(3,4-dichloro-5-
0.96 (d, 3H), 1.73-1.76 (m, 2H),
491
Example 121



methyl-1H-pyrrol-2-
2.17 (s, 3H), 3.14 (s, 1H), 3.28-





yl)carbonyl]amino}-3-(2-
3.67 (difficult to integrate as the





methoxypropoxy)piperidin-1-
peaks are buried under water





yl]-1,3-thiazole-5-carboxylic
peak), 3.89-3.92 (m, 1H), 4.20-





acid
4.45 (m, 2H), 7.12 (d, 1H),






7.72 (s, 1H), 12.15 (s, 1H)




293
2-((3R,4S)-4-{[(3,4-dichloro-5-
1.85 (m, 2H), 2.25 (s, 3H), 3.41-
483
Example 123



methyl-1H-pyrrol-2-
3.48 (m, 6H), 4.16 (m, 1H), 5.35





yl)carbonyl]amino}-3-
(m, 1H), 4.41 (m, 1H), 7.26 (d,





methoxypiperidin-1-yl)-1,3-
1H), 7.49 (t, 1H), 7.72 (t, 2H0,





benzothiazole-7-carboxylic
12.23 (s, 1H)




294
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.85 (m, 2H), 2.25 (s, 3H), 3.41-
483
Example 122



methyl-1H-pyrrol-2-
3.48 (m, 6H), 4.16 (m, 1H), 5.35





yl)carbonyl]amino}-3-
(m, 1H), 4.41 (m, 1H), 7.26 (d,





methoxypiperidin-1-yl)-1,3-
1H), 7.49 (t, 1H), 7.72 (t, 2H),





benzothiazole-7-carboxylic acid
12.23 (s, 1H)




295
Cis(±)2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-4-carboxylic acid embedded image
1.74 (m, 2H), 2.10 (s, 3H), 3.29 (m, 1H), 3.48 (d, 1H), 3.85 (d, 1H), 4.14 (m, 1H), 4.29 (m, 1H), 4.83 (d, 1H), 7.18 (d, 1H), 7.53 (s, 1H), 12.03 (s, 1H)
421
Example 124





296
2-((3S,4R)-4-{[(4-chloro-5-
1.85 (m, 1H), 2.14 (m, 1H), 2.23
449
Example 125



methyl-1H-pyrrol-2-
(s, 3H), 3.33 (s, 3H), 3.62-3.81





yl)carbonyl]amino}-3-
(m, 2H), 4.29 (m, 1H), 4.43 (m,





methoxypiperidin-1-yl)-1,3-
1H), 4.51 (m, 1H), 7.09 (s, 1H),





benzothiazole-7-carboxylic
7.59 (t, 1H), 7.82-7.90 (m, 2H),





acid
11.84 (s, 1H)




297
Cis(±)2-(4-{[(4-chloro-3,5-
1.47 (m, 1H), 1.62 (m, 1H), 1.95
413
Example 126



dimethyl-1H-pyrrol-2-
(s, 3H0, 1.98 (s, 3H), 3.13 (m,





yl)carbonyl]amino}-3-
1H), 3.32 (m, 1H), 3.42 (s, 3H),





methoxypiperidin-1-yl)-1,3-
3.68 (m, 1H), 4.04 (m, 2H), 6.89





thiazole-5-carboxylic acid
(d, 1H), 7.53 (s, 1H), 11.22 (s, 1H)




299
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.74 (m, 2H), 2.10 (s, 3H), 3.29
421
Example 128



methyl-1H-pyrrol-2-
(m, 1H), 3.48 (d, 1H), 3.85 (d,





yl)carbonyl]amino}-3-
1H0, 4.14 (m, 1H), 4.29 (m, 1H),





fluoropiperidin-1-yl)-1,3-
4.83 (d, 1H), 7.18 (d, 1H), 7.53





thiazole-4-carboxylic acid
(s, 1H), 12.03 (s, 1H)




300
2-((3S,4R)-4-{[(4-chloro-3,5-
1.69 (m, 1H), 1.82 (m, 1H), 2.09
401
Example 129



dimethyl-1H-pyrrol-2-
(s, 3H), 2.13 (s, 3H), 3.19-3.30





yl)carbonyl]amino}-3-
(m, 2H), 3.89 (m, 1H), 4.14 (m,





fluoropiperidin-1-yl)-1,3-
2H), 4.83 (d, 1H), 7.38 (d, 1H),





thiazole-4-carboxylic acid
7.56 (s, 1H), 11.29 (s, 1H)




301
2-((3R,4S)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-4-carboxylic acid embedded image
1.74 (m, 2H), 2.10 (s, 3H), 3.29 (m, 1H), 3.48 (d, 1H), 3.85 (d, 1H0, 4.14 (m, 1H), 4.29 (m, 1H), 4.83 (d, 1H), 7.18 (d, 1H), 7.53 (s, 1H), 12.03 (s, 1H)
421
Example 130





302
Cis(±)2-(3-chloro-4-{[(3,4-
1.87 (m, 1H), 1.93 (m, 1H), 2.20
437
Example 131



dichloro-5-methyl-1H-pyrrol-
(s, 3H), 3.41 (m, 1H), 3.82 (d,





2-yl)carbonyl]amino}piperidin-
1H), 4.01 (d, 1H), 4.27 (d, 1H),





1-yl)-1,3-thiazole-5-carboxylic
4.75 (s, 1H), 7.18 (d, 1H), 7.75 (s,





acid
1H), 12.15 (s, 1H)




303
2-{(3S,4R)-4-[({4-chloro-3-
1.86 (m, 2H), 2.35 (s, 3H), 3.33
444
Example 132



[(E)-(methoxyimino)methyl]-5-
(m, 1H), 3.61 (dd, 1H), 3.82 (s,





methyl-1H-pyrrol-2-
3H), 4.00 (d, 1H), 4.34 (m, 2H),





yl}carbonyl)amino]-3-
4.93 (d, 1H), 7.28 (d, 1H), 7.76





fluoropiperidin-1-yl}-1,3-
(s, 1H), 8.02 (s, 1H), 12.14 (s,





thiazole-5-carboxylic acid
1H), 12.66 (s, 1H)




304
Cis(±)-2-(3-chloro-4-{[(3,4-
1.82 (m, 2H), 2.25 (s, 3H), 3.41
489
Example 133



dichloro-5-methyl-1H-pyrrol-
(m, 1H), 3.42 (m, 2H), 4.19 (m,





2-yl)carbonyl]amino}piperidin-
1H), 5.35 (m, 1H), 4.41 (m, 1H),





1-yl)[1,3]thiazolo[4,5-
7.28 (d, 1H), 7.43 (t, 1H), 7.72 (t,





b]pyridine-7-carboxylic acid
2H), 12.23 (s, 1H)




305
Cis(±)-2-(3-chloro-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}piperidin- 1-yl)-4-(hydroxymethyl)-1,3- thiazole-5-carboxylic acid embedded image
1.84 (m, 1H), 1.91 (m, 1H), 2.20 (s, 3H), 3.33 (m, 1H), 3.79 (m, 1H), 4.04 (m, 1H), 4.21 (m, 1H), 4.48 (m, 1H), 4.59 (m, 2H), 4.75 (s, 1H), 7.20 (d, 1H), 12.17 (s, 1H)
468
Example 134





306
Cis(±)-2-(3-chloro-4-{[(4-
1.72 (m, 1H), 2.07 (m, 1H), 2.14
403
Example 135



chloro-5-methyl-1H-pyrrol-2-
(s, 3H), 3.34 (t, 1H), 3.81 (d, 1H),





yl)carbonyl]amino}piperidin-1-
4.03 (d, 1H), 4.22 (d, 1H), 4.36





yl)-1,3-thiazole-5-carboxylic
(m, 1H), 4.73 (s, 1H), 6.91 (s,





acid
1H), 7.75 (s, 1H), 7.95 (d, 1H),






11.70 (s, 1H)




307
Cis(±)-2-(3-chloro-4-{[(3,4-
1.83 (m, 1H), 1.92 (m, 1H), 2.20
481
Example 136



dichloro-5-methyl-1H-pyrrol-
(s, 3H), 3.28 (s, 3H0, 3.35 (m,





2-yl)carbonyl]amino}piperidin-
1H), 3.80 (d, 1H), 4.01 (m, 1H),





1-yl)-4-(methoxymethyl)-1,3-
4.22 (m, 1H), 4.43 (m, 1H), 4.56





thiazole-5-carboxylic acid
(m, 2H), 4.75 (s, 1H), 7.18 (d,






1H), 12.15 (s, 1H)




308
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.78 (m, 1H), 1.91 (m, 1H), 2.19
470
Intermediate



methyl-1H-pyrrol-2-
(s, 3H), 3.32 (m, 2H), 3.55 (d,

131 and 2-



yl)carbonyl]amino}-3-
1H), 3.90 (s, 1H), 4.03 (m, 1H),

bromo-1,3-



hydroxypiperidin-1-yl)-1,3-
4.17 (m, 1H), 5.53 (d, 1H), 7.15

benzthiazole-



benzothiazole-7-carboxylic
(d, 1H), 7.41 (t, 1H), 7.64 (t, 2H),

7-carboxylate



acid
12.15 (s, 1H), 13.47 (s, 1H)




309
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.65 (m, 1H), 1.8 (m, 1H), 2.2 (s,
500
Example 137



methyl-1H-pyrrol-2-
3H), 3.3 (m), 3.55 (s, 1H), 4.3 (m,





yl)carbonyl]amino}-3-
1H), 7.1 (m 2H), 8.9 (s, 1H), 12.2





methoxypiperidin-1-yl)-5-
(s, 1H), 13.9 (s, 1H)





nitroisonicotinic acid





310
Cis(±)-2-(4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-5- [(methoxycarbonyl)amino] isonicotinic acid embedded image
1.7 (m, 2H), 2.2 (s, 3H), 2.4-2.5 (m), 3.0-3.2 (m 2H), 3.3 (s, 3H), 3.5 (m 1H), 3.6 (s, 3H), 4.1 (m, 1H), 4.2 (m, 1H), 4.5 (m, 1H), 7.1 (m, 2H), 8.6 (s, 1H), 12.1 (s, 1H), 13.7 (s, 1H)
500
Example 195





311
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.7 (m, 2H) 2.2 (s, 3H), 2.9 (s,
506
Example 196



methyl-1H-pyrrol-2-
3H), 3.1 (m, 2H), 3.3-3.5 (m),





yl)carbonyl]amino}-3-
3.5 (m, 1H), 4.2 (m, 2H), 4.6 (d,





methoxypiperidin-1-yl)-5-
1H), 7.1 (m, 2H), 8.1 (s, 1H),





[(methylsulfonyl)amino]isonicotinic
12.1 (s, 1H).





acid





312
Cis(±)-2-(4-{[(3,4-dichloro-5-
0.9 (d, 3H), 1.8 (m, 2H), 2.2 (m,
431
Example 138



methyl-1H-pyrrol-2-
4H), 3.3-3.8 (m, 4H), 4.25 (m,





yl)carbonyl]amino}-3-
1H), 4.25 (m, 1H), 7.2 (d, 1H),





methylpiperidin-1-yl)-1,3-
7.8 (s, 1H), 12.0 (s, 1H), 12.6 (s,





thiazole-5-carboxylic acid
1H)




313
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.3 (d, 1H), 1.8-2.1 (m, 4H), 2.2
417;
Example 139



methyl-1H-pyrrol-2-
(s, 3H), 3.6 (m, 1H), 3.8 (m 1H),





yl)carbonyl]amino}-2-
4.1 (m, 2H), 7.3 (s, 1H), 7.8 (s,





methylpiperidin-1-yl)-1,3-
1H), 12.1 (s, 1H)





thiazole-5-carboxylic acid





314
Cis(±)-2-(4-{[(3,4-dichloro-5-
0.9 (m, 1H), 1.3 (d, 6H), 1.7, (m,
441
Example 140



methyl-1H-pyrrol-2-
1H), 2.2 (s, 3H), 2.4 (s, 3H), 3.1





yl)carbonyl]amino}-3-
(m, 2H), 3.5 (m, 1H), 4.2 (m,





methoxypiperidin-1-yl)-6-
2H), 4.7 (d, 1H), 5.1 (m, 1H), 6.8





methylisonicotinic acid
(s, 1H), 7.0 (s, 1H), 7.15 (s, 1H),






12.1 (s, 1H).




315
Cis(±)-5-chloro-4-(4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1- yl)pyridine-2-carboxylic acid embedded image
NMR: 1.8, (m, 3H), 2.2 (s, 3H), 3.3 (s, 3H), 3.6 (m, 2H), 4.0 (m, 1H), 4.2 (m, 1H), 7.2 (s, 1H), 7.7 (s, 1H), 8.5 (s, 1H), 12.1 (s, 1H), 12.4 (s, broad, 1H).
461
Example 141





316
2-((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.85 (m, 2H), 2.2 (s, 3H),
451
Example 142



methyl-1H-pyrrol-2-
3.3-3.7 (m, 2H), 4.0 (m, 1H), 4.3

and



yl)carbonyl]amino}-3-
(m, 2H), 4.6 (s, 2H), 4.95 (d, 1H),

Intermediate



fluoropiperidin-1-yl)-4-
7.3 (d, 1H), 12.1 (s, 1H), 12.7 (s,
215




(hydroxymethyl)-1,3-thiazole-
1H).





5-carboxylic acid





317
Cis(±)-2-(4-{[(3,4-dichloro-5-
NMR: 1.2 (t, 3H), 1.7 (m, 2H),
463
Example 143



methyl-1H-pyrrol-2-
2.2 (s, 3H), 3.4 (s, 3H), 3.55 (m,





yl)carbonyl]amino}-3-
1H), 4.0 (m, 1H), 4.1-4.4 (m,





methoxypiperidin-1-yl)-4-
4H), 4.6 (s, 2H), 7.1 9d, 1H), 12.1





(hydroxymethyl)-1,3-thiazole-
(s, 1H).





5-carboxylic acid





318
Cis(±)-2-(4-{[(4-chloro-3-
NMR: 1.6-1.9 (m, 2H), 2.2 (s,
424
Example 144



cyano-5-methyl-1H-pyrrol-2-
3H), 3.3 (s, 3H), 3.6 (m, 1H), 3.7





yl)carbonyl]amino}-3-
(s, 3H), 3.9 (m, 1H), 4.3 (m, 2H),





methoxypiperidin-1-yl)-1,3-
7.75 (m, 2H), 12.6 (2s, 2H).





thiazole-5-carboxylicacid





319
Cis(±)-2-(4-{[(4-chloro-3-
NMR: 1.6-2.0 (m, 2H), 2.2 (s,
479
Example 145



cyano-5-methyl-1H-pyrrol-2-
3H), 3.3 (s, 3H), 3.4 (m, 1H), 3.6





yl)carbonyl]amino}-3-
(s, 3H), 4.1 (m, 1H), 4.2-4.4 (m,





methoxypiperidin-1-yl)-1,3-
2H), 7.4 (t, 1H), 7.65 (m, 2H), 7.8





benzothiazole-7-carboxylic acid
(m, 1H), 12.6 (s, 1H), 13.5 (s, 1H).




320
Cis(±)-2-(4-{[(4-chloro-3- cyano-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-1,3- thiazole-5-carboxylic acid embedded image
NMR: 1.7 (m, 2H), 2.2 (s, 3H), 3.0-3.7 (m), 4.2 (m, 2H), 4.6 (m, 1H), 7.0 (s, 1H), 7.25 (s, 1H), 7.7 (s, 1H), 8.2 (s, 1H), 12.6 (s, 1H), 13.5 (s, 1H).
418
Example 146





322
2-((3S,4R)-4-{[(4-chloro-3-
NMR: 1.9 (m, 2H), 2.2 (s, 3H),
462
Example 148



cyano-5-methyl-1H-pyrrol-2-
3.4 (m, 1H), 3.4 (m, 1H), 3.6 (s,





yl)carbonyl]amino}-3-
3H), 4.1 (m, 1H), 4.3 (m, 1H), 4.4





fluoropiperidin-1-yl)-1,3-
(q, 2H), 7.7 (m, 2H), 7.8 (m, 1H),





benzothiazole-7-carboxylic acid
7.9 (t, 1H), 12.7 (s, 1H), 13.5 (s, 1H).




323
2-((3S,4R)-4-{[(4-chloro-3-
NMR: 1.8 (m, 2H), 2.2 (s, 3H),
406
Example 149



cyano-5-methyl-1H-pyrrol-2-
3.0 (m, 2H), 3.3 (m), 4.0-4.5 (m,





yl)carbonyl]amino}-3-
2H), 4.7 (m, 1H), 4.95 (d, 1H),





fluoropiperidin-1-
7.0 9d, 1H), 7.3 (s, 1H), 8.05 (m,





yl)isonicotinic acid
1H), 8.25 (d, 1H), 12.6 (s, 1H),






13.4 (s, 1H).




324
Cis(±)-2-(4-{[(3,4-dichloro-5-
NMR: 1.7 (m, 2H), 2.2 (s, 3H),
546
Example 150



methyl-1H-pyrrol-2-
3.3 (m), 3.4 (m, 4H), 3.5 (m, 4H),





yl)carbonyl]amino}-3-
3.8-3.9 (m, 1H), 4.0-4.2 (m, 4H),





methoxypiperidin-1-yl)-5-
7.3 (s, 1H), 12.3 (s, 1H), 12.9 (s,





(morpholin-4-ylcarbonyl)-1,3-
1H).





thiazole-4-carboxylic acid





325
Cis(±)-6-cyano-4-(4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1- yl)pyridine-2-carboxylic acid embedded image
NMR: 1.7 (m, 2H), 2.1 (s, 3H), 3.3 (s, 3H), 3.45 (m, 1H), 4.0 (d, 1H), 4.2 (m, 1H), 4.4 (d, 1H), 7.0 (d, 1H), 7.5 (s, 1H), 7.7 (s, 1H), 12.1 (s, 1H), 13.3 (s, 1H).
452
Example 151





326
2-((3S,4R)-4-{[(3,5-dichloro-4-
NMR: 1.8 (m, 2H), 1.9 (s, 3H),
421
Example 155



methyl-1H-pyrrol-2-
3.3 (m, 1H), 3.5 (dd, 1H), 4.0 (m,





yl)carbonyl]amino}-3-
1H), 4.3 (m, 2H), 5.0 (d, 1H),





fluoropiperidin-1-yl)-1,3-
7.35 (d, 1H), 7.8 (s, 1H), 12.6 (s,





thiazole-5-carboxylic acid
1H), 12.7 (s, 1H).




327
4-acetyl-2-((3S,4R)-4-{[(3,4-
NMR: 1.7 (m, 2H), 2.2 (s, 3H),
475
Example 157



dichloro-5-methyl-1H-pyrrol-
3.3 (s, 3H), 3.9 (m, 2H), 4.3 (m,





2-yl)carbonyl]amino}-3-
2H), 7.15 (m, 1H), 12.2 (s, 1H),





methoxypiperidin-1-yl)-1,3-
13.2 (s, 1H).





thiazole-5-carboxylic acid





328
2-((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.5 (s, 6H), 1.7 (m, 2H),
491
Example 158



methyl-1H-pyrrol-2-
2.2 (s, 3H), 3.3 (s, 3H), 3.5 (m,





yl)carbonyl]amino}-3-
1H), 3.8 (m, 2H), 4.3 (m, 1H), 4.4





methoxypiperidin-1-yl)-4-(1-
(m, 1H), 7.15 (d, 1H), 12.2 (s,





hydroxy-1-methylethyl)-1,3-
1H).





thiazole-5-carboxylic acid





329
2-((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.8 (m, 2H), 2.2 (s, 3H),
489
Example 159



methyl-1H-pyrrol-2-
3.3 (s, 3H), 3.6 (m, 1H), 4.0 (m,





yl)carbonyl]amino}-3-
1H), 4.3 (m, 2H), 7.2 (d, 1H), 7.9





methoxypiperidin-1-
(s, 1H), 12.2 (s, 1H), 13.1 (s, 1H).





yl)thieno[2,3-d][1,3]thiazole-6-






carboxylic acid





330
Cis(±)-2-(3- (cyclopropylmethoxy)-4- {[(3,4-dichloro-5-methyl-1H- pyrrol-2- yl)carbonyl]amino}piperidin-1- yl)-1,3-thiazole-5-carboxylic acid embedded image
0.10 (m, 2H), 0.38 (m, 2H), 0.91 (m, 1H), 1.75 (m, 1H), 2.17 (s, 3H), 3.15-3.43 (m, 4H), 3.67 (m, 1H), 3.92 (m, 1H), 4.26 (m, 2H), 7.14 (d, 1H), 7.72 (s, 1H), 12.16 (s, 1H), 12.60 (bs, 1H).
473
Example 160





331
2-[4-{[(3,4-dichloro-5-methyl-
1.80 (m, 2H), 2.16 (s, 3H), 3.40
515
Example 161



1H-pyrrol-2-
(d, 2H), 3.94 (m, 2H), 4.33 (td,





yl)carbonyl]amino}-3-(1,3-
1H), 4.46 (d, 1H), 4.81-4.99 (dd,





thiazol-2-ylmethoxy)piperidin-
2H), 7.13 (d, 1H), 7.65 (d, 1H),





1-yl]-1,3-thiazole-5-carboxylic
7.69 (s, 1H), 7.71 (d, 1H), 12.12





acid
(s, 1H), 12.60 (bs, 1H).




332
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.05 (t, 3H); 1.74 (m, 2H); 2.17
447,
Example 162



methyl-1H-pyrrol-2-
(s, 3H); 3.35-3.45 (m, 3H); 3.63-
449




yl)carbonyl]amino}-3-
3.73 (m, 2H); 3.97 (m, 1H); 4.25





ethoxypiperidin-1-yl)-1,3-
(m, 2H); 7.12 (d, 1H); 7.72 (s,





thiazole-5-carboxylic acid
1H); 12.16 (s, 1H); 12.55 (br s, 1H).




333
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.06 (t, 3H); 1.74 (m, 2H); 2.17
435,
Example 163



methyl-1H-pyrrol-2-
(s, 3H); 3.27 (m, 4H); 3.42 (m,
437




yl)carbonyl]amino}-3-
1H); 3.62-3.71 (m, 2H); 3.82 (m,





ethoxypiperidin-1-yl)-4-
1H); 4.08-4.21 (overlapping m,





(methoxymethyl)-1,3-thiazole-
3H); 4.55 (s, 2H); 6.64 (s, 1H);





5-carboxylic acid
7.11 (d, 1H); 12.16 (s, 1H).




334
2-((3S,4R)-4-{[(3,4-Dichloro-
1.83 (m, 2H); 2.18 (s, 3H); 2.40
435,
Example 165



5-methyl-1H-pyrrol-2-
(s, 3H); 3.32 (m, overlapping
437




yl)carbonyl]amino}-3-
water); 3.50 (dd, 1H); 3.97 (m,





fluoropiperidin-1-yl)-4-methyl-
1H); 4.21-4.31 (m, 2H); 4.93 (d,





1,3-thiazole-5-carboxylic acid
1H); 7.26 (d, 1H); 12.11 (s, 1H);






12.44 br s, 1H).




335
2-((3S,4R)-4-{[(3,4-Dichloro- 5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- methyl-1,3-thiazole-5- carboxylic acid embedded image
1.72 (m, 2H); 2.17 (s, 3H); 2.39 (s, 3H); 3.26-3.35 (m overlapping with water, 5H); 3.52 (m, 1H); 3.90 (m, 1H); 4.25 (m, 2H); 7.14 (d, 1H); 12.15 (s, 1H); 12.40 (s, 1H).
447, 449
Example 166





337
Trans(±)2-[4-{[(3,4-dichloro-5-
1.89 (m, 1H), 2.14 (m, 1H), 2.17
516
Example 167



methyl-1H-pyrrol-2-
(s, 3H), 3.24-3.70 (m, 11H [under





yl)carbonyl]amino}-3-
H2O peak]), 3.74 (dd, 1H), 3.90





(morpholin-4-
(dd, 1H), 4.51 (m, 1H),_7.33 (d,





ylcarbonyl)piperidin-1-yl]-1,3-
1H), 7.74 (s, 1H), 12.09 (s, 1H),





thiazole-5-carboxylic acid
12.64 (s, 1H)




338
Cis(±)2-[4-{[(3,4-dichloro-5-
1.79 (dq, 1H), 1.89 (m, 1H), 2.15
516
Example 168



methyl-1H-pyrrol-2-
(s, 3H), 3.21-3.42 (m, 6H), 3.49-





yl)carbonyl]amino}-3-
3.72 (m, 5H), 3.95 (m, 1H), 4.02





(morpholin-4-
(m, 1H), 4.40 (m, 1H), 7.17 (d,





ylcarbonyl)piperidin-1-yl]-1,3-
1H), 7.78 (s, 1H), 12.02 (s, 1H),





thiazole-5-carboxylic acid
12.69 (s, 1H)




339
Cis(±)-2-[4-{[(3,4-dichloro-5-
1.51 (dq, 1H), 1.98 (m, 1H), 2.18
546
Example 169



methyl-1H-pyrrol-2-
(s, 3H), 3.18 (m, 2H), 3.23-3.56





yl)carbonyl]amino}-3-(2-
(m, 10H [under H2O peak]), 3.77





morpholin-4-yl-2-
(m, 1H), 4.04 (m, 2H), 4.32 (q,





oxoethoxy)piperidin-1-yl]-1,3-
2H), 7.36 (s, 1H), 8.26 (broad s,





thiazole-5-carboxylic acid
2H)




340
2-(4-{[(3,4-dichloro-5-methyl- 1H-pyrrol-2- yl)carbonyl]amino}-3- {[(ethylamino)carbonyl]oxy} piperidin-1-yl)-1,3-thiazole-5- carboxylic acid embedded image
MS (ES) MH+: 490, 492 for C18H21Cl2N5O5S; NMR: 0.96 (t, 3H), 1.82 (m, 2H), 2.17 (s, 3H), 2.96 (m, 2H), 3.19-3.40 (m, 2H) [under H2O peak]), 3.47 (d, 1H), 3.95 (m, 1H), 4.08 (m, 1H), 4.33 (m, 1H), 4.83 (m, 1H), 6.84 (broad s, 1H), 7.14 (d, 1H), 7.21 (t, 1H), 7.46 (s, 1H)
490
Example 172





341
2-(3-
NMR: 1.22 (s, 1H), 1.84 (m, 2H),
502
Example 173



{[(allylamino)carbonyl]oxy}-4-
2.17 (s, 3H), 3.52 (m, 1H), 3.57,





{[(3,4-dichloro-5-methyl-1H-
(m, 1H), 4.03 (m, 1H), 4.14 (m,





pyrrol-2-
1H), 4.36 (m, 1H), 4.78-4.91 (m,





yl)carbonyl]amino}piperidin-1-
2H), 4.99 (dd, 1H), 5.07 (dd, 1H),





yl)-1,3-thiazole-5-carboxylic
5.52 (broad s, 1H), 5.73 (m 1H),





acid
7.00 (d, 1H), 7.10 (broad s, 1H),






7.44 (t, 1H), 7.62 (s, 1H)




342
Cis(±)-4-(4-{[(4-chloro-5-
1.56-1.72 (m, 2H) 2.08-2.20
393
Example 177



methyl-1H-pyrrol-2-
(m, 3H) 3.24 (s, 3H) 3.55 (s, 2





yl)carbonyl]amino}-3-
H) 3.71-3.86 (m, 2H) 4.16 (s, 2





methoxypiperidin-1-
H) 6.88 (d, 1H) 7.44 (s, 1H)





yl)pyridine-2-carboxylic acid
7.68 (s, 1H) 7.97 (d, 1H) 11.69






(s, 1H)




343
Cis(±)-4-(aminocarbonyl)-2-(4-
1.74 (s, 2H) 2.19 (s, 3H) 3.38 (s,
476
Example 242



{[(3,4-dichloro-5-methyl-1H-
3H) 3.55 (s, 2H) 4.01 (s, 1H)





pyrrol-2-yl)carbonyl]amino}-3-
4.25 (s, 3H) 4.49 (s, 1H) 7.16 (d,





methoxypiperidin-1-yl)-1,3-
1H) 8.93 (s, 2H) 12.16 (s, 1 H





thiazole-5-carboxylic acid





344
4-((3S,4R)-4-{[(3,4-dichloro-5-
1.81-1.95 (m, 2H) 2.14-2.21
415
Example 174



methyl-1H-pyrrol-2-
(m, 3H) 3.73 (s, 2H) 4.26 (t, 2





yl)carbonyl]amino}-3-
H) 4.62 (s, 1H) 4.93 (s, 1H) 7.22





fluoropiperidin-1-yl)pyridine-
(s, 1H) 7.36 (s, 1H) 7.49 (s, 1H)





2-carboxylic acid
7.69 (s, 1H) 8.04 (d, 1H) 12.30






(s, 1H)




345
2-((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1- yl)isonicotinic acid embedded image
1.80 (m, 2H) 2.13-2.26 (s, 3H) 4.14 (dd, 1H) 4.27 (s, 1H) 4.41 (s, 2H) 4.72 (s, 1H) 4.84-5.00 (d, 1H) 7.02 (d, 1H) 7.17-7.32 (m, 1H) 7.66-7.78 (m, 1H) 8.24 (d, 1H) 12.11 (s, 1H)
415
Example 179





346
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.85 (s, 2H) 2.19 (s, 3H) 3.28 (s,
465
Example 180



methyl-1H-pyrrol-2-
3H) 3.50-3.64 (dd, 1H) 3.98 (s,





yl)carbonyl]amino}-3-
1H) 4.32 (s, 2H) 4.57 (s, 2H)





fluoropiperidin-1-yl)-4-
4.88-5.04 (d, 1H) 7.29 (d, 1H)





(methoxymethyl)-1,3-thiazole-
12.12 (s, 1H) 12.79 (s, 1H)





5-carboxylic acid





347
4-((3S,4R)-4-{[(3,4-dichloro-5-
2.00 (s, 2H) 2.21 (s, 3H) 3.33 (s,
465
Example 181



methyl-1H-pyrrol-2-
1H) 3.78 (d, 1H) 4.08 (s, 2H)





yl)carbonyl]amino}-3-
4.32-4.42 (m, 1H) 4.95-5.11 (d,





fluoropiperidin-1-yl)quinoline-
1H) 7.34 (d, 1H) 7.60 (s, 2H)





2-carboxylic acid
7.69 (t, 1H) 7.84 (t, 1H) 8.08-






8.22 (m, 2H) 12.15 (s, 1H)




348
Cis(±)-2-(4-{[(4-chloro-5-
1.57 (d, 1H) 1.86 (d, 1H) 2.14
393
Example 182



methyl-1H-pyrrol-2-
(s, 3H) 3.04-3.18 (m, 2H) 3.19-





yl)carbonyl]amino}-3-
3.25 (s, 3H) 3.49 (s, 1H) 4.19





methoxypiperidin-1-
(s, 1H) 4.21 (d, 1H) 4.55 (d, 1





yl)isonicotinic acid
H) 6.89 (d, 1H) 6.96 (d, 1H)






7.23 (s, 1H) 7.64 (d, 1H) 8.22






(d, 1H) 11.62 (s, 1H) 13.39 (s, 1H)




349
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.68 (s, 2H) 2.12 (s, 3H) 3.21 (s,
477
Example 183



methyl-1H-pyrrol-2-
3H) 3.33 (m, 5H) 3.48 (s, 1H)





yl)carbonyl]amino}-3-
3.85 (s, 1H) 4.19 (s, 2H) 4.49 (s,





methoxypiperidin-1-yl)-4-
2H) 7.08 (s, 1H) 12.09 (s, 1H)





(methoxymethyl)-1,3-thiazole-






5-carboxylic acid





350
2-((3R,4S)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- (methoxymethyl)-1,3-thiazole- 5-carboxylic acid embedded image
1.68 (s, 2H) 2.12 (s, 3H) 3.21 (s, 3H) 3.25 (m, 2H) 3.30 (s, 3H) 3.48 (s, 1H) 3.84 (s, 1H) 4.19 (s, 2H) 4.49 (s, 2H) 7.09 (d, 1H) 12.09 (s, 1H)
477
Example 184





351
Cis(±)-4-(4-{[(3,4-dichloro-5-
1.68 (s, 1H) 1.77 (s, 1H) 2.18 (s,
471
Example 185



methyl-1H-pyrrol-2-
3H) 3.21 (s, 2H) 3.31 (s, 3H)





yl)carbonyl]amino}-3-
3.55 (s, 1H) 4.02 (s, 1H) 4.28 (s,





methoxypiperidin-1-
1H) 4.41 (s, 1H) 7.13 (s, 1H)





yl)pyridine-2,6-dicarboxylic acid
7.61 (s, 2H) 12.13 (s, 1H)




352
4-((3S,4R)-4-{[(3,4-dichloro-5-
1.71-1.86 (m, 2H) 2.22 (s, 3H)
486
Example 187



methyl-1H-pyrrol-2-
2.93-3.04 (m, 3H) 3.04-3.15





yl)carbonyl]amino}-3-
(m, 3H) 3.80-3.96 (m, 1H) 4.08





fluoropiperidin-1-yl)-6-
(s, 1H) 4.28-4.43 (m, 2H) 4.77





[(dimethylamino)carbonyl]
(s, 1H) 4.94 (s, 1H) 6.87 (d, 1H)





pyridine-2-carboxylic acid
7.10 (d, 1H) 7.58 (d, 1H) 9.33






(s, 2H)




353
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.75 (s, 2H) 2.18 (s, 3H) 3.33 (s,
477
Example 175



methyl-1H-pyrrol-2-
2H) 3.37 (s, 3H) 3.55 (s, 1H)





yl)carbonyl]amino}-3-
3.92 (s, 1H) 4.26 (s, 2H) 7.15 (d,





methoxypiperidin-1-yl)-1,3-
1H) 12.14 (s, 1H)





thiazole-4,5-dicarboxylic acid





354
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.85 (s, 2H) 2.19 (s, 3H) 3.33 (s,
465
Example 176



methyl-1H-pyrrol-2-
1H) 3.60 (s, 1H) 3.99 (s, 1H)





yl)carbonyl]amino}-3-
4.31 (s, 2H) 4.88-5.04 (s, 1H)





fluoropiperidin-1-yl)-1,3-
7.28 (s, 1H) 12.09 (s, 1H)





thiazole-4,5-dicarboxylic acid





355
Cis(±)-2-(4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- formyl-1,3-thiazole-5- carboxylic acid embedded image
1.75 (s, 2H) 2.18 (s, 3H) 3.17 (s, 1H) 3.36 (s, 3H) 3.56 (s, 1H) 4.01 (s, 2H) 4.25 (s, 2H) 7.15 (d, 1H) 10.35 (s, 1H) 12.15 (s, 1H)
461
Example 252





356
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.69 (s, 2H) 2.12 (s, 3H) 2.72 (s,
504
Example 203



methyl-1H-pyrrol-2-
3H) 2.82-2.88 (m, 3H) 3.22 (s,





yl)carbonyl]amino}-3-
1H) 3.29 (s, 3H) 3.32 (s, 1H)





methoxypiperidin-1-yl)-4-
3.48 (d, 1H) 3.81 (s, 1H) 4.21 (s,





[(dimethylamino)carbonyl]-
2H) 7.09 (d, 1H) 12.03-12.13





1,3-thiazole-5-carboxylic acid
(m, 1H) 12.68 (s, 1H)




357
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.75 (s, 2H) 2.18 (s, 3H) 3.12-
546
Example 204



methyl-1H-pyrrol-2-
3.22 (m, 2H) 3.35 (s, 3H) 3.53





yl)carbonyl]amino}-3-
(d, 6H) 3.60 (d, 2H) 3.85 (s, 2





methoxypiperidin-1-yl)-4-
H) 4.27 (s, 2H) 7.14 (d, 1H)





(morpholin-4-ylcarbonyl)-1,3-
12.13 (s, 1H) 12.81 (s, 1H)





thiazole-5-carboxylic acid





358
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.84 (s, 2H) 2.18 (s, 3H) 3.16 (s,
534
Example 205



methyl-1H-pyrrol-2-
2H) 3.51 (s, 2H) 3.52-3.64 (m,





yl)carbonyl]amino}-3-
5H) 3.96 (s, 1H) 4.29 (s, 2H)





fluoropiperidin-1-yl)-4-
4.37 (s, 1H) 4.87-5.04 (d, 1H)





(morpholin-4-ylcarbonyl)-1,3-
7.26 (d, 1H) 12.07 (s, 2H)





thiazole-5-carboxylic acid





359
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.79 (s, 2H) 2.19 (s, 3H) 3.38 (s,
506
Example 206



methyl-1H-pyrrol-2-
3H) 3.56 (s, 2H) 3.64 (s, 1H)





yl)carbonyl]amino}-3-
3.75 (s, 3H) 4.03 (s, 1H) 4.25 (s,





methoxypiperidin-1-yl)-4-
2H) 7.16 (d, 1H) 12.16 (s, 1H)





[(methoxyamino)carbonyl]-1,3-






thiazole-5-carboxylic acid






trifluoroacetate





360
2-((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-4- [(methoxyamino)carbonyl]-1,3- thiazole-5-carboxylic acid embedded image
1.83-1.92 (m, 2H) 2.19 (s, 3H) 3.50-3.63 (dd, 1H) 3.76 (s, 3H) 4.11 (s, 1H) 4.30 (s, 1H) 4.42 (s, 2H) 4.90-5.07 (s, 1H) 7.29 (d, 1+nlH) 12.11 (s, 1H) 12.39 (s, 1H)
494
Example 207





361
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.51 (s, 3H) 1.57 (s, 1H) 1.75 (s,
544
Example 208



methyl-1H-pyrrol-2-
2H) 2.18 (s, 3H) 3.07-3.17 (m,





yl)carbonyl]amino}-3-
2H) 3.35 (s, 3H) 3.54 (d, 2H)





methoxypiperidin-1-yl)-4-
3.87 (s, 1H) 4.27 9s, 2H) 7.16 (d,





(piperidin-1-ylcarbonyl)-1,3-
1H) 12.16 (s, 1H) 12.76 (s, 1H)





thiazole-5-carboxylic acid





362
4-(aminocarbonyl)-2-((3S,4R)-
1.74 (d, 2H) 2.19 (s, 3H) 3.32 (s,
476
Example 243



4-{[(3,4-dichloro-5-methyl-1H-
2H) 3.38 (s, 3H) 3.55 (s, 1H)





pyrrol-2-yl)carbonyl]amino}-3-
4.25 (s, 2H) 4.49 (s, 1H) 7.17 (d,





methoxypiperidin-1-yl)-1,3-
1H) 8.87 (s, 1H) 12.17 (s, 1H)





thiazole-5-carboxylic acid





363
4-(aminocarbonyl)-2-((3S,4R)-
1.84 (s, 2H) 2.19 (s, 3H) 3.19 (s,
464
Example 244



4-{[(3,4-dichloro-5-methyl-1H-
1H) 3.95 (s, 2H) 4.24 (s, 2H)





pyrrol-2-yl)carbonyl]amino}-3-
4.86-5.02 (s, 1H) 7.28 (s, 1H)





fluoropiperidin-1-yl)-1,3-
12.12 (s, 1H)





thiazole-5-carboxylic acid





364
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.60-1.73 (m, 2H) 2.12 (s, 3H)
520
Example 212



methyl-1H-pyrrol-2-
3.14-3.25 (m, 2H) 3.30 (s, 3H)





yl)carbonyl]amino}-3-
3.41 (t, 2H) 3.86 (s, 2H) 4.19 (s,





methoxypiperidin-1-yl)-5-{[(2-
2H) 7.09 (d, 1H) 9.66 (t, 1H)





hydroxyethyl)amino]carbonyl}-
12.09 (s, 1H)





1,3-thiazole-4-carboxylic acid






trifluoroacetate (salt)





365
Cis(±)-2-(4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-{[(2- hydroxyethyl)amino]carbonyl}- 1,3-thiazole-5-carboxylic acid embedded image
1.69 (s, 2H) 2.12 (s, 3H) 3.25 (s, 2H) 3.31 (s, 3H) 3.43-3.53 (m, 2H) 4.03 (s, 1H) 4.23 (s, 2H) 4.80 (s, 1H) 7.07-7.22 (m, 1H) 9.23 (s, 1H) 12.09 (s, 1H)
520
Example 212





366
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.84 (s, 2H) 2.18 (s, 3H) 2.76 (s,
478
Example 211



methyl-1H-pyrrol-2-
3H) 3.31 (s, 1H) 3.40 (s, 1H)





yl)carbonyl]amino}-3-
3.61 (s, 1H) 3.98 (s, 1H) 4.29 (s,





fluoropiperidin-1-yl)-5-
1H) 4.87-5.03 (s, 1H) 7.26 (s, 1





[(methylamino)carbonyl]-1,3-
H) 9.43 (s, 1H) 12.11 (s, 1H)





thiazole-4-carboxylic acid





367
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.87 (s, 2H) 2.19 (s, 3H) 2.87 (s,
478
Example 211



methyl-1H-pyrrol-2-
3H) 3.53 (s, 1H) 4.13 (s, 1H)





yl)carbonyl]amino}-3-
4.30 (s, 1H) 4.43 (s, 2H) 4.91-





fluoropiperidin-1-yl)-4-
5.07 (d, 1H) 7.31 (s, 1H) 9.40 (s,





[(methylamino)carbonyl]-1,3-
1H) 12.11 (s, 1H)





thiazole-5-carboxylic acid





368
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.76 (s, 2H) 2.19 (s, 3H) 2.91 (q,
476
Example 355



methyl-1H-pyrrol-2-
1H) 3.03 (d, 1H) 3.35-3.38 (m,





yl)carbonyl]amino}-3-
3H) 3.53 (s, 1H) 3.93 (s, 1H)





methoxypiperidin-1-yl)-4-
4.03 (d, 1H) 4.23 (s, 1H) 7.20





[(hydroxyimino)methyl]-1,3-
(d, 1H) 7.54 (s, 1H) 7.83 (s, 1H)





thiazole-5-carboxylic acid
8.76 (s, 1H)




369
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.70-1.82 (m, 2H) 2.19 (s, 3H)
490
Example 214



methyl-1H-pyrrol-2-
3.32 (s, 3H) 3.38 (s, 3H) 3.41 (s,





yl)carbonyl]amino}-3-
1H) 3.56 (s, 1H) 4.09 (s, 1H)





methoxypiperidin-1-yl)-4-
4.29 (d, 2H) 4.46 (s, 1H) 7.17





[(methylamino)carbonyl]-1,3-
(d, 1H) 9.38 (s, 1H) 12.17 (s, 1





thiazole-5-carboxylic acid
H)




370
Cis(±)-2-(4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-[(E)- (methoxyimino)methyl]-1,3- thiazole-5-carboxylic acid embedded image
1.69 (s, 2H) 2.12 (s, 3H) 3.31 (s, 3H) 3.49 (s, 2H) 3.84 (s, 3H) 3.96 (s, 2H) 4.21 (s, 2H) 7.10 (d, 1H) 8.62 (s, 1H) 12.10 (s, 1H)
490
Example 251





371
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.61-1.71 (m, 2H) 2.10-2.14
532
Example 246



methyl-1H-pyrrol-2-
(m, 3H) 2.68 (s, 3H) 3.29 (s, 3





yl)carbonyl]amino}-3-
H) 3.47 (d, 1H) 3.58 (s, 4H)





methoxypiperidin-1-yl)-4-
3.67-3.80 (m, 2H) 3.84 (d, 2H)





(morpholin-4-ylmethyl)-1,3-
4.19 (t, 2H) 7.10 (d, 1H) 12.12





thiazole-5-carboxylic acid
(s, 1H)




372
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.60-1.74 (m, 2H) 2.12 (s, 3H)
483
Example 253



methyl-1H-pyrrol-2-
3.27 (s, 1H) 3.30 (s, 3H) 3.34 (s,





yl)carbonyl]amino}-3-
1H) 3.49 (s, 1H) 3.87 (s, 1H)





methoxypiperidin-1-yl)-4-
4.21 (s, 2H) 7.10 (d, 1H) 7.27 (s,





(difluoromethyl)-1,3-thiazole-
1H) 12.10 (s, 1H)





5-carboxylic acid





373
Cis(±)-4-[(tert-
1.26 (s, 9H) 1.72 (s, 2H) 2.18 (s,
518
Example 247



butylamino)methyl]-2-(4-
3H) 3.32 (m, 3H) 3.36 (s, 3H)





{[(3,4-dichloro-5-methyl-1H-
3.52 (s, 1H) 3.95 (s, 2H) 4.18 (s,





pyrrol-2-yl)carbonyl]amino}-3-
2H) 7.15 (d, 1H) 12.18 (s, 1H)





methoxypiperidin-1-yl)-1,3-






thiazole-5-carboxylic acid





374
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.11-1.20 (m, 3H) 1.76 (s, 2H)
534
Example 216



methyl-1H-pyrrol-2-
2.19 (s, 3H) 3.38 (s, 3H) 3.48 (d,





yl)carbonyl]amino}-3-
3H) 3.57 (s, 1H) 4.04 (s, 1H)





methoxypiperidin-1-yl)-4-{[(2-
4.27 (s, 2H) 4.91 (s, 2H) 7.17 (d,





hydroxy-1-
1H) 8.83 (s, 1H) 12.16 (s, 1H)





methylethyl)amino]carbonyl}-






1,3-thiazole-5-carboxylic acid





375
Cis(±)-2-(4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-{[(2- methoxyethyl)amino]carbonyl}- 1,3-thiazole-5-carboxylic acid embedded image
1.79 (s, 3H) 2.19 (s, 3H) 3.23- 3.28 (m, 3H) 3.38 (s, 3H) 3.42 (s, 2H) 3.46-3.52 (m, 2H) 3.57 (s, 1H) 4.30 (d, 2H) 7.17 (d, J = 8.48 Hz, 1H) 9.38 (s, 1H) 12.16 (s, 1H)
534
Example 215





376
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.06 (d, 3H) 1.69-1.79 (m, 3H)
534
Example 217



methyl-1H-pyrrol-2-
2.18 (s, 3H) 3.37 (s, 3H) 3.54 (s,





yl)carbonyl]amino}-3-
2H) 3.71 (s, 1H) 3.94 (s, 1H)





methoxypiperidin-1-yl)-5-{[(2-
4.25 (s, 3H) 4.79 (s, 1H) 6.55 (s,





hydroxypropyl)amino]carbonyl}-
1H) 7.17 (s, 1H) 9.78 (s, 1H)





1,3-thiazole-4-carboxylic acid
12.16 (s, 1H)




377
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.06 (dd, 3H) 1.75 (s, 2H) 2.19
534
Example 217



methyl-1H-pyrrol-2-
(s, 3H) 3.24 (s, 2H) 3.38 (s, 3H)





yl)carbonyl]amino}-3-
3.43 (s, 1H) 3.56 (s, 1H) 3.83 (s,





methoxypiperidin-1-yl)-4-{[(2-
1H) 4.05 (s, 1H) 4.26 (s, 2H)





hydroxypropyl)amino]carbonyl}-
4.90 (s, 1H) 7.17 (d, 1H) 9.21 (s,





1,3-thiazole-5-carboxylic acid
1H) 12.16 (s, 1H)




378
Cis(±)-2-(4-{[(3,4-dichloro-5-
1.69 (s, 6H) 2.18 (s, 3H) 3.34 (s,
530
Example 248



methyl-1H-pyrrol-2-
3H) 3.40 (m, 3H) 3.54 (s, 5H)





yl)carbonyl]amino}-3-
4.24 (s, 4H) 7.14 (d, 1H) 12.16





methoxypiperidin-1-yl)-4-
(s, 1H)





(piperidin-1-ylmethyl)-1,3-






thiazole-5-carboxylic acid





379
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.75 (s, 2H) 2.19 (s, 3H) 3.17
433
Example 192



methyl-1H-pyrrol-2-
(d, 1H) 3.27 (s, 1H) 3.36 (s, 3H)





yl)carbonyl]amino}-3-
3.54 (s, 1H) 3.85 (s, 1H) 4.21 (d,





methoxypiperidin-1-yl)-1,3-
2H) 7.16 (d, 1H) 7.58 (s, 1H)





thiazole-4-carboxylic acid
12.16 (s, 1H) 12.57 (s, 1H)




380
2-((3S,4R)-4-{[(3,4-dichloro-5-
1.73 (d, 3H) 2.07 (s, 1H) 2.18 (s,
532
Example 249



methyl-1H-pyrrol-2-
3H) 2.95 (s, 2H) 3.26 (s, 2H)





yl)carbonyl]amino}-3-
3.36 (s, 3H) 3.53 (s, 1H) 3.85 (s,





methoxypiperidin-1-yl)-4-[(3-
1H) 4.15 (s, 4H) 4.35 (s, 1H)





hydroxypyrrolidin-1-
5.20 (s, 1H) 7.16 (d, 1H) 12.16





yl)methyl]-1,3-thiazole-5-
(s, 1H)





carboxylic acid





381
4-{[(1-
1.25 (s, 2H) 1.48 (s, 2H) 1.75 (s,
560
Example 402



carboxycyclopropyl)amino]
2H) 2.19 (s, 3H) 3.39 (s, 4H)





carbonyl}-2-((3S,4R)-4-{[(3,4-
3.56 (s, 2H) 4.26 (s, 2H) 4.42 (s,





dichloro-5-methyl-1H-pyrrol-
1H) 7.15 (s, 1H) 9.80 (s, 1H)





2-yl)carbonyl]amino}-3-
12.15 (s, 1H) 12.78 (s, 1H)





methoxypiperidin-1-yl)-1,3-
16.05 (s, 1H)





thiazole-5-carboxylic acid









Example 382
Cis(±)-5-(aminocarbonyl)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-4-carboxylic acid

A solution of 55 mg (23 mmol) of Cis(±)-3,4-dichloro-N-[3-methoxypiperidin-4-yl]-5-methyl-1H-pyrrole-2-carboxamide (Intermediate 50), 55 mg (0.23 mmol) of ethyl 5-(aminocarbonyl)-2-chloro-1,3-thiazole-4-carboxylate (Intermediate 220) and 33 mg (0.23 mmol) K2CO3 in 3 ml NMP was heated at 150° C. for 1 h in a microwave reactor. Water (0.1 ml) was added and the mixture was heated at 150° C. for another hour. The solution was diluted with water and acidified with 1N HCl before being extracted 2 times with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO4) and concentrated to give a solid that was triturated with MeOH to give 41 mg of a white solid. MS (ES) MH+: 479 for C17H19Cl2N5O5S; NMR: 1.75 (m, 2H), 2.2 (s, 3H), 3.3 (s), 3.5 (s, 1H), 3.9 (m, 1H), 4.2 (m, 2H), 7.15 (d, 1H), 7.8 (s, 1H), 8.9 (s, 1H), 12.2 (s, 1H).


Example 383
Cis(±)-5-(aminocarbonyl)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinic acid

A mixture of 85 mg (0.17 mmol) of Cis(±)-ethyl 5-(aminocarbonyl)-2-(4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)isonicotinate (Example 198) and 86 mg (0.50 mmol) Ba(OH)2 in 3 ml MeOH and 2 ml water was heated at 120° C. for 1 h. The mixture was acidified to about pH=4 with 1N HCl and extracted 4 times with EtOAc. The EtOAc was concentrated and the residue was purified by reverse phase HPLC (20-40% CH3CN gradient in water with 0.1% TFA) to afford 8 mg of product as a white solid. MS (ES) MH+: 470 for C19H21Cl2N5O5; NMR: 1.5-1.8, (m, 3H), 2.2 (s, 3H), 3.0-3.2 (m, 2H), 3.3 (s, 3H), 3.5 (m, 2H), 4.2-4.5 (m, 2H), 4.9 (d, 1H), 6.9 (s, 1H), 7.1-7.3 (m, 2H), 7.8 (s, 1H), 8.4 (s, 1H), 12.1 (s, 1H), 13.1 (s, 1H).


Examples 384-385

The following Examples were synthesized by an analogous method to Example 383 from the starting materials (SM) given in the table below.
















Ex
Compound
NMR
m/z
SM



















384
2-((3S,4R)-4-{[(3,5-dichloro-4-
NMR: 1.8 (m,
MS (ES) MH+: 577
Intermediate 138



methyl-1H-pyrrol-2-
2H), 1.9 (s, 3H),
for




yl)carbonyl]amino}-3-
3.5-4.0 (m, 8H),
C22H27Cl2FN6O5S




fluoropiperidin-1-yl)-4-{[(2-
4.0-4.4 (m, 3H),





morpholin-4-
5.0 (d, 1H), 7.4





ylethyl)amino]carbonyl}-1,3-
(d, 1H), 9.5 (s,





thiazole-5-carboxylic acid
1H), 12.6 (s, 1H).







385
4-(aminocarbonyl)-2-((3S,4R)- 4-{[(3,5-dichloro-4-methyl- 1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylic acid embedded image
NMR: 1.8 (m, 2H), 1.9 (s, 3H), 3.5-4.0 (m, 8H), 4.0-4.4 (m, 3H), 5.0 (d, 1H), 7.4 (d, 1H), 9.5 (s, 1H, 12.6 (s, 1H.)
MS (ES) MH+: 464 for C16H16Cl2FN5 O4S
Example 202









Example 386
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-[(methylamino)carbonyl]-1,3-thiazole-5-carboxylic acid

To a suspension/solution of ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-[(methylamino)carbonyl]-1,3-thiazole-5-carboxylate (0.078 g, 0.15 mmol, Example 218) in methanol (2 mL) was added barium hydroxide (0.052 g, 0.30 mmol) and water (0.5 mL). After stirring several hours the reaction was complete. The reaction was acidified with 1N HCl and then concentrated to remove methanol. The residue was extracted with EtOAc (×3), dried with MgSO4 and concentrated to a white solid (0.059 g). MS (ES) M+H+: 490 for C18H21Cl2N5O5S; NMR: 1.76 (s, 2 H) 2.18 (s, 3 H) 2.86 (s, 3 H) 3.38 (s, 3 H) 3.56 (s, 2 H) 4.02 (s, 1 H) 4.27 (s, 2 H) 4.40 (s, 1 H) 7.15 (s, 1 H) 9.38 (s, 1 H) 12.15 (s, 1 H).


Examples 387-412

The following Examples were prepared by the procedure described in Example 386 from the starting materials (SM) indicated.















Ex
Compound
Data
SM


















387
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 534 for
Example 219



methyl-1H-pyrrol-2-
C20H25Cl2N5O6S;




yl)carbonyl]amino}-3-
NMR: 1.72 (s, 2H) 2.18 (s, 3H)




methoxypiperidin-1-yl)-4-{[(2-
3.24 (s, 3H) 3.36 (s, 3H) 3.51 (s,




methoxyethyl)amino]carbonyl}-
2H) 3.84 (s, 2H) 4.15 (s, 2H)




1,3-thiazole-5-carboxylic acid
7.15 (s, 1H) 12.16 (s, 1H) 13.18





(s, 1H)



388
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 534 for
Example 220



methyl-1H-pyrrol-2-
C20H25Cl2N5O6S;




yl)carbonyl]amino}-3-
NMR: 1.19 (s, 3H) 1.77 (s, 2H)




methoxypiperidin-1-yl)-4-
2.19 (s, 3H) 3.38 (s, 3H) 3.47 (s,




({[(1S)-2-hydroxy-1-
3H) 3.58 (s, 1H) 4.04 (s, 1H)




methylethyl]amino}carbonyl)-
4.29 (s, 2H) 4.91 (s, 1H) 7.18 (s,




1,3-thiazole-5-carboxylic acid
1H) 8.79-8.94 (m, 1H) 12.16





(s, 1H)



389
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 534 for
Example 221



methyl-1H-pyrrol-2-
C20H25Cl2N5O6S




yl)carbonyl]amino}-3-





methoxypiperidin-1-yl)-4-





({[(1R)-2-hydroxy-1-





methylethyl]amino}carbonyl)-





1,3-thiazole-5-carboxylic acid







390
Cis(±)-2-(4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-{[(2,2- difluoroethyl)amino]carbonyl}- 1,3-thiazole-5-carboxylic acid embedded image
MS (ES) MH+: 540 for C19H21Cl2F2N5O5S; NMR: 1.76 (s, 2H) 2.19 (s, 3H) 3.38 (s, 3H) 3.44 (s, 1H) 3.57 (s, 2H) 3.73 (s, 3H) 4.10 (s, 1H) 4.27 (d, 2H) 4.43 (s, 1H) 7.17 (d, 1H) 9.60 (s, 1H) 12.16 (s, 1+nlH) 15.77 (s, 1H)
Example 222





391
Cis(±)-2-(4-{[(3,4-dichloro-5-
MS (ES) MH+: 543 for
Example 223



methyl-1H-pyrrol-2-
C20H20Cl2N6O6S;




yl)carbonyl]amino}-3-
NMR: 1.74 (s, 2H) 2.19 (s, 3H)




methoxypiperidin-1-yl)-4-
3.22 (s, 2H) 3.38 (s, 3H) 3.52 (s,




[(isoxazol-3-ylamino)carbonyl]-
1H) 3.88 (s, 1H) 4.24 (s, 2H)




1,3-thiazole-5-carboxylic acid
6.99 (d, 1H) 7.16 (s, 1H) 8.75





(s, 1H) 12.16 (s, 1H)



392
Cis(±)-2-(4-{[(3,4-dichloro-5-
MS (ES) MH+: 546 for
Example 224



methyl-1H-pyrrol-2-
C21H25Cl2N5O6S;




yl)carbonyl]amino}-3-
NMR: 1.76 (s, 3H) 1.94-2.08




methoxypiperidin-1-yl)-4-{[(3R)-
(m, 1H) 2.19 (s, 3H) 3.38 (s, 3




tetrahydrofuran-3-
H) 3.44 (s, 1H) 3.56 (s, 1H)




ylamino]carbonyl}-1,3-thiazole-
3.63-3.76 (m, 2H) 3.81-3.92




5-carboxylic acid
(m, 2H) 4.12 (s, 1H) 4.26 (s, 1





H) 4.51 (s, 1H) 7.16 (d, 1H)





9.17 (d, 1H) 12.15 (s, 1H) 15.97





(s, 1H)






393
Cis(±)-2-(4-{[(3,4-dichloro-5-
MS (ES) MH+: 534 for
Example 225



methyl-1H-pyrrol-2-
C20H22Cl2FN5O5S;




yl)carbonyl]amino}-3-
NMR: 1.23 (dd, 2H) 1.75 (s, 2




methoxypiperidin-1-yl)-4-
H) 2.19 (s, 3H) 2.87 (s, 1H)




({[(1R,2S)-2-
3.37 (d, 3H) 3.42 (s, 1H) 3.56




fluorocyclopropyl]amino}carbon-
(s, 2H) 4.10 (s, 1H) 4.26 (s, 3H)




yl)-1,3-thiazole-5-carboxylic acid
4.45 (s, 1H) 4.73 (d, 1H) 4.96





(s, 1H) 7.16 (d, 1H) 9.29 (dd, 1





H) 12.15 (s, 2H) 16.02 (d, 1H)



394
4-(azidomethyl)-2-((3S,4R)-4-
MS (ES) MH+: 488 for
Example 254



{[(3,4-dichloro-5-methyl-1H-
C17H19Cl2N7O4S;




pyrrol-2-yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.18 (s, 3H)




methoxypiperidin-1-yl)-1,3-
3.37 (s, 5H) 3.56 (s, 1H) 3.92 (s,




thiazole-5-carboxylic acid
1H) 4.28 (s, 2H) 4.54 (d, 2H)





7.18 (s, 1H) 12.16 (s, 1H) 12.97





(s, 1H)






395
2-((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- ({[(1S)-2-methoxy-1- methylethyl]amino}carbonyl)- 1,3-thiazole-5-carboxylic acid embedded image
MS (ES) MH+: 548 for C21H27Cl2N5O6S; NMR: 1.18 (d, 3H) 1.76 (s, 2H) 2.18 (s, 3H) 3.24 (s, 3H) 3.38 (s, 3H) 3.49 (s, 2H) 3.57 (s, 1H) 4.06 (s, 1H) 4.26 (s, 2H) 7.15 (s, 1H) 8.95 (s, 1H) 12.16 (s, 1H) 16.33 (s, 1H)
Example 226





396
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 514 for
Example 227



methyl-1H-pyrrol-2-
C20H21Cl2N5O5S;




yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.19 (s, 3H)




methoxypiperidin-1-yl)-4-[(prop-
3.26 (s, 2H) 3.38 (s, 3H) 3.57 (s,




2-yn-1-ylamino)carbonyl]-1,3-
2H) 4.10 (d, 2H) 4.27 (s, 2H)




thiazole-5-carboxylic acid
7.17 (d, 1H) 9.78 (s, 1H) 12.16





(s, 1H) 15.96 (s, 1H)



397
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 548 for
Example 228



methyl-1H-pyrrol-2-
C21H27Cl2N5O6S;




yl)carbonyl]amino}-3-
NMR: 1.29 (s, 6H) 1.73 (s, 2H)




methoxypiperidin-1-yl)-4-{[(2-
2.17 (s, 3H) 3.37 (m, 6H) 3.46




hydroxy-1,1-
(s, 2H) 3.54 (s, 1H) 3.91 (s, 1H)




dimethylethyl)amino]carbonyl}-
4.23 (s, 2H) 7.16 (s, 1H) 12.19




1,3-thiazole-5-carboxylic acid
(s, 1H)



398
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 546 for
Example 224



methyl-1H-pyrrol-2-
C21H25Cl2N5O6S;




yl)carbonyl]amino}-3-
NMR: 1.23 (s, 1H) 1.76 (s, 2H)




methoxypiperidin-1-yl)-4-{[(3R)-
2.00 (d, 1H) 2.19 (s, 3H) 3.38




tetrahydrofuran-3-
(s, 6H) 3.43 (s, 1H) 3.56 (s, 1H)




ylamino]carbonyl}-1,3-thiazole-
3.64-3.77 (m, 2H) 3.79-3.94




5-carboxylic acid
(m, 2H) 4.26 (s, 1H) 4.51 (s, 1





H) 7.16 (d, 1H) 9.17 (s, 1H)





12.16 (s, 1H) 15.98 (s, 1H)



399
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 534 for
Example 229



methyl-1H-pyrrol-2-
C20H22Cl2FN5O5S;




yl)carbonyl]amino}-3-
NMR: 1.21 (d, 1H) 1.40 (s, 1H)




methoxypiperidin-1-yl)-4-
1.76 (s, 2H) 2.19 (s, 3H) 2.85 (s,




({[(1R,2S)-2-
1H) 3.38 (s, 3H) 3.43 (s, 3H)




fluorocyclopropyl]amino}carbon-
3.56 (s, 1H) 4.26 (s, 1H) 4.74-




yl)-1,3-thiazole-5-carboxylic acid
4.97 (d, 1H) 7.17 (d, 1H) 9.27





(d, 1H) 12.16 (s, 2H) 16.01 (s, 2





H)






400
2-((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1- yl)isonicotinic acid embedded image
MS (ES) MH+: 427 for C18H20Cl2N4O4 NMR: 1.72 (s, 2H) 2.18 (s, 3H) 3.13 (d, 2H) 3.30 (s, 3H) 3.49 (s, 1H) 4.17-4.31 (m, 2H) 4.68 (d, 1H) 6.97 (d, 1H) 7.15 (d, 1+nlH) 7.23 (s, 1H) 8.22 (d, 1H) 12.16 (s, 1H) 13.39 (s, 1H)
Example 193





401
4-[(cyclopropylamino)carbonyl]-
MS (ES) MH+: 516 for
Example 231



2-((3S,4R)-4-{[(3,4-dichloro-5-
C20H23Cl2N5O5S;




methyl-1H-pyrrol-2-
NMR: 0.77 (d, 2H) 0.80 (s, 2H)




yl)carbonyl]amino}-3-
1.76 (s, 2H) 2.19 (s, 3H) 2.86-




methoxypiperidin-1-yl)-1,3-
2.99 (m, 1H) 3.30 (s, 1H) 3.37




thiazole-5-carboxylic acid
(s, 3H) 3.56 (s, 1H) 4.16 (s, 1H)





4.26 (d, 2H) 4.41 (s, 1H) 7.16





(d, 1H) 9.22 (d, 1H) 12.15 (s, 1H)



402
1-({[2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 574 for
Example 230



dichloro-5-methyl-1H-pyrrol-2-
C22H25Cl2N5O7S;




yl)carbonyl]amino}-3-





methoxypiperidin-1-yl)-5-





(methoxycarbonyl)-1,3-thiazol-4-





yl]carbonyl}amino)cyclopropane





carboxylic acid




403
4-{[(1-carboxy-2-
MS (ES) MH+: 564 for
Example 233



hydroxyethyl)amino]carbonyl}-
C20H23Cl2N5O8S;




2-((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.78 (s, 2H) 2.19 (s, 3H)




methyl-1H-pyrrol-2-
3.39 (s, 3H) 3.47 (s, 2H) 3.59 (s,




yl)carbonyl]amino}-3-
1H) 3.87 (s, 2H) 4.30 (s, 2H)




methoxypiperidin-1-yl)-1,3-
4.53 (s, 1H) 7.16 (s, 1H) 9.03 (s,




thiazole-5-carboxylic acid
1H) 12.16 (s, 1H) 15.97 (s, 1H)



404
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 589 for
Example 234



methyl-1H-pyrrol-2-
C23H30Cl2N6O6S;




yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.19 (s, 3H)




methoxypiperidin-1-yl)-4-{[(2-
3.14 (d, 2H) 3.39 (s, 4H) 3.57




morpholin-4-
(s, 3H) 3.72 (s, 3H) 3.78 (s, 1H)




ylethyl)amino]carbonyl}-1,3-
3.96 (s, 2H) 4.27 (s, 2H) 7.18




thiazole-5-carboxylic acid
(d, 1H) 9.59 (s, 1H) 12.21 (s, 1H)






405
2-((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-{[(1,3- dioxolan-2- ylmethyl)amino]carbonyl}-1,3- thiazole-5-carboxylic acid embedded image
MS (ES) MH+: 562 for C21H25Cl2N5O7S; NMR: 1.77 (s, 2H) 2.19 (s, 3H) 3.39 (s, 9H) 3.44-3.52 (m, 2H) 3.58 (s, 1H) 3.79-3.87 (m, 2H) 3.89-3.97 (m, 2H) 4.27 (s, 2H) 5.05 (t, 1H) 7.17 (d, 1H) 9.39 (t, 1H) 12.16 (s, 1H) 16.20 (s, 1H)
Example 235





406
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 567 for
Example 237



methyl-1H-pyrrol-2-
C23H24Cl2N6O5S;




yl)carbonyl]amino}-3-
NMR: 1.77 (s, 2H) 2.19 (s, 3H)




methoxypiperidin-1-yl)-4-
3.40 (s, 3H) 3.58 (s, 2H) 4.28 (s,




{[(pyridin-2-
2H) 4.67 (s, 2H) 7.16 (s, 1H)




ylmethyl)amino]carbonyl}-1,3-
7.31-7.45 (m, 2H) 7.85 (s, 1H)




thiazole-5-carboxylic acid
8.56 (s, 1H) 9.97 (s, 1H) 12.17





(s, 1H) 16.14 (s, 1H)



407
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 601 for
Example 236



methyl-1H-pyrrol-2-
C24H30Cl2N6O6S;




yl)carbonyl]amino}-3-
NMR: 1.71 (s, 1H) 1.74 (d, 3H)




methoxypiperidin-1-yl)-4-({[3-
1.85-2.00 (m, 2H) 2.19 (s, 3H)




(2-oxopyrrolidin-1-
2.20-2.27 (m, 2H) 3.19-3.35




yl)propyl]amino}carbonyl)-1,3-
(m, 11H) 3.39 (s, 4H) 3.56 (s, 1




thiazole-5-carboxylic acid
H) 4.20-4.34 (m, 1H) 7.17 (d, 1





H) 9.45 (t, 1H) 12.16 (s, 1H)



408
Cis(±)-4-[cyano(morpholin-4-
MS (ES) MH+: 557 for
Example 255



yl)methyl]-2-(4-{[(3,4-dichloro-
C22H26Cl2N6O5S;




5-methyl-1H-pyrrol-2-
NMR: 1.75 (s, 2H) 2.18 (s, 3H)




yl)carbonyl]amino}-3-
2.71 (s, 3H) 3.39 (s, 2H) 3.43 (s,




methoxypiperidin-1-yl)-1,3-
5H) 3.59 (s, 4H) 3.80 (s, 2H)




thiazole-5-carboxylic acid
4.27 (s, 2H) 4.44 (s, 1H) 7.14 (s,





1H) 12.15 (s, 1H)



409
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 582 for
Example 256



methyl-1H-pyrrol-2-
C20H25Cl2N5O7S2




yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.19 (s, 3H)




methoxypiperidin-1-yl)-4-({[2-
3.06 (s, 3H) 3.38 (s, 5H) 3.44 (t,




(methylsulfonyl)ethyl]amino}
3H) 3.57 (s, 1H) 3.68-3.81 (m,




carbonyl)-1,3-thiazole-5-
2H) 4.26 (s, 2H) 7.16 (d, 1H)




carboxylic acid
9.45-9.56 (m, 1H) 12.15 (s, 1H)






410
2-((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-{[(1,3- oxazol-2- ylmethyl)amino]carbonyl}-1,3- thiazole-5-carboxylic acid embedded image
MS (ES) MH+: 557 for C21H22Cl2N6O6S; NMR: 1.76 (s, 2H) 2.19 (s, 3H) 3.38 (s, 3H) 3.45 (s, 1H) 3.57 (s, 1H) 4.26 (d, 2H) 4.65 (s, 2H) 7.11-7.24 (m, 2H) 8.09 (s, 1H) 9.98 (s, 1H) 12.16 (s, 1H) 15.92 (s, 1H)
Example 239





411
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 522 for
Example 240



methyl-1H-pyrrol-2-
C19H22Cl2FN5O5S;




yl)carbonyl]amino}-3-
NMR: 1.76 (s, 2H) 2.19 (s, 3H)




methoxypiperidin-1-yl)-4-{[(2-
3.38 (s, 4H) 3.45 (s, 1H) 3.58 (s,




fluoroethyl)amino]carbonyl}-1,3-
2H) 3.68 (s, 1H) 4.14 (s, 1H)




thiazole-5-carboxylic acid
4.27 (s, 2H) 4.47-4.54 (m, 1H)





4.67 (t, 1H) 7.26 (d, J = 8.29 Hz,





1H) 9.55 (s, 1H) 12.29 (s, 1H)





16.19 (s, 1H)



412
2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES) MH+: 548 for
Example 241



methyl-1H-pyrrol-2-
C21H27Cl2N5O6S;




yl)carbonyl]amino}-3-
NMR: 1.11 (d, 6H) 1.77 (s, 2H)




methoxypiperidin-1-yl)-4-{[(2-
2.18 (s, 3H) 3.23 (s, 3H) 3.38 (s,




hydroxy-2-
3H) 3.57 (s, 1H) 4.29 (s, 1H)




methylpropyl)amino]carbonyl}-
4.76 (s, 1H) 7.18 (s, 1H) 8.94 (s,




1,3-thiazole-5-carboxylic acid
1H) 12.16 (s, 1H)









Example 413
4-{[(1-cyanocyclopropyl)amino]carbonyl}-2-((3S,4R) -4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid

To a solution of ethyl 4-{[(1-cyanocyclopropyl)amino]carbonyl}-2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylate (0.09 g, 0.16 mmol, Example 230) in methanol (2 mL) was added potassium carbonate (0.022 g, 0.16 mmol) and water (0.5 mL). After heating in the microwave for 30 min at 80°, reaction was complete by LCMS analysis. The reaction mixture was diluted with water and acidified with 1N HCl. After concentrating to remove methanol, the resulting white precipitate was filtered, washed with water and dried (0.071 g). MS (ES) M+H+: 541 for C21H22Cl2N6O5S; NMR: 1.33-1.41 (m, 2 H) 1.64 (s, 2 H) 1.75 (s, 2 H) 2.19 (s, 3 H) 3.37 (s, 3H) 3.43 (s, 1 H) 3.57 (s, 1 H) 4.08 (s, 1 H) 4.27 (d, 2 H) 4.40 (s, 1 H) 7.16 (d, 1 H) 9.87 (s, 1 H) 12.17 (s, 1 H).


Example 414

The following Example was prepared by the procedure described in Example 413 from the starting materials (SM) indicated.















Ex
Compound
Data
SM







414
4-{[(1-cyano-1-
MS (ES) MH+: 543 for
Example 232



methylethyl)amino]carbonyl}-
C21H24Cl2N6O5S;



2-((3S,4R)-4-{[(3,4-dichloro-5-
NMR: 1.68 (s, 6 H) 1.76 (s, 2 H)



methyl-1H-pyrrol-2-
2.19 (s, 3 H) 3.38 (s, 4 H)



yl)carbonyl]amino}-3-
3.44 (s, 1 H) 3.56 (s, 1 H) 4.11 (s, 1



methoxypiperidin-1-yl)-1,3-
H) 4.25 (s, 2 H) 7.14 (s, 1 H)



thiazole-5-carboxylic acid
9.10 (s, 1 H) 12.17 (s, 1 H)









Example 415
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-N-methoxy-N-methyl-1,3-thiazole-5-carboxamide



embedded image


2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (10 mg, 0.024 mmol) was dissolved in dry DMF (10 ml), HATU (9.1 mg, 0.024 mmol), triethylamine (7.27 mg, 0.072 mmol) and N,O-dimethylhydroxyamine (4.65 mg, 0.048 mmol) were added. The mixture was stirred at room temperature for 30 minutes, then was poured into cold water (30 ml), the precipitate was filtered, washed with water and collected as the desired product (off white solid, 10 mg).


MS (ESP): 465 (MH+) for C17H20Cl2FN5O3S.


NMR (CDCl3) δ: 1.87 (m, 2H); 2.19 (s, 3H); 3.07 (m, 2H); 3.21 (s, 3H); 3.72 (s, 3H); 4.01 (m, 1H); 4.30 (m, 2H); 4.96 (d, br, 1H); 7.28 (d, 1H); 7.85 (s, 1H); 12.09 (s, 1H).


The following compound was produced following the procedure described for Example 415 from Example 334 and N-methoxy amine hydrochloride.


Example 416
2-((3S,4R)-4-{[(3,4-Dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-N-methoxy-4-methyl-1,3-thiazole-5-carboxamide

MS (ES) MH+: 476 for C18H23Cl2N5O4S; NMR: 1.66-1.79 (m, 1H), 2.17(s, 3H), 2.37 (s, 3H), 3.20-3.35 (m, buried under water peak), 3.35 (s, 3H), 33.50-3.55 (m, 1H), 3.61 (s, 3H), 3.82-3.91 (m, 1H), 4.15-4.31 (m, 2H), 7.14 (d, 1H), 10.79 (s, 1H), 12.14 (s, 1H).


Example 417
sodium 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylate

Sodium hydroxide (0.056 mL, 0.056 mmol, Acros 1N) was added to a suspension of 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylic acid (0.03 g, 0.056 mmol, Example 387) in methanol (5 mL). After stirring five minutes the reaction was homogeneous. The reaction mixture was concentrated and the resulting white solid was dried overnight (0.030 g). MS (ES) MH+: 534 for C20H24C2N5O6SNa; NMR: 1.73 (s, 2 H) 2.19 (s, 3 H) 3.24 (s, 3 H) 3.32 (s, 2 H) 3.36 (s, 3 H) 3.51 (s, 1 H) 3.84 (s, 1 H) 4.22 (d, 2 H) 7.17 (d, 1 H) 12.17 (s, 1 H) 13.26 (s, 1 H).


Examples 419-423

The following Examples were prepared by the procedure described in Example 417 from the starting materials (SM) indicated.















Ex
Compound
Data
SM


















419
sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 548 for
Example 395



dichloro-5-methyl-1H-pyrrol-2-
C21H26Cl2N5O6SNa




yl)carbonyl]amino}-3-
NMR: 1.04-1.15 (m, 3H) 1.71




methoxypiperidin-1-yl)-4-
(s, 2H) 2.18 (s, 3H) 3.08-3.21




({[(1S)-2-methoxy-1-
(m, 3H) 3.25 (s, 3H) 3.36 (s, 4




methylethyl]amino}carbonyl)-
H) 3.50 (s, 1H) 3.87 (d, 1H) 3.99




1,3-thiazole-5-carboxylate
(dt, 1H) 4.11 (s, 1H) 4.22 (s, 1





H) 7.21 (d, 1H) 13.17 (d, 1H)






420
sodium 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- ({[(1S)-2-methoxy-1- methylethyl]amino}carbonyl)- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 582 for C20H24Cl2N5O7S2Na NMR: 1.67-1.78 (m, 2H) 2.18 (s, 3H) 3.00 (s, 3H) 3.10-3.21 (m, 2H) 3.24-3.31 (m, 3H) 3.36 (s, 3H) 3.47-3.60 (m, 3H) 3.85 (s, 1H) 4.10 (s, 1H) 4.17 (s, 2H) 7.17 (d, 1H) 12.16 (s, 1H) 13.71 (s, 1H)
Example 409





421
sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 556 for
Example 410



dichloro-5-methyl-1H-pyrrol-2-
C21H21Cl2N6O6SNa




yl)carbonyl]amino}-3-
NMR: 1.71 (d, 2H) 2.15 (s, 3H)




methoxypiperidin-1-yl)-4-{[(1,3-
3.09-3.24 (m, 2H) 3.35 (s, 3H)




oxazol-2-
3.49 (s, 1H) 3.84 (s, 1H) 4.16 (s,




ylmethyl)amino]carbonyl}-1,3-
2H) 4.48 (d, 2H) 7.12 (s, 12H)




thiazole-5-carboxylate
7.18 (d, 1H) 8.01 (s, 1H) 12.17





(s, 1H) 13.95-14.07 (m, 1H)



422
sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 534 for
Example 399



dichloro-5-methyl-1H-pyrrol-2-
C20H21Cl2FN5O5SNa




yl)carbonyl]amino}-3-





methoxypiperidin-1-yl)-4-





({[(1R,2S)-2-





fluorocyclopropyl]amino}carbon-





yl)-1,3-thiazole-5-carboxylate




423
Sodium-2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 435,437 for
Example 42



dichloro-5-methyl-1H-pyrrol-2-
C16H17Cl2FN4O3S; NMR: 1.77-




yl)carbonyl]amino}-3-
1.79 (m, 1H), 1.99 (m, 1H), 2.24




fluoropiperidin-1-yl)-1,3-
(s, 3H), 3.25-3.27 (m, 1H), 3.74




thiazole-5-carboxylate
(d, 1H), 4.16 (m, 1H), 4.22 (m,





1H), 4.38 (t, 1H), 4.83 (d, 1H),





7.19 (s, 1H), 8.13 (br d, 1H)









Example 424
N-ethylethanaminium 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylate

Diethylamine (0.0058 mL, 0.056 mmol, Aldrich) was added to a suspension of 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-4-{[(2-methoxyethyl)amino]carbonyl}-1,3-thiazole-5-carboxylic acid (0.03 g, 0.056 mmol, Example 387) in methanol (5 mL). After stirring five minutes, methylene chloride was added until solution was homogeneous. The reaction was concentrated and the resulting solid was dried overnight (0.024 g). MS (ES) MH+: 534 for C24H37Cl2N6O6S; NMR: 1.16 (t, 3 H) 1.74 (s, 2 H) 2.19 (s, 3 H) 2.91 (q, 3 H) 3.25 (s, 3 H) 3.32 (s, 4 H) 3.37 (s, 3 H) 3.42 (d, 2 H) 3.53 (s, 1 H) 3.94 (s, 1 H) 4.22 (s, 2 H) 7.17 (d, 1 H).


Example 425

The following compound was synthesized according to the procedure described for Example 424.















Ex
Compound
Data
SM







425
N-ethylethanaminium-2- ((3S,4R)-4-{[(3,4-dichloro-5- methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidin-1-yl)-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 435,437 for C16H17Cl2FN4O3S; NMR: 1.14 (t, 3H), 1.81 (m, 2H), 2.21 (s, 3H), 2.84 (q, 2H), 3.34 (m, 2H), 3.86 (m, 1H), 4.30 (m, 1H), 4.89 (d, 1H), 7.32 (s, 1H), 7.61 (d, 1H)
Example 42









Example 426
Potassium 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylate

An aqueous solution of potassium hydroxide (0.1 M, 4.75 ml, 0.475 mmol) was added to a solution of 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (Example 42, 200 mg, 0.475 mmol) in methanol (35 ml). The mixture was stirred for 1 h and then concentrated under reduced pressure to provide the crude salt (230 mg). The salt was dissolved in acetone/water (50 ml; 48:2) and acetone was added slowly to the stirred mixture until it became cloudy. Stirring was continued and more acetone was added very slowly over 20 min. The mixture was stored at 4° C. overnight. The solid was collected by filtration and air dried for 24 h to provide the salt (160 mg).


MS (ESP): 421 (M+H) for C15H15Cl2FN4O3S.



1H NMR (300 MHz, DMSO-d6) δ: 1.75 (d, 1H); 2.04 (m, 1H); 2.24 (s, 3H); 3.34 (m, 2H); 3.75 (d, 1H); 4.20 (m, 1H); 4.39 (t, 1H); 4.83 (d, 1H); 7.17 (s, 1H); 8.18 (s, 1H); 14.12 (s, 1H).


Example 427
1,3-Dihydroxy-2-(hydroxymethyl)propan-2-aminium 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylate

Tromethamine (43 mg, 0.36 mmol), 2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidin-1-yl)-1,3-thiazole-5-carboxylic acid (Example 42, 150 mg, 0.36 mmol), methanol (50 ml) and water (5 ml) were combined and stirred at 60° C. until the mixture was a homogeneous solution (30 min). The mixture was cooled to room temperature and concentrated under reduced pressure. The crude salt (80 mg) was dissolved in ethyl acetate/methanol (8 ml; 50:50) and ethyl acetate was added slowly to the stirred solution until it became cloudy. Stirring was continued and additional ethyl acetate (˜15 ml) was added slowly to the mixture. The mixture was stored at 4° C. overnight. The solid was collected by filtration and air dried for 24 h to provide the salt (64 mg).


MS (ESP): 421 (M+H) for C15H15Cl2FN4O3S.



1H NMR (300 MHz, Methanol-d4) δ: 2.00 (m, 2H); 2.25 (s, 3H); 3.33 (m, 2H); 3.30-3.55 (m, 2H); 3.67 (s, 6H); 4.10 (d, 1H); 4.35 (m, 2H); 4.90 (d, 1H); 7.57 (s, 1H).


Example 428

The following Example was prepared by the procedure described in Example 1 from the starting materials (SM) indicated in the table below.















Ex
Compound
Data
SM







428
methyl 2-((3S,4R)-4-{[(4-chloro-
MS (ESP): 419 (MH+) for
Intermediate 261



3-fluoro-5-methyl-1H-pyrrol-2-
C16H17ClF2N4O3S



yl)carbonyl]amino}-3-

1H-NMR (CDCl3) δ:




fluoropiperidin-1-yl)-1,3-
1.96 (m, 2H); 2.25 (s, 3H);



thiazole-5-carboxylate
3.37 (m 2H); 3.84 (s, 3H);




4.17 (m, 1H); 4.38 (m, 1H);




4.56 (m, 1H); 4.87 (d, br, 1H);




6.21 (m, 1H); 7.87 (s, 1H);




9.35 (s, br, 1H);





19F-NMR (CDCl3) δ: −158(s)










Example 429

The following Example was synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.
















Ex
Compound
NMR
m/z
SM







429
2-((3S,4R)-4-{[(4-chloro-3-
1.85 (m, 2H); 2.15 (s, 3H);
405
Example



fluoro-5-methyl-1H-pyrrol-2-
3.31 (m 2H); 4.0 (m, 1H); 4.31 (m,

428



yl)carbonyl]amino}-3-
2H); 4.90 (d, br, 1H); 7.43 (d, 1H);



fluoropiperidin-1-yl)-1,3-
7.75 (s, 1H); 11.95 (s, br, 1H);



thiazole-5-carboxylic acid

19F-NMR (CDCl3) δ: −158(s)ppm










Examples 430-433

The following Examples were prepared by the procedure described in Example 1 from the starting materials (SM) indicated in the table below.















Ex
Compound
Data
SM







430
Ethyl 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol- 2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- ({[(2R)-2- methoxypropyl]amino}carbonyl)- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH: 575 for C23H31Cl2N5O6S; NMR: 1.08 (d, 3H), 1.20 (t, 3H), 1.68-1.76 (m, 2H), 2.17 (s, 3H), 3.14-3.19 (m, 1H), 3.25 (s, 3H), 3.35 (s, 3H), 3.54 (brs, 1H), 3.90-4.05 (m, 2H), 4.15 (q, 2H), 4.20-4.30 (m, 2H), 7.15 (d, 1H), 8.32 (d, 1H), 12.16 (s, 1H)
Example 191 and Intermediate 1725-162





431
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH: 575 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C23H31Cl2N5O6S;
(2S)-2-



2-yl)carbonyl]amino}-3-
NMR: 1.09 (d, 3H), 1.21 (t,
methoxypropan-1-



methoxypiperidin-1-yl)-4-
3H), 1.68-1.76 (m, 2H), 2.18
amine hydrochloride



({[(2S)-2-
(s, 3H), 3.15-3.21 (m, 1H),
(1725-163)



methoxypropyl]amino}carbonyl)-
3.26 (s, 3H), 3.36 (s, 3H),




1,3-thiazole-5-carboxylate
3.54 (brs, 1H), 3.95-4.05 (m,





2H), 4.16 (q, 2H), 4.20-4.30





(m, 2H), 7.15 (d, 1H), 8.32





(d, 1H), 12.16 (s, 1H)



432
Ethyl 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 576 for
Example 191 and



dichloro-5-methyl-1H-pyrrol-
C23H31Cl2N5O6S;
(2R)-1-



2-yl)carbonyl]amino}-3-
NMR: 1.08 (d, 3H), 1.21 (t,
methoxypropan-2-



methoxypiperidin-1-yl)-4-
3H), 1.68-1.76 (m, 2H), 2.17
amine hydrochloride



({[(1R)-2-methoxy-1-
(s, 3H), 3.14-3.20 (m, 1H),
(1725-177)



methylethyl]amino}carbonyl)-
3.25 (s, 3H), 3.35 (s, 3H),




1,3-thiazole-5-carboxylate
3.54 (brs, 1H), 3.95-4.05 (m,





2H), 4.16 (q, 2H), 4.20-4.30





(m, 2H), 7.14 (d, 1H), 8.30





(d, 1H), 12.15 (s, 1H)



433
Cis(±)-methyl 2-(3-azido-4-
1.8 (m, 2H), 2.19 (s, 3H),
Intermediate 272 and



{[(3,4-dichloro-5-methyl-1H-
3.35 (m, 1H), 3.6 (d, 1H),
methyl 2-bromo-1,3-



pyrrol-2-
3.75 (s, 3H), 3.95 (d, 1H),
thiazole-5-



yl)carbonyl]amino}piperidin-
4.24 (m, 3H), 7.23 (d, 1H),
carboxylate



1-yl)-1,3-thiazole-5-
7.86 (s, 1H), 12.1 (s, 1H).




carboxylate









Examples 434-437

The following Examples were synthesized by an analogous method to Example 35 from the starting materials (SM) given in the table below.
















Ex
Compound
NMR
m/z
SM



















434
2-((3S,4R)-4-{[(3,4-Dichloro-
1.07 (d, 3H), 1.70-1.76 (m, 2H),
546
Example



5-methyl-1H-pyrrol-2-
2.17 (s, 3H), 3.25 (s, 3H), 3.36 (s,

430



yl)carbonyl]amino}-3-
3H), 3.37-3.50 (m, 2H), 3.55 (brs,





methoxypiperidin-1-yl)-4-
1H), 4.20-4.30 (m, 2H), 4.45 (brs,





({[(2R)-2-
1H), 7.16 (d, 1H), 8.98 (d, 1H),





methoxypropyl]amino}carbonyl)-
12.13 (s, 1H), 16.30 (s, 1H)





1,3-thiazole-5-carboxylic






acid








435
2-((3S,4R)-4-{[(3,4-Dichloro- 5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- ({[(2S)-2- methoxypropyl]amino}carbonyl)- 1,3-thiazole-5-carboxylic acid embedded image
1.16 (d, 3H), 1.70-1.76 (m, 2H), 2.18 (s, 3H), 3.23 (s, 3H), 3.37 (s, 3H), 3.44-3.50 (m, 2H), 3.55 (brs, 1H), 4.20-4.30 (m, 2H), 4.45 (brs, 1H), 7.16 (d, 1H), 8.98 (d, 1H), 12.14 (s, 1H), 16.31 (s, 1H)
546
Example 431





436
2-((3S,4R)-4-{[(3,4-Dichloro-
1.16 (d, 3H), 1.70-1.76 (m, 2H),
547
Example



5-methyl-1H-pyrrol-2-
2.17 (s, 3H), 3.26 (s, 3H), 3.38 (s,

432



yl)carbonyl]amino}-3-
3H), 3.46-3.52 (m, 2H), 3.55 (brs,





methoxypiperidin-1-yl)-4-
1H), 4.20-4.30 (m, 2H), 4.45 (brs,





({[(1R)-2-methoxy-1-
1H), 7.16 (d, 1H), 8.96 (d, 1H),





methylethyl]amino}carbonyl)-
12.14 (s, 1H), 16.31 (s, 1H)





1,3-thiazole-5-carboxylic acid





437
Cis(±)-2-(3-azido-4-{[(3,4-
.8 (m, 2H), 2.2 (s, 3H), 3.3 (m,
444
Example



dichloro-5-methyl-1H-pyrrol-2-
1H), 3.6 (d, 1H), 3.9 (d, 1H), 4.24

433



yl)carbonyl]amino}piperidin-1-
(m, 3H), 7.23 (d, 1H), 7.7 (s, 1H),





yl)-1,3-thiazole-5-carboxylic
12.1 (s, 1H), 12.7 (S, 1H)





acid









Examples 438-440

The following Examples were prepared by the procedure described in Example 417 from the starting materials (SM) indicated















Ex
Compound
Data
SM


















438
sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 547 for
Example 434



dichloro-5-methyl-1H-pyrrol-2-
C21H26Cl2N5O6S; NMR: 1.07 (d,




yl)carbonyl]amino}-3-
3H), 1.60-1.75 (m, 2H), 2.14 (s,




methoxypiperidin-1-yl)-4-
3H), 3.10-3.19 (m, 3H), 3.24 (s,




({[(2R)-2-
3H), 3.34 (s, 3H), 3.47 (brs, 1H),




methoxypropyl]amino}carbonyl)-
3.81-3.85 (m, 1H), 3.90-4.00 (m,




1,3-thiazole-5-carboxylate
1H), 4.05-4.20 (m, 2H), 7.17 (d,





1H), 12.16 (brs, 1H), 13.22 (d,





1H)



439
Sodium 2-((3S,4R)-4-{[(3,4-
MS (ES) MH+: 547 for
Example 435



dichloro-5-methyl-1H-pyrrol-2-
C21H26Cl2N5O6S; NMR: 1.07 (d,




yl)carbonyl]amino}-3-
3H), 1.60-1.75 (m, 2H), 2.17 (s,




methoxypiperidin-1-yl)-4-
3H), 3.10-3.22(m, 3H), 3.24 (s,




({[(2S)-2-
3H), 3.35 (s, 3H), 3.49 (brs, 1H),




methoxypropyl]amino}carbonyl)-
3.81-3.85 (m, 1H), 3.90-4.00 (m,




1,3-thiazole-5-carboxylate
1H), 4.05-4.20 (m, 2H), 7.15 (d,





1H), 12.15 (brs, 1H), 13.22 (d,





1H)






440
Sodium 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4- ({[(1R)-2-methoxy-1- methylethyl]amino}carbonyl)- 1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 547 for C21H26Cl2N5O6S; NMR: 1.07 (d, 3H), 1.65-1.73 (m, 2H), 2.17 (s, 3H), 3.10-3.22 (m, 3H), 3.24 (s, 3H), 3.35 (s, 3H), 3.49 (brs, 1H), 3.81-3.85 (m, 1H), 3.90-4.00 (m, 1H), 4.05-4.20 (m, 2H), 7.17 (d, 1H), 12.18 (brs, 1H), 13.19 (d, 1H)
Example 436









Preparation of Starting Materials
Intermediate 83-278
Intermediate 83
Cis(±)-ethyl (4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-methylpiperidine-1-carboxylate

A solution of 167 mg (0.9 mmol) of Cis(±)-ethyl (4-amino-3-methylpiperidine-1-carboxylate (Intermediate 152), 235 μl (1.25 mmol) diisopropylethylamine and 280 mg (1.35) of 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride (Intermediate 202) was stirred at room temperature for 1 h. The mixture was diluted with EtOAc and washed with aqueous Na2CO3 and brine. Drying MgSO4 and removal of solvent gave an oil that was purified by chromatography (100% CH2Cl2 followed by gradient elution to 100% EtOAc) to afford 145 mg of product. MS (ES)(MH+): 362 for C15H21Cl2N3O3; NMR (d6-DMSO): 0.8 (d, 3H), 1.2 (t, 3H), 1.65 (m, 2H), 1.9 (m, 1H), 2.2 (s, 3H), 3.5 (m, 1H), 4.0 (m, 2H), 4.1 (m, 1H), 7.1 (d, 1H), 12.0 (s, 1H).


Intermediates 84-114

The following Intermediates were synthesized by an analogous method to Intermediate 37 or Intermediate 83 from the starting materials (SW) given in the table below.















Int
Compound
Data
SM







84
Cis(±)-tert-butyl 4-{[(3,4-
N/A
Intermediate 72



dichloro-5-methyl-1H-pyrrol-2-





yl)carbonyl]amino}-3-





[(methylthio)methyl]piperidine-





1-carboxylate







85
Cis(±)-tert-butyl-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- (methylthio)piperidine-1- carboxylate embedded image
MS (ESP): 420.1 (M −+0H) for C17H25Cl2N3O3S; NMR: 1.40 (s, 9H); 1.45-1.70 (m, 2H); 2.10 (s, 3H); 2.18 (s, 3H); 2.80-3.20 (m, 2H); 3.31 (m, 1H); 3.90 (m, 2H); 4.30 (m, 1H); 7.15 (d, 1H); 12.13 (s, 1H)
Intermediate 184 and Intermediate 1





86
Cis(±)-ethyl 3-(benzyloxy)-4-
MS (ESP): 454 (M ++0H) for
Intermediate 158



{[(3,4-dichloro-5-methyl-1H-
C21H25Cl2N3O4; NMR: 1.20
and Intermediate 1



pyrrol-2-
(q, 3H); 1.70 (m, 2H); 2.15 (s,




yl)carbonyl]amino}piperidine-1-
3H); 3.05 (m, 2H); 3.68 (s,




carboxylate
1H); 4.00 (m, 3H); 4.15 (m,





1H); 4.40 (m, 2H); 4.70 (d,





1H); 7.08 (d, 1H); 7.30 (m,





5H); 12.06 (s, 1H).



87
Cis(±)-ethyl 4-{[(3,4-dichloro-5-
MS (ESP): 424 (M + Na) for
Intermediate 256



methyl-1H-pyrrol-2-
C17H21Cl2N3O4; 1H NMR
and Intermediate 1



yl)carbonyl]amino}-3-(prop-2-
(300 MHz, CDCl3) δ: 1.27 (t,




yn-1-yloxy)piperidine-1-
3H); 1.79 (m, 2H); 2.27 (s,




carboxylate
3H); 2.40 (t, 1H); 2.90 (m,





2H); 3.85 (m, 1H); 4.10-4.55





(m, 7H); 7.25 (m, 1H); 9.53





(s, 1H).



88
Trans-(±)tert-butyl 4-{[(3,4-
MS (ES) MH+: 392 for
Intermediate 185



dichloro-5-methyl-1H-pyrrol-
C16H23Cl2N3O4; NMR: 1.45
and Intermediate 1



2yl)carbonyl]amino}3-
(s, 9H), 1.54 (m, 1H), 2.02




hydroxypiperidine-1-
(m, 1H), 2.27 (s, 3H), 2.67




carboxylate
(dd, 1H), 2.84 (brt, 1H), 3.34





(m, 1H), 3.50 (m, 1H), 3.90





(m, 1H), 4.11 (m, 1H), 4.27





(m, 1H), 6.75 (brd, 1H),





10.06 (br s, 1H)



89
tert-butyl (3S,4R)-4-{[(3-chloro-
MS (ES) MH+: 360 for
Intermediate 196



5-methyl-1H-pyrrol-2-
C16H23ClFN3O3
and Intermediate 64



yl)carbonyl]amino}-





3-fluoropiperidine-1-carboxylate







90
tert-butyl (3S,4R)-4-{[(4-bromo- 5-methyl-1H-pyrrol-2-yl) carbonyl]amino}-3- fluoropiperidine-1-carboxylate embedded image
MS (ESN): 404 (M − 1) for C16H23BrN3O3 NMR (CDCl3) δ: 1.47 (t, 9H); 1.80 (m, 2H); 2.26 (s, 3H); 2.81 (s, 3H); 2.96 (m, 1H); 4.27 (m, 1H); 4.65 (d, br, 1H); 6.11 (d, 1H); 6.59 (s, 1H); 9.97 (s, br, 1H)
Intermediate 197 and Intermediate 64





91
tert-butyl (3S,4R)-4-{[(4-bromo-
MS (ES) MH+: 440 for
Intermediate 198



3-chloro-5-methyl-1H-pyrrol-2-
C16H22BrClFN3O3
and Intermediate 64



yl)carbonyl]amino}-3-
NMR (CDCl3) δ: 1.47 (s,




fluoropiperidine-1-carboxylate
9H); 1.85 (m, 2H); 2.29 (s,





3H); 2.85 (m, 2H); 4.24 (m,





2H); 4.50 (m, 1H); 4.72 (d,





br, 1H); 6.96 (d, 1H); 9.30 (s,





br, 1H)



92
Cis(±)-Ethyl (4-{[(3,4-dichloro-
MS (ES) MH: 420 for
Intermediate 159



5-methyl-1H-pyrrol-2-
C17H25Cl2N4O5
and Intermediate 1



yl)carbonyl]amino}-3-(2-





methoxyethoxy)piperidine-1-





carboxylate




93
Cis(±)-Ethyl 4-{[(3,4-dichloro-
MS (ES) MH+: 436 for
Intermediate 160



5-methyl-1H-pyrrol-2-
C18H27Cl2N3O5
and Intermediate 1



yl)carbonyl]amino}-3-(2-





methoxypropoxy)piperidine-1-





carboxylate




94
Cis(±)-Ethyl 4-{[(3,4-dichloro-
MS (ES) MH+: 422 for
Intermediate 161



5-methyl-1H-pyrrol-2-
C17H25Cl2N3O5
and Intermediate 1



yl)carbonyl]amino}-3-(2-





hydroxypropoxy)piperidine-1-





carboxylate







95
tert-Butyl (3S,4R)-4-{[(4- chloro-1H-pyrrol-2- yl)carbonyl]amino}-3- fluoropiperidine-1-carboxylate embedded image
C15H21ClFN3O3 NMR: 1.39 (s, 9H), 1.50-1.60 (m, 1H), 1.69-1.80 (m, 1H), 2.73-3.11 (m, 2H), 3.95-4.23 (m, 3H), 4.71 (d, 1H), 6.94- 6.96 (m, 2H), 8.03 (d, 1H), 11.78 (s, 1H)
2,2,2-trichloro-1- (4-chloro-1H- pyrrol-2- yl)ethanone (Tett lett. 27, 2505-2508, 1979) and Intermediate 64





96
tert-Butyl (3S, 4R)-4- {[(4,5-
C15H21ClFN3O3
Intermediate 203



dichloro-1H-pyrrol-2-
NMR: 1.39 (s, 9H), 1.50-1.60
and Intermediate 64



yl)carbonyl]amino}-3-
(m, 1H), 1.69-1.80 (m, 1H),




fluoropiperidine-1-carboxylate
2.73-3.11 (m, 2H), 3.95-4.23





(m, 3H), 4.71 (d, 1H), 6.94-





6.96 (m, 2H), 8.03 (d, 1H),





11.78 (s, 1H)



97
Ethyl (3S,4R)-4-{[(4-chloro-5-
MS (ES) MH+: for
Intermediate 6



methyl-1H-pyrrol-2-
C15H22ClN3O4; NMR: 1.18 (t,
and Intermediate 25



yl)carbonyl]amino}-3-
J = 7.06 Hz, 3H), 1.48 (d,




methoxypiperidine-1-
J = 3.58 Hz, 1H), 1.75 (td,




carboxylate
J = 12.29, 7.82 Hz, 1H), 2.10-





2.18 (m, 3H), 2.95 (d,





J = 13.38 Hz, 2H), 3.20-3.27





(m, 3H), 3.27-3.35 (m, 2H),





3.38 (s, 1H), 3.97-4.09 (m,





J = 10.53, 7.08, 7.08, 3.39 Hz,





2H), 4.19 (s, 1H), 6.88 (d,





J = 2.64 Hz, 1H), 7.62 (d,





J = 7.91 Hz, 1H), 11.60 (s, 1H)



98
Cis(±)-ethyl-4-{[(4-chloro-3,5-
MS (ES) MH+: 358 for
Intermediate 195



dimethyl-1H-pyrrol-2-
C16H24ClN3O4.
and Intermediate 26



yl)carbonyl]amino}-3-





methoxypiperidine-1-





carboxylate




99
tert-butyl (Cis(±)-3-chloro-4-
1.40 (s, 9H), 1.67 (m, 2H),
Intermediate 1 and



{[(3,4-dichloro-5-methyl-1H-
2.19 (s, 3H), 2.68 (m, 1H),
Intermediate 162



pyrrol-2-
3.43 (m, 1H), 4.02 (m, 1H),




yl)carbonyl]amino}piperidine-1-
4.17 (m, 1H), 4.36 (m, 1H),




carboxylate
4.58 (s, 1H), 7.05 (d, 1H),





12.12 (s, 1H)






100
tert-butyl (3S,4R)-4-[({4-chloro- 3-[(E)-(methoxyimino)methyl]- 5-methyl-1H-pyrrol-2- yl}carbonyl)amino]-3- fluoropiperidine-1-carboxylate embedded image
MS (ES) MH+: 415 for C18H26ClFN4O4; NMR: 1.40 (s, 9H), 1.70 (m, 2H), 2.34 (s, 3H), 3.29 (m, 1H), 3.31 (s, 3H), 3.35 (m, 1H), 3.99 (m, 1H), 4.24 (m, 2H), 4.78 (d, 1H), 7.19 (d, 1H), 8.02 (s, 1H), 12.11 (s, 1H)
Intermediate 199 and Intermediate 64





101
tert-butyl Cis(±)-3-chloro-4-
1.40 (s, 9H), 1.54 (m, 1H),
162 and



{[(4-chloro-5-methyl-1H-pyrrol-
1.83 (m, 1H), 2.14 (s, 3H),
Intermediate 6



2-yl)carbonyl]amino}piperidine-
3.28 (m, 1H), 3.41 (m, 1H),




1-carboxylate
4.02-4.22 (m, 3H), 4.56 (s,





1H), 6.89 (s, 1H), 7.80 (d,





1H), 11.63 (s, 1H)



102a
Cis(±)-ethyl (4-{[(3,4-dichloro-
MS (ES) (MH+): 362 for
Intermediate 202



5-methyl-1H-pyrrol-2-
C15H21Cl2N3O3; NMR (d6-
and Intermediate 164



yl)carbonyl]amino}-2-
DMSO): 0.8 (d, 3H), 1.2 (t,




methylpiperidine-1-carboxylate
3H), 1.65 (m, 2H), 1.9 (m,





1H), 2.2 (s, 3H), 3.5 (m, 1H),





4.0 (m, 2H), 4.1 (m, 1H), 7.1





(d, 1H), 12.0 (s, 1H)



102b
Cis(±)-ethyl (4-{[(4-chloro-3-
MS (ES) (MH+): 369 for
Intermediate 200



cyano-5-methyl-1H-pyrrol-2-
C16H21ClN4O4; NMR (d6-
and Intermediate 21



yl)carbonyl]amino}-3-
DMSO): 1.2 (t, 3H), 2.2 (s,




methoxypiperidine-1-
3H), 2.8-3.1 (m, 2H), 3.3 (s,




carboxylate
3H), 3.4 (m, 1H), 3.8-4.3 (m





5H), 7.7 (d, 1H), 12.7 (s, 1H)



103
tert-butyl (3S,4R)-4-{[(4-chloro-
MS (ES) (MH+): 383 for
Intermediate 200



3-cyano-5-methyl-1H-pyrrol-2-
C17H22ClFN4O3; NMR (d6-
and Intermediate 59



yl)carbonyl]amino}-3-
DMSO): 1.4 (s, 9H), 1.7 (m,




fluoropiperidine-1-carboxylate
2H), 2.2 (s, 3H), 3.8-4.2 (m,





4H), 4.8 (d, 1H), 8.0 (d, 1H),





12.5 (s, 1H)



104
tert-butyl (3S,4R)-4-{[(3,5-
MS (ES) (MH+): 394 for
Intermediate 201



dichloro-4-methyl-1H-pyrrol-2-
C16H22Cl2FN3O3; NMR (d6-
and Intermediate 59



yl)carbonyl]amino}-3-
DMSO): 1.4 (s, 9H), 1.6-1.8




fluoropiperidine-1-carboxylate
(m, 2H), 1.9 (s, 3H), 2.9 (m,





2H), 4.0-4.3 (m, 3H), 4.8 (d,





1H), 7.3 (d, 1H), 12.5 (s, 1H)






105
Cis(±)-Ethyl3- (cyclopropylmethoxy)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}piperidine-1- carboxylate embedded image
MS (ESI) M: 418 for C18H25Cl2N3O4; NMR: 0.22 (m, 2H), 0.50 (m, 2H), 1.04 (m, 1H), 1.24 (t, 3H), 1.69 (m, 2H), 2.24 (s, 3H), 2.87- 3.09 (m, 2H), 3.28 (m, 1H), 3.59 (bs, 1H), 3.92-4.36 (m, 5H), 7.20 (m, 1H), 12.21 (bs, 1H)
Interemdiate 165 and Intermediate 1





106
Cis(±)-ethyl 4-{[(3,4-dichloro-5-
MS (ESI) M: 461 for
Intermediate 166



methyl-1H-pyrrol-2-
C18H22Cl2N4O4S; NMR
and Intermediate 1



yl)carbonyl]amino}-3-(1,3-
(DMSO): 1.10 (m, 3H), 1.65




thiazol-2-ylmethoxy)piperidine-
(m, 2H), 2.16 (s, 3H), 2.82-




1-carboxylate
3.10 (m, 2H), 3.79 (bs, 1H),





3.97 (m, 3H), 4.21 (dt, 1H),





4.35 (t, 1H), 4.78 (d, 1H),





4.95 (d, 1H), 7.10 (d, 1H),





7.72 (dd, 2H), 12.12 (bs, 1H)



107
Cis(±)-Ethyl (rel 3S,4R)-4-
MS (ES) MH+: 392, 394 for
Intermediate 257



{[(3,4-dichloro-5-methyl-1H-
C16H23Cl2N3O4; NMR: 1.04-
and Intermediate 1



pyrrol-2-yl)carbonyl]amino}-3-
1.21 (m, 6H); 1.60 (m, 2H);




ethoxypiperidine-1-carboxylate
2.17 (s, 3H); 2.95 (m, 2H);





3.48 (br s, 1H); 3.65 (m, 1H);





3.92 (br s, 1H); 3.98-4.05 (m,





2H); 4.09-4.25 (m, 2H); 7.09





(d, 1H) 12.14 (s, 1H)



108
1-tert-butyl 3-methyl 4-{[(3,4-
MS (ES) MH+: 434, 436 for
Intermediate 167



dichloro-5-methyl-1H-pyrrol-2-
C18H25Cl2N3O5; NMR
and Intermediate 1



yl)carbonyl]amino}piperidine-
(CDCl3): 1.45 (s, 9H), 1.60




1,3-dicarboxylate
(m, 1H), 2.16 (m, 1H), 2.27





(s, 3H), 2.45 (dt, 1H), 2.93





(m, 1H), 3.10 (m, 1H), 3.66





(s, 3H), 4.05 (m, 1H), 4.29





(m, 2H), 6.68 (d, 1H), 9.66 (s,





1H)



109
1-(tert-butoxycarbonyl)-4-
MS (ES) MH+: 420, 422 for
Intermediate 108



{[(3,4-dichloro-5-methyl-1H-
C17H23Cl2N3O5.
and Intermediate 1



pyrrol-2-





yl)carbonyl]amino}piperidine-3 -





carboxylic acid







110
Cis(±)tert-butyl 4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- (morpholin-4- ylcarbonyl)piperidine-1- carboxylate embedded image
MS (ES) MH+: 489, 491 for C21H30Cl2N4O5; NMR: 1.40 (s, 9H), 1.54 (m, 1H), 1.82 (m, 1H), 2.15 (s, 3H), 2.81 (broad s, 2H), 3.14 (dt, 1H), 3.24-3.40 (m, 2H [under H2O peak]), 3.41-3.68 (m, 6H), 3.93 (m, 2H), 4.24 (m, 1H), 7.14 (d, 1H), 11.98 (s, 1H)
Intermediate 109 and Intermediate 1





111
Trans(±)tert-butyl 4-{[(3,4-
MS (ES) MH+: 489, 491 for
Intermediate 109



dichloro-5-methyl-1H-pyrrol-2-
C21H30Cl2N4O5; NMR: 1.37
and Intermediate 1



yl)carbonyl]amino}-3-
(s, 9H), 1.64 (m, 1H), 2.11




(morpholin-4-
(m, 1H), 2.16 (s, 3H), 3.14




ylcarbonyl)piperidine-1-
(m, 1H), 3.18-3.68 (m, 11H




carboxylate
[under H2O peak]), 3.73 (dd,





1H), 4.37 (m, 1H), 7.24 (d,





1H), 12.08 (s, 1H)



112
Cis(±)ethyl 3-(2-tert-butoxy-2-
MS (ES) MH+: 478, 480 for
Intermediate 240



oxoethoxy)-4-{[(3,4-dichloro-5-
C20H29Cl2N3O6; NMR: 1.17
and Intermediate 1



methyl-1H-pyrrol-2-
(t, 3H), 1.41 (s, 9H), 1.90 (m,




yl)carbonyl]amino}piperidine-1-
1H), 2.16 (s, 3H), 2.78-3.06




carboxylate
(m, 3H), 3.46 (m, 1H), 3.74





(m, 1H), 3.94 (m, 1H), 4.03





(q, 2H), 4.09 (s, 2H), 4.12 (m,





1H), 7.39 (d, 1H), 11.97 (s,





1H)



113
Trans(±)ethyl 3-(2-tert-butoxy-
NMR: 1.17 (t, 3H), 1.38 (s,
Intermediate 240



2-oxoethoxy)-4-{[(3,4-dichloro-
9H), 1.58 (m, 1H), 1.68 (m,
and Intermediate 1



5-methyl-1H-pyrrol-2-
1H), 2.17 (s, 3H), 2.81-3.02




yl)carbonyl]amino}piperidine-1-
(m, 2H), 3.66 (m, 1H), 3.86-




carboxylate
4.27 (m, 7H), 7.40 (d, 1H),





12.07 (s, 1H)



114
Ethyl 3-{[tert-
MS (ES)MH+: 478, 480 for
Intermediate 112



butyl(dimethyl)silyl]oxy}-4-
C20H33Cl2N3O4Si; NMR: -
and Intermediate 1



{[(3,4-dichloro-5-methyl-1H-
0.07 (s, 3H), 0.07 (s, 3H),




pyrrol-2-
0.83 (s, 9H), 1.16 (t, 3H),




yl)carbonyl]amino}piperidine-1-
1.56 (m, 1H), 1.72 (m, 1H),




carboxylate
2.17 (s, 3H), 3.04 (m, 2H),





3.85-4.11 (m, 6H), 6.66 (m,





1H), 12.12 (s, 1H)









Intermediates 115-144

The following Intermediates were synthesized by an analogous method to Intermediate 50 or Intermediate 74 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







115
Cis(±)-3,4-dichloro-N-[3- (hydroxymethyl)piperidin-4- yl]-5-methyl-1H-pyrrole-2- carboxamide hydrochloride embedded image
MS (ES) MH+: 306, 308 for C12H17Cl2N3O2.
Intermediate 71





116
Cis(±)-3,4-dichloro-5-methyl- N-{3- [(methylthio)methyl]piperidin- 4-yl}-1H-pyrrole-2- carboxamide hydrochloride
MS (ES) MH+: 336, 338 for C13H19Cl2N3OS.
Intermediate 84





117
Cis(±)-3,4-dichloro-5-methyl-
MS (ESP): 463.1 (M + H) for
Intermediate



N-[3-(methylthio)piperidin-4-
C17H20Cl2N4O3S2; NMR: 1.90 (m,
85



yl]-1H-pyrrole-2-
2H); 2.14 (s, 3H); 2.28 (s, 3H); 3.28-



carboxamide
3.45 (m, 2H); 3.74 (s, 3H); 3.77 (m,




1H); 3.95 (m, 2H); 4.44 (m, 1H); 7.25




(d, 1H); 7.85 (s, 1H); 12.14 (s, 1H)


118
Cis(±)-N-[3-
MS (ESP): 382 (M + H) for
Intermediate



(benzyloxy)piperidin-4-yl]-
C18H21Cl2N3O2
86



3,4-dichloro-5-methyl-1H-



pyrrole-2-carboxamide


119
Cis(±)-3,4-dichloro-5-methyl-
MS (ESP): 330 (M + H) for
Intermediate



N-[3-(prop-2-yn-1-
C14H17Cl2N3O2
87



yloxy)piperidin-4-yl]-1H-



pyrrole-2-carboxamide





120
Trans(±)3,4-dichloro-N-[3- hydroxypiperidin-4-yl]-5- methyl-1H-pyrrole-2- carboxamide trifluoroacetate embedded image
MS (ES) MH+: 292 for C11H15Cl2N3O2
Intermediate 88





121
3-chloro-N-[(3S,4R)-3-
MS (ES) MH+: 260 for
Intermediate



fluoropiperidin-4-yl]-5-
C11H15ClFN3O; 1.91 (m, 2H); 2.17 (s,
89



methyl-1H-pyrrole-2-
3H); 3.13 (m, 1H); 3.35 (m, 2H); 3.57



carboxamide
(s, 1H); 4.35 (m, 1H); 5.05 (d, br, 1H);




5.96 (s, 1H); 7.26 (d, 1H); 8.67 (br,




1H); 9.16 (br, 1H); 11.70 (s, br, 1H)


122
4-bromo-N-[(3S,4R)-3-
MS (ES) MH+: 306 for C11H15BrN3O
Intermediate



fluoropiperidin-4-yl]-5-

90



methyl-1H-pyrrole-2-



carboxamide


123
4-bromo-3-chloro-N-
MS (ES) MH+: 340 for C11H14BrN3O
Intermediate



[(3S,4R)-3-fluoropiperidin-4-
NMR δ: 1.91 (m, 2H); 2.20 (s, 3H);
91



yl]-5-methyl-1H-pyrrole-2-
3.13 (m, 1H); 3.35 (m, 2H); 3.62 (m,



carboxamide
1H); 4.35 (m, 1H); 5.05 (d, br, 1H);




7.39 (d, 1H); 8.60 (s, br, 1H); 8.99 (s,




br, 1H); 12.17 (s, br, 1H)


124
Cis(±)-3,4-dichloro-N-[(3-(2-
MS (ES) MH+: 350 for C14H21Cl2N3O3
Intermediate



methoxyethoxy)piperidin-4-

92



yl]-5-methyl-1H-pyrrole-2-



carboxamide





125
Cis(±)-3,4-Dichloro-N-[3-(2- methoxypropoxy)piperidin-4- yl]-5-methyl-1H-pyrrole-2- carboxamide embedded image
MS (ES) MH+: 364 for C15H23Cl2N3O3
Intermediate 93





126
Cis(±)-3,4-Dichloro-N-3-(2-
MS (ES): MH+: 350 for
Intermediate



hydroxypropoxy)piperidin-4-
C14H21Cl2N3O3;
94



yl]-5-methyl-1H-pyrrole-2-



carboxamide


127
4-Chloro-N-[(3S,4R)-3-
MS (ES) MH+: 246 for C10H13ClFN3O
Intermediate



fluoropiperidin-4-yl]-1H-

95



pyrrole-2-carboxamide



hydrochloride


128
4,5-dichloro-N-[(3S,4R)-3-
MS (ES) MH+: 280 for
Intermediate



fluoropiperidin-4-yl]-1H-
C10H12Cl2FN3O
96



pyrrole-2-carboxamide



hydrochloride


129
4-chloro-N--[(3S,4R)-(3-
1.41 (s, 1H), 1.67 (s, 1H), 2.13 (s, 3H),
Intermediate



methoxypiperidin-4-yl)]1-5-
2.47 (s, 1H), 2.55 (s, 1H), 2.86 (s, 1H),
97



methyl-1H-pyrrole-2-
3.08 (d, J = 13.19 Hz, 1H), 3.25 (s, 3H),



carboxamide
3.31 (s, 1H), 6.89 (d, J = 2.45 Hz, 1H),




7.52 (s, 1H), 11.59 (s, 1H)





130
Cis(±)-4-chloro-N-[(3S,4R)- 3-methoxypiperidin-4-yl]-3,5- dimethyl-1H-pyrrole-2- carboxamide embedded image
MS (ES) MH+: 287 for C13H20ClN3O2.
Intermediate 98





131
3,4-dichloro-N-[Cis(±)-3-
MS (ES) MH+: 310 for C11H14Cl3N3O
Intermediate



chloropiperidin-4-yl]-5-

99



methyl-1H-pyrrole-2-



carboxamide hydrochloride


132
4-chloro-N-[(3S,4R)-3-
MS (ES) MH+: 317 for
Intermediate



fluoropiperidin-4-yl]-3-[(E)-
C17H18ClFN4O2
100



(methoxyimino)methyl]-5-



methyl-1H-pyrrole-2-



carboxamide hydrochloride


133
Cis(±)-3-chloro-N-[3-
MS (ES) MH+: 276 for C11H15Cl2N3O
Intermediate



chloropiperidin-4-yl]-5-

101



methyl-1H-pyrrole-2-



carboxamide hydrochloride


134
Cis(±)-3,4-dichloro-5-methyl-
MS (ES) (MH+): 290 for
Intermediate



N-[(3-methylpiperidin-4-yl]-
C12H17Cl2N3O.
83



1H-pyrrole-2-carboxamide





135
Cis(±)-3,4-dichloro-5-methyl- N-[2-methylpiperidin-4-yl]- 1H-pyrrole-2-carboxamide embedded image
MS (ES) (MH+): 290 for C12H17Cl2N3O. NMR: 1.0 (d, 3H), 1.2-1.4 (m, 1H), 1.7-1.9 (m, 1H), 2.2 (s, 3H), 2.5-2.7 (m, 2H), 3.0 (m, 1H), 3.3 (m, 1H), 3.7- 3.8 (m, 1H), 7.1 (d, 1H)
Intermediate 101





136
Cis(±)-4-chloro-3-cyano-N-
MS (ES) (MH+): 297 for
Intermediate



[(3-methoxypiperidin-4-yl]-5-
C12H17Cl2N3O2.
102



methyl-1H-pyrrole-2-
NMR: 1.6-1.9 (m, 2H), 2.2 (s, 3H), 2.8



carboxamide
(m, 2H), 3.0 (m, 1H), 3.3 (s, 3H), 3.5




(s, 1H), 4.15 (m, 1H), 7.7 (d, 1H), 8.7




(s, broad, 1H)


137
4-chloro-3-cyano-N-[(3S,4R)-
MS (ES) (MH+): 285 for
Intermediate



3-fluoropiperidin-4-yl]-5-
C11H14Cl2FN3O.
103



methyl-1H-pyrrole-2-
NMR: 1.6 (m, 2H), 2.2 (s, 3H), 2.3 (m,



carboxamide
1H), 2.3 (m, 1H), 2.5-3.0 (m, 2H), 3.1-




3.3 (m, 1H), 3.5 (s, 1H), 4.0-4.2 (dd,




1H), 4.7 (d, 1H), 7.9 (d, 2H)


138
(3S,4R)-4-{[(3,5-dichloro-4-
MS (ES) (MH+): 294 for
Intermediate



methyl-1H-pyrrol-2-
C11H14Cl2FN3O.
104



yl)carbonyl]amino}-3-
NMR: 1.9 (s, 3H), 3.0-3.7 (m, 4H), 4.3



fluoropiperidinium chloride
(m, 1H), 5.0 (d, 1H), 7.65 (d, 1H), 8.7




(s, broad, 1H), 9.4 (s, broad, 1H), 12.7




(s, 1H)


139
Cis(±)-3,4-dichloro-N-[3-
MS (ES) MH+: 347 for
Intermediate



(cyclopropylmethoxy)piperidin-
C15H21Cl2N3O2; NMR: 0.17 (m, 2H),
105



4-yl]-5-methyl-1H-pyrrole-
0.44 (m, 2H), 1.01 (m, 1H), 1.34 (s,



2-carboxamide
1H), 1.62 (m, 2H), 2.17 (s, 3H), 2.55-




2.70 (m, 2H), 2.89 (m, 2H), 3.10-3.23




(m, 2H), 3.38-3.49 (m, 1H), 4.09 (m,




1H), 7.12 (d, 1H), 12.10 (bs, 1H).





140
Cis(±)-3,4-dichloro-5-methyl- N-[3-(1,3-thiazol-2- ylmethoxy)piperidin-4-yl]- 1H-pyrrole-2-carboxamide embedded image
MS (ESI) M: 389 for C15H18Cl2N4O2S
Intermediate 106





141
Cis(±)-3,4-Dichloro-N-[(rel
MS (ES): MH+: 320 for
Intermediate



3S,4R)-3-ethoxypiperidin-4-
C13H19Cl2N3O2; NMR: 1.14 (t, 3H);
107



yl]-5-methyl-1H-pyrrole-2-
1.60 (br s, 2H); 2.17 (s, 3H); 2.62 (m,



carboxamide
2H); 2.89 (m, 2H); 3.14 (m, 2H); 3.64




(m, 2H); 4.05 (m, 2H); 7.10 (d, 1H)


142
Trans(±)3,4-dichloro-5-
MS (ES) MH+: 389, 391 for
Intermediate



methyl-N-[3-(morpholin-4-
C16H22Cl2N4O3
111



ylcarbonyl)piperidin-4-yl]-



1H-pyrrole-2-carboxamide



hydrochloride


143
Cis(±)3,4-dichloro-5-methyl-
MS (ES) MH+: 389, 391 for
Intermediate



N-[3-(morpholin-4-
C16H22Cl2N4O3
110



ylcarbonyl)piperidin-4-yl]-



1H-pyrrole-2-carboxamide



hydrochloride


144
Cis(±)[(4-{[(3,4-dichloro-5-
MS (ES)[(M + H)+]: 350, 352 for
Intermediate



methyl-1H-pyrrol-2-
C13H17Cl2N3O4
112



yl)carbonyl]amino}piperidin-



3-yl)oxy]acetic acid









Intermediates 145-157

The following Intermediates were synthesized by an analogous method to Intermediate 59 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







145
Cis(±)-ethyl 3-(benzyloxy)-4- [(tert- butoxycarbonyl)amino]piper- idine-1-carboxylate embedded image
MS (ES): 401 (M + Na) for C20H30N2O5; NMR (CDCl3) δ: 1.25 (m, 3H); 1.43 (s, 9H); 1.65- 1.85 (m, 2H); 2.81 (m, 2H); 3.58 (s, 1H); 3.71 (m, 1H); 4.05-4.30 (m, 3H); 4.30 (m, 2H); 4.76 (t, 1H); 4.94 (m, 1H); 7.26-7.38 (m, 5H)
cis(±)ethyl 4- [(tert- butoxycarbonyl)- amino]-3- hydroxypiperidine- 1-carboxylate (WO9412494) and Benzyl bromide





146
Cis(±)-ethyl 4-[(tert-
NMR: (CDCl3) 1.26 (t, 3H); 1.45
cis(±)ethyl 4-



butoxycarbonyl)amino]-3-
(s, 9H); 1.67 (m, 2H); 2.43 (t,
[(tert-



(prop-2-yn-1-
1H); 2.79 (m, 2H); 3.74 (m, 2H);
butoxycarbonyl)



yloxy)piperidine-1-
4.00-4.45 (m, 6H); 5.00 (s, 1H)
amino]-3-



carboxylate

hydroxypiperidine-





1-carboxylate





(WO9412494)





and Propargyl





bromide


147
Cis(±)-Ethyl (4-
MS (ES) MH+: 337 for
Intermediate 169



benzylamino)-3-(2-
C18H28N2O4



methoxyethoxy)piperidine-1-



carboxylate


148
Cis(±)-Ethyl 4-[(tert-
MS (ES) M + Na: 383 for
Intermediate 149



butoxycarbonyl)amino]-3-(2-
C17H32N2O6
and methyl iodide



methoxypropoxy)piperidine-



1-carboxylate


149
Cis(±)-Ethyl 4-[(tert-
MS (ES) M + Na: 369 for
Intermediate 150



butoxycarbonyl)amino]-3-(2-
C16H30N2O6
(J. Org. Chem, 60,



hydroxypropoxy)piperidine-

4922-4924, 1995)



1-carboxylate





150
Cis(±)-Ethyl 4-[(tert- butoxycarbony)amino]-3- (oxiran-2- ylmethoxy)piperidine-1- carboxylate embedded image
MS (ES) M + Na: 367 for C16H28N2O6
Intermediate 27 and m-CPBA





151
tert-butyl (Cis(±)-4-
1.39 (s, 9H), 1.54 (m, 2H), 1.93
Intermediate 170



(benzylamino)-3-
(m, 1H), 2.80 (m, 2H), 3.20 (m,



chloropiperidine-1-
1H), 3.75 (q, 2H), 4.06 (m, 1H),



carboxylate
4.57 (s, 1H), 7.22-7.36 (m, 5H).


152
Cis(±)-ethyl 4-
NMR (CDCl3): 0.9 (d, 3H),1.2
ethyl 3-methyl-4-



(benzylamino)-3-
(t, 3H), 1.6 (m, 2H), 2.0 (m, 1H),
oxopiperidine-1-



methylpiperidine-1-
2.8 (m, 1H), 2.9-3.2 (m, 2H), 3.7
carboxylate



carboxylate
(m, 1H), 3.8 (s, 2H), 4.1 (m, 2H),
(Ebnoether, A.;




7.2-7.4 (m, 5H).
Niklaus, P.;





Suess, R.





Helvetica





Chimica Acta





(1969), 52(3),





629-38)


153
Cis(±)-ethyl (4-
MS (ES) (MH+): 277 for
Intermediate 164



(benzylamino)-2-
C16H24N2O2:



methylpiperidine-1-
NMR (d6-DMSO): 1.25 (t, 3H),



carboxylate
1.3 (d, 3H), 1.3-1.5 (m, 2H), 1.65




(s, broad, 2H), 1.8-2.0 (m, 2H),




3.2-3.4 (m, 2H), 3.8 (m, 1H), 4.1




(3, 3H)


154
Cis(±)-Ethyl 4-
MS (ES) MH+: 333 for
Intermediate 171



(benzylamino)-3-
C19H28N2O3; NMR: 0.14 (m, 2H),



(cyclopropylmethoxy)piper-
0.42 (m, 2H), 0.97 (m, 1H), 1.15



idine-1-carboxylate
(t, 3H), 1.51 (m, 2H), 2.67 (m,




1H), 2.79-3.01 (m, 2H), 3.19 (m,




1H), 3.53 (m, 1H), 3.73 (m, 3H),




3.88-4.02 (m, 3H), 7.18-7.35 (m,




5H)





155
Cis(±)-ethyl 4-[(tert- butoxycarbonyl)amino]-3- (1,3-thiazol-2- ylmethoxy)piperidine-1- carboxylate embedded image
MS (ES) MH+: 386 for C17H27N3O5S; NMR (CDCl3): 1.24 (t, 3H), 1.42 (s, 9H), 1.63 (s, 1H), 1.69-1.81 (m, 2H), 2.82 (m, 2H), 3.67 (m, 2H), 4.10 (q, 2H), 4.40-4.60 (m, 1H), 4.76 (d, 1H), 4.94-5.25 (m, 2H), 7.31 (d, 1H), 7.74 (d, 1H)
Intermediate 235





156
Cis(±)-Ethyl (4-
MS (ES) MH+: 307 for
Intermediate 172



(benzylamino)-3-
C17H26N2O3; NMR: 1.08 (t, 3H);



ethoxypiperidine-1-
1.15 (t, 3H); 1.50 (m, 2H); 1.75



carboxylate
(br s, 1H); 2.65 (br s, 1H); 2.92




(m, 2H); 3.47 (br s, 1H); 3.55 (m,




1H); 3.71 (m, 3H); 3.88 (br s,




1H); 3.98-4.05 (m, 2H); 7.18-




7.34 (m 5H)


157
Cis(±)-ethyl 4-
MS (ES) MH+: 293 for
Intermediate 168



(benzylamino)-3-
C16H24N2O3. NMR: 1.16 (t, 3H),



methoxypiperidine-1-
1.50 (m, 2H), 1.89 (s, 2H), 2.66



carboxylate
(m, 1H), 2.89 (dd, 2H), 3.26 (s,




3H), 3.67-3.83 (m, 3H), 3.99 (m,




3H), 7.18-7.37 (m, 5H)









Intermediates 158-167

The following Intermediates were synthesized by an analogous method to Intermediate 28 or Intermediate 59 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







158
Cis(±)-ethyl 4-amino-3-
MS (ESP): 279 (M + H) for
Intermediate 145



(benzyloxy)piperidine-1-
C15H22N2O3



carboxylate





160
Cis(±)-Ethyl 4-amino-3-(2- methoxypropoxy)piperidine- 1-carboxylate hydrochloride embedded image
MS (ES) MH+: 261 for C12H24N2O4
Intermediate 148





161
Cis(±)-Ethyl 4-amino-3-(2-
MS (ES) MH+: 247 for
Intermediate 149



hydroxypropoxy)piperidine-
C11H22N2O4



1-carboxylate hydrochloride


162
tert-butyl Cis(±)-4-amino-3-
1.39 (s, 9H), 1.45 (m, 1H), 1.58
Intermediate 151



chloropiperidine-1-
(m, 2H), 2.95 (m, 1H), 3.31 (m,



carboxylate
1H), 3.82 (m, 1H), 4.03 (m, 1H),




4.26 (m, 1H)


163
ethyl Cis(±)-4-amino-3-
NMR (CDCl3): 0.9 (d, 3H), 1.2
Intermediate 152



methylpiperidine-1-
(t, 3H), 1.5 (m, 2H), 1.6 (m, 1H),



carboxylate
2.2 (s, broad, 2H), 3.0 (m, 1H),




3.2 (m, 2H), 3.4 (m, 1H), 4.0-4.2




(m, 2H)


164
Cis(±)-ethyl (4-amino-2-
NMR: 1.25 (t, 3H), 1.3 (d, 3H),
ethyl 2-methyl-4-



methylpiperidine-1-
1.3-1.5 (m, 2H), 1.65 (s, broad,
oxopiperidine-1-



carboxylate
2H), 1.8-2.0 (m, 2H), 3.2-3.4 (m,
carboxylate (EP




2H), 3.9 (m, 1H), 4.1 (3, 3H)
121972 A2)





165
Cis(±)-Ethyl 4-amino-3- (cyclopropylmethoxy)piper- idine-1-carboxylate embedded image
MS (ES) MH+: 243 for C12H22N2O3; NMR (CDCl3): 0.19 (m, 2H), 0.49 (m, 2H), 1.05 (m, 1H), 1.24 (t, 3H), 1.65-1.84 (m, 2H), 2.93 (d, 2H), 3.09 (m, 1H), 3.25-3.44 (m, 2H), 3.52 (bs, 1H), 3.85-4.21 (m, 6H)
Intermediate 154





166
Cis(±)-ethyl 4-amino-3-(1,3-
MS (ES) MH+: 286 for
Intermediate 155



thiazol-2-
C12H19N3O3S; NMR (DMSO):



ylmethoxy)piperidine-1-
1.00 (t, 1.8H), 1.15 (t, 1.2H), 1.70



carboxylate
(m, 2H), 2.79-3.03 (m, 2H), 3.44




(m, 1H), 3.74-4.02 (m, 4H), 4.29




(m, 1H), 4.91 (t, 2H), 7.25 (bs,




1H), 7.77 (dd, 2H), 8.34 (s, 1H)


167
1-tert-butyl 3-methyl-4-
MS (GC-EI)[(M)+]: 258 for
Intermediate 237



aminopiperidine-1,3-
C12H22N2O4



dicarboxylate









Intermediate 168
ethyl 3-methoxy-4-oxopiperidine-1-carboxylate

To a stirred solution of the methoxyketal (Intermediate 173, 55.15 g, 223 mmol, crude) in dry THF (30 mL), at room temperature and under ambient atmosphere, was added an aqueous solution of H2SO4 (5%, v/v, 190 mL). Temperature was increased to 60° C.; the reaction was stirred at this temperature. Complete conversion was suggested after 2 hours by TLC (50% ethyl acetate in hexanes; Hanessian's stain; Rf˜0.43). The reaction mixture was allowed to come to room temperature. THF was removed under vacuum. To the aqueous solution was added solid sodium bicarbonate until basic, and solid sodium chloride until saturated, with the addition of more water necessary. Crude product was extracted with methylene chloride (3×300 mL); the organic layers were combined, dried over magnesium sulfate, and concentrated. The crude material was used without further purification; yield was assumed quantitative.


MS (ESI) M: 201 for C9H15NO4. 1H NMR (CDCl3): 1.28 (t, 3H), 2.38-2.60 (m, 2H), 3.30-3.41 (m, 2H), 3.45 (s, 3H), 3.69 (m, 1H), 4.05 (m, 2H), 4.17 (q, 2H).


Intermediates 169-172

The following Intermediates were synthesized by an analogous method to Intermediate 168 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







169
Ethyl 3-(2-methoxyethoxy)-4-
MS (ES) MH+: 246 for
Intermediate 174



oxopiperidine-1-carboxylate
C11H19NO5





170
tert-butyl 3-chloro-4- oxopiperidine-1-carboxylate embedded image
1.30 (m, 1H), 1.34 (s, 9H), 2.45 (t, 2H), 3.34 (m, 1H), 3.17 (m, 1H), 4.10 (m, 1H), 4.66 (m, 1H)
J. Org. Chem., 1994, 59, 6955- 6964.





171
Ethyl 3-(cyclopropylmethoxy)-
MS (ES) MH+: 242 for
Intermediate 255



4-oxopiperidine-1-carboxylate
C12H19NO4; NMR (CDCl3):
and




0.21 (m, 2H), 0.53 (m, 2H),
cyclopropylmethyl




1.07 (m, 1H), 1.28 (t, 3H),
bromide




2.37-2.58 (m, 2H), 3.32-3.51




(m, 4H), 3.85 (bs, 1H), 4.04-




4.41 (m, 4H)


172
Ethyl 3-ethoxy-4-
MS (ES) NMa+: 238 for
Intermediate 175



oxopiperidine-1-carboxylate
C10H17NO4—Na adduct; NMR:




1.09 (t, 3H); 1.20 (t, 3H); 2.31




(m, 1H); 3.12 (br s, 1H); 3.45




(m, 1H); 3.59 (m, 1H); 3.94




(m, 2H); 4.03-4.11 (m, 4H).









Intermediate 173
ethyl 3,4,4-trimethoxypiperidine-1-carboxylate

To a stirred solution of sodium hydride (6.96 g, 290 mmol) in dry THF (100 mL), at 0° C. and under an atmosphere of N2, was added a solution of the hydroxyketal (Intermediate 255, 223 mmol) in THF (125 mL) over approximately 30 minutes, via addition funnel. The resulting solution was stirred at 0° C. under an atmosphere of N2 for approximately 15 minutes; to it was then added methyl iodide (18.0 mL, 41.0 g, 290 mmol) portionwise, via syringe, over approximately 5 minutes. The reaction was stirred overnight under an atmosphere of N2, gradually reaching room temperature. Complete conversion was suggested by TLC (50% ethyl acetate in hexanes; Hanessian's stain; Rf˜0.57) in the morning. The reaction was quenched with a small volume of water, then concentrated under vacuum. To the residue was added approximately 50 mL of water; from this mixture was extracted the crude product with ethyl acetate (3×150 mL). The organic layers were combined, dried over magnesium sulfate, and concentrated. The crude material was used without further purification; yield was assumed quantitative.


MS (ESI) M: 247 for C11H21NO5. 1H NMR (CDCl3): 1.24 (t, 3H), 1.72-1.83 (m, 2H), 2.82 (m, 2H), 2.98 (t, 1H), 3.20 (s, 3H), 3.21 (s, 3H), 3.41 (s, 3H), 4.10 (q, 2H), 4.20-4.37 (m, 2H).


Intermediates 174-175

The following Intermediates were synthesized by an analogous method to Intermediate 173 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







174
Ethyl 4,4-dimethoxy-3-
NMR (CDCl3): 1.23 (t, 3H),
Intermediate 255 and 1-



(2-
1.73-1.85 (m, 2H), 2.75-2.88
bromo-2-methoxyethane



methoxyethoxy)piper-
(m, 1H), 2.93-3.10 (m, 1H),



idine-1-carboxylate
3.19 (s, 3H), 3.23 (s, 3H), 3.34




(s, 3H), 3.40-3.60 (m, 4H),




3.68-3.80 (m, 2H), 4.11 (q, 2H),




3.98-4.30 (m, 1H)





175
Ethyl 3-ethoxy-4,4- dimethoxypiperidine-1- carboxylate embedded image
MS (ES) MNa+: 284 for C12H23NO5—Na adduct; NMR: 1.07 (t, 3H); 1.15 (t, 3H); 1.52 (m, 1H); 1.66 (m, 1H); 3.08 (s, 3H); 3.10 (s, 3H); 3.59 (m, 1H); 3.81 (m, 2H); 3.96-4.07 (m, 4H); 4.12 (m, 1H)
Intermediate 255 and ethyl iodide









Intermediate 176
Ethyl 2-oxobutanoate

Diethyl oxalate (10 g; 68 mmol) was dissolved in Et2O (100 ml) and cooled to −78 C. Ethyl magnesium bromide (1.0 M in THF; 72 ml; 71.8 mmol; 1.05 equiv.) was added slowly via syringe. The dry ice/acetone bath was allowed to melt and warm to 10 C. Monitored the reaction by 1H NMR. The reaction was cooled to 0 C and quenched with saturated NH4Cl. Dilute with H2O and separate phases. The organic layer was dried over Na2SO4, filtered and concentrated. Isolation gave 7.6 g of a crude yellow oil in 86% yield. No further purification.


Intermediate 177
Ethyl 3-bromo-2-oxobutanoate

CuBr2 (39.3 g; 176 mmol; 3 equiv.) was suspended in EtOAc (160 ml). A CHCl3 solution containing ethyl 2-oxobutanoate (Intermediate 176, 7.6 g; 58.7 mmol) was added dropwise. The suspension was then heated to reflux for 6 hours and monitored by 1H NMR. The solids were filtered through a pad of Celite and the mother liquor was concentrated. The crude oil was passed through a short plug of silica gel and eluted with a 1:1 mixture of EtOAc/hexanes. The yellow band was collected and concentrated to give 12.2 g of product. No further purification.


Intermediate 178
Ethyl 2-amino-5-methyl-1,3-thiazole-4-carboxylate

Ethyl 3-bromo-2-oxobutanoate (Intermediate 177, 12.2 g; 58.7 mmol) and thiourea (4.46 g; 76.1; 58.7 mmol) were combined and heated to reflux. The solution was allowed to cool to room temperature and stir for 12 hours. The reaction was monitored by LC/MS. The base was precipitated with 20% NH4OH (10 ml) and then redissolved with 1N HCl (100 ml) and then finally reprecipitated with 20% NH4OH. The precipitate was collected and washed with H2O. The crude product was then crystallized from 9:1 ethanol/water to give 5.95 g of product in 55% yield. MS (ES) MH+: 187 for C7H10N2O2S.


Intermediate 179
Ethyl 2-chloro-5-methyl-1,3-thiazole-4-carboxylate

Ethyl 2-amino-5-methyl-1,3-thiazole-4-carboxylate (Intermediate 178, 3 g; 16.1 mmol) and anhydrous CuCl2 (3.25 g; 24.2 mmol; 1.5 equiv.) were combined in dry acetonitrile (28 ml). t-butyl nitrite (90% tech; 2.77 g; 24.2 mmol; 1.5 equiv.) was added dropwise. The suspension was stirred at room temperature for 12 hours and monitored by LC/MS. The acetonitrile was removed in vacou and the solid was redissolved in CHCl3 and H2O. The aqueous layer was acidified with 2N HCl and the phases were separated. Back extracted the aqueous with CHCl3. The organic extracts were combined, dried over Na2SO4 and decolorizing carbon for 1 hour. Filtered through a pad of Celite and concentrated to an oil. Isolation gave 2.62 g of the title compound in 80% yield. The compound can be further purified via flash column chromatography and crystallization. MS (ES) MH+: 206, 208 for C7H8ClNO2S.


Intermediate 180
Ethyl 5-(bromomethyl)-2-chloro-1,3-thiazole-4-carboxylate



embedded image


Ethyl 2-chloro-5-methyl-1,3-thiazole-4-carboxylate (Intermediate 179, 2.8 g; 13.6 mmol) was dissolved in CCl4 (25 ml). NBS (2.3 g; 13 mmol) and AIBN (2.12 g; 13 mmol) were added in a single portion and the resultant reaction mixture was heated to reflux for 24 hours. Additional NBS (690 mg; 0.3 equiv.) and AIBN (636 mg; 0.3 mmol) were added to push the reaction to completion. Continued to heat for another 4 hours. Cooled to room temperature, filtered and concentrated the mother liquor. Redissolved in minimal DMSO (7 ml) and purified by Gilson HPLC (5-95% ACN/0.1% TFA; run time=35 min). Isolated 1.15 g of desired product in 29% yield MS (ES) MH+: 284, 286, 288 for C7H7BrClNO2S.


Intermediate 181
Ethyl 2-chloro-5-formyl-1,3-thiazole-4-carboxylate

Ethyl 5-(bromomethyl)-2-chloro-1,3-thiazole-4-carboxylate (Intermediate 180, 920 mg; 3.2 mmol) was dissolved in acetonitrile dried over molecular sieves. The solution was cooled to 0 C and NMO (570 mg; 1.5 equiv.) was added in a single portion. The reaction was monitored by LC/MS. An additional 1.5 equivalents of NMO was added in two portions over two hours. The reaction was concentrated to a solid residue, redissolved in EtOAc and washed with H2O. Dried the organic over Na2SO4, filtered and concentrated. No further purification. MS (ES) MH+: 220, 222 for C7H6ClNO3S.


Intermediate 182
tert-Butyl 3-bromo-4-oxopiperidine-1-carboxylate

Chlorotrimethylsilane (5.6 ml, 44 mmol) was added slowly to a solution of tert-butyl 4-oxopiperidine-1-carboxylate (commercial, 8 g, 40 mmol), triethylamine (12.3 ml, 88 mmol) and DMF (40 ml) at room temperature. The resultant solution was heated to 75° C. and stirred overnight under nitrogen. The reaction mixture was cooled to room temperature and then in an ice bath. Cold hexane (250 ml) was added slowly to the reaction mixture followed by cold (saturated) aqueous sodium bicarbonate (50 ml). The organic phase was separated and washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude silyl enolether was dissolved in THF (15 ml) and cooled to 0° C. N-Bromosuccinimide (7.1 g, 40 mmol) was dissolved in THF (120 ml) and added slowly (45 min.) to the reaction mixture. The resultant mixture was allowed to slowly warm to room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure. The crude residue was purified by flash chromatography (hexanes/ethyl acetate, 5:1) to provide the title compound as a white solid (11 g).


MS (ESP): 222.1 (M-tBu) for C10H16BrNO3.



1H NMR (300 MHz, DMSO-d6) δ: 1.25 (s, 9H); 2.30 (m, 1H); 2.55 (m, 1H); 3.42-3.80 (m, 3H); 3.93 (m, 1H); 4.60 (m, 1H).


Intermediate 183
tert-Butyl 3-(methylthio)-4-oxopiperidine-1-carboxylate

Sodium thiomethoxide (805 mg, 11.5 mmol) was added to a solution of tert-butyl 3-bromo-4-oxopiperidine-1-carboxylate (Intermediate 182, 3.20 g, 11.5 mmol) and THF (15 ml) at 0° C. The resultant mixture was allowed to slowly warm to room temperature and stirred overnight. The reaction was quenched with water (15 ml) and diluted with ethyl acetate (150 ml). The organic phase was separated and washed with brine. The combined aqueous phase was back extracted with ethyl acetate (50 ml). The combined organic layer was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography (hexanes/ethyl acetate, 7:1) to provide the title compound (2.4 g).


MS (ESP): 190.2 (M-tBu) for C11H19NO3S.



1H NMR (300 MHz, CDCl3) δ: 1.43 (s, 9H); 2.02 (s, 3H); 2.23 (dt, 1H); 2.95 (m, 1H); 3.20-3.40 (m, 2H); 3.65 (m, 1H); 3.90-4.20 (m, 2H).


Intermediate 184
Cis(±)-tert-butyl-4-amino-3-(methylthio)piperidine-1-carboxylate

Sodium cyanoborohydride (344 mg, 5.48 mmol) was added to a solution of tert-butyl 3-(methylthio)-4-oxopiperidine-1-carboxylate (Intermediate 183, 1.07 g, 4.40 mmol), ammonium acetate (3.24 g, 42 mmol) and methanol (15 ml). The resultant mixture was stirred for 4 h. The reaction was quenched by addition of 1N HCl (3 ml). Aqueous sodium bicarbonate (saturated, 50 ml) was added slowly to the reaction mixture followed by extraction with ethyl acetate (3×75 ml). The combined organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure to yield the crude amine


MS (ESP): 247.3 (M+H) for C11H22N2O2S.


Intermediate 185
Trans(±)tert-butyl 4-amino-3-hydroxypiperidine-1-carboxylate



embedded image


The title compound was prepared as described in Marquis R. W. et al. J. Med. Chem. 1998, 41,3563-3567 and/or WO 9805336. MS (ES) MH+: 217 for C10H20N2O3; NMR: 1.45 (s, 9H), 1.80 (m, 1H), 1.95 (m, 1H), 2.21 (m, 1H), 2.62 (m, 1H), 2.75 (m, 1H), 3.28 (m, 1H), 3.47 (m, 1H), 3.81 (m, 1H), 4.11 (m, 1H), 4.28 (m, 1H), 8.20 (m, 1H).


Intermediate 186
Ethyl 3-chloro-5-methyl-1H-pyrrole-2-carboxylate

The compound was prepared by the procedure described for Intermediate 2.


MS (ESP): 188 (MH+) for C8H10ClNO2.



1H-NMR (CDCl3) δ: 1.37 (t, 3H); 2.26 (s, 3H); 4.32 (q, 2H); 5.96 (s, 1H); 8.81 (br, 1H).


Intermediate 187
Ethyl 4-bromo-5-methyl-1H-pyrrole-2-carboxylate

The compound was prepared by the procedure described for Intermediate 2.


MS (ESP): 234 (MH+) for C8H10BrNO2.



1H-NMR δ: 1.27 (t, 3H); 2.17 (s, 3H); 4.22 (q, 2H); 6.74 (s, 1H); 12.10 (s, br, 1H).


Intermediate 188
4 Ethyl 4-bromo-3-chloro-5-methyl-1H-pyrrole-2-carboxylate

Ethyl 4-bromo-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 187, 2.87 g, 12.4 mmol) was dissolved in dry DMF (30 ml), N-chlorosuccinimide (1.66 g, 12.4 mmol) was added and resulting mixture was stirred at room temperature over night, more N-chlorosuccinimide (0.83 g, 6.2 mmol) was added and the reaction temperature was increased to 35° C., stirred for 4 hours. The mixture was poured into cold sodium hydroxide aqueous solution (2M) (50 ml), extracted with diethyl ether (2×50 ml). The organic phase was then washed with water (20 ml) and brine (20 ml), dried over anhydrous sodium sulfate and purified by column chromatography(hexanes/ethyl acetate, gradient) to give the desired product as a white crystal. (1.2 g).


MS (ESP): 268 (MH1) for C8H9BrClNO2.



1H-NMR (CDCl3) δ: 1.38 (t, 3H); 2.30 (s, 3H); 4.34 (q, 2H); 9.0 (br, 1H).


Intermediate 189
ethyl 4-chloro-3,5-dimethyl-1H-pyrrole-2-carboxylate

N-Chlorosuccinimide (1.77 g, 13.25 mmol) was added to a solution of ethyl 3,5-dimethyl-2-pyrrole carboxylate (2.11 g, 12.62 mmol) in chloroform (45 mL). The reaction mixture was stirred at room temperature for 24 h and then poured into 2 N NaOH. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to give a crude solid. The crude solid was dissolved in hot MeOH, cooled to room temperature, and the precipitate was collected by filtration (493 mg, 19%). MS (ES) MH+: 174 for C9H12ClNO2.


Intermediate 190
ethyl 4-chloro-3-[(E)-(methoxyimino)methyl]-5-methyl-1H-pyrrole-2-carboxylate



embedded image


A solution of Intermediate 191 (300 mg, 1.39 mmol) in MeOH (5 mL) and pyridine (1.5 mL) with methylamine hydrochloride (255 mg, 3.06 mmol) was heated to 60° C. overnight. The reaction was cooled to room temperature and then partitioned between methylene chloride and 10% HCl. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give an off-white solid.


MS (ES) MH+: 245 for C10H13ClN2O3;


NMR (DMSO-d6): 1.29 (t, 3H), 2.36 (s, 3H), 3.83 (s, 3H), 4.27 (q, 2H), 8.03 (s, 1H), 12.31 (s, 1H).


Intermediate 191
ethyl 4-chloro-3-formyl-5-methyl-1H-pyrrole-2-carboxylate

POCl3 in 1,2-dichloroethane (14 mL) was slowly added to a solution of DMF (4.37 mL, 59.79 mmol) in 1,2-dichloroethane (10 mL). The reaction mixture was stirred for 15 min and then Intermediate 7 (2.04 g, 10.87 mmol) was added. The reaction mixture was heated at reflux for 3 h and then cooled to room temperature. The reaction mixture was treated with sodium acetate (10 g) in water (25 mL) and stirred for 1 h. The mixture was extracted with methylene chloride, washed with water, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 2:1 hexanes/ethyl acetate) gave the desired compound (720 mg).


MS (ES) MH+: 216 for C9H10ClNO3.


Intermediate 192
ethyl 3-bromo-4-chloro-5-methyl-1H-pyrrole-2-carboxylate

Bromine (0.56 ml, 11 mmol) was added to a solution of 1 g (5.3 mmol) of ethyl 4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 7) and 0.8 ml (5.7 mmol) Et3N in CH2Cl2. After stirring at room temperature for 2 h, aqueous NaHSO3 was added and the CH2Cl2 was removed and the aqueous residue was partitioned between water and EtOAc. The EtOAc was separated and washed with brine. Drying (MgSO4) and removal of solvent gave 1.5 g of product as a solid. MS (ES) (MH+): 240 for C8H9BrClNO2; NMR (d6-DMSO): 1.3 (t, 3H), 2.2 (s, 3H), 4.2 (q, 2H), 12.3 (s, 1H).


Intermediate 193
ethyl 4-chloro-3-cyano-5-methyl-1H-pyrrole-2-carboxylate

Nitrogen gas was bubbled through a mixture of 1.4 g (5.25 mmol) of ethyl 3-bromo-4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 192), 470 g (4 mol) Zn(CN)2, 250 mg (0.26 mmol) Pd2(dba)3 and 302 mg (0.26 mmol) dppf in 15 ml DMF for 15 min. The mixture was heated at 130° C. for 1 h. Additional Zn(CN)2 (1 g), Pd2(dba)3 (500 mg) and dppf (604 mg) were added. After bubbling through N2 for 15 min and heating at 130° C. for 2 h, additional Zn(CN)2 (0.5 g), Pd2(dba)3 (250 mg) and dppf (302 mg) were added. Heating was continued at 130° C. for 2h. Solvent was removed and the residue was partitioned between EtOAc and water. The EtOAc was separated and washed with brine. Combined aqueous layers were extracted again with EtOAc, which was washed with brine. Combined EtOAc extracts were dried (MgSO4) and concentrated. The residue was purified by silica gel chromatography (100% CH2Cl2 followed by gradient elution to 5% MeOH in CH2Cl2) to afford 750 mg of product as a solid. MS (ES) (MH+): 213 for C9H9ClN2O2; NMR (d6-DMSO): 1.3 (t, 3H), 2.2 (s, 3H), 4.3 (q, 2H), 13.1 (s, 1H).


Intermediate 194
ethyl 3,5-dichloro-4-methyl-1H-pyrrole-2-carboxylate

Et3N (5.5 ml, 39 mmol) was added slowly to a solution of 2.0 g (13 mmol) of ethyl 4-methyl-1H-pyrrole-2-carboxylate and 3.1 ml SO2Cl2 in 30 ml CH2Cl2 cooled in an ice water bath. The mixture was warmed to room temperature with stirring overnight. After treatment with aqueous NaHSO3, the CH2Cl2 was removed and the aqueous residue was diluted with water and extracted twice with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO4) and concentrated. The solid residue was twice recrystallized from 50% aqueous EtOH to afford 1.38 g of product as a white solid. MS (ES) (M−H): 222 for C8H9Cl2NO2; NMR (d6-DMSO): 1.3 (t, 3H), 1.9 (s, 3H), 4.25 (q, 2H), 12.8 (s, 1H).


Intermediate 195
4-chloro-3,5-dimethyl-1H-pyrrole-2-carboxylic acid



embedded image


Prepared using the procedure described for Intermediate 1 using Intermediate 189 as the starting material.


MS (ES) MH+: 174 for C7H8ClNO2.


Intermediate 196
3-chloro-5-methyl-1H-pyrrole-2-carboxylic acid

Prepared using the procedure described for Intermediate 1 using Intermediate 186 as the starting material.


MS (ESP): 160 (MH+) for C6H6ClNO2.



1H-NMR (CDCl3) δ: 2.29 (s, 3H); 6.02 (s, 1H); 8.83 (br, 1H).


Intermediate 197
4-bromo-5-methyl-1H-pyrrole-2-carboxylic acid

Prepared by the procedure described for Intermediate 1 using Intermediate 187 as the starting material.


MS (ESP): 206 (MH+) for C6H6BrNO2.


NMR (CDCl3) δ: 2.31 (s, 3H); 6.97 (s, 1H); 9.08 (s, br, 1H).


Intermediate 198
4-bromo-3-chloro-5-methyl-1H-pyrrole-2-carboxylic acid

Prepared using the procedure described for Intermediate 1 and Intermediate 188. MS (ESP): 240 (MH+) for C6H5BrClNO2.


Intermediate 199
4-chloro-3-[(E)-(methoxyimino)methyl]-5-methyl-1H-pyrrole-2-carboxylic acid

Synthesized as described for Intermediate 1 from Intermediate 190.


MS (ES) MH+: 217 for C9H9ClN2O3.


Intermediate 200
4-chloro-3-cyano-5-methyl-1H-pyrrole-2-carboxylic acid



embedded image


A solution of 670 mg (3.2 mmol) of ethyl 4-chloro-3-cyano-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 193) and 3.2 ml (3.2 mmol) 1N NaOH in 20 ml MeOH was heated at 100° C. in a microwave reactor for 2 h. The mixture was diluted with water and extracted with EtOAc. The EtOAc was washed with 1N NaOH. The combined aqueous layers were acidified with concentrated HCl and extracted 2 times with EtOAc, each extract being washed with brine. Drying (MgSO4) and removal of solvent gave 535 mg of product as a solid. MS (ES) (M−H): 183 for C7H5ClN2O2; NMR (d6-DMSO): 2.2 (s, 3H), 12.9 (s, 1H), 13.3 (s, 1H).


Intermediate 201
3,5-dichloro-4-methyl-1H-pyrrole-2-carboxylic acid

A solution of 1.1 gm (4.95 mmol) of ethyl 3,5-dichloro-4-methyl-1H-pyrrole-2-carboxylate (Intermediate 194) and 1.7 g (9.9 mmol) of Ba(OH)2 in 50 ml 1:1 EtOH—H2O was heated at 85° C. for 9 h. The mixture was diluted with water, acidified with 20 ml 1N HCl and extracted 3 times with ether. The ether was washed with water, dried (MgSO4) and concentrated to give 1.0 g of product as a solid. MS (ES) (M−H): 194 for C6H5Cl2NO2; NMR (d6-DMSO): 1.9 (s, 3H), 12.7 (s, 1H), 12.8 (s, 1H).


Intermediate 202
3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride

A solution of 10.4 g (54 mmol) of 3,4-Dichloro-5-methyl-1H-pyrrole-2-carboxylic acid (Intermediate 1) in 100 ml SOCl2 was heated at reflux for 30 min. Solvent was removed to afford product. NMR (CDCl3): 2.3 (s, 1H), 8.8 (s, 1H).


Intermediate 203
2,2,2-trichloro-1-(4,5-dichloro-1H-pyrrol-2-yl)ethanone

To a solution of 2,2,2-trichloro-1-(1H-pyrrol-2-yl)ethanone (1.00 g, 47.06 mmol) in dichloromethane (8 mL), sulfuryl chloride (1.60 mL, 0.188 mol) was added slowly at room temperature. The reaction was stirred overnight and quenched with water and extracted with dichloromethane. The extract was washed with saturated sodium bicarbonate, water and brine. Then it was dried over magnesium sulfate and concentrated to give the desired product as a white solid (0.90 g).


MS (ES) M: 279 for C6H2Cl5O.


Intermediate 204
ethyl 2-bromo[1,3]thiazolo[4,5-b]pyridine-7-carboxylate

To a 0° C. mixture of CuBr2 (229 mg, 1.02 mmol) in acetonitrile (3 mL) was slowly added t-Butyl nitrite (0.15 mL, 1.28 mmol). The reaction mixture was stirred for 15 min and then added Intermediate 205 (250 mg, 0.85 mmol). The reaction mixture was stirred for 2 h, partitioned between diethyl ether and water, and filtered through diatomaceous earth. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (silica, 1:1 hexanes/ethyl acetate) gave the desired product (38 mg, 16%).


MS (ES) MH+: 174 for C9H7BrN2O2S.


Intermediate 205
ethyl 2-amino[1,3]thiazolo[4,5-b]pyridine-7-carboxylate

To a solution of Intermediate 206 (944 mg, 4.20 mmol) in acetic acid (12 mL) was added benzyltrimethyl ammonium tribromide (1.67 g, 4.28 mmol). The reaction mixture was stirred at room temperature for 2 h and the solid that formed was collected by filtration to provide the desired compound as the acetic acid salt (1.20 g).


MS (ES) MH+: 224 for C9H9N3O2S.


Intermediate 206
ethyl 2-[(aminocarbonothioyl)amino]isonicotinate

A solution of Intermediate 207 (2.10 g, 6.38 mmol) in ethanol (20 mL) and potassium carbonate (882 mg, 6.38 mmol) was heated to 80° C. for 2 h. The reaction mixture was cooled to room temperature and the solid that formed was collected by filtration to give the desired compound.


MS (ES) MH+: 226 for C9H11N3O2S;


NMR (DMSO-d6): 1.17 (t, 3H), 4.18 (q, 2H), 7.29 (m, 1H), 7.59 (s, 1H), 8.25 (m, 1H), 8.87 (s, 1H), 10.24 (s, 1H), 10.63 (s, 1H).


Intermediate 207
ethyl 2-{[(benzoylamino)carbonothioyl]amino} isonicotinate

To a 0° C. solution of benzyl isothiocyanate (1.25 mL, 9.27 mmol) in acetone (15 mL) was slowly added ethyl 2-aminoisonicotinate (1.4 g, 8.43 mmol). The reaction mixture was stirred for 1 h and then poured onto ice. The solid that formed was collected by filtration and washed with water to give the desired product (2.10 g).


MS (ES) MH+: 330 for C16H15N3O3S.


Intermediate 208
2-chloro-5-nitroisonicotinic acid

A solution of 13.7 g (46 mmol) of Na2Cr2O3 in 100 ml concentrated H2SO4 was added slowly to a solution of 3.0 g (17.4 mmol) of 2-chloro-4-methyl-5-nitropyridine dissolved in 100 ml concentrated H2SO4 while cooling in ice water. Allowed to warm to room temperature and stir overnight. The solution was poured onto 600 ml ice and extracted twice with EtOAc, each extract being washed with brine. The combined organic extracts were dried (MgSO4) and concentrated to afford product as a gummy oil. MS (ES) MH+: 203 for C6H3ClN2O4.


Intermediate 209
ethyl 2-amino-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate

A solution of 5.0 g (37 mmol) of 3-chlorofuran-2,4(3H,5H) -dione and 3.3 g (43 mmol) of thiourea in 50 ml EtOH was heated at reflux for 4 h. Solvent was removed and the residue was dissolved in water with 1N HCl added. The aqueous solution was basified with aqueous Na2CO3. Thick solids that formed were filtered, rinsed with water and dried in vacuo. NMR: 1.2 (t, 3H), 4.2 (q, 2H), 4.6 (s, 2H), 4.9 (s, broad, 1H), 7.8 (s, 2H).


Intermediate 210
ethyl 2-amino-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1,3-thiazole-5-carboxylate



embedded image


To a solution of 2.0 g (9.8 mmol) of ethyl 2-amino-4-(hydroxymethyl) -1,3-thiazole-5-carboxylate (Intermediate 209) and 1.3 g (19.4 mmol) of imidazole in 20 ml DMF was added 1.6 g (10.6 mmol) of t-butyldimethylsilyl chloride. After stirring for 2 h, solvent was removed and the residue was taken up in water. Insoluble solids were collected, ground up, washed with water and dried in vacuo to afford 2.95 g of product. MS (ES) (MH+): 317 for C13H24N2O3SSi; NMR (d6-DMSO): 0.03 (s, 6H), 0.86 (s, 9H), 1.2 (t, 3H), 4.1 (q, 2H), 4.8 (s, 2H), 7.8 (s, 2H).


Intermediate 211
ethyl 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazole-5-carboxylate

t-Butylnitrite (1.8 ml (14 mmol) was added slowly to a mixture of 2.9 g (9.2 mmol) of ethyl 2-amino-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1,3-thiazole-5-carboxylate (Intermediate 210) and 1.95 g (14 mmol) CuCl2 in CH3CN. After stirring at room temperature for 2 h, solvent was removed and the residue was taken up in EtOAc, which was washed 2 times with 1NHCl and once with brine. Drying (MgSO4) and removal of solvent gave 2.95 g of product as an oil. NMR (CDCl3): 0.1 (s, 6H), 0.9 (s, 9H), 1.35 (t, 3H), 4.3 (q, 2H), 5.0 (s, 2H).


Intermediate 212

The following Intermediate was synthesized by an analogous method to Intermediate 211 from the starting materials (SM) given in the table below















Int
Compound
Data
SM







212
methyl 4-acetyl-2-
NMR (CDCl3): 2.6 (s,
Intermediate 222



chloro-1,3-thiazole-
3H), 3.9 (s, 3H)



5-carboxylate









Intermediate 214
methyl 2-chloro-4-(1-hydroxy-1-methylethyl)-1,3-thiazole-5-carboxylate

A solution of 5.6 ml (11.2 mmol) 2N AlMe3 in toluene was added to a dry ice-acetone bath of 1.14 g (5.2 mol) of methyl 4-acetyl-2-chloro-1,3-thiazole-5-carboxylate (Intermediate 212) in 20 ml dry CH2Cl2. The mixture was allowed to warm to room temperature slowly before being quenched with MeOH. After stirring at room temperature overnight, the mixture was diluted with 1N HCl and stirred 15 min before being diluted with water and extracted twice with EtOAc. The EtOAc was washed with brine, dried (MgSO4) and concentrated to give an oil that was purified by chromatography (50% hexanes in CH2Cl2 with gradient elution to 100% CH2Cl2) affording 720 mg of product as an oil. NMR (CDCl3): 1.5 (s, 6H), 3.8 (s, 3H), 5.7 (s, broad, 1H).


Intermediate 215
ethyl 2-chloro-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate



embedded image


A solution of 17.7 g (53 mmol) of ethyl 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazole-5-carboxylate (Intermediate 211) and 53 ml (53 mmol) of 1N HCl in dioxane was stirred at room temperature for 1 h. The mixture was extracted 3 times with EtOAc, which was dried (MgSO4) and concentrated to give 11.3 g of an orange oil. Purification by silica gel chromatography affords a solid. NMR (CDCl3): 1.2 (t, 3H), 3.1 (s, broad, 1H), 4.2 (q, 2H), 4.8 (s, 2H).


Intermediate 216
4-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazol-5-yl]carbonyl}morpholine

A solution of 2N Me3Al in hexanes (0.91 ml, 1.82 mmol) was added slowly to a solution of 0.16 ml (1.8 mmol) of morpholine in 4 ml CH2Cl2. After stirring for 15 min, a solution of 0.5 g (1.5 mmol) of ethyl 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazole-5-carboxylate (Intermediate 218) in 4 ml CH2Cl2 was added. The solution was heated at 80° C. in a microwave reactor for 1 hour before pouring into dilute aqueous HCl. The mixture was extracted 3 times with CH2Cl2, which was washed with brine, dried (MgSO4) and concentrated. The residue was purified by silica gel chromatography (100% CH2Cl2 followed by gradient elution to 30% EtOAc in CH2Cl2 to give 315 mg of product. MS (ES) (MH+): 377 for C15H25ClN2O3SSi; NMR (d6-DMSO): 0.1 (s, 6H), 0.9 (s, 9H), 3.6 (m, 4H), 3.7 (m, 4H), 4.1 (q, 2H), 4.75 (s, 2H).


Intermediate 217

The following Intermediate was synthesized by an analogous method to Intermediate 216 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







217
4-({[tert-
NMR (d6-DMSO):
Intermediate 211 and



butyl(dimethyl)silyl]oxy}methyl)-
0.04 (s, 6H), 0.8 (s, 9H), 1.6 (s,
cumylamine



2-chloro-N-(1-methyl-1-
6H), 4.9 (s, 2H), 7.2 (7,



phenylethyl)-1,3-thiazole-5-
1H), 7.3 (t, 2H), 7.4 (d,



carboxamide
2H), 8.6 (s, 1H).









Intermediate 218
2-chloro-5-(morpholin-4-ylcarbonyl)-1,3-thiazole-4-carboxylic acid

A solution of 173 mg (1.7 mmol) CrO3 in 1 ml of 4:1 water/H2SO4 was added to as solution of 310 mg (0.82 mmol) of 4-{[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-1,3-thiazol-5-yl]carbonyl}morpholine (Intermediate 216) in 3 ml acetone cooled in an ice water bath. The mixture was stirred with warming room temperature over 90 min. A few drops of isopropanol were added, and the mixture was diluted with water and extracted 2 times with EtOAc. The EtOAc extracts were washed with brine, dried (MgSO4) and concentrated to give 190 mg of a white solid. MS (ES) (MH+): 277 for C9H9ClN2O4S; NMR (d6-DMSO): 3.3 (m, 4H), 3.6 (m, 4H), 13.7 (s, 1H).


Intermediate 219

The following Intermediate was synthesized by an analogous method to Intermediate 218 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







219
2-chloro-5-{[(1-methyl-1-
MS (ES) (M − H):
Inter-



phenylethyl)amino]carbonyl}-1,3-
323 for
mediate



thiazole-4-carboxylic acid
C14H13ClN2O2S
217









Intermediate 220
ethyl 5-(aminocarbonyl)-2-chloro-1,3-thiazole-4-carboxylate



embedded image


A solution of 210 mg of ethyl 2-chloro-5-{[(1-methyl-1-phenylethyl)amino]carbonyl}-1,3-thiazole-4-carboxylate (Intermediate 233) in 5 ml TFA was stirred at room temperature overnight. Solvent was removed and the residue was dissolved in 5 ml MeOH. Solvent was again removed and the residue was triturated with ether to give 57 mg of a white solid. NMR (d6-DMSO): 1.3 (t, 3H), 4.3 (q, 2H), 8.2 (s, 1H), 8.8 (s, 1H).


Intermediate 221
methyl 2-chloro-4,4-dimethoxy-3-oxopentanoate

SO2Cl2 (2.2 ml, 27 mmol) was added slowly to a solution of 5.0 g (26 mmol) of methyl 4,4-dimethoxy-3-oxopentanoate in 30 ml CH2Cl2 cooled in an ice water bath. The solution was warmed to room temperature and stirred for 1 h. Solvent was removed and the residue was taken up in EtOAc, which was washed with water and brine. Drying (MgSO4) and removal of solvent gave 6.1 g of an oil. NMR: (CDCl3): 1.5 (s, 3H), 3.25 (2s, 6H), 4.8 (s, 3H), 5.3 (s, 1H).


Intermediate 222
methyl 4-acetyl-2-amino-1,3-thiazole-5-carboxylate

A solution of 4.37 g (19 mmol) methyl 2-chloro-4,4-dimethoxy-3-oxopentanoate (Intermediate 221) and 1.8 g (24 mmol) thiourea in 50 ml EtOH was heated at reflux for 3 h. Solvent was removed and the residue was dissolved in 1:1 acetone-5N HCl and the solution was heated at reflux for 4 h. Acetone was removed and the aqueous residue was neutralized with 50% NaOH and then basified with aqueous Na2CO3. Precipitated solids were filtered, washed with water and dried in vacuo. NMR (d6-DMSO): 2.4 (s, 3H), 3.7 (s, 3H), 8.0 (s, 2H).


Intermediate 223
isopropyl 4-chloropyridine-2-carboxylate 1-oxide

A solution of 2.55 g (14 mmol) of isopropyl 4-chloropyridine-2-carboxylate (Intermediate 232) and 1.4 g (26 mmol) of m-CPBA in 30 ml CH2Cl2 was stirred at room temperature for 2 d. The mixture was quenched with aqueous NaHSO3 and CH2Cl2 was removed. The aqueous residue was basified with aqueous Na2CO3, saturated with NaCl and extracted repeatedly with EtOAc. The EtOAc was dried (MgSO4) and concentrated. The residue was taken up in ether and insoluble material was filtered off. The filtrate was concentrated and the residue was chromatographed on silica gel (100% CH2Cl2 with gradient elution to 100% EtOAc) to afford 2.1 g of product as an oil. NMR (d6-DMSO): 1.3 (d, 6H), 5.3 (septet, 1H), 7.25 (m, 1H), 7.5 (d, 1H), 8.1 (d, 1H).


Intermediate 224
isopropyl 4-chloro-6-cyanopyridine-2-carboxylate

A solution of 200 mg (0.86 mmol) of isopropyl 4-chloropyridine-2-carboxylate 1-oxide (Intermediate 223), 0.14 ml (1 mmol) Et3N and 0.36 ml (2.7 mmol) of trimethylsilylcyanide in 3 ml CH3CN was heated at 90° C. overnight. The solution was diluted with EtOAc and washed with water and brine. Drying (MgSO4) and removal of solvent gave an oil that was purified by chromatography on silica gel (100% CH2Cl2 followed by gradient elution to 10% EtOAc in CH2Cl2) to afford 130 mg of product as a white solid. MS (ES) (MH+): 224 for C19H9ClN2O2; NMR (d6-DMSO): 1.35 (d, 6H), 5.2 (septet, 1H), 8.4 (s, 1H), 8.6 (s, 1H).


Intermediate 225
ethyl 2-chloro-5-formylisonicotinate



embedded image


A solution of 51 ml (128 mmol) of 2.5 N n-butyllithium in hexanes was added slowly to a THF solution of 16 ml (95 mmol) of tetramethylpiperidine cooled in a dry ice-acetone bath. The solution was warmed to −30° C. and cooled to −60° C. before 5.0 g (32 mmol) of 6-chloronicotinic acid was added portion wise. The mixture was warmed to −25° C. and stirred for 30 min. It was then cooled to −70° C. and 10 ml (129 mmol) DMF was added quickly. After quenching with 1N HCl, the solution was warmed to room temperature. The pH was brought to about 4 with additional 1N HCl and the solution was continuously extracted with EtOAc overnight. The EtOAc was dried (MgSO4) and concentrated. The residue was dissolved in 100 ml EtOH and 2 ml concentrated H2SO4 was added. The solution was heated at reflux for 24 h. The mixture was brought to about pH=4 with 50% NaOH and was extracted twice with ether. The ether was dried (MgSO4) and concentrated to gave an oil that was chromatographed on silica gel (50% hexanes in CH2Cl2 with gradient elution to 100% CH2Cl2) to afford 1 g of product as an oil that slowly solidified. NMR (CDCl3): 1.4 (t, 3H), 4.5 (q, 2H), 7.7 (s, 1H), 9.1 (s, 1H), 10.7 (s, 1H).


Intermediate 226
ethyl 2-chloro-5-nitroisonicotinate

A mixture of 2-chloro-5-nitroisonicotinic acid (Intermediate 208) and 16 ml triethylorthoacetate in 100 ml toluene was heated at reflux for 2 h. The mixture as stirred with 1N HCl for 30 min before being partitioned between EtOAc and water. The EtOAc was separated, washed with water and brine, dried (MgSO4) and concentrated. Chromatographed on silica gel (100% hexanes with gradient elution to 100% CH2Cl2 to give product as an oil. MS (ES) (MH+): 231 for C8H7ClN2O4; NMR (d6-DMSO): 1.3 (t, 3H), 4.4 (m, 2H), 8.1 (s, 1H), 9.2 (s, 1H).


Intermediates 227-233

The following compounds were prepared in a manner analogous to Intermediate 226 from the starting material (SM) indicated.















Int
Compound
Data
SM







227
isopropyl 2-chloro-6-
MS (ES) (MH+): 214
2-chloro-6-methylisonicotinate



methylisonicotinate
for C10H12ClNO2;
and trisopropylorthoformate




NMR (d6-DMSO): 1.3




(d, 6H), 2.55 (s, 3H),




5.2 (septet, 1H), 7.65




(s, 1H), 7.7 (s, 1H)


228
isopropyl 4-
NMR (CDCl3): 1.35 (d,
4-chloropyridine-2-carboxylate



chloropyridine-2-
6H), 5.3 (septet, 1H),
and trisopropylformate



carboxylate
7.4 (dd, 1H), 8.05 (d,




1H), 8.6 (d, 1H)


229
isopropyl 4,5-
NMR (CDCl3): 1.35 (d,
4,5-dichloropyridine-2-



dichloropyridine-2-
6H), 5.3 (septet, 1H),
carboxylate (Graf, R. J. fuer



carboxylate
8.1 (s, 1H), 8.7 (s, 1H)
Prakt. Chem. (Leipzig) (1932),





133 36-50) and





trisopropylorthoformate





230
isopropyl 2- fluoroisonicotinate embedded image
NMR (CDCl3): 1.4 (d, 6H), 5.3 (septet, 3H), 7.5 (m, 1H), 7.7 (m, 1H), 8.35 (d, 1H)
2-fluoroisonicotinic acid and trisopropylorthoformate





231
ethyl 2-chloro-5-
NMR: 1.3 (t, 3H), 3.3
Intermediate 218 and



(morpholin-4-ylcarbonyl)-
(m, 2H), 3.5 (m, 2H),
triethylorthoacetate



1,3-thiazole-4-carboxylate
3.6 (m, 2H), 3.65 (m




2H), 4.3 (q, 2H)


232
isopropyl 4-
NMR (CDCl3): 1.35 (d,
4-chloropyridine-2-carboxylic



chloropyridine-2-
6H), 5.3 (septet, 1H),
acid and



carboxylate
7.4 (dd, 1H), 8.05 (d,
trisopropylorthoformate




1H), 8.6 (d, 1H)


233
ethyl 2-chloro-5-{[(1-
MS (ES) (MH+): 353
Intermediate 219



methyl-1-
for C16H17ClN2O2S
and triethylorthoacetate



phenylethyl)amino]car-



bonyl}-1,3-thiazole-4-



carboxylate









Intermediate 234
1,3-thiazol-2-ylmethanol

To a stirred solution of commercially available 1,3-thiazole-2-carbaldehyde (5.36 g, 47 mmol) in dry methanol (100 mL), at 0° C. and under an atmosphere of N2, was added sodium borohydride (2.15 g, 57 mmol) as a solid over approximately 20 minutes. The reaction was stirred for an hour at ambient temperature, under an atmosphere of N2. Complete conversion was suggested by TLC (50% ethyl acetate in hexanes; Rf˜0.23). The reaction was concentrated under vacuum. To the residue was added 15 mL of an aqueous solution of ammonium chloride, and 15 mL of an aqueous solution of sodium chloride; from this mixture was extracted the crude product with ethyl acetate (4×50 mL). The organic layers were combined, dried over magnesium sulfate, and concentrated. The crude material was used without further purification.


MS (ES) MH+: 116 for C4H5NOS. 1H NMR (DMSO): 4.72 (d, 2H), 6.03 (t, 1H), 7.61 (d, 1H), 7.71 (d, 1H).


Intermediate 235
2-(bromomethyl)-1,3-thiazole



embedded image


This compound was synthesized from Intermediate 234 above, using the procedure described in Tetrahedron 61 (2005), p. 137. The crude material was purified by column chromatography (silica gel, 15% ethyl acetate in hexanes). A pale orange liquid (57% yield) was obtained; this material decomposed rapidly, and was used immediately in the next step.


MS (ES) MH+: 179 for C4H4BrNS. 1H NMR (CDCl3): 4.75 (s, 2H), 7.37 (d, 1H), 7.74 (d, 1H).


Intermediate 236
Ethyl 2-chloro-4-methyl-1,3-thiazole-5-carboxylate

Synthesized according to the procedure described for Intermediate 17. MS (ES) MH+: 206, 208 for C7H8ClNO2S; 1H-NMR (300 MHz; DMSO-d6) δ: 1.28 (t, 3H); 2.60 (s, 3H); 4.28 (q, 2H).


Intermediate 237
1-tert-butyl 3-methyl 4-hydroxy-5,6-dihydropyridine-1,3(2H)-dicarboxylate

Methyl 4-oxopiperidine-3-carboxylate hydrochloride (13.0 g) was suspended in anhydrous DCM (100 mL) under an argon atmosphere. DIEA (29.2 mL) was added slowly via syringe, producing a slightly cloudy solution. The reaction was cooled to 0° C., and di-tert-butyl dicarboxylate (16.1 g) was added, resulting in an exothermic reaction. The reaction mixture was left stirring overnight, slowly warming to room temperature. The reaction mixture was then concentrated in vacuo and partitioned between EtOAc (500 mL) and saturated aqueous NH4Cl (350 mL). The EtOAc layer was washed with brine (125 mL), dried over anhydrous MgSO4 and concentrated in vacuo, producing a yellow oil. The product was purified by silica gel chromatography (1-25% EtOAc in hexanes), producing the title compound as a clear, colourless oil (14.7 g, 85.1%). MS (ES)[(M−H)]: 256 for C12H19NO5; NMR (CDCl3): 1.46 (s, 9H), 2.36 (t, 2H), 3.55 (t, 2H), 3.76 (s, 3H) 4.04 (s, 2H), 11.97 (s, 1H).


Intermediate 238
Ethyl 4-azido-3-hydroxypiperidine-1-carboxylate

Ethyl 4-bromo-3-hydroxypiperidine-1-carboxylate (Preparation: Izamanishi, T. et al; 1982, Chem. Pharm. Bull., 30: 3617-3623) (5.1 g) was dissolved in anhydrous DMF (20 mL) under an argon atmosphere, followed by the addition of 18-crown-6 (0.27 g) and sodium azide (2.89 g). The reaction was heated at 90° C. for twenty-three hours, then stirred overnight, slowly cooling to room temperature. The reaction was then added to deionised water (150 mL) to quench it, saturated with solid sodium chloride, and extracted with EtOAc (2×200 mL). The combined EtOAc layers were washed with brine (100 mL), dried over anhydrous MgSO4 and concentrated in vacuo, yielding the title compound (4.3 g, 100%). MS (GC-EI)[(M-N2)+]: 186 for C8H14BrN4O3.


Intermediate 239
Ethyl 4-azido-3-(2-tert-butoxy-2-oxoethoxy)piperidine-1-carboxylate

Ethyl 4-azido-3-hydroxypiperidine-1-carboxylate (Intermediate 238, 1.71 g) was dissolved in anhydrous THF (15 mL) and cooled to 0° C. Sodium hydride (60% in mineral oil) (0.42 g) was added as a shot, stirred for twenty minutes at 0° C., followed by the slow addition of tert-butyl bromo acetate (0.86 mL) via syringe, and stirred for an additional two hours at 0° C. The reaction was partitioned between EtOAc (250 mL) and saturated aqueous NaHCO3 (200 mL), and the aqueous layer was washed with EtOAc (200 mL). The combined EtOAc layers were washed with brine (50 mL), dried over anhydrous MgSO4 and concentrated in vacuo, yielding the title compound as a crude product (1.78 g, 103%). MS (GC-EI)[(M-N2)+]: 300 for C14H24N4O5.


Intermediate 240
Ethyl 4-amino-3-(2-tert-butoxy-2-oxoethoxy)piperidine-1-carboxylate



embedded image


Ethyl 4-azido-3-(2-tert-butoxy-2-oxoethoxy)piperidine-1-carboxylate (Intermediate 239, 1.75 g) was dissolved in THF (60 mL), followed by the addition of deionised water (5 mL) and PS-triphenylphosphine resin (10.6 g), and stirred at room temperature over the week-end. The reaction mixture was filtered, and the resin was rinsed repeatedly with MeOH and a 1:5 MeOH:DCM mixture, and the filtrate was concentrated in vacuo, yielding the title compound (1.20 g, 75%). MS (GC-EI)[(M)+]: 302 for C14H26N2O5.


Intermediate 241
Ethyl 4-bromo-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate

Ethyl 4-bromo-3-hydroxypiperidine-1-carboxylate (Preparation: Izamanishi, T. et al; 1982, Chem. Pharm. Bull., 30: 3617-3623) (10.17 g) was dissolved in anhydrous DCM (100 mL) under an argon atmosphere and cooled to 0° C. tert-Butyldimethylsilyl trifluoromethylsulfonate (10.2 mL) was added dropwise via syringe, followed by 2,6-lutidine (4.7 mL), also added dropwise via syringe. The reaction was stirred overnight, slowly warming to room temperature, then diluted with DCM (200 mL) and washed with saturated aqueous NaHCO3 (150 mL), saturated aqueous NH4Cl ((150 mL), brine (100 mL), dried over anhydrous MgSO4 and concentrated in vacuo, yielding the title compound as a crude product (15.1 g, 102%). MS (GC-EI)[(M-C4H7)+]: 310, 312 for C14H28BrNO3Si; NMR (CDCl3): 0.10 (s, 3H), 0.12 (s, 3H), 0.88 (s, 9H), 1.24 (t, 3H), 1.87 (m, 1H), 2.34 (m, 1H), 2.84-3.40 (m, 2H), 3.69 (m, 2H), 3.93 (m, 2H), 4.13 (q, 2H).


Intermediate 242
Ethyl 4-azido-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate

The title compound was prepared in a manner analogous to (Intermediate 238) starting with ethyl 4-bromo-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate (Intermediate 241). MS (GC-EI)[(M-N2)+]: 300 for C14H28N4O3Si.


Intermediate 243
Ethyl 4-amino-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate

The title compound was prepared in a manner analogous to (Intermediate 240) starting with ethyl 4-azido-3-{[tert-butyl(dimethyl)silyl]oxy}piperidine-1-carboxylate (Intermediate 242. MS (GC-EI)[(M)+]: 302 for C14H30N2O3Si.


Intermediate 244
3,4-dichloro-N-(3-hydroxypiperidin-4-yl)-5-methyl-1H-pyrrole-2-carboxamide

Ethyl 3-{[tert-butyl(dimethyl)silyl]oxy}-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-1-carboxylate (Intermediate 114, 0.805 g) was dissolved in a mixture of MeOH (10 mL) and 1,4-dioxane (15 mL), to which was added 1N NaOH (10 mL) and heated to reflux for twenty-four hours. An additional 5 mL of 1N NaOH was added, with 5 mL of 1,4-dioxane, and the reaction was heated for an additional forty-two hours, then cooled to 0° C. and acidified to ˜pH 9 with 2N HCl (6 mL). The cold mixture was filtered and washed with deionised water, yielding the title compound as a crude product. MS (ES) MH+: 292, 294 for C11H15Cl2N3O2.


Intermediate 245

The following Intermediate was prepared by the procedure described in Intermediate 16 from the starting materials (SM) indicated.















Int
Compound
Data
SM







245
ethyl 4-{[(1-methyl-1- phenylethyl)amino]carbonyl}- 2-(methylsulfonyl)-1,3- thiazole-5-carboxylate embedded image
MS (ES) MH+: 397 for C17H20N2O5S2 NMR: 1.24-1.32 (m, 3H) 1.66 (s, 6H) 3.57 (s, 3H) 4.36 (q, 2H) 7.22 (t, 1H) 7.34 (t, 2H) 7.41-7.50 (m, 2H) 8.91 (s, 1H)
Intermediate 246









Intermediate 246
ethyl 4-{[(1-methyl-1-phenylethyl)amino]carbonyl}-2-(methylthio)-1,3-thiazole-5-carboxylate

Diisopropylamine (5.3 ml) was dissolve in anhydrous THF (100 ml) was cooled to −78° C. and to this was added n-butyl lithium (15 ml) slowly. The solution was slowly warmed to 0° C. and then cooled back to −78° C. A solution of N-(1-methyl-1-phenylethyl)-2-(methylthio)-1,3-thiazole-4-carboxamide (Intermediate 13; 3.7 g) in anhydrous THF was added slowly maintaining the temperature below −70° C. After stirring for 30 min, a solution of ethyl cyano formate (2.5 ml) in anhydrous THF was added in one portion and the reaction was stirred at −78° C. for 30 min followed by slow warming to room temperature. The reaction mixture was diluted with water and extracted with ethyl acetate (×3), dried with MgSO4 and concentrated to a black oil (0.84 g) NMR: 1.22-1.29 (m, 3 H) 1.63 (s, 6 H) 2.76 (s, 3 H) 4.28 (q, 2 H) 7.20 (t, 1 H) 7.32 (t, 2 H) 7.46 (d, 2 H) 8.75 (s, 1 H).


Intermediate 247
diethyl 2-chloro-1,3-thiazole-4,5-dicarboxylate

To a solution of tert-butyl nitrite (3.4 mL, 28 mmol) and copper (II) chloride (3.7 g, 28 mmol) in acetonitrile (50 mL) was added diethyl 2-amino-1,3-thiazole -4,5-dicarboxylate (4.6 g, 19 mmol, Intermediate 248) all in one portion. Gas evolution was observed. After 45 min of stirring at room temperature LCMS indicated complete product formation. After concentrating to remove acetonitrile the residue was partitioned with chloroform and 1N HCl (Fisher), washed with chloroform, dried with MgSO4 and concentrated to an orange oil. Purification by flash column yielded a pale yellow oil (4.2 g, 85%). MS (ES): 264; NMR: 1.25-1.29 (t, 3 H) 1.29-1.33 (t, 3 H) 4.28-4.33 (q, 2 H) 4.33-4.39 (q, 2 H).


Intermediate 248
diethyl 2-amino-1,3-thiazole-4,5-dicarboxylate

A solution of thiourea (1.7 g, 22 mmol) and diethyl 2-chloro-3-oxosuccinate (5.0 g, 22 mmol) in absolute ethanol (50 mL) was heated at reflux for one hour. After cooling to room temperature the solvent was removed leaving a white solid. The solid was dissolved in water (100 mL) and the resulting precipitate was filtered and dried (4.6 g, 87%). MS (ES): 245;


NMR: 1.21 (t, 3 H) 1.26 (t, 3 H) 4.16 (q, 2 H) 4.26 (q, 2 H) 8.04 (s, 2 H).


Intermediate 249
isopropyl 4-chloro-6-(morpholin-4-ylcarbonyl)pyridine-2-carboxylate

n-butyllithium (1.92 mL, 2.5M in hexanes) was added dropwise to a −78° C. solution of morpholine (0.42 mL, 4.8 mmol) in anhydrous THF followed by slow warming to room temperature. The solution was transferred to an addition funnel via cannulation and then added dropwise to a solution of dimethyl 4-chloropyridine-2,6-dicarboxylate (1.0 g, 4.4 mmol, Intermediate 251) in anhydrous THF. A slight precipitate was observed during the addition. After stirring two hrs at room temperature an additional 0.5 equivalence of the morpholino-lithium reagent was added to the reaction and after an additional two hrs of stirring another 0.5 equivalence was added followed by stirring one hour to reach completion. The solvent was removed under reduced pressure and the residue was suspended in methylene chloride and the product was extracted with a sat. sodium bicarbonate solution (×3). The sodium bicarbonate portion was acidified with conc. HCl to pH 3 and then extracted with EtOAc (×10), followed by drying with MgSO4 and concentrating to a solid (0.8 g, 70%). MS (ES) MH+: 271 for C11H11ClN2O4. The solid was suspended in anhydrous toluene (75 mL) and to this was added triisopropylorthoformate (1.97 mL, 8.9 mmol) slowly followed by heating to reflux for 12 hours. After cooling to room temperature the solvent was removed under reduced pressure and the residue was suspended in 1N HCl. Basification to pH8 with saturated sodium bicarbonate followed by extraction with EtOAc (×3), drying with MgSO4 and removal of solvent yielded a tan solid. Purification by silica gel flash column (gradient elution to 3:1 EtOAc:CH2Cl2) yielded a white solid (0.23 g) MS (ES) MH+: 313 for C14H17ClN2O4; NMR: 1.33 (s, 3 H) 1.35 (s, 3 H) 3.41 (s, 2 H) 3.44 (d, 2 H) 3.58 (d, 2 H) 3.68 (s, 4 H) 5.17 (dt, 1 H) 8.01 (d, 1H) 8.13 (d, 1 H).


Intermediate 250

The following Intermediate was prepared by the procedure described in Intermediate 249 from the starting materials (SM) indicated.















Int
Compound
Data
SM







250
isopropyl 4-chloro-6- [(dimethylamino)carbonyl] pyridine-2-carboxylate embedded image
MS (ES) MH+: 271 for C12H15ClN2O3 NMR: 1.35 (d, 6H) 2.93 (s, 3H) 3.03 (s, 3H) 5.18 (dt, 1H) 7.96 (d, 1H) 8.11 (d, 1H)
Intermediate 251 and dimethylamine









Intermediate 251
dimethyl 4-chloropyridine-2,6-dicarboxylate

Phosphorus pentachloride (45.5 g, 218 mmol) was weighed into a closed flask and suspended in chloroform. 4-hydroxypyridine-2,6-dicarboxylic acid (10.0 g, 55 mmol) was added and after heating at a gentle reflux for 3 days the reaction was complete (60% conversion). After cooling to 0° C. anhydrous methanol (150 mL) was added dropwise. Once the exotherm subsided the solvent was removed under reduced pressure and the residue was partitioned with EtOAc and water and the insoluble material was filtered, washed with EtOAc and dried (6.7 g). The EtOAc layer was washed with water, dried with MgSO4 and concentrated. Recrystallization with methanol yielded additional pure product (0.64 g). MS (ES) MH+: 230 for C9H8ClNO4; NMR: 3.94 (s, 3 H) 8.32 (s, 1 H).


Intermediate 252
2-chloro-5-(ethoxycarbonyl)-1,3-thiazole-4-carboxylic acid

To a solution of ethyl 2-chloro-4-(hydroxymethyl)-1,3-thiazole-5-carboxylate (2.5 g, 11 mmol, Intermediate 215) in acetone at 0° C. was slowly added a solution of chromium trioxide (2.26 g, 22 mmol) in 20% conc. Sulfuric acid in water (20 mL). After stirring at room temperature for 2 hrs, isopropanol (1 mL) was added to quench unreacted chromium trioxide. The reaction was diluted with water and the acetone was removed. Partitioning with methylene chloride (×3), drying with MgSO4 and concentrating yielded a white solid (2.3 g, 90%). MS (ES) MH+: 236 for C7H6ClNO4S; NMR: 1.26 (t, 3 H) 4.31 (q, 2 H) 13.99-14.15 (m, 1 H).


Intermediate 253
3,4-Dichloro-5-chloromethyl-1H-pyrrole-2-carboxylic acid ethyl ester

To a 4-neck 22 L round bottom flask equipped with an overhead stirrer, liquid addition funnel, nitrogen inlet and an internal temperature probe was charged (Intermediate 254, 2000 g, 13.6 mol) and carbon tetrachloride (12 L). The reaction mixture was cooled to −5° C. and sulfuryl chloride was added at a rate that the temperature did not exceed 0° C. (1 h). Resulting reaction mixture became very thick (as precipitate becomes heavy, significant gas evolution was observed) and was allowed to stir at 0° C. for a total of 4 h after addition. Precipitate was filtered and solid azeotroped with toluene to remove excess sulfuryl chloride. The solid was and dried in convection oven at 50° C. yielding 3 (2077 g, 62%) as a dark purple solid.


Intermediate 254
5-Methyl-1H-pyrrole-2-carboxylic acid ethyl ester

To a 4-neck 22 L round bottom flask equipped with an overhead stirrer, liquid addition funnel, nitrogen inlet and an internal temperature probe was charged ethyl 3-oxobutanoate (1952 g, 15.0 mol) and glacial acetic acid (5 L). The resulting solution was cooled to 0° C. with an ice water bath and an aqueous solution of sodium nitrite (1242 g, 18.0 mol, 1.2 eq, in 1875 ml of water) was added slowly (4.5 h) not allowing the internal temperature above 10° C. The homogeneous red solution was allowed to warm to ambient and stirred for 48 h. The solution color changed from light red to yellow. Reaction vessel was then placed in a heating mantle, fitted with a reflux condenser and acetylacetaldehyde dimethyl acetal (1982 g, 15.0 mol, 1 eq) was added in one portion (the top of the reflux condenser was left open to air to allow for the rapid gas evolution during the addition of the zinc). Zinc (dust, 2156 g, 33 mol, 2.2 eq) was added in portions (at a rate such that gas evolution was controlled) over 4 h. The addition of zinc brought the reaction to reflux and after addition the dark red solution was heated at reflux for an additional 1.5 h. Contents of the reaction were poured hot into a 50 L container with 20 kg of ice and allowed to stir for 16 h. Resulting suspension was filtered, dried in convection oven and recrystallized with hot heptane yielding a light yellow solid (312 g, 13.6% yield).


Intermediate 255
ethyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate



embedded image


To a stirred solution of potassium hydroxide (42 g, 752 mmol) in dry methanol (100 mL), at 0° C. and under an atmosphere of N2, was added a solution of ethyl 4-oxopiperidine-1-carboxylate (26.4 mL, 29.96 g, 175 mmol) in dry methanol (75 mL) via syringe. The resulting solution was stirred for an additional 30 minutes under an atmosphere of N2 at 0° C. To it, in small portions over approximately 90 minutes, was added iodobenzene diacetate (84.6 g, 262 mmol). Temperature was kept near 0° C. throughout this time. The reaction was stirred overnight under an atmosphere of N2, gradually reaching room temperature. Complete conversion was suggested by TLC (50% ethyl acetate in hexanes; Hanessian's stain; Rf˜0.25) in the morning. The reaction was concentrated under vacuum. To the residue was added approximately 50 mL water; from this mixture was extracted the crude product with ethyl acetate (3×200 mL). The organic layers were combined, dried over magnesium sulfate, and concentrated. The crude product was purified using column chromatography (silica gel; 10-65% ethyl acetate in hexanes), yielding 26.74 g (66%) of a pale yellow oil.


MS (ESI) M: 233 for C10H19NO5. 1H NMR (CDCl3): 1.22 (t, 3H), 1.69-1.86 (m, 2H), 2.20 (m, 2H), 2.86 (t, 1H), 3.22 (s, 3H), 3.23 (s, 3H), 3.74 (m, 1H), 3.95 (m, 2H), 4.11 (q, 2H).


Intermediates 256-257

The following Intermediates were synthesized by an analogous method to Intermediate 28 or Intermediate 59 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







256
Cis(±)-ethyl 4-amino-3-
MS (ESP): 227 (M + H)
Intermediate



(prop-2-yn-1-
for C11H18N2O3
146



yloxy)piperidine-1-



carboxylate


257
Cis(±)-Ethyl (4-amino-3-
MS (ES) MH+: 217 for
Intermediate



ethoxypiperidine-1-
C10H20N2O3
156



carboxylate









Intermediates 258-259

The following Intermediates were synthesized by an analogous method to Intermediate 37 or Intermediate 83 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







258
tert-Butyl (3S,4R)-4-{[(4-chloro-5-methyl-1H-
MS (ES) MH+: 360
Intermediate



pyrrol-2-yl)carbonyl]amino}-3-
for C16H23ClFN3O3;
64 and



fluoropiperidine-1-carboxylate

Intermediate 6


259
tert-butyl (3S,4R)-4-{[(4-chloro-3-fluoro-5-
MS (ESP):
Intermediate



methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-
530 (MNa+) for
263 and



1H-pyrrol-2-yl)carbonyl]amino}-3-
C22H36ClF2N3O4Si
Intermediate



fluoropiperidine-1-carboxylate

64









Intermediates 260-261

The following Intermediates were synthesized by an analogous method to Intermediate 50 or Intermediate 74 from the starting materials (SM) given in the table below.















Int
Compound
Data
SM







260
4-Chloro-N-[(3S,4R)-3-fluoropiperidin-4- yl]-5-methyl-1H-pyrrole-2-carboxamide embedded image
MS (ES): MH+: 260 for C11H15ClFN3O
Intermediate 258





261
4-chloro-3-fluoro-N-[(3S,4R)-3-

MS (ESP): 278

Intermediate 262



fluoropiperidin-4-yl]-5-methyl-1H-pyrrole-
(MH+) for



2-carboxamide
C11H14ClF2N3O









Intermediate 262
tert-butyl (3S,4R)-4-{[(4-chloro-3-fluoro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidine-1-carboxylate

tert-butyl (3S,4R)-4-{[(4-chloro-3-fluoro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrol-2-yl)carbonyl]amino}-3-fluoropiperidine-1-carboxylate (Intermediate 259, 80 mg, 0.16 mmol) was dissolved in anhydrous THF (6 ml), followed by the addition of tetra-butyl ammonium fluoride (1 ml, 1M in THF) and ethylene diamine (1 mmol), the mixture was then stirred at 50° C. over night. After cooling down to room temperature, the reaction mixture was diluted with ethyl acetate (20 ml) and washed with saturated aqueous sodium bicarbonate (10 ml) and brine (10 ml), dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (100%˜70% hexanes/ethyl acetate) to give the desired product (55 mg).


MS (ESP): 378 (MNa+) for C16H22ClF2N3O3.



1H-NMR (CDCl3) δ: 1.46 (s, 9H); 1.84 (m, 2H); 2.24 (s, 3H); 2.89 (m, 2H); 4.28 (m, 2H); 4.50 (m, 1H); 4.70 (m, br, 1H); 6.32 (m, 1H); 9.36 (br, 1H).


Intermediate 263
4-chloro-3-fluoro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylic acid

tert-butyl 4-chloro-3-fluoro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate (Intermediate 264, 100 mg) was dissolved in N-methylpyrrolidinone (10 ml), heated to 200° C. for 30 minutes. The resulting solution was carried on to the next step without further purification.


MS (ESP): 307 (M) for C12H19ClFNO3Si.


Intermediate 264
tert-butyl 4-chloro-3-fluoro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate

tert-butyl 3-bromo-4-chloro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate (Intermediate 265, 480 mg, 1.13 mmol) was dissolved in dry THF (8 ml), cooled down to −78° C., n-BuLi (2.5M in Hexane, 3.39 mmol) was added dropwise into the mixture via syringe and the mixture was stirred at −78° C. for 30 min followed by a quick addition of N-Fluorobenzensulfonimide (1.25 g, 3.96 mmol in 5 ml of THF/Toluene 1:1), the resulting mixture was then stirred at −78° C. for 30 min and slowly warmed up to room temperature during a period of 12 hrs. The reaction was quenched at 0° C. with drops of saturated NH4Cl solution and further diluted with EtOAc (50 ml). The organic phase was washed with brine and dried over anhydrous MgSO4, concentrated to an oil and purified by flash column chromatography eluted with 10% EtOAc in Hexanses. The desired product was obtained as an oil (125 mg).


MS (ESP): 364 (MH+) for C16H27ClFNO3Si.



1H-NMR (CDCl3) δ: 0.00 (s, 9H); 0.90 (t, 2H); 1.58 (s, 9H); 2.31 (s, 3H); 3.52 (t, 2H); 5.70 (s, 2H).



19F-NMR (CDCl3) δ: −148.85.


Intermediate 265
tert-butyl 3-bromo-4-chloro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate



embedded image


Ethyl 3-bromo-4-chloro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate (Intermediate 266, 564 mg, 1.42 mmol), t-Butylacetate (330 mg, 2.84 mmol) and potassium t-butoxide (0.14 mmol) were mixed together and stirred at room temperature for 10 minutes, concentrated to an oil under vacuum. t-Butylacetate (330 mg, 2.84 mmol) and potassium t-butoxide (0.14 mmol) were added again into the reaction mixture, repeated the same procedure again. The resulting reaction crude was filtered through a short pass silica gel, washed with ethyl acetate, the combined filtrate was concentrated to an oil and purified by column chromatography (2% ethyl acetate in hexanses) to give the desired product as an oil (485 mg).



1H-NMR (CDCl3) δ: 0.00 (s, 9H); 0.90 (t, 2H); 1.58 (s, 9H); 2.33 (s, 3H); 3.52 (t, 2H); 5.75 (s, 2H).


Intermediate 266
Ethyl 3-bromo-4-chloro-5-methyl-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrole-2-carboxylate

To a suspension of sodium hydride (76 mg, 3.16 mmol) in dry DMF (5 ml), solution of ethyl 3-bromo-4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 267, 420 mg, 1.58 mg) was added, the resulting mixture was stirred at 0° C. for 30 minutes until gas evolution seized. Trimethylsilyl-ethylmethyl chloride (315 mg, 1.89 mmol) was added drop wise and stirred over night while allowing the reaction mixture warmed up to room temperature slowly. The reaction was quenched with cold water, diluted with ether (20 ml), washed with water and brine, the organic layer was dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (95% hexanes in ethyl acetate) to give the desired product as an oil (624 mg).


MS (ESP): 397 (MH+) for C14H23BrClNO3Si.



1H-NMR (CDCl3) δ: 0.00 (s, 9H); 0.90 (t, 2H); 1.43 (t, 3H); 2.38 (s, 3H); 3.55 (t, 2H); 4.34 (q, 2H); 5.75 (s, 2H).


Intermediate 267
Ethyl 3-bromo-4-chloro-5-methyl-1H-pyrrole-2-carboxylate

Ethyl 4-chloro-5-methyl-1H-pyrrole-2-carboxylate (Intermediate 7, 300 mg, 1.6 mmol) was dissolved in dry dichloromethane (10 ml), N-bromosuccinimide (285 mg, 1.6 mmol) was added at 0° C. and resulting mixture was stirred at room temperature over night. The mixture was poured into cold sodium hydroxide aqueous solution (2M) (20 ml), extracted with diethyl ether (2×20 ml). The organic phase was then washed with water (20 ml) and brine (20 ml), dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (hexanes/ethyl acetate, gradient) to give the desired product as a yellowish solid. (424 mg).


MS (ESP): 266 (MH+) for C8H9BrClNO2.



1H-NMR (CDCl3) δ: 1.39 (t, 3H); 2.32 (s, 3H); 4.34 (q, 2H); 9.04 (s, br, 1H).


Intermediate 268
Trans(±)-tert-butyl-4-[(diphenylmethylene)amino]-3-hydroxypiperidine-1-carboxylate

tert-butyl-4-amino-3-hydroxypiperidine-1-carboxylate (11.9 g; 55 mmol) and benzophenone imine (10 g; 59 mmol; 1.05 eq.) were dissolved in anhydrous toluene and heated to reflux for 18 hrs. Monitored the reaction by TLC (30% EtOAc/hexanes with 0.1% triethylamine). The crude reaction was concentrated and purified by flash column chromatography. Isolation gave 18.4 g of the title compound in an 86% yield. LC/MS (ES+)[(M+H)+]: 381 for C23H28N2O3.


Intermediate 269
Cis(±)-tert-butyl-3-azido-4-[(diphenylmethylene)amino]piperidine-1-carboxylate

In a flame-dried flask triphenylphosphine (3.86 g; 14.7 mmol; 2 eq.) was dissolved in anhydrous THF (15 ml) and cooled to 0 C. DIAD (2.97 g; 14.7 mmol; 2 eq.) was slowly added dropwise. Upon addition a white precipitate formed. A THF solution containing tert-butyl-4-[(diphenylmethylene)amino]-3-hydroxypiperidine-1-carboxylate (Intermediate 268, 2.8 g; 7.36 mmol) was added (amount of THF added was such that the final concentration of alcohol was ca. 0.5-1M). The resultant reaction slurry was stirred at 0 C for 30 minutes. (PhO)2PON3 (4.05 g; 14.7 mmol; 2 eq.) was then added and the reaction was allowed to warm to RT and stirred for 12 hrs. Monitored by LC/MS. The reaction was concentrated and purified by flash column chromatography (0-30% EtOAc/hexanes with 0.1% triethylamine). Isolation gave 2.13 g of the title compound in 71% yield. LC/MS (ES+)[(M+H)+]: 406 for C23H27N5O2.


Intermediate 270
Cis(±)tert-butyl-4-amino-3-azidopiperidine-1-carboxylate



embedded image


tert-butyl-3-azido-4-[(diphenylmethylene)amino]piperidine-1-carboxylate (Intermediate 269, 1.36 g; 3.3 mmol) was dissolved in 10 ml's of aqueous THF (5% H2O). PPTS (850 mg; 3.4 mmol; 1.03 eq.) was added in a single portion. The initial cloudy solution became clear within minutes. Upon completion (as determined by LC/MS analysis) the reaction was concentrated and azeotropically dried with acetonitrile. No further purification. (LC/MS: see disappearance of starting material and formation of Ph2C═O. Product is not observable due to lack of chromophore).


Intermediate 271
Cis(±)tert-butyl-3-azido-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-1-carboxylate

Crude tert-butyl-4-amino-3-azidopiperidine-1-carboxylate (Intermediate 270, 3.3 mmol) was dissolved in anhydrous CH2Cl2 (10 ml) and DIEA (1.27 g; 1.6 ml; 9.9 mmol; 3 eq.). The solution was cooled to 0 C and 3,4-dichloro-5-methyl-1H-pyrrole-2-carbonyl chloride (736 mg; 3.5 mmol; 1.05 eq.) was added. The reaction was complete within 30 minutes. Dilute with CH2Cl2 and wash with H2O (×2), brine and dried over Na2SO4. Filter and concentrate. Purify by flash column chromatography (0-60% EtOAc/hexanes). Isolation gave 967 mg in 69% yield over the two-step sequence. LC/MS (ES)[(M−H)+]: 415, 417 for C16H22Cl2N6O3.


Intermediate 272
Cis(±)N-(-3-azidopiperidin-4-yl)-3,4-dichloro-5-methyl-1H-pyrrole-2-carboxamide hydrochloride

tert-butyl-3-azido-4-{[(3,4-dichloro-5-methyl-1H-pyrrol-2-yl)carbonyl]amino}piperidine-1-carboxylate (Intermediate 271, 967 mg; 2.3 mmol) was dissolved in 4N HCl in dioxanes (20 ml) and methanol (10 ml). The solution was stirred for 2 hours and monitored by LC/MS. Upon completion the solvent was removed and the crude reaction mixture was azeotroped with methanol to remove excess HCl. No further purification. LC/MS (ES+)[(M+H)+]: 317, 319 for C11H14Cl2N6O.


Intermediate 273
(2R)-2-Methoxypropan-1-amine hydrochloride (1725-162)

tert-Butyl [(2R)-2-methoxypropyl]carbamate (Intermediate 277, 0.33 g, 1.74 mmol) and Hydrochloric acid (4 M, 1.5 mL) were combined and stirred at room temperature for two hours. Then it was concentrated and triturated with diethyl ether to give white crystalline solid (0.20 g) as the product.


NMR: 1.14 (d, 3H), 3.30 (s, 3H), 3.35-3.45 (m, 2H), 7.99 (brs, 3H).


Intermediates 274-275

The following compounds were produced according to the procedure for Intermediate 273 or by hydrogenation using the starting materials listed.















Int
Compound
Data
SM







274
(2S)-2-
NMR: 1.14 (d, 3H), 3.30
Intermediate



methoxypropan-1-
(s, 3H), 3.35-3.45 (m, 2H),
278



amine hydrochloride
7.99 (brs, 3H)


275
(2R)-1-
NMR: 1.14 (d, 3H), 3.29
Intermediate



Methoxypropan-2-
(s, 3H), 8.07 (brs, 3H), rest of
276



amine hydrochloride
the peaks are buried under




huge water peak









Intermediate 276
Benzyl [(1R)-2-methoxy-1-methylethyl]carbamate

To a solution of benzyl [(1R)-2-hydroxy-1-methylethyl]carbamate (0.5 g, 2.38 mmol) in acetonitrile (20 mL), silver oxide (3.8 g, 13.09 mmol) is added followed by the addition of methyl iodide (1.94 mL, 23.8 mmol). The resultant mixture was stirred overnight at room temperature. The insoluble salt was filtered off and the filtrate was concentrated. The residue was flashed using silica and Ethyl acetate/hexanes system as eluent to give the desired product as clear oil (0.38 g).


MS (ES) MH+Na: 246 for C12H17NO3;


NMR: 1.01 (d, 3H), 3.12-3.17 (m, 1H), 3.22 (s, 3H), 3.25-3.26 (m, 1H), 3.60-3.75 (m, 1H), 5.00 (s, 2H), 7.16 (d, 1H), 7.29-7.36 (m, 5H).


Intermediate 277
tert-Butyl [(2R)-2-methoxypropyl]carbamate

To a solution of tert-butyl [(2R)-2-hydroxypropyl]carbamate (0.4 g, 2.28 mmol) in THF (5 mL), sodium hydride (0.06 g, 2.51 mmol) was added at 0° C. The resulting solution was stirred for 30 minutes at that temperature and then methyl iodide (0.14 mL, 2.28 mmol) was added. The reaction was warmed to room temperature slowly and allowed to stir for an additional two hours. The reaction was quenched by adding water and extracted with ethyl acetate. The extract was washed with sodium bicarbonate solution, water and brine. It was dried over magnesium sulfate and concentrated. The desired product was obtained as clear oil (0.31 g) and it did not need any further purification.


NMR (CDCl3): 1.15 (d, 3H), 1.43 (s, 9H), 3.31-3.33 (m, 2H), 3.34 (s, 3H), 3.77-3.81 (m, 1H), 4.66 (brs, 1H).


Intermediate 278
tert-Butyl [(2S)-2-methoxypropyl]carbamate

The title compound was synthesized by using the method analogous to the synthesis of Intermediate 277 starting with tert-butyl [(2S)-2-hydroxypropyl]carbamate and alkylating it with methyl iodide.


NMR (CDCl3): 1.15 (d, 3H), 1.43 (s, 9H), 3.31-3.33 (m, 2H), 3.34 (s, 3H), 3.77-3.81 (m, 1H), 4.66 (brs, 1H).


Example 441

The following Example was prepared by the procedure described in Example 203 from the starting materials (SM) indicated.















Ex
Compound
Data
SM







441
ethyl 2-((3S,4R)-4-{[(3,4-dichloro-5-
MS (ES)
Example 188 and [2-



methyl-1H-pyrrol-2-
MH+: 605 for
methoxy-1-



yl)carbonyl]amino}-3-
C24H33Cl2N5O7S;
(methoxymethyl)ethyl]amine



methoxypiperidin-1-yl)-4-({[2-

(ChemPacific)



methoxy-1-



(methoxymethyl)ethyl]amino}carbonyl)-



1,3-thiazole-5-carboxylate









Example 442

The following Example was prepared by the procedure described in Example 383 from the starting materials (SM) indicated.














Ex
Compound
Data
SM


















442
2-((3S,4R)-4-{[(3,4-dichloro-5-methyl-1H- pyrrol-2-yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-({[2-methoxy-1- (methoxymethyl)ethyl]amino}carbonyl)-1,3- thiazole-5-carboxylic acid embedded image
MS (ES) MH+: 578 for C22H29Cl2N5O7S NMR: 1.77 (s, 2H) 2.19 (s, 3H) 3.24 (s, 3H) 3.27 (s, 3H) 3.38 (s, 5H) 3.49 (s, 6H) 4.32 (s, 2H) 7.18 (s, 1H) 8.93 (s, 1H) 12.16 (s, 1H) 16.17 (s, 1H)
Example 441









Example 443

The following Example was prepared by the procedure described in Example 417 from the starting materials (SM) indicated















Ex
Compound
Data
SM







443
sodium 2-((3S,4R)-4-{[(3,4- dichloro-5-methyl-1H-pyrrol-2- yl)carbonyl]amino}-3- methoxypiperidin-1-yl)-4-({[2- methoxy-1- (methoxymethyl)ethyl]amino}car- bonyl)-1,3-thiazole-5-carboxylate embedded image
MS (ES) MH+: 578 for C22H28Cl2N5O7SNa NMR: 1.70 (s, 2H) 2.17 (s, 3H) 3.21-3.26 (m, 6H) 3.34 (s, 4H) 3.35-3.38 (m, 6H) 3.49 (s, 1H) 3.86 (d, 1H) 4.04-4.16 (m, 3H) 4.22 (s, 1H) 7.18 (d, 1H) 12.17 (s, 1H) 13.33 (d, 1H)
Example 442








Claims
  • 1. A compound:
  • 2. A compound:
  • 3. The compound of claim 2, in the form of a free acid.
  • 4. The compound of claim 2, in the form of a mixture of a free acid and a pharmaceutically acceptable salt thereof.
  • 5. The compound of claim 2, in the form of a pharmaceutically acceptable salt.
  • 6. The compound of claim 5, in the form of a potassium salt.
  • 7. The compound of claim 5, in the form of a sodium salt.
  • 8. A pharmaceutical composition comprising a compound of claim 2, and/or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent and/or carrier.
  • 9. The pharmaceutical composition of claim 8, wherein the compound is in the form of a potassium salt.
Parent Case Info

This application is a US National Stage under 35 U.S.C. §371 of International Application No. PCT/GB2006/000529 filed 16 Feb. 2006, the text of which is hereby incorporated by reference, which claims priority under 35 U.S.C. §119(e) to Application No. 60/654,670 filed on 18 Feb. 2005.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/GB2006/000529 2/16/2006 WO 00 11/12/2009
Publishing Document Publishing Date Country Kind
WO2006/087543 8/24/2006 WO A
US Referenced Citations (10)
Number Name Date Kind
3963480 Bailey Jun 1976 A
4046775 Bailey Sep 1977 A
4791112 Bagley et al. Dec 1988 A
4912109 Bagley et al. Mar 1990 A
5712279 Biller et al. Jan 1998 A
5739135 Biller et al. Apr 1998 A
7709503 Green et al. May 2010 B2
20050234033 Anandan et al. Oct 2005 A1
20050250784 Anandan et al. Nov 2005 A1
20080312255 Basarab et al. Dec 2008 A1
Foreign Referenced Citations (35)
Number Date Country
0894805 Feb 1999 EP
1253142 Oct 2002 EP
1431267 Jun 2004 EP
9626205 Aug 1996 WO
0112601 Feb 2001 WO
0152845 Jul 2001 WO
0152846 Jul 2001 WO
0153267 Jul 2001 WO
0196307 Dec 2001 WO
02085886 Oct 2002 WO
02096908 Dec 2002 WO
03016254 Feb 2003 WO
2003048129 Jun 2003 WO
03072554 Sep 2003 WO
2003072553 Sep 2003 WO
2004002490 Jan 2004 WO
2004083177 Sep 2004 WO
2004089947 Oct 2004 WO
2004089954 Oct 2004 WO
2005014579 Feb 2005 WO
2005026149 Mar 2005 WO
2005026149 Mar 2005 WO
2005044797 May 2005 WO
2005086898 Sep 2005 WO
2006030975 Mar 2006 WO
2006047277 May 2006 WO
2006047504 May 2006 WO
2006087544 Aug 2006 WO
2006087548 Aug 2006 WO
2006087543 Aug 2006 WO
2006092599 Sep 2006 WO
2006092608 Sep 2006 WO
2007071965 Jun 2007 WO
2008020222 Feb 2008 WO
2008152418 Dec 2008 WO
Non-Patent Literature Citations (26)
Entry
CHEMCATS 0078994164 (2011).
Eakin Novel DNA Gyrase Inhibitors: Fragment-Based NMR Screening to Antibacterial Agents. Presentation at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC, Oct. 25, 2008).
Green et al. “Novel DNA Gyrase Inhibitors: Structure Guided Discovery and Optimization of Pyrrolamides” Poster at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC, Oct. 25, 2008) F1-2025.
Hull et al. “Novel DNA Gyrase Inhibitors: The Effect of Pyrrolamide Variations at Site 1 and Site 2 Upon Potency” Poster at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC, Oct. 25, 2008) F1-2027
Illingworth et al. “Novel DNA Gyrase Inhibitors: Microbiological Characterization and In Vivo Efficacy of Pyrrolamides” Poster at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC, Oct. 25, 2008) F1-2028.
Sherer et al. “Novel DNA Gyrase Inhibitors: The Effects of Pyrrolamide Linker Variations Upon Potency” Poster at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC, Oct. 25, 2008) F1-2026.
Sherer et al. “Novel DNA Gyrase Inhibitors: Improvement of Pyrrolamide Antibacterial Activity by 3-Fluoropiperidine Linkers” Poster at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA, Sep. 15, 2009) F1-1977.
Uria-Nickelsen et al. “Novel DNA Gyrase Inhibitors: Investigation of the Mechanism of Action of Pyrrolamides” Poster at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA, Sep. 15, 2009) F1-2029.
Uria-Nickelsen et al. “Novel DNA Gyrase Inhibitors: Microbiological Characterization and In Vivo Efficacy 3-Fluoropiperidine Pyrrolamides” Poster at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA, Sep. 15, 2009) F1-1978.
Bisacchi et al. “Recent Advances in the Inhibition of Bacterial Type 11 Topoisomerases” in Annual Reports in Medicinal Chemistry; John E. Macon Ed. (Elsevier); 2009; pp. 379 to 396; vol. 44.
Ann E. Eakin; “Inhibition of Bacterial DNA Replication: Novel DNA Gyrase Inhibitors” Presentation at Gordon Research Conferences (Lucca, Italy) Mar. 10, 2008.
Beccalli, Egle M., et al., Pd-catalyzed intramolecular cyclization of pyrrolo-2-carboxamides: regiodivergent routes to pyrrolo-pyrazines and pyrrolo-pyridines, Tetrahedon, 2005, pp. 1077-1082, vol. 61.
Brown, J.W. et al., Some Three-Ring Esters Containing a Five-Membered Heteroaromatic Ring. A Comparison of Liquid Crystal Properties, Mol. Cryst. Liq. Cryst., 1989, pp. 121-140, vol. 173.
XP002397870 retrieved from STN, Database accession No. 784198-11-4 abstract; 784198-11-4 compounds, Nov. 19, 2004, Database Registry [Online], Chemical Abstracts Service, Columbus, OH.
XP002397871 retrieved from STN, Database accession No. 785802-22-4 abstract; 785802-22-4 compounds, Nov. 22, 2004, Database Registry [Online], Chemical Abstracts Service, Columbus, OH.
XP002397872 retrieved from STN, Database accession No. 784198-41-0 abstract; 784198-41-0 compounds, Nov. 19, 2004, Database Registry [Online], Chemical Abstracts Service, Columbus, OH.
XP002397873 retrieved from MDL, Database accession No. 432931, compounds 13254-12-1 & NL 6 510 290 a, Feb. 8, 2006, Database Beilstein [Online], Chemical Abstracts Service, Columbus, OH.
Gilles Klopman et al., Computer Automated Structure Evaluation of Quinolone Antibacterial Agents, Antimicrobial Agents and Chemotherapy, Nov. 1987, 1831-1840, 31(11).
Patrick Laurin et al., Structure-Activity Relationship in Two Series of Aminoalkyl Substituted Coumarin Inhibitors of Gyrase B, Bioorganic & Medicinal Chemistry Letters, 1999, 2875-2880, 9.
Laurent Schio et al., Fine Tuning of Physico-Chemical Parameters to Optimise a New Series of Novobiocin Analogues, Bioorganic & Medicinal Chemistry Letters, 2001, 1461-1464, 11.
Richard L. Wynn et al., Evaluation of the Morphine Reversal Actions and Antinociceptive Activity of a New Class of Opiate Antagonists Structurally Related to Fentanyl, Drug Development Research, 1991, 189-195, 22.
Yuichi Kanaoka et al., Synthesis of Thieno[2,3-c]-, Pyrrolo[2,3-c]- and Indolo[2,3-c]diazanaphthalenes by Photocyclization of Acylaminopyridines, Heterocycles, 1977, 29-32, 6(1).
John M. Domagala et al., New Structure-Activity Relationships of the Quinolone Antibacterials Using the Target Enzyme. The Development and Application of an DNA Gyrase Assay, J. Med. Chem., 1986, 394-404, 29(3).
James A. Waters et al., Anticonvulsant Activity of Piperidinol and (Dialkylamino)alkanol Esters, J. Med. Chem., 1986, 1512-1516, 29(8).
Krzysztof Sieradzki et al., Suppression of B-Lactam Antibiotic Resistance in a Methicillin-Resistant Staphyloccous aureus through synergic action of early cell wall inhibitors and some other antibiotics, Journal of Antimicrobial Chemotherapy, 1997, 47-51, 39, Suppl. A.
Branislav Musicki et al., Noviose Mimics of the Coumarin Inhibitors of Gyrase B, Tetrahedron Letters, 2003, 9259-9262, 44.
Related Publications (1)
Number Date Country
20100179150 A1 Jul 2010 US
Provisional Applications (1)
Number Date Country
60654670 Feb 2005 US